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Toxoplasma gondii y Neospora caninum son parásitos apicomplejos muy relacionados 
filogenéticamente y considerados como unas de las principales causas de aborto infeccioso en 
pequeños rumiantes y ganado vacuno respectivamente en todo el mundo. Sin embargo, recientemente, 
la importancia de N. caninum como agente causante de abortos en ganado ovino se ha incrementado 
enormemente. T. gondii en pequeños rumiantes y N. caninum en ganado vacuno presentan una 
elevada prevalencia y producen importantes pérdidas económicas como consecuencia del fallo 
reproductivo. T. gondii en ganado ovino produce principalmente aborto tras una primoinfección con 
ooquistes durante la gestación mientras que N. caninum puede producir abortos tras una infección 
durante la gestación o tras la recrudescencia de una infección crónica. Para el control de la 
toxoplasmosis en ganado ovino existe una vacuna viva atenuada comercializada (ToxovaxTM), la cual 
reduce parcialmente los abortos asociados a T. gondii, mientras que la la única vacuna comercializada 
hasta el momento para la neosporosis en ganado vacuno (Neoguard), basada en taquizoitos muertos, 
se ha retirado del mercado debido a su baja eficacia. En relación al tratamiento, se han probado 
diferentes clases de fármacos tales como macrólidos, poliéteres ionóforos, inhibidores de la síntesis 
del folato, quinolonas y triazinas y han mostrado eficacia moderada. Por lo tanto, hasta el momento, 
no hay fármacos disponibles para el tratamiento de la toxoplasmosis y la neosporosis en rumiantes. 
Asi pues, el desarrollo de medidas de control es de gran importancia.  
Los modelos in vitro representan una alternativa para optimizar el uso de animales, pero los 
modelos in vivo son la mejor opción para ensayos terapéuticos y vacunales asi como para estudiar la 
patogenia, la respuesta inmune y las consecuencias de la infección. El modelo murino es 
frecuentemente utilizado para determinar la virulencia de T. gondii y para estudiar la toxoplasmosis 
congénita. Sin embargo, no se conoce si las diferencias en placentación, fisiología reproductiva y 
respuesta inmune entre el ratón y los rumiantes podrían conllevar unas consecuencias diferentes tras 
la infección durante la gestación. Aunque varios aislados tipo II de T. gondii, el más prevalente en 
todos los hospedadores en Europa incluyendo la oveja, han sido evaluados en ovejas gestantes, 
ninguno de estos aislados se ha estudiado profundamente en ratón.  
En la neosporosis, el interés por el modelo ovino gestante se ha incrementado en los últimos años 
ya que representa una alternativa viable al costoso modelo bovino y al modelo murino que es 
escasamente extrapolable al bovino. Sin embargo, la influencia de la dosis de infección y la ruta de 
administración en el resultado de la infección apenas se ha estudiado.  
Para intentar progresar en el control de la toxoplasmosis y neosporosis, se han evaluado in vitro y 
en modelos de animales de laboratorio grupos farmacológicos tales como tiazolidas, diamidinas, 
artemisininas, naftoquinonas, agentes anticancerígenos, “endochin-like quinolones” y inhibidores de 
la proteína quinasa dependiente de calcio tipo 1 (CDPK1), mostrando unos resultados prometedores. 
La CDPK1 es una buena diana terapéutica ya que está ausente en células de hospedadores mamíferos, 
pero conservada entre los parásitos apicomplejos y esencial para numerosas etapas en el ciclo lítico 
del parásito. Esta CDPK1 puede ser inhibida por unos compuestos competidores por el sitio de unión 
del ATP de la CDPK1 llamados “BKIs”, los cuales son eficaces frente a T. gondii y N. caninum in 
vitro y en modelos murinos gestantes. Sin embargo, la seguridad y eficacia de los BKIs en ovejas 
gestantes y su eficacia en modelos ovinos gestantes de toxoplasmosis y neosporosis no se conoce.  
Con estos antecedentes, el objetivo general de la presente Tesis Doctoral fue estandarizar modelos 
murinos y ovinos gestantes de infección por T. gondii y comparar la virulencia de aislados tipo II de 
T. gondii entre ratón y oveja, estandarizar un modelo ovino gestante para el estudio de la infección 
por N. caninum y evaluar la seguridad y eficacia frente a T. gondii y N. caninum de los BKIs en ovejas 
gestantes. 
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En el primer objetivo específico, el fenotipo in vitro, la virulencia en ratón y la infección 
congénita en ratón y oveja de un aislado tipo II de T. gondii recientemente obtenido (TgShSp1) fueron 
comparadas con el aislado de laboratorio tipo II de referencia (TgME49). Un mayor crecimiento y 
menor formación de quistes in vitro y una mayor mortalidad de las crías y transmisión vertical tras la 
infección de ratones gestantes con el aislado de laboratorio TgME49 en comparación con el aislado 
TgShSp1 asi como una DL50 de 103 taquizoitos en ratones para el aislado TgME49 sugieren un 
incremento en la virulencia del aislado TgME49 probablemente debido al alto número de pases en 
cultivo o ratón. Por lo tanto, parece razonable especular que los resultados de los estudios que utilizan 
aislados de laboratorio deberían ser validados con aislados de pase bajo antes de extrapolar las 
características generales de un determinado tipo. La presencia de signos clínicos leves, sin mortalidad 
en ratones no gestantes y gestantes inoculados por vía intraperitoneal con taquizoitos (1-105 
taquizoitos) o por vía oral con ooquistes (25-2000 ooquistes) del aislado de tipo II TgShSp1 sugiere 
una virulencia muy baja en ratones adultos para este aislado.  
En ovejas infectadas por vía oral con ooquistes, no se observaron diferencias entre estos dos 
aislados en la mortalidad perinatal o en las lesiones o número de corderos positivos a T. gondii. La 
infección congénita del aislado TgShSp1, evaluada mediante la mortalidad perinatal y la transmisión 
vertical fue diferente en función del hospedador. En ratones, se observó mortalidad en el 50% de las 
crías cuando una ratona fue desafiada con una dosis alta de ooquistes (500 ooquistes del aislado 
TgShSp1) mientras que en las ovejas inoculadas con la misma dosis de ooquistes, todos los fetos 
murieron (100%). Asimismo, se observó mortalidad en el 9% y 27% de las crias tras la infección en 
ratones con 100 y 25 ooquistes del aislado TgShSp1, respectivamente, mientras que en ovejas, la 
infección con 50 y 10 ooquistes del aislado TgShSp1 produjo mortalidad en el 68% y 66% de los 
fetos/corderos. Tan solo se observaron diferencias en la transmisión vertical en crias que sobreviven 
tras la infección de ratones y ovejas con una dosis baja de ooquistes (100% tras la infección de ovejas 
con 10 ooquistes del aislado TgShSp1 y 37% en ratones tras la infección con 25 ooquistes del aislado 
TgShSp1). En conclusión, la virulencia en ratón de los aislados tipo II de T. gondii quizás no sea un 
buen indicador para predecir las consecuencias de las infección en ovejas gestantes.  
 En el segundo objetivo específico, se investigó la clínica, la respuesta inmune, la detección y 
carga del parásito y la gravedad de las lesiones en tejidos placentarios y cerebro fetal tras el desafío 
por vía intravenosa de ovejas a mitad de gestación con 105, 104, 103 ó 102 taquizoitos o por vía 
subcutánea con 104 taquizoitos del aislado virulento Nc-Spain7. Todas las ovejas gestantes inoculadas 
con 105 taquizoitos abortaron, mostrando además un incremento más temprano de la temperatura 
rectal y de los niveles de IFNγ y una mayor respuesta inmune humoral y carga parasitaria en el cerebro 
fetal en comparación con aquellas ovejas desafiadas por vía intravenosa con dosis más bajas. Incluso 
la infección por vía intravenosa con la dosis más baja (102 taquizoitos) produjo mortalidad fetal en el 
50% de las ovejas y 100% de transmisión vertical, sin diferencias en la carga parasitaria comparando 
con la infección intravenosa con 105 taquizoitos. Por otro lado, las ovejas gestantes desafiadas por vía 
subcutánea con 104 taquizoitos mostraron menor incremento de las temperaturas rectales y niveles de 
IFNγ comparadas con las ovejas desafiadas por vía intravenosa con la misma dosis de taquizoitos. 
Sin embargo, no se observaron diferencias dependientes de la vía de administración en la respuesta 
inmune humoral, la mortalidad fetal ni en la trasmisión vertical. Estos resultados sugieren que una 
dosis superior a 105 taquizoitos por vía intravenosa es un desafío excesivamente agresivo para ovejas 
que podría ocasionar el descarte de fármacos o vacunas potencialmente eficaces. Esa dosis, 10 veces 
inferior a la que se había testado previamente, y esa vía de administración parecen ser suficientes para 
ocasionar 100% de aborto. En base a estos resultados se propone el uso de un modelo basado en la 
inoculación de una dosis máxima de 105 taquizoitos por vía intravenosa en futuros experimentos, para 
así obtener resultados más fiables y realistas.  
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En el tercer objetivo específico, las ovejas gestantes se dosificaron por vía oral con el BKI-
1294 (5 dosis de 100 mg/kg cada 48 horas) o por vía subcutánea con el BKI-1553 (2 pautas de 
dosificación: 1ª dosis de 35 mg/kg y una semana después una 2ª dosis de 10 mg/kg ó 7 dosis de 
10 mg/kg cada 48 horas). La eficacia de estos fármacos fue evaluada tras la administración a las 
48 horas después de la infección con ooquistes del aislado TgShSp1 por vía oral (BKI-1294) con 
taquizoitos del aislado Nc-Spain7 por vía intravenosa (BKI-1553). Además, se determinaron las 
concentraciones de fármaco en las ovejas y sus fetos (solo para el BKI-1553). Las ovejas gestantes 
dosificadas por vía subcutánea con el BKI-1553 o por vía oral con el BKI-1294 presentaron 
concentraciones terapéuticas de fármaco en plasma, con concentraciones máximas de 11 μM y 2 
μM y mínimas de 4 μM y 0.4 μM para el BKI-1553 y el BKI-1294 respectivamente. Asimismo, 
el BKI-1553 fue capaz de cruzar la barrera placentaria encontrándose concentraciones terapéuticas 
de 1 μM en el plasma fetal. Sin embargo, el BKI-1553 y de forma más acusada el BKI-1294 
mostraron un rápido aclaramiento plasmático. El BKI-1294 y el BKI-1553 parecen ser seguros ya 
que no se encontraron alteraciones en la temperatura rectal ni en los parámetros hematológicos y 
bioquímicos ni en la gestación ni daño local asociado con estos fármacos. Sin embargo sí que se 
encontraron diferencias en seguridad en función de la vía de administración. Mientras que la 
dosificación oral no incrementó la temperatura rectal ni modificó la consistencia fecal, la 
administración subcutánea desencadenó la aparición de nódulos dérmicos asociados a un 
incremento de temperatura rectal y monocitosis. 
 La administración del BKI-1294 a ovejas infectadas con T. gondii y del BKI-1553 a ovejas 
infectadas con N. caninum se asoció a un menor incremento de las temperaturas rectales, por lo 
tanto a una menor replicación del parásito. Los estudios in vitro han evidenciado la presencia de 
complejos intracelulares multinucleados asociados al tratamiento con el BKI-1294 y BKI-1553 de 
cultivos celulares infectados con T. gondii y N. caninum, con una sobreexpresión del antígeno de 
taquizoito SAG1 y el marcador de bradizoito BAG1. Estos complejos multinucleados, compuestos 
por pre-zoitos incapaces de separarse y formar taquizoitos podrían influir en la respuesta inmune 
celular y humoral frente a T. gondii y N. caninum ya que la administración de estos fármacos 
desencadenó un incremento en la producción de IFNγ y la presencia de anticuerpos anti-T. gondii 
SAG1. En modelos ovinos gestantes de infección por T. gondii y N. caninum en los cuales todas 
las ovejas sin tratar abortaron, el tratamiento con el BKI-1294  en ovejas infectadas con T. gondii 
evitó la mortalidad en el 76% de los fetos y  el tratamiento con el BKI-1553 en ovejas infectadas 
con N. caninum protegió del aborto al 37-50% de las ovejas. En relación a la transmisión vertical, 
mientras que el BKI-1553 no evitó la transmisión vertical de N. caninum, aunque disminuyo 
parcialmente los efectos de la infección reduciendo las lesiones y la presencia del parásito y la 
carga en cerebro fetal, el BKI-1294 fue capaz de prevenir la transmisión vertical de T. gondii en 
el 53% de los corderos. 
En definitiva, en esta Tesis Doctroal se ha profundizado en la comparación entre el ratón y la 
oveja de la virulencia de aislados tipo II de T. gondii, se ha estandarizado un modelo ovino gestante 
de infección por N. caninum y se ha evaluado la seguridad de los BKIs y su eficacia en frente a T. 
gondii y N. caninum en modelos ovinos gestantes. 
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Toxoplasma gondii and Neospora caninum are apicomplexan parasites very related 
phylogenetically and considered one of the main causes of infectious abortion in small ruminants and 
cattle respectively worldwide. However, recently, the importance of N. caninum as causative agent 
of abortion in sheep has greatly increased. T. gondii in small ruminants and N. caninum in cattle show 
high prevalence and produce important economic losses as a consequence of the reproductive failure. 
T. gondii in sheep mainly induces abortion triggered by primoinfection with oocysts during 
pregnancy, while N. caninum related abortions can be found after infection during pregnancy or 
recrudescence. For the control of toxoplasmosis in sheep there is a commercial attenuated live vaccine 
available (ToxovaxTM), which partially reduced T. gondii related abortions. No vaccine is available 
in the market for the control of neosporosis in cattle, since the only vaccine commercialised so far 
(Neoguard), based on killed tachyzoites, was withdrawn from the market on account of the low 
efficacy shown. Concerning treatment, different drug classes such as macrolide antibiotics, polyether 
ionophore antibiotics, folate inhibitors, quinolones and triazinones have been evaluated in ruminants 
showing moderate efficacy. Therefore, to date, no drug is available for the treatment of toxoplasmosis 
and neosporosis in ruminants and the improvement and development of control measures is of 
paramount importance.  
In vitro models represent an alternative to optimize the use of animals, but in vivo models represent 
the best option to carry out therapeutic or vaccine trials, as well as to study pathogenesis, immune 
responses and outcomes of infection. Mice model is often used to determine the virulence of T. gondii 
isolates and to study congenital toxoplasmosis. However, it is remains as an open question if 
differences on placentation, reproductive physiology and immune responses between mice and 
ruminants could trigger a differential outcome of infection during pregnancy. While several T. gondii 
type II isolates, the most prevalent lineage in all hosts in Europe including sheep, have been evaluated 
in pregnant sheep, none of this isolates have been studied deeply in mice.  
In neosporosis, the interest of pregnant sheep models has increased in the last years as a valid 
alternative to the costly bovine model and to the poorly comparable murine model. However, little is 
known concerning the outcome of infection with differerent infectious doses or routes of 
administration.    
In an attempt to progress in the control of toxoplasmosis and neosporosis, drug classes such as 
thiazolides, diamidines, artemisinins, naphthoquinones, anticancer agents, endochin-like quinolones 
and calcium-dependent protein kinase have been evaluated in vitro and in small animal models 
showing highly promising results. Calcium dependent protein kinase 1 (CDPK1) represents a 
promising drug target, as it is absent in mammalian hosts, but conserved among apicomplexan 
parasites and essential for several processes in the lytic cycle of the parasite. CDPK1 can be 
effectively targeted by a class of ATP-competitive compounds named bumped kinase inhibitors 
(BKIs), which were effective against T. gondii and N. caninum in vitro and in pregnant mice models. 
However, the safety of BKI compounds in pregnant sheep and their efficacy in pregnant sheep models 
of toxoplasmosis and neosporosis are unknown.  
With this background, the general objective of the present Doctoral Thesis was standardize 
pregnant mice and sheep models of T. gondii infection and compare the virulence of T. gondii type II 
isolates between mice and sheep, standardize a pregnant sheep model for the study of N. caninum 
infection, and evaluate the safety and efficacy against T. gondii and N. caninum infections of BKI 
compounds in pregnant sheep. 
In the first specific objective, the in vitro phenotype, the virulence in mice and the congenital 
infection in mice and in sheep of a newly obtained T. gondii type II isolate (TgShSp1) were compared 
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with that of the laboratory type II reference isolate (TgME49). A higher growth rate and formation of 
cysts in vitro and higher pup mortality and vertical transmission after infection of pregnant mice with 
the laboratory TgME49 isolate compared to the recently obtained TgShSp1 isolate as well as a LD50 
of 103 tachyzoites in mice for the TgME49 isolate suggest an enhanced virulence for the TgME49 
isolate probably due to successive passage in cell culture and mice. Therefore, it seems logical to 
speculate that results from studies using laboratory isolates should be validated with low passage 
isolates before they can be extrapolated as general features of the respective lineage. The presence of 
slight clinical signs, but no mortality, in non-pregnant and pregnant mice inoculated intraperitoneally 
with tachyzoites (1-105 tachyzoites) or orally with oocysts (25-2000 oocysts) of the type II isolate 
TgShSp1 suggest very low virulence in adult mice for this isolate.  
In sheep orally infected with oocysts, no differences between these two isolates were found with 
respect to perinatal mortality or lesions and number of T. gondii-positive lambs. The congenital 
infection of TgShSp1 isolate, measured as perinatal mortality and vertical transmission, was different 
depending on the challenged host. In mice, mortality in 50% of the pups was observed when a dam 
was challenged with a high oocyst dose (500 TgShSp1 oocysts), whereas in sheep infected with the 
same dose of oocysts, mortality occurred in all fetuses. Likewise, mortality of 9% and 27% of the 
pups was observed in mice after infection with 100 and 25 TgShSp1 oocysts, respectively, while in 
sheep, infection with 50 and 10 TgShSp1 oocysts triggered mortality in 68% and 66% of the 
fetuses/lambs. Differences in vertical transmission in the surviving offspring between mice and sheep 
were only found with the lower oocyst doses (100% after infection with 10 TgShSp1 oocysts in sheep 
and only 37% in mice after infection with 25 TgShSp1 oocysts). In conclusion, virulence of T. gondii 
type II isolates in mice may not be a good indicator to predict the outcome of experimental infection 
in pregnant sheep.  
In the second specific objective, the clinical outcome, immune responses, parasite detection and 
burden, and lesion severity in placental tissues and foetal brains were investigated in sheep at mid-
pregnancy inoculated intravenously with 105, 104, 103, or 102 tachyzoites or subcutaneously with 104 
tachyzoites of the virulent Nc-Spain7 isolate. Pregnant ewes inoculated intravenously with 105 
tachyzoites showed 100% abortion, with an earlier increase on rectal temperature and IFNγ levels and 
higher humoral immune responses and parasite load in the foetal brain in these pregnant ewes 
compared to those challenged intravenously with lower doses. Even intravenous infection with the 
lowest dose (102 tachyzoites) resulted in foetal mortality of 50% of infected ewes and 100% vertical 
transmission, with no differences on parasite load in the foetal brains compared to infection with 105 
tachyzoites. On the other hand, pregnant ewes challenged subcutaneously with 104 tachyzoites 
exhibited lower rectal temperature increase and IFNγ levels compared to pregnant ewes challenged 
intravenously with the same dose of tachyzoites. However, no differences between both routes of 
administration were found on humoral immune responses, fetal mortality and vertical transmission. 
These results suggest that a dose beyond 105 Nc-Spain7 tachyzoites intravenously implies excessively 
aggressive conditions for sheep, which might lead to a dismissal of potential active formulations. This 
dose, 10 times lower than previously assayed, and infection route seems to be sufficient to trigger 
abortion in all foetuses. Considering these results, we propose the usage of a model based on a 
maximum dose of 105 tachyzoites intravenously in further assays, so that more accurate and realistic 
conclusions could be obtained in such studies.  
In the third specific objective, pregnant ewes were orally dosed with BKI-1294 (5 doses of 100 
mg/kg every other day) or subcutaneously dosed with BKI-1553 (with two dosages: 1st dose of 35 
mg/kg and a week later and a 2nd dose at 10 mg/kg or 7 doses at 10 mg/kg every other day). The 
efficacy of these drugs administered 48 hours after infection was evaluated in pregnant ewes infected 
orally with TgShSp1 oocysts (BKI-1294) or intravenously with Nc-Spain7 tachyzoites (BKI-1553). 
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In addition, drug levels in ewes and foetuses (only BKI-1553) were determined. Subcutaneous 
administration of BKI-1553 and oral administration of BKI-1294 in pregnant sheep resulted in 
therapeutic plasma exposures, with maximum concentrations of 11 μM and 2 μM and trough 
concentrations of 4 μM and 0.4 μM for BKI-1553 and BKI-1294, respectively. In addition, BKI-1553 
was able to cross the placental barrier since therapeutic plasma concentrations of 1 μM were found in 
the foetuses. However, BKI-1553 and more markedly BKI-1294 exhibit a rapid clearance from the 
plasma. BKI-1294 and BKI- 1553 seems to be safe since no alterations on rectal temperatures, 
hematological and biochemical parameters, pregnancy or local damage were associated with these 
drugs. However, differences on safety between both routes of administration were found. While oral 
administration did not increase rectal temperature nor modified fecal consistency, subcutaneous 
administration induced the formation of dermal nodules with associated increase on rectal 
temperature and monocytosis. 
The administration of BKI-1294 to T. gondii infected ewes and BKI-1553 to N. caninum infected 
ewes resulted in a lower rectal temperature increase, therefore in a lower parasite replication. In vitro 
observations demonstrated the formation of intracellular multinucleated complexes induced by BKI-
1294 and BKI-1553 in T. gondii and N. caninum infected cultures, with increased expression of the 
tachyzoite antigen SAG1 and the bradyzoite marker BAG1. These multinucleated complexes, 
composed of multiple pre-zoites unable to separate and form tachyzoites, could influence the cellular 
and humoral immune responses against T. gondii and N. caninum since administration of these drugs 
triggered an increase on IFNγ production and the presence of anti-T. gondii SAG1 antibodies. 
Concerning protection against abortion, in pregnant sheep models of toxoplasmosis and neosporosis 
in which all untreated ewes aborted, treatment with BKI-1294 of T. gondii infected ewes protected in 
a 76% against perinatal mortality and treatment with BKI-1553 of N. caninum infected ewes confered 
a 37-50% of protection against abortion. As for vertical transmission, while BKI-1553 did not prevent 
vertical transmission of N. caninum, although partially alleviated the effects of infection, by reducing 
lesions, parasite presence and parasite loads in foetal brains, the BKI-1294 was able to prevent vertical 
transmission of T. gondii in 53% of the lambs. 
 To summarise, in this Doctoral Thesis a deepeing in the knowledge of the comparative 
virulence of T. gondii type II isolates between pregnant mice and pregnant sheep, the standardization 
of a pregnant model sheep of neosporosis and the evaluation of the safety and effectiveness of BKI 
compounds against T. gondii and N. caninum infection in pregnant sheep have been performed.   
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1. Etiological agents 
1.1. Taxonomy 
Toxoplasma gondii and Neospora caninum are obligate intracelular protozoan parasites 
belonging to subphylum Apicomplexa (Adl et al., 2012). This subphylum is characterized by typical 
placement of some of its organelles in the anterior part of the cell, forming what is called apical 
complex. In addition, it is included within Sarcocystidae family, which comprises other genus of cyst-
forming apicomplexan parasites with heteroxenous life cycle (Hammondia, Besnoitia, Sarcocystis 
and Frenkelia). Differences on protein, antigenic, structural, molecular and, particularly, biological 
features between Toxoplasma, Neospora and the other members of Sarcocystidae family are 
significant enough to be considered different genus (Ellis et al., 1994; Dubey et al., 2002). The 
taxonomic classification of T. gondii and N. caninum and their main characteristics are summarized 
in Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2. Parasite stages  
In the T. gondii and N. caninum life cycle, three different parasite stages have been described: 
tachyzoites, bradyzoites within tissue cysts and sporozoites within oocysts (Figure 2). Tachyzoites 
and bradyzoites are the infectious stages that can be found in several tissues from intermediate host, 
whereas oocysts are shed to the environment in the faeces of the definitive host (cat and other felids 
in the case of T. gondii and dog and other canids in the case of N. caninum).  
 
 
 
 
Figure 1 – Taxonomic classification of Toxoplasma gondii and Neospora caninum. 
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Tachyzoites are the invasive forms, with high replication rate, being responsible of acute phase 
of the infection, intraorganic dissemination and tissue damage in the intermediate host (Dubey et al., 
1998; Dubey et al., 2006). Tachyzoites shows an ovoid, lunar or ovate morphology depending on the 
replication stage they are and its size range from 3-7 μm length and 1-5 μm width (Dubey et al., 2002; 
Dubey, 2010). Ultrastructurally, the tachyzoite has, in addition to typical organelles of any eukaryotic 
cell, the typical organelles in apicomplexan parasites (Figure 2). The typical organelles in 
apicomplexan parasites are: the rhoptries and the micronemes distributed in the apical complex, and 
the dense granules and amylopectin granules homogenously distributed in the tachyzoite (Speer et 
al., 1999; Dubey, 2010). The rhoptries play an important role on the formation of the parasitophorous 
vacuole in the host cell. Micronemes are small vesicles which secrete proteins involved in recognition 
and adhesion to the host cell (Soldati et al., 2001; Hemphill et al., 2013). Dense granules contribute, 
through secretion products, in formation and maintenance of the parasitophorous vacuole in the host 
cell (Cesbron-Delauw, 1994; Hemphill et al., 1999).  
Bradyzoites are the slow-replicating form of T. gondii and N. caninum and it is associated to the 
chronic stage of the infection in the intermediate host. The bradyzoites are approximately 5-8.5 µm x 
1-3 µm in size and have the same organelles than the tachyzoites, although there are certain 
differences in the arrangement and number of secretory organelles (Speer and Dubey, 1989; Dubey 
et al., 2004; Dubey, 2010). This stage is localized within tissue cysts and formed in the 
intracytoplasmatic space, mainly in the central nervous system (CNS) and skeletal muscle (Dubey 
and Lindsay, 1996; Peters et al., 2001; Dubey, 2003; Dubey, 2010). Tissue cysts have round or oval 
shape with approximately 100 µm diameter and can hold 200 bradyzoites (Figure 2). The cyst wall is 
thicker and more irregular for N. caninum than for T. gondii (Speer et al., 1999).  
Finally, the sporozoites are localized within the sporulated oocysts, which are the resistant stage 
of T. gondii and N. caninum, and shed in faeces of the definitive host (Figure 2). The oocysts are shed 
Figure 2 – Graphical representation and microscopic images of T. gondii and N. caninum parasite stages. 
Graphical representation of tachyzoite ultrastructure (A). Graphical representation and microscopic image of 
sporulated oocyst (B). Graphical representation and microscopic image of a brain tissue cyst stained with 
hematoxylin-eosin (HE) (C). 
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unsporulated to the environment and must undergo a sporogony to be infective. Sporulation occurs 
within 1 to 5 days depending upon aeration and temperature. Sporulated oocysts from T. gondii and 
N. caninum, as well as Hammondia spp. are morphologically very similar, with spherical shape and 
approximately 12 μm length and 11 μm witdh in size. Each sporulated oocyst contain two ellipsoidal 
sporocysts. Each sporocyst contains four sporozoites and a residual body (Dubey et al., 1998; Dubey 
et al., 2002).   
2. Ovine toxoplasmosis 
T. gondii is the causative agent of toxoplasmosis, considered one of the main infectious cause of 
abortion in sheep (Dubey, 2009b). Likewise, T. gondii is a zoonotic parasite with importance in public 
health (Tenter et al., 2000). 
 
2.1. T. gondii: host range and life cycle 
T. gondii is a ubiquitous parasite that occurs in most areas of the world. It is capable of infecting 
an unusually wide range of hosts and many different host cells (Dubey, 2010). The life cycle of T. 
gondii is facultatively heteroxenous (Figure 3). Intermediate hosts are probably all warm-blooded 
animals including most livestock, and humans. Definitive hosts are members of the family Felidae, 
for example domestic cats (Dubey and Beattie, 1988). 
In intermediate hosts, T. gondii undergoes two phases of asexual development. In the first phase, 
tachyzoites multiply rapidly by repeated endodyogeny in many different types of host cells. 
Tachyzoites of the last generation initiate the second phase of development which results in the 
formation of tissue cysts. Within the tissue cyst, bradyzoites multiply slowly by endodyogeny (Dubey, 
1998). They are located predominantly in the CNS, the eye as well as skeletal and cardiac muscles. 
However, to a lesser extent they may also be found in visceral organs, such as lungs, liver, and kidneys 
(Dubey, 1993). Tissue cysts are the terminal life-cycle stage in the intermediate host and are 
immediately infectious. If ingested by a definitive host, the bradyzoites initiate another asexual phase 
of proliferation which consists of initial multiplication by endodyogeny followed by repeated 
endopolygeny in epithelial cells of the small intestine. The terminal stages of this asexual 
multiplication initiate the sexual phase of the life cycle. Gametogony and oocyst formation also take 
place in the epithelium of the small intestine. Unsporulated oocysts are released into the intestinal 
lumen and passed into the environment with the faeces. Sporogony occurs outside the host and leads 
to the development of infectious oocysts which contain two sporocysts, each containing four 
sporozoites (Evans, 1992). 
There are three infectious stages in the life cycle of T. gondii, i.e. tachyzoites, bradyzoites 
contained in tissue cysts, and sporozoites contained in sporulated oocysts. All three stages are 
infectious for both intermediate and definitive hosts which may acquire a T. gondii infection mainly 
via one of the following routes: (A) horizontally by oral ingestion of infectious oocysts from the 
environment, (B) horizontally by oral ingestion of tissue cysts contained in raw or undercooked meat 
or viscera of intermediate hosts, or (C) vertically by transplacental transmission of tachyzoites 
(Dubey, 1998) (Figure 3).  
Thus, T. gondii may be transmitted from definitive to intermediate hosts, from intermediate to 
definitive hosts, as well as between definitive and between intermediate hosts (Figure 3). The 
prevalence of T. gondii infections is not confined to the presence of a certain host species. Its life 
cycle may continue indefinitely by transmission of tissue cysts between intermediate hosts (even in 
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the absence of definitive hosts) and also by transmission of oocysts between definitive hosts (even in 
the absence of intermediate hosts). 
  
2.2. Parasite isolates and intraspecific variability  
Many T. gondii isolates have been obtained from different host species around the world, 
including humans, as well as from different organs and parasite stages (Dubey, 2010). T. gondii 
presents three different clonal lineages classified as I (such as RH and GT1 isolates), II (such as 
TgME49 and PRU isolates) and III (such as VEG isolate). While clonality is the predominant pattern 
in North American and European isolates, South American isolates are highly diverse and some of 
them divergent from the three major lineages, referred to as ‘exotic or atypical genotypes’ (Shwab et 
al., 2014).  
A variety of different methods exist to genotype T. gondii isolates, such as multilocus enzyme 
electrophoresis (Dardé et al., 1992), microsatellite markers (Ajzenberg et al., 2002) and restriction 
fragment length polymorphism (RFLP) analysis (Su et al., 2006), and they have distinct advantages 
and disadvantages. All of the above methods underestimate the true rate of polymorphism and hence 
may misclassify variants owing to homoplasy or insufficient resolving power. In contrast, direct 
sequencing of genomic regions reveals the complete genetic diversity including single nucleotide 
polymorphisms (SNPs) and small insertions and deletions. The obvious disadvantage of sequence-
based typing is its increased cost and need for access to sophisticated technology (Sibley et al., 2009).  
Laboratory mice are generally sensitive to T. gondii infection and are often used as the preferred 
animal model to determine the virulence of the parasite (Saraf et al., 2017). Type I are highly virulent 
in mice (LD100 of 1 tachyzoite) whereas types II and III exhibited median lethal doses (LD50) that 
Figure 3 – Life cycle and routes of transmission of T. gondii  
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range from 102 to 105 (Saeij et al., 2006). Type II T. gondii is the most prevalent in all hosts in Europe, 
including sheep (Dumètre et al., 2006; Halos et al., 2010b; Su et al., 2010). 
 
2.3. Transmission  
Transmission of T. gondii in sheep was historically linked to the contamination of feed and water 
with cat faeces (Plant et al., 1974; Faull et al., 1986; Innes et al., 2009) (Figure 3). There is a 
widespread environmental contamination with T. gondii oocysts (Dabritz et al., 2007), and field 
investigations have shown an association between cats on farms and the exposure of sheep to T. gondii 
(Skjerve et al., 1998). Likewise, environmental contamination with oocysts also explains serological 
surveys in which sheep show an increasing seroprevalence to T. gondii with age (Waldeland, 1977; 
Lunden et al., 1994).Therefore, after primoinfection with T. gondii during pregnancy, exogenous 
transplacental transmission is the most frequent mode of transmission (Trees and Williams, 2005).  
It is estimated that less than 4% of chronically infected sheep transmit T. gondii to offspring 
(Dubey and Beattie, 1988; Buxton et al., 2006; Buxton et al., 2007). Several studies indicate that 
endogenous transplacental transmission is rare and plays a minor role in transmission of T. gondii in 
sheep (Watson and Beverley, 1971; Munday, 1972; Rodger et al., 2006). By contrast, some studies 
have suggested that chronically infected sheep can transmit infection to offspring, but despite a large 
proportion of abortions and lambs being T. gondii positive by polymerase chain reaction (PCR) was 
found, there is a lack of serological and pathological data (Duncanson et al., 2001; Williams et al., 
2005). 
 
2.4. Pathogenesis, clinical signs and lesions  
Despite decades of research, there are remain gaps in knowledge about this disease, especially 
regarding the pathogenesis of abortion in sheep (Benavides et al., 2017). The stage of pregnancy 
when transplacental transmission of T. gondii takes place is important in determining the clinical 
outcome. If infection occurs early in gestation, when the foetal immune system is relatively immature, 
foetal death is likely to occur. Infection at mid-gestation can result in birth of a stillborn or weak lamb 
which may have an accompanying small mummified foetus, whereas infection in later gestation may 
result in birth of a live, clinically normal, but infected lamb (Watson and Beverley, 1971; Hartley and 
Moyle, 1974; Blewett et al., 1982).  
The reason for this variation in the pathogenesis of abortion is unclear, but several hypotheses 
have been proposed, all of them related to the immune response of the host. Both maternal and foetal 
immune responses are subject to change during pregnancy (Entrican, 2002), but the precise role of 
immunity is not known. While foetal immunocompetence evolves throughout gestation, it is not until 
mid-gestation onwards that more specific immune responses can be elicited (Castaño et al., 2016). 
Therefore, from mid-gestation there is more control of parasite replication in foetal tissues and hence 
greater foetal survival. At the same time the maternal immune response also influences the 
pathogenesis of any infection. As such, it is widely accepted that the placenta is under 
immunomodulation during pregnancy and that local and peripheral immune responses differ at this 
time; however, how immunity varies during gestation and the influence of the immune response on 
the outcome of T. gondii infection remain in large part to be elucidated (Benavides et al., 2017). 
The histopathological changes in the placenta and foetal viscera instigated after T. gondii infection 
are basically the same, and comprise of non-purulent inflammation and necrosis, regardless of the 
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period of gestation when infection occurred. However, the stage of gestation influences the severity 
of these lesions and the time post infection when they appear (Buxton et al., 1982; Buxton and 
Finlayson, 1986). In the foetal tissues, the brain is the most frequent location of lesions, which appear 
as scattered foci of necrosis following infection in early pregnancy, while in infections initiated in 
older fetuses foci of gliosis with central areas of necrosis and occasional mineralization predominate. 
Skeletal muscle, heart, lung and liver are the other target locations where lesions may be found. When 
evaluating lesion severity, those occurring due to infection in mid-gestation are more severe in terms 
of size and involvement of inflammatory cells. These findings appear to be related directly to the 
maturation of the foetal immune system, as from mid-gestation the immune system becomes able to 
respond to the infection and promote a specific inflammatory reaction (Castaño et al., 2016). In the 
placenta lesions are mainly of necrosis and the number and size of lesions increases as gestation 
advances. Infection in early gestation causes necrotic lesions affecting the caruncular septa and there 
is an increase in the number of inflammatory cells, mainly macrophages and lymphocytes, in the 
foetal villi adjacent to the lesions. Infection later in gestation is associated with greater damage to the 
placenta, which shows more frequent and more extensive necrotic foci involving both maternal and 
foetal tissues. There is also a greater inflammatory component, which is mainly mononuclear and 
more evident in the foetal villi, but also includes scant neutrophils in maternal tissue. These lesions 
are usually appreciable grossly as multiple white foci in the cotyledons (Buxton, 1998). Inflammation 
in the maternal compartment of the placenta is largely similar during the different stages of gestation, 
and is not the main pathological feature. In the foetal part of the placenta, the infiltration of 
inflammatory cells is greater in late gestation than in midgestation and very scant in early pregnancy, 
as is the case in the foetal viscera (Castaño et al., 2016; Benavides et al., 2017).  
Maternal and foetal immune responses to the infection are key players in its outcome, and the 
influence of stage of gestation is also crucial. The maturation of the foetal immune system from 
midgestation contributes to control of multiplication of the parasite in the foetal viscera and explains 
the increased number of inflammatory cells as the main component of the lesions at this stage of 
pregnancy. While this influence on the pathogenesis of toxoplasmosis is generally accepted, the role 
and modulation of the maternal immune response during gestation is a more controversial issue, not 
only in toxoplasmosis, but in other infections occurring during pregnancy. The T helper (Th)1/Th2 
paradigm of immunoregulation by CD4+ Th lymphocytes, which has been used to explain a shift 
towards Th2 immunity in the maternal immune response from mid-pregnancy, has been under 
reappraisal in recent years, as it fails to explain several immunological aspects of gestation, such as 
the role of innate immunity or the role of Th1- derived cytokines and/or cells in supporting gestation. 
The combination of these variations in the foetal and maternal immune response may explain why 
vertical transmission is less common in early pregnancy and why it takes longer for the parasite to 
reach the fetus, as the peripheral maternal immune response may control dissemination of the 
organism, but once it invades the fetus, with an immature immune response, it invariably causes its 
death. In contrast, in late gestation, the parasite disseminates more easily to the placenta, possibly 
facilitated by the modulation of the maternal immune response, and therefore, invades the fetus 
earlier. Probably, also due to local immunomodulation, the organism can multiply in the placenta 
more easily than in earlier stages of gestation, and so cause more severe lesions. However, once it 
invades the foetus, its dissemination is controlled by the more mature foetal immune response, which 
can mobilize an adequate contingent of inflammatory cells. The specific mechanisms, which are 
modulated in the maternal immune response, innate or adaptive, peripheral or local, as well as those 
responsible for the parasite control in the fetus, remain to be elucidated (Benavides et al., 2017).  
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Recent experimental studies have defined an unacknowledged clinical presentation of ovine 
toxoplasmosis, where abortions occur during the acute phase of infection, resulting in as high as 100% 
foetal loss in susceptible sheep (Trees et al., 1989; Owen et al., 1998a; Castaño et al., 2014; Castaño 
et al., 2016). The pathogenesis of this clinical form differs from that of classically described ovine 
toxoplasmosis. It can occur in any period of gestation and is characterized by the occurrence of 
abortion 7-12 days after infection (Castaño et al., 2016), while “classical” abortion due to the parasite 
is likely to occur from the 28th day (Buxton, 1998). This interesting clinical presentation has been 
noted only following experimental infection; however, it is thought likely to cause a significant 
proportion of abortions caused by T. gondii under natural conditions. The differences between these 
two presentations of abortion are also evident at the pathological level. While necrotic lesions with a 
variable degree of inflammatory infiltration are the hallmark histological finding in the placenta and 
foetal brain in “classical” T. gondii abortions, in abortions during the acute phase of the disease, 
placental infarcts associated with thrombosis in the maternal vessels and periventricular leukomalacia 
in foetal brain are found. Although the pathogenesis of this clinical form is still largely unknown, it 
seems reasonable to hypothesize that the vascular lesion in the placenta contributes to foetal hypoxia 
(Castaño et al., 2014). The fact that these abortions occur shortly after infection, suggesting that there 
is not enough time for T. gondii to invade and multiply in the placenta, would seem to be relevant. 
While it is probable that the parasite plays a direct role in the pathogenesis of this clinical form, it is 
also tempting to suggest that there are other factors, such as the maternal immune response, both local 
and peripheral, involved in its pathogenesis. The cause of the thrombosis, as related to T. gondii 
infection, needs to be investigated (Benavides et al., 2017).  
 
2.5. Immunity 
During pregnancy the ewe´s immune responses are modulated to accommodate the presence of 
the semiallogeneic fetus and as a result maternal immunity at the materno-fetal interface suppresses 
mechanisms that activate inflammatory cells (Entrican and Wheelhouse, 2006). Thus, there is 
minimal maternal expression of cytokines, such as interleukin 2 (IL-2), tumour necrosis factor alpha 
(TNFα) and gamma interferon (IFN-γ) (Entrican and Wheelhouse, 2006). However, while permitting 
a successful pregnancy these mechanisms also represent a vulnerability, making the placenta and 
foetus peculiarly susceptible to certain pathogens. Thus, when T. gondii circulate in the blood of a 
pregnant ewe they are able to become established in the placenta where they parasitise the maternal 
caruncular septa in the placentome before invading the adjacent trophoblast cells of the fetal villi, 
from where they can spread to the rest of the foetus (Buxton and Finlayson, 1986). 
Following initial infection of the ewe both the innate and adaptive immune responses work 
together to limit multiplication of the fast replicating tachyzoite stage (Innes and Vermeulen, 2006). 
T. gondii are able to stimulate innate immune mechanisms directly upon entry into the host. This 
direct stimulation of macrophages results in production of interleukin 12 (IL-12) which directly 
stimulates natural killer (NK) cells to produce IFN-γ (Gazzinelli et al., 1993). IFN-γ is known to be 
important in inhibiting the intracellular multiplication of T. gondii and in addition will create the 
appropriate cytokine microenvironment for the priming of the adaptive immune response towards a 
Th-1 type pro-inflammatory immune response (Innes and Vermeulen, 2006). Studies in sheep using 
the technique of chronic lymphatic cannulation allowed the study of the development of a primary 
immune response to T. gondii in real time (Innes and Wastling, 1995).  
Interestingly, the first immune response detected within 48 hours of T. gondii inoculation was 
IFN-γ (Innes et al., 1995). Four to five days after inoculation of T. gondii, T cells responding to the 
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infection were detected in the efferent lymph. Using phenotypic markers specific for ovine 
lymphocytes the experiment showed that initially the predominant lymphocyte population comprised 
CD4+ T cells (Innes et al., 1995). At day 9–10 postinoculation, the lymphocyte population peaked 
(Buxton et al., 1994). At peak lymphocyte output the predominant population switched to CD8+T 
cells and in vitro studies showed that these activated CD8+ T cells were able to inhibit multiplication 
of T. gondii infected autologous ovine target cells directly (Innes et al., 1995). Following the peak 
lymphocyte response, the parasite was no longer detected in the efferent lymph indicating that the 
immune system of the sheep had successfully controlled the infection (Innes and Wastling, 1995). 
Specific antibodies to T. gondii were detected from day 10-12 after inoculation indicating that cell 
mediated immune responses involving, CD4+, CD8+ T cells and IFN-γ are important in protective 
immunity and recovery from a primary infection and specific antibody may play more of a role in 
protection against a secondary infection (Innes and Vermeulen, 2006). These results, taken together 
with the work published by Watson and Beverley (1971), showing that ewes infected in one 
pregnancy are unlikely to have infected lambs in subsequent pregnancies. 
 
2.6. Prevalence and economic impact 
Antibodies to T. gondii have been found in sheep worldwide (Dubey, 2009b). However, the data 
are not comparable among different locations because of the use of different serological tests and 
different cut-off values used to determine seropositivity. The prevalence of antibodies in ewes was 
more than twice that in lambs, but results were dependent on the age of the sampled lambs (Lunden 
et al., 1994; Gorman et al., 1999; Figliuolo et al., 2004; Rozette et al., 2005; Dumètre et al., 2006; 
Ragozo et al., 2008). Seroprevalence was shown to increase with age, reaching 95% in 6-year-old 
ewes in some flocks (Dubey and Kirkbride, 1989), suggesting that most animals acquire infection 
post-natally. In general, most sheep acquired infection before 4 years of age, but one-third of old ewes 
were still seronegative in highly endemic flocks (Dubey and Kirkbride, 1989). Prevalence was also 
higher in ewes on farms where epizootics of abortions were reported (Dubey and Kirkbride, 1989). 
Seroprevalence in intensively managed sheep was lower than in semi-intensive management (Savio 
and Nieto, 1995; Romanelli et al., 2007; Samraa et al., 2007; Ragozo et al., 2008).  
In Spain, the individual seroprevalence rate of T. gondii infection in sheep ranged from 11% to 
57% (Mainar et al., 1996; Marca et al., 1996; Panadero et al., 2010; Garcia-Bocanegra et al., 2013; 
Díaz et al., 2014; Almería et al., 2018) and the flock seroprevalence rate is estimated on 84% (García-
Bocanegra et al., 2013). Regarding abortions, between 5.4% and 23% of ovine abortions in Spain 
were associated with T. gondii (Pereira-Bueno et al., 2004; Moreno et al., 2012). Actual losses in 
lambs due to toxoplasmosis are difficult to estimate because (1) the disease is usually sporadic, (2) 
only a small number of aborted lambs are submitted for diagnosis, (3) those submitted may be 
inadequately examined, (4) unsuitable material may be sent for diagnosis, (5) the serologic test may 
not be specific, and (6) toxoplasmosis does not produce clinical disease in the ewe, so this disease 
does not alarm the farmer as much as other bacterial and viral infections. In the EU, losses due 
toxoplasmosis was estimated around 1.5 millions of lambs per year, representing a significant loss to 
producers (Innes et al., 2009). 
 
2.7. Diagnosis 
Different serological techniques have been used for the detection of T. gondii infection in sheep 
(Dubey, 2009b). An excellent correlation between modified agglutination test (MAT) and indirect 
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immunofluorescent test (IFAT) has been found (Marca et al., 1996). In addition, various enzyme-
linked immunosorbent assay (ELISA) methods using crude, fractionated, or recombinant antigens 
have been used to detect T. gondii antibodies in ovine sera. Tenter et al. (1992) compared ELISA 
based on crude and recombinant antigens and found varying degrees of specificity in naturally and 
experimentally infected sheep. Caballero-Ortega et al. (2008) reported a good correlation between 
their in-house crude T. gondii antigen ELISA and Western blot (WB). They also reported on the value 
of an avidity ELISA to investigate the duration of infection in sheep. 
For the diagnosis of toxoplasmosis in ovine abortions, detection of T. gondii antibodies in foetal 
fluids or serum is useful (Arthur and Blewett, 1988). In addition, foetal tissues should be submitted 
for molecular detection of T. gondii deoxyribonucleic acid (DNA) by PCR (Hurtado et al., 2001). 
Although foetal serology and DNA detection are useful aids, histopathology is essential to establish 
a cause – effect association, because T. gondii can be passively transmitted transplacentally and 
fetuses can die due to other causes (Dubey, 2009b).  
 The diagnosis of ovine abortions during the acute phase of the disease (7-11 days after infection) 
is actually problematic since specific antibodies against T. gondii in the maternal sera have not been 
detected, and the parasite is not in placental and foetal tissues or the parasite burden is very low, 
which considerably hinders the diagnosis of the disease (Castaño et al., 2016). Therefore, the 
histological evaluation of the placental tissues looking for placental infarcts is essential (Castaño et 
al., 2014).  
 
3. Bovine neosporosis 
N. caninum is the causative agent of bovine neosporosis, considered one of the main infectious 
agent of abortion in cattle, causing important economic losses in cattle industry worldwide (Dubey et 
al., 2017).  
 
3.1. N. caninum: host range and life cycle   
N. caninum has a facultative heteroxenous life cycle with two different hosts, a definitive host 
and an intermediate host, in which sexual and asexual multiplication are found, respectively. To date, 
as definitive hosts are been described, the domestic dog (McAllister et al., 1998), the coyote (Gondim 
et al., 2004), the dingo (King et al., 2010) and the wolf (Dubey and Schares, 2011). On the other 
hand, as intermediate hosts are involved, mainly, cattle and sheep (Thilsted and Dubey, 1989), being 
the former the main intermediate host. Nevertheless, recent evidence suggests that N. caninum is also 
an important abortifacient in sheep (Moreno et al., 2012; Benavides et al., 2014; González-Warleta 
et al., 2014). However, although N. caninum infection has been detected by different diagnostic 
thecniques in a wide range of wild and domestic animals, isolation has been only possible in a few 
host species (cattle, European Bison, sheep, white-tail deer, horses and dogs) (Dubey et al., 2007; 
Dubey and Schares, 2011). Conversely, although N. caninum infection was experimentally 
reproduced in macaques, there is no evidence that N. caninum could infect humans (Dubey et al., 
2007; McCann et al., 2008).  
Oocyst shedding by dogs, the most important definitive host in the domestic cycle, has been 
described by several authors (McAllister et al., 1998; Dubey et al., 2007; Dubey and Schares, 2011). 
Once in the environment, oocysts must undergo sporulation to be infective. Similarly to other 
coccidia, oocysts have a very high environmental resistance (Uzeda et al., 2007; Alves Neto et al., 
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2011). The schizogony of N. caninum takes place in the intermediate host. Following ingestion of 
food or water contaminated with sporulated oocysts, sporozoites are released in the gut and 
transformed into tachyzoites. Later, they reach bloodstream, through mesenteric lymph nodes, taking 
place the intraorganic dissemination of the parasite. Tachyzoites can invade a wide range of tissues 
and organs, such as heart, lungs, liver, skeletal muscle, placenta, brain or skin (Dubey and Lindsay, 
1996; Maley et al., 2003; Dubey et al., 2006). Over time, the host build an immune response capable 
of eliminate the majority of the tachyzoites, although a few of them evade immune response through 
conversion to latent bradyzoite stage, mainly in the CNS and skeletal muscle, thus starting  the chronic 
phase of the infection (Peters et al., 2001; Buxton et al., 2002). In this way, N. caninum persists in 
the host for long periods of time without showing clinical signs (Peters et al., 2001; Buxton et al., 
2002). 
The ingestion of infected tissues containing bradyzoites is the only mode of transmission of 
infection between the intermediate host and the definitive host, thus closing the life cycle (Dubey and 
Schares, 2011). In addition, N. caninum can also be transplacentally transmitted in the intermediate 
host (Dubey, 2003). Finally, the presence of a sylvatic life cyle in addition to the already known 
domestic life cycle has been described (Gondim, 2006). N. caninum can circulate between both 
cycles, being possible the transmission of N. caninum from wild animals to the dogs and after that, to 
cattle, as well as from cattle to wild canids and from this to the wild ruminants (Gondim et al., 2004d).  
 
3.2. Parasite isolates and intraspecific variability 
Since the first N. caninum isolation in 1988 (Nc-1 isolate) (Dubey et al., 1988), the total number 
of isolates obtained has been relatively low (around 100). So far, N. caninum isolates have been 
obtained from domestic (cattle, sheep, dog, horses) and wild (deer, buffalo, bison and wolf) animals 
(Dubey and Schares, 2011; Dubey et al., 2014). In Spain, SALUVET research group has obtained a 
large number of isolates (10), mainly from congenitally infected but healthy calves (Regidor-Cerrillo 
et al., 2008; Rojo-Montejo et al., 2009). 
Several authors have demonstrated differences after in vitro assays on invasion and proliferation 
rate (Schock et al., 2001; Regidor-Cerrillo et al., 2011; Dellarupe et al., 2014b), as well as in 
dissemination and transmigration ability (Collantes-Fernández et al., 2012). Similarly, studies in 
experimental mice models revealed differences on virulence between isolates by evaluating parasite 
load, morbidity, vertical transmission and neonatal mortality (Lindsay et al., 1995; Atkinson et al., 
1999; Collantes-Fernández et al., 2006a; Rojo-Montejo et al., 2009; Regidor-Cerrillo et al., 2010; 
Dellarupe et al., 2014a). In addition, there is a large correlation between invasion and proliferation 
rate and the pathogenesis in mice (Regidor-Cerrillo et al., 2011; Dellarupe et al., 2014b) and even, 
between observations in mice and bovine models, at least with Nc-1, Nc-Spain1H and Nc-Spain7 
isolates. Altogether, these studies allow to classify some isolates according to their virulence. 
Thereby, it has been confirmed a high virulence in Nc-Liverpool and Nc-Spain7 isolates and a low 
virulence in Nc-Spain1H isolate (Rojo-Montejo et al., 2009; Regidor-Cerrillo et al., 2010; Regidor-
Cerrillo et al., 2011; Dellarupe et al., 2014a; Dellarupe et al., 2014a; Dellarupe et al., 2014b). 
The classification of N. caninum isolates based on the virulence, opens new research fields, since 
their comparisons allow to identify new potential virulence factors, whose understanding is essential 
for the development of pharmacological and immunoprophylatic tools capable of blocking essential 
processes for the parasite.  
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3.3. Transmission 
Two different modes of N. caninum transmission are described in cattle: horizontal and vertical. 
Horizontal transmission, also called postnantal, takes place through ingestion of food or water 
contaminated with oocysts shed by the definitive host. In turn, vertical or transplacental transmission 
occurs when in a pregnant female, tachyzoites cross the placental barrier and reach the foetus (Figure 
4). Transplacental transmission (congenital transmission) is the most efficient mode of transmission, 
since percentages of transmission of 40-95% have been described (Dubey et al., 2007), playing a key 
role in the propagation and maintenance of the disease in a flock. In addition, a congenitally infected 
cow can transmit the infection to the offspring, repeatedly, in different pregnancies (Boulton et al., 
1995; Wouda et al., 1998; Guy et al., 2001; Fioretti et al., 2003). 
 From the point of view of the origin of the transplacental infection, two different modes of 
transmission have been described, exogenous and endogenous (Trees and Williams, 2005). Both 
modes of transmission exhibit different pathological and epidemiological consequences, and 
therefore different control measures. Endogenous transplacental transmission takes place after 
recrudescence of a chronic infection during pregnancy in a persistently infected female. By contrast, 
exogenous transplacental transmission occurs in cows being infected by ingestion oocysts for the first 
time during pregnancy and being transmitted to the offspring. Chronically infected herds show an 
endemic pattern of abortions. By contrast, herds showing a first exposure to sporulated oocyst 
infection show an abortion outbreak (30-57%), due to an exogenous transplacental transmission 
(Trees and Williams, 2005; Dubey et al., 2007). Consequently, endogenous transplacental 
transmission is the most frequent mode of transmission in many herds, while controversy exists about 
the significance of exogenous transplacental transmission on the establishment of a chronic infection 
(McCann et al., 2007; Dijkstra et al., 2008).  
Notwithstanding the above, vertical transmission rates decline with age. This, together with the 
fact that transplacental transmission does not happen in 100% of the cases, means that without oocyst 
as source of infection (horizontal transmission), the disease tends to disappear over generations 
(Dubey et al., 2007; Eiras et al., 2011). Thus, exogenous and endogenous modes of transmission seem 
to complement each other to avoid this phenomenon. In fact, different epidemiological scenarios have 
been described in Spain, with exogenous and endogenous modes of transmission being present 
independently or in combination (Rojo-Montejo et al., 2009).  
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3.4. Pathogenesis, clinical signs and lesions   
N. caninum infection in non-pregnant cattle is usually asymptomatic, while in pregnant animals 
the most relevant clinical sign is the abortion (Dubey, 2005). N. caninum is a primary pathogen in 
terms of triggering the abortion, although mechanism by which the foetus dies and triggers the 
abortion is not completely understood. During parasitaemia, caused by primoinfection or most 
commonly by reactivation of a chronic infection during pregnancy, tachyzoites are disseminated, 
invading different tissues and being able to cross the placental barrier and reach the foetus (Dubey et 
al., 2006). Different mechanisms causing foetal death have been postulated. On the one hand, the 
direct action of N. caninum, through invasion and replication in placental and foetal tissues, would 
lead severe lesions, affecting foetal survival. In turn, placental lesions could lead abortion due to 
reduced oxygen and nutrients supply, either by tachyzoite replication or by maternal inflammatory 
immune response in response to N. caninum infection (Dubey et al., 2006). On the other hand, once 
N. caninum invade placental and foetal tissues, the different outcomes of infection (abortion, birth of 
calves showing neurological signs and most frequently, birth of clinically healthy but congenitally 
infected calves) will depend on different factors related to both the parasite and the host, being the 
most important the period of gestation in which the infection occurs, directly related to the maternal 
and foetal immunity. Abortion can occur from the third month of pregnancy, albeit it is more frequent 
between the 5th and the 7th months of pregnancy (Dubey et al., 2007; Almería and López-Gatius, 
2013). If infection occurs in the first term of gestation, the foetus is often reabsorbed, and clinically a 
repeat breeding is observed. However, no association was found between N. caninum infection and 
early reproductive failure (Almería and López-Gatius, 2013). On the other hand, if foetal death takes 
Figure 4 – Graphical representation of N. caninum routes of transmission 
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place between 3 and 8 months of pregnancy, foetus is usually expelled exhibiting a moderate 
autolysis. However, foetuses dying before 5th month of pregnancy could exhibit mummification and 
remain in utero for months. If infection occurs later in gestation, from 5th month of pregnancy, risk of 
foetal death decrease and the more frequent clinical sign is the delivery of healthy, but congenitally 
infected, calves, which generate precolostral antibodies (Quintanilla-Gozalo et al., 2000; Williams et 
al., 2000).  
In a limited number of cases, weak infected calves showing neurological signs, ranging from 
slight ataxia to complete paralysis could be delivered. In the most severe cases, dorsal spine 
malformations, hycrocephalus or pneumonia can appear (Dubey et al., 1992; Bryan et al., 1994; 
Gunning et al., 1994). These clinical signs are more likely to appear during the first week after 
delivery, although it could be delayed until two weeks after delivery (Dubey and Lahunta, 1993; 
Duivenvoorden and Lusis, 1995) and evolve until total paralysis and death of the animal during first 
month after birth (Dubey et al., 1992; Gunning et al., 1994; Dubey et al., 2006). 
Lesions associated to infection can be observed in different organs, depending on the stage and 
severity of infection, being, in general, inflammatory non suppurative lesions. In placental tissues, 
necrotic foci and inflammatory areas with mononuclear cells are often observed, although chronicity 
could lead to regeneration with connective tissue, hyperplasia, fibrosis and even, calcification of 
necrotic foci (Barr et al., 1994; Maley et al., 2003). Placental lesions are more severe and necrosis 
more extensive when foetal death takes place compared to those from ewes that give birth (Gibney et 
al., 2008).  
Regarding lesions from foetuses or congenitally infected calves and lambs, they are mainly found 
in the CNS. The lesions consist of multifocal lymphocyte infiltration, often surrounding blood vessels 
(perivascular cuffing), microgliosis and presence of astrocytes, likely with necrosis and 
mineralization (Barr et al., 1991; Dubey and Lindsay, 1996). This type of non-suppurative 
inflammation is also observed in heart, liver tissues and less frequently in kidney, skeletal muscle and 
lung tissues (Dubey et al., 2006). N. caninum associated lesions are more severe in aborted foetuses 
from an epidemic pattern of abortions compared to those from endemic abortions. In congenitally 
infected calves without clinical signs is also possible to find lesions, but less frequently, less severe 
and mainly in the CNS (Barr et al., 1991; Bryan et al., 1994; Sawada et al., 2000). Lesions can be 
associated in most cases to the presence of tachyzoites or cysts in the tissues, mainly in the CNS 
(Dubey and Lindsay, 1996), and less frequently in the heart, liver and skeletal muscle (Wouda, 1997; 
Morales et al., 2001; Peters et al., 2001). 
 
3.5. Immunity  
N. caninum infection in cattle triggers a combination of innate and adaptative immune responses 
trying to control parasite dissemination in the animals (Innes et al., 2001b; Almería et al., 2003; 
Staska et al., 2003; Andrianarivo et al., 2005; Rosbottom et al., 2008; Bartley et al., 2013). These 
mechanisms are activated early after infection, and components of the innate immunity such as 
dentritic cells, NK cells and macrophages are mobilized. These cell types act as the first line in 
defence, destroying infected cells and releasing cytokines such as IL-12 and IFN-γ (Boysen et al., 
2006; Klevar et al., 2007; Strohbusch et al., 2009b; Feng et al., 2010; Dion et al., 2011). Parasite 
recognition by antigen presenting cells and early cytokine production is essential for the control of 
tachyzoite proliferation early after infection. 
Intracellular location of N. caninum suggests that cell mediated immune response is the most 
important component related to protection (Hemphill, 1999; Innes et al., 2000). Thus, control of N. 
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caninum infection is associated with a Th1 immune response, in which different proinflammatory 
cytokines, mainly IFN-γ, and T cells are involved (Khan et al., 1997; Hemphill et al., 2006). 
Importance of IFN-γ has been demonstrated in vitro and in vivo, in which inhibition of N. caninum 
proliferation was found after IFN-γ addition in cell culture (Innes et al., 1995; Yamane et al., 2000), 
as well as a higher susceptibility to infection in a murine model after treatment with anti-IFN-γ 
antibodies (Khan et al., 1997; Baszler et al., 1999).  
Finally, the role of humoral immune response in the control of neosporosis is unclear and remains 
to be elucidated. It is possible that antibodies specifically generated against the parasite have several 
functions, such as opsonisation of extracellular parasites, with the consequent phagocytosis by 
macrophages, similarly as observed in toxoplasmosis (Sibley et al., 1985).  
In fact, knockout -B cell-deficient- mice, showed a higher susceptibility to N. caninum infection 
(Eperon et al., 1999). In any case, antibody levels fluctuate during gestation (Stenlund et al., 1999; 
Guy et al., 2001; Andrianarivo et al., 2005; Nogareda et al., 2007), which might be associated with 
the proliferation of the parasite (Weston et al., 2005; Innes, 2007).  
 
3.6. Prevalence and economic impact 
At present, there are relatively large number of seroprevalence studies of N. caninum in cattle, and 
variable prevalence rates have been described depending on geographic location and purpose of the 
breeding (beef cattle vs dairy cattle) (Dubey et al., 2007). However, data are difficult to compare since 
they were obtained using different techniques, and very variable experimental designs and sample 
sizes. Despite this, in Europe, Nordic countries and Germany have the lowest seroprevalence rates 
(0.7-12.8%), while in South America, Argentina and Brazil have the highest seroprevalence rates 
(80.9-97.2%) (Dubey and Schares, 2011).  
In Spain, the first studies showed very high herd prevalences, of 55% and 83% in beef cattle and 
dairy cattle, respectively. Individual prevalence rates showed values of 18% in beef cattle and until 
36% in dairy cattle (Mainar-Jaime et al., 1999; Quintanilla-Gozalo et al., 1999). These results were 
similar to those found in Galician cattle, where herd seroprevalence rate reached 88% in dairy cattle 
and 77% in beef cattle. Individual seroprevalence ranged from 16 to 22% in dairy cattle herds and 
was of 25% in beef cattle herds (Gonzalez-Warleta et al., 2008; Eiras et al., 2011). 
Regarding aborted bovine foetuses, it is estimated that between 12 and 40% of them are infected 
with N. caninum around the world (Dubey et al., 2007). In Spain, N. caninum infection was detected 
in 58% of analyzed foetuses using different diagnostic techniques (Gonzalez et al., 1999). In a later 
study, 39% of analyzed foetuses were positive, at least, by one of the diagnostic techniques used. 
These results revealed the importance of N. caninum as an abortifacient agent in our country, even 
ahead of bovine viral diarrhoea virus (Pereira-Bueno et al., 2003).  
Bovine neosporosis, thus, has been regarded one of the main infective causes of reproductive 
failure worldwide (Dubey and Schares, 2011; Reichel et al., 2014), causing important economic 
impact in dairy and meat industry. Economic losses are related to abortion, neonatal mortality, as well 
as other indirect effects such as prolonged calving intervals, decrease on the milk production, or 
devaluation of the animals because of early elimination of those presenting reproductive failure 
(Thurmond and Hietala, 1997b; Trees et al., 1999). It is noteworthy that economic losses seem to be 
more relevant in dairy cattle, due to higher abortion risk (Moore et al., 2009). In a review carried out 
by Reichel et al. (2013) about economic impact of bovine neosporosis, it was estimated in one billion 
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dollars per year, and since this study is restricted to several of the most important countries on cattle 
population (10 countries), it is thought that the economic impact could be substantially greater.  
 
3.7. Diagnosis 
Diagnosis of bovine neosporosis is not easy and should be addressed in a proper and systematic 
way. Clinical and epidemiological information may suggest N. caninum infection and its involvement 
in the abortion. However the definitive diagnostic always need to be confirmed by laboratory 
techniques. Selection of the most adequate tool in each case, as well as its correct interpretation, play 
an essential role (Ortega-Mora et al., 2006). In this way, individual diagnosis to determine the 
abortion cause in an animal or the presence of infection in replacement heifers can be performed. 
Also, diagnosis at herd level can be evaluated when attempting to determine infection in the herd, 
involvement of N. caninum in reproductive problems, as well as the main mode of transmission, in 
order to stablish appropriate control measures. Nowadays, there is a wide a range of diagnostic 
techniques, but not all provided the same information or have the same accuracy. However, since 
animals are chronically infected with N. caninum, the most useful diagnostic techniques in live 
animals are based on detection of specific N. caninum antibodies in serum. To date, different 
techniques for serological diagnosis have been established, such as IFAT, agglutination and 
immunoblot, being the ELISA the most commonly used (Alvarez-Garcia et al., 2013). ELISA test 
can be used in adult animals and newborn animals, when precolostral serum is utilized. Furthermore, 
avidity ELISAs capable of differentiate recent and chronic infections are available (Schares et al., 
2002; Aguado-Martínez et al., 2005; Bjorkman et al., 2006) and ELISAs based on NcGRA7 and 
NcSAG4 proteins (tachyzoite -acute phase- and bradyzoite -chronic phase- specific proteins, 
respectively), allow the differentiation between primoinfection, recrudescence and chronic infection 
(Aguado-Martínez et al., 2008). Likewise, ELISA in milk samples has been achieved, exhibiting 
comparable results with ELISA from sera, with the added advantages of lower costs and animal 
management (Bjorkman et al., 1997; Schares et al., 2004; Schares et al., 2005; Hall et al., 2006). 
The serological status in the herd and aborted cows allows to determine if abortions are 
associated to N. caninum infection and its extent. This first serological approach must be accompanied 
with techniques for parasite detection (PCR) and evaluation of compatible lesions in tissues from 
aborted foetuses (mainly brain) (Buxton, 1998; Dubey and Schares, 2006; Ortega-Mora et al., 2006). 
In addition, despite the limited value of serology as diagnostic tool in aborted foetuses, the detection 
of specific antibodies in fluids from foetuses above 5 months of gestation can complement the 
diagnosis, since in ruminants, antibodies are not able to cross the placental barrier and therefore, 
antibodies are produced by the foetus (Pereira-Bueno et al., 2003; Dubey and Schares, 2006; Ortega-
Mora et al., 2006). 
Once N. caninum infection and herd serological status are confirmed, and in order to implement 
the most appropriate control measures, is important to determine the pattern of abortions, as well as 
the main mode of transmission in the herd. In this sense, relation between maternal and foetal 
serology, odds ratio (OR) calculation, evaluation of avidity antibodies in aborted animals and the age 
distribution of seropositive animals, can guide about the main mode of transmission in the herd. The 
OR evaluates the risk of abortion in seropositive animals, while avidity tests determine the antiquity 
of infection in the herd. Thus, epidemic abortions associated to horizontal transmission are 
characterized by OR>2, low avidity antibodies, heterogeneous age distribution of abortions and lack 
of association between seropositivity of dam and its offspring. By contrast, endemic abortions typical 
after recrudescence in chronically infected herds, exhibit OR<2, high avidity antibodies, 
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homogeneous age distribution of abortions and association between serology in dam and its offspring 
(Dubey et al., 2007).  
 
4. Control of toxoplasmosis and neosporosis in ruminants 
 
For the control of toxoplasmosis and neosporosis different measures have been suggested, 
including management practices, chemotherapy and vaccination, however, the combination of 
different approaches is known to be the optimal strategy (Dubey et al., 2007; Dubey, 2009b). For ovine 
toxoplasmosis there is a live vaccine available, while no vaccine is currently in the market for bovine 
neosporosis. Likewise, there is lack of registered drugs for the treatment of toxoplasmosis and 
neosporosis in ruminants. In the case of high prevalence of the neosporosis, drugs and vaccination 
are considered the best strategies from an economic point of view to avoid reactivation (Reichel and 
Ellis, 2006). However, in toxoplasmosis, drugs and vaccination should be preferable applied if there 
is a likely environmental contamination with oocysts or after an abortion outbreak to avoid the clinical 
manifestation of the disease. 
 
4.1. Control of the transmission   
The implementation of farm biosecurity protocols, hygienic measures and management practices 
should be adopted in all farms, for reducing the level of environmental contamination with T. gondii 
oocysts via cat faeces or N. caninum oocysts via dog faeces (if present) and for avoiding novel 
infections through the introduction of infected animals to the herd. Among the biosafety practices that 
should be conducted to achieve this aim, the following are highlighted: limit cat and dog access to 
ruminant areas, especially to those housing pregnant ruminants, or to the areas for food storage and 
water supplies; promptly remove of placentas or foetal materials; appropriately dispose of dead 
livestock; and establish rodent control. Reproductive practices considering the artificial insemination 
of seropositive dams or the use of embryo transfer and test and cull strategies based on serological 
diagnosis are also recommended for the control of N. caninum infections (Dubey et al., 2007; Reichel 
et al., 2014; McAllister, 2016). Despite being properly designed and meticulously practised, globally, 
these control measures alone are not cost-viable or completely effective in eliminating toxoplasmosis 
and neosporosis from a herd, and it is necessary to complement them with an immune-
chemotherapeutical approach (Zhang et al., 2013; Hemphill et al., 2016; McAllister, 2016).  
 
4.2. Treatment 
4.2.1. Available drug treatments for ruminant toxoplasmosis and neosporosis 
In this section the efficacy of drugs against T. gondii and N. caninum in ruminants is presented. 
Efficacy of this drugs in vitro and in mice models can be found in Appendix 1.   
4.2.1.1. Macrolide antibiotics 
Spiramycin has been tested in pregnant ewes infected with T. gondii (RH strain) between the 85th 
and 100th days of pregnancy and treated orally (PO) with 100 mg/kg spiramycin from 3 weeks after 
infection until parturition. All ewes gave birth, with only one stillbirth in the untreated group. Analysis 
of the placental tissues did not show differences neither in the histopathological lesions, nor in the 
presence of T. gondii between the treated and untreated groups. However, the humoral immune 
response in pregnant ewes decreased in the treated group compared to that in the untreated group. 
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Additionally, a lower number of lambs were seropositive to T. gondii in the treated group than in the 
untreated one. It was concluded that spiramycin treatment in ewes during the mid-stage of gestation 
exhibited a reduction in the humoral immune response in dams and in T. gondii seropositive lambs 
(Dubreuil, 1972).  
4.2.1.2. Polyether ionophore antibiotics 
The efficacy of monensin against ovine toxoplasmosis was evaluated in experimentally infected 
pregnant sheep. Ninety-days pregnant ewes were experimentally infected PO with 2,000 and 12,000 
T. gondii (M1 strain) oocysts and were treated PO with monensin (15 or 30 mg) daily from day 80 of 
gestation until parturition (Buxton et al., 1988). Ewes receiving monensin showed a reduction in 
foetal mortality compared with the non-treated ewes (83.3% vs 44.8% alive lambs, respectively). In 
this study, monensin seems to act earlier in the infection, possibly by effects on the sporozoites 
released from infectious oocysts within the intestinal lumen. Ewes infected and treated with monensin 
showed a lesser febrile response. In addition, ewes receiving monensin showed lower anti-T. gondii 
IgG levels. However, when monensin administration ceased after lambing, circulating specific IgG 
antibodies against T. gondii increased over three months to reach values similar to those observed in 
infected and non-treated ewes. This observation suggests that monensin could also have a systemic 
effect, possibly acting on the tachyzoites present in the pregnant uterus. In addition, lambs born from 
ewes receiving monensin had higher live weights, and less of these animals showed evidence of 
infection and pathological changes in foetal or placental tissues than the lambs born from infected 
and non-treated ewes. 
The possible systemic effect of monensin after T. gondii infection could be of value, as the time 
of infection during natural outbreaks of toxoplasmosis can only rarely be clearly defined. To avoid 
intestinal infection, and hence any intestinal effect of monensin PO at day 90 of pregnancy, the 
pregnant ewes were challenged subcutaneously (SC) with 100 T. gondii (M1 strain) tissue cysts 
(Buxton et al., 1987). No differences in febrile and serological responses were found between the 
treated and non-treated groups. However, the treated ewes produced more viable lambs (less 
premature and greater live weight) than the untreated ewes (75% vs 42%, respectively). In addition, 
58% of the lambs from treated ewes survived 72 hours after birth, whereas only 33% survived from 
the untreated ewes. Based on this evidence, it would appear that monensin, while being most effective 
in the gut lumen, does have a lesser systemic action, presumably by suppressing the multiplication of 
T. gondii in the placentome. 
The accidental poisoning of domestic animals with monensin PO has been reported in cattle, 
horses, poultry and dogs (Beck and Harries, 1979; Wilson, 1980). The clinical findings in sheep 
include lethargy, stiffness, muscular weakness, a stilted gait and recumbency, followed by a decrease 
in the muscle volume of the rump and thigh. The post-mortem lesions in the skeletal muscles consisted 
of pale streaking, with atrophy in the chronic stages. In lambs younger than one month old, diffuse 
gastrointestinal haemorrhage was the only finding (Nation et al., 1982). Later, another researcher 
reported an outbreak of monensin poisoning in sheep and highlighted the need for a licensed, safe 
product (Synge, 1989). An option to avoid monensin poisoning in sheep would be to use blocks 
containing monensin or slow-release boluses. In addition, this option would overcome the practical 
problems of monensin delivery to grazing sheep (Trees, 1989; Ellis and Costigan, 1990). 
Lasalocid has also been tested for its efficacy against ovine toxoplasmosis (Kirkbride et al., 1992). 
Ewes were treated PO with lasalocid (30 g/day) daily
 
from day 55 of pregnancy until lambing and 
were PO inoculated with 100 T. gondii (TS-1 strain) oocysts 5 days after beginning lasalocid 
administration. Similar specific antibody titres and histopathological lesions were found in the ewes 
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and foetuses, and there were no differences in the rate of abortion and neonatal mortality in both the 
treated and untreated ewes. These results suggest that lasalocid was not effective in preventing T. 
gondii abortion in sheep.  
Concerning N. caninum infection in cattle, a risk factor analysis in dairy farms showed that cows 
receiving monensin as a feed additive were 1.5 times less likely to be infected with this parasite than 
the cows that did not receive monensin (Vanleeuwen et al., 2010). Thus, the effect of monensin was 
tested against experimental neosporosis in cattle (Vanleeuwen et al., 2011). Non-pregnant cows were 
treated with a slow-release bolus PO that delivered 100 days of monensin (335 mg/day) and were 
challenged with 5x106 N. caninum (Nc-1 strain) tachyzoites by the SC route three weeks after bolus 
administration. The cows treated with monensin showed a significantly lower humoral immune 
response than those treated with a placebo at week 4 post-challenge. Before recommendations on 
monensin use for neosporosis could be made, further research on other larger populations of cattle, 
preferably pregnant, must be explored. Furthermore, trials on monensin’s effectiveness in more 
natural modes of N. caninum transmission (e.g., bradyzoite recrudescence leading to transplacental 
transmission, or oocyst ingestion) would also be needed. 
In summary, PO administered monensin was shown to be partially effective in the control of 
ovine toxoplasmosis, but it is not licensed for use in the EU and may be toxic at high dosages. In 
contrast, PO dosed lasalocid did not exhibit efficacy in reducing the ovine toxoplasmosis outcome. 
In N. caninum-infected non-pregnant cows, monensin was associated with a lower specific humoural 
immune response, but further research on the outcome of infection in pregnant animals is needed. 
4.2.1.3. Folate inhibitors 
 Experimentally induced toxoplasmosis in pregnant ewes with 2,000 oocysts (M3 strain) at 89 
days of pregnancy was treated with a combination of sulphamezathine and pyrimethamine sulphate 
for three consecutive days on days 100, 115 and 130 of gestation. Sulphamezathine (1 g per 3 ml of 
solution) was injected SC at an initial dose of 5 ml/10 kg on the first day, with subsequent doses on 
the following two days of 2.5 ml/10 kg. Pyrimethamine sulphate (10 mg/ml) was injected IP at 2 
mg/kg on the first treatment day and at 1 mg/kg on the two subsequent days. After 130 days of 
gestation, 30% of foetuses from untreated ewes died, whereas all the lambs from the treated ewes 
were born and were viable. In addition, the gestational period of infected and untreated ewes was 
shorter than that observed in the infected and treated ewes. At birth, all the lambs showed a specific 
antibody response to the protozoa, indicating that the infection was in utero. However, the mean IFAT 
titres of lambs born from the infected and treated ewes were lower than those of the lambs born from 
the infected and untreated ewes (1/256 vs 1/730 for IgG and 1/665 vs 1/5206 for IgM). 
Histopathological examination showed less severe placental lesions in the lambs born from the treated 
ewes (Buxton et al., 1993a).  
In field conditions, the therapeutic efficacy of sulphonamides in an ovine toxoplasmosis outbreak 
has been evaluated. Before treatment, 60% of the ewes in the flock had aborted, and treatment with 
sulphadimine at 20 mg/kg intramuscularly (IM), 4 times every 48 hours, reduced the abortion rate to 
25%; the rest of the ewes gave birth normally, but 61.1% of their lambs were stillbirths and did not 
survive. A higher dosage at 33 mg/kg IM, 4 times every 48 hours, reduced the abortion rate to 7%, 
and 75% of the lambs survived (Giadinis et al., 2011). Folate inhibitors have also been evaluated in 
field conditions for the treatment of neosporosis in cattle. A combination of toltrazuril given 
intravenously (IV) at 20 mg/kg/day for 3 consecutive days to newborn calves during the first week of 
age and sulphadiazine/trimethoprim given IV at 20 mg/kg to cattle once a year from 3 months of age 
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along with dog treatment with toltrazuril and periodic disinfection of environment resulted in a 
significant reduction of abortion (from 188 to 9) (Cuteri et al., 2005). 
In brief, parenteral administration of sulphonamides, in combination with pyrimethamine, could 
be a valuable option for chemotherapy of ovine toxoplasmosis in the third term of gestation, as a 
reduction in abortion rates, but not in the percentage of transplacental transmission, is observed. There 
is some evidence in field experiments that folate inhibitor administration can reduce abortions in 
ruminants, although more research is needed. 
4.2.1.4. Quinolones 
In a study, sheep were challenged PO with 200 T. gondii (M3 strain) oocysts at 90 days of 
gestation, and decoquinate was administered PO at 1 or 2 mg⁄kg⁄day from 10 days prior to oocyst 
challenge until lambing (Buxton et al., 1996). The administration of decoquinate at the higher rate of 
2 mg⁄kg⁄day was associated with a delayed onset of the febrile response to infection, reduction in the 
overall severity of fever and a delay in the production of specific antibodies to the parasite. This 
treatment also reduced the placental damage caused by the protozoa, lengthened the mean gestation 
period by five days and increased the proportion of viable lambs (up 61.8%) and the mean weight of 
the lambs (up 33.3%) in comparison with ewes that were not treated with decoquinate but were 
challenged with T. gondii oocysts. 
In addition, it is necessary to note that the decoquinate-medicated feed distributed to pregnant 
heifers that are chronically infected or primo-infected with N. caninum at the dose of 2 mg/kg from 
1.5 months of gestation until the end of the 8th month of pregnancy tends to reduce the associated 
abortions (from 38% to 21% in chronically infected heifers and from 17% to 6% in primo-infected 
heifers) and neonatal infections, as more seronegative calves were born (28% in the treated group vs 
21% in the untreated group for chronically infected heifers and 59% in the treated group vs 35% in 
the untreated group for primo-infected heifers) (Journel et al., 2002) 
To summarize, PO administration of decoquinate reduces the effect of experimentally induced 
toxoplasmosis in pregnant ewes. These results support the indication of decoquinate as an aid in the 
prevention of abortion due to ovine toxoplasmosis if used during mid and late pregnancy. Decoquinate 
may have an application in the treatment of bovine neosporosis. 
4.2.1.5. Triazinones 
It has been emphasized that the production of T. gondii free lamb, sheep or goat meat for human 
consumption is critically important for public health (Kijlstra and Jongert, 2009). The in vivo 
therapeutic efficacy of toltrazuril on T. gondii tissue cysts in experimentally infected lambs has been 
studied after a chronic infection in newborn lambs through a parenteral inoculation of 105 T. gondii 
(ME-49 strain) oocysts (Kul et al., 2013). Beginning at the 15th day after inoculation, the lambs were 
treated with toltrazuril PO 2 times, once every week at a dose of 20 mg/kg and 40 mg/kg. Following 
toltrazuril treatment, at day 90 after inoculation, the specific immune humoral response in lambs of 
both treatment groups was lower. On day 90 after inoculation, the lambs were necropsied. The 
histopathological findings in the toltrazuril-treated lambs include morphologic and structural changes 
of the tissue cysts in the musculature, which were characterized by initial degenerative changes in the 
cyst wall and a minimal inflammatory cell response. The presence of T. gondii DNA in heart, brain 
and semitendinosus muscle from the treated groups was lower than that in tissues of the non-treated 
lambs. Moreover, in the treated groups, 4 out of 9 (44.4%) lambs did not contain any tissue cysts in 
the examined tissues, but untreated animals showed T. gondii tissue cysts at least in one of the sampled 
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muscles. The administration of toltrazuril seems to be associated with a reduction of T. gondii cysts 
in the musculature. 
It is doubtful that encysted N. caninum bradyzoites were susceptible to toltrazuril treatment. 
Congenitally infected calves born from Neospora-seropositive cows were PO treated with toltrazuril 
at 20 mg/kg three times at 48-hour intervals within 7 days after birth, following a humoral immune 
response (Haerdi et al., 2006). Four to six months after birth, a stronger antibody reactivity was found 
in the treated animals than in the untreated calves. Conversely, in a study to evaluate whether the 
treatment of congenitally infected lambs with toltrazuril PO at 20 mg/kg on days 0, 7, 14 and 21 after 
birth eliminated N. caninum, toltrazuril did not show any effect on the reduction of N. caninum 
presence or on the severity of histopathological lesions, and the lambs were all seropositive, although 
they had significantly lower specific antibody levels than those in the untreated animals, suggesting 
higher antigenic stimulation in the non-treated lambs than in the treated lambs (Syed-Hussain et al., 
2015a). 
The efficacy of ponazuril has been tested in calves that were experimentally infected with N. 
caninum at 2x108 tachyzoites (Nc-1 strain) (Kritzner et al., 2002). Medication was performed PO 
with 20 mg/kg of ponazuril. The first medication dose was applied 24 hours after infection, and if 
repeated, it was administered every subsequent 24 hours for six days. Ponazuril allows a complete 
abrogation of parasite DNA detection by PCR in the brain and other organs. Regarding the non-
medicated calves, it is noteworthy that there was a relatively lower susceptibility of calves to 
experimental infection, since only 50% of the calves became PCR-positive in the brain and muscles. 
The efficacy of a six-day treatment was also suggested by the significantly lower anti-N. caninum 
antibody response and later seroconversion than those in the infected and non-medicated calves. 
In addition, as explained above, toltrazuril administration to newborn calves, along with 
sulphadiazine/trimethoprim administration, resulted in reduced abortions and N. caninum 
seroprevalence in naturally infected cattle herds (Cuteri et al., 2005). 
In summary, toltrazuril PO administered in lambs would be a valuable strategy to minimize human 
exposure to T. gondii tissue cysts from the consumption of raw or undercooked mutton. Triazinon 
derivatives are directed against an N. caninum tachyzoite challenge, whereas treatment of 
congenitally infected young ruminants remains an elusive goal. In addition, it would likely result in 
considerable unacceptable milk or meat residues or withdrawal periods (Dubey et al., 2007). 
4.2.2. Present approaches in drug development for ruminant toxoplasmosis and 
neosporosis  
Experimental studies have revealed that several compounds have potentially interesting effects on 
T. gondii and N. caninum in vitro, but only a few drugs have been tested in laboratory animal models 
in vivo. The most interesting drugs tested for toxoplasmosis and neosporosis were derived from 
screenings in other intracellular protozoan parasites, including Plasmodium, Trypanosoma and 
Leishmania species, and some drugs exhibited broad-spectrum anti-parasitic activity against various 
protozoan and helminth parasites. However, it is notable that T. gondii was the least responsive to 
these sets of drugs, suggesting that it may be more difficult to target chemotherapeutically than the 
aforementioned parasites (Guiguemde et al., 2010). In addition, other approaches identified 
compounds that inhibited targets that were conserved almost exclusively within the group of 
apicomplexan parasites; thus, drug repurposing is a valuable option (Brown and Superti-Furga, 2003; 
Hemphill et al., 2016). The main prospective drug classes with in vitro and in vivo activity in small 
animal models against T. gondii and N. caninum are reviewed below, although more 
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chemotherapeutic options for toxoplasmosis and neosporosis have been described (Neville et al., 
2015; Hemphill et al., 2016).  
4.2.2.1. Thiazolides 
Nitazoxanide (2-acetolyloxy-N-(5-nitro 2-thiazolyl) benzamide), the mother compound of this 
class, is essentially composed of a nitrothiazole-ring and a salicylic acid moiety, which are linked 
together through an amide bond (Hemphill et al., 2006; Hemphill et al., 2007). Since nitazoxanide 
non-selectivity can lead to undesired side effects in both human and animals, nitazoxanide derivatives 
were designed without the undesirable nitro group (Esposito et al., 2007b). The nitazoxanide 
derivative RM4847 produces the upregulation of NQO1 (quinone reductase) expression by N. 
caninum but not by T. gondii. This fact may reflect differences between these parasites in terms of 
the mechanisms of circumventing host cell apoptosis (Müller and Hemphill, 2011). Thiazolides have 
favourable effects against N. caninum in vitro, with an IC50 of 4.23 µM and 13.68 µM for nitazoxanide 
and RM4847, respectively. Host cell invasion of extracellular N. caninum tachyzoites is inhibited by 
RM4847, but not by nitazoxanide (Esposito et al., 2007a), and RM4847 was shown to be much more 
effective against T. gondii tachyzoites, with an IC50 of 0.2 µM (Müller et al., 2009). For the treatment 
of N. caninum in mice, nitazoxanide fails when it is applied PO, or it is even toxic when applied IP 
(Debache et al., 2011). In calves, the use of nitazoxanide to treat Cryptosporidium infection showed 
acute diarrhoea in non-infected animals, which indicates that this compound severely affects the 
intestinal flora (Schnyder et al., 2009). In conclusion, thiazolides might be interesting tools to study 
the biology of N. caninum and possibly T. gondii, but they are useless as drugs since they exert acute 
toxicity in small and large animals.   
4.2.2.2. Diamidines 
Diamidines represent a class of broad-spectrum antimicrobial compounds in which pentamidine 
and its analogues exhibit activity against intracellular and extracellular protozoan parasites (Wilson 
et al., 2008; Buckner and Navabi, 2010). Pentamidine displays in vitro activity against T. gondii by 
inhibiting the replication of the parasites in cell cultures (Lindsay et al., 1991).  
Pentamidine derivatives, and the more recently synthesised di-cationic arylimidamides, which 
have more favourable pharmacokinetic profiles, improved bioavailability, lowered host toxicity and 
had a higher chance of passing the blood-brain barrier to exert its activity by binding to AT-rich sites 
in the DNA minor groove, thus inhibiting transcription or the interaction with DNA-binding enzymes, 
such as topoisomerases or nucleases (Wilson et al., 2008). This result indicates that these compounds 
could influence gene expression, and thus many diverse cellular functions could be affected. Di-
cationic arylimidamides, such as DB786, DB750 and DB745, showed in vitro activity against T. 
gondii tachyzoites, with an IC50 of 0.22 µM, 0.16 µM and 0.03 µM, respectively (Leepin et al., 2008; 
Kropf et al., 2012). In contrast to DB750, DB745 also had a profound negative impact on extracellular 
T. gondii tachyzoites. In addition, a lower adaptation of T. gondii tachyzoites to DB745 was observed 
(Kropf et al., 2012). The lowest IC50s against N. caninum tachyzoites were found for DB786, DB750 
and DB745 (0.21 µM, 0.23 µM, 0.08 µM, respectively), which caused damage to the parasite’s 
ultrastructure. The activities of DB750 and DB786 are limited to intracellular N. caninum tachyzoites; 
however, DB745 had an impact on both host cell invasion and intracellular proliferation (Leepin et 
al., 2008; Schorer et al., 2012). Di-cationic arylimidamides have also been found to be effective 
against neosporosis in mice. DB750 that was administered IP prior to infection or 14 days after 
infection reduced the severity of clinical signs and the cerebral parasite load, while PO application 
resulted in weight loss, indicating toxicity (Debache et al., 2011; Schorer et al., 2012). In addition, 
DB745 IP treatment initiated 14 days after infection had similar positive effects on the percentage of 
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surviving mice and the parasite load in the brain (Schorer et al., 2012). Arylimidamide treatments in 
mice beginning 14 days post-infection, after the N. caninum tachyzoites had crossed the blood-brain 
border and invaded the central nervous system (CNS) (Collantes-Fernández et al., 2006a), indicated 
that DB745, just like DB750, most likely crossed the blood–brain barrier and also exerted its action 
within the cerebral tissues (Debache et al., 2011; Schorer et al., 2012). Potentially, features of DB745 
could open the door for testing this compound against neosporosis in ruminants.   
4.2.2.3. Artemisinins 
Chinese herbal extracts are thought to possess the desired properties of potency and low toxicity, 
and they show promise for the identification of new therapeutic agents. Artemisinin, a sesquiterpene 
lactone with an unusual endoperoxide bond in a unique 1,2,4-trioxane heterocycle 
[3R,5aS,6R,8aS,9R,12S,12aR)-octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-
benzodioxepin-10(3H)-one] is present in the leaves and flowers of the sweet wormwood (Artemisia 
annua) (Bilia et al., 2006), and its derivatives are highly potent antimalarial drugs. This safe drug 
class is also effective against apicomplexan parasites causing abortions in ruminants such as T. gondii 
and N. caninum. The mechanism of action of artemisinin and its derivatives is dependent upon the 
presence of the endoperoxide bridge (Haynes and Krishna, 2004), although the difference in potencies 
between P. falciparum and T. gondii suggests that different targets may be affected in these two 
organisms (Dunay et al., 2009). Additionally, it is known that artemisinin perturbs calcium 
homeostasis in T. gondii, supporting the idea that Ca2-ATPases (SERCA) are potential drug targets 
in parasites (Nagamune et al., 2007). Artemisinin, when administered in vitro at 0.4 µg/ml for 5 days 
or 1.3 µg/ml for 14 days, completely eliminated T. gondii (Ke et al., 1990). Artesunate showed an 
IC50 of 0.075 μM (Gomes et al., 2012). Artesunate and its active metabolite, dihydroartemisinin, 
resulted in approximately 40% and 70% growth inhibition in vitro, respectively, and the combination 
resulted in approximately 65% inhibition. As they are able to cross the blood-brain barrier, in vivo 
experiments with low virulence T. gondii (DUR strain) challenge causing a chronic infection in mice, 
different from previous artemisinin derivatives studies with RH strain, showed a 40% reduction in 
the number of T. gondii tissue cysts found in the brain of mice treated 5 days with artesunate-
dihydroartemisinin and also modifications in the microscopic aspect of the cysts (Sarciron et al., 
2000). Artemisone, a second-generation semi-synthetic artemisinin derivative, and artemiside, the 
thiomorpholine precursor of artemisone, with an improved half-live, oral bioavailability, metabolic 
stability in various animal systems (Haynes et al., 2006), tolerance in vivo (Nagelschmitz et al., 2008) 
and a lack of detectable neurotoxic potential (Nontprasert et al., 1998; Schmuck et al., 2009), are the 
most potent artemisinin analogues to date in terms of inhibiting the growth of T. gondii in vitro, with 
an IC50 of 0.12 µM and 0.10 µM for artemisone and artemiside, respectively. Both of these 
compounds (artemiside and artemisone) were effective in reducing mortality during an acute 
challenge (60% of artemiside-treated mice and more than 50% of artemisone-treated mice survived) 
and during the reactivation of chronic infection in a mouse model (80% of artemiside-treated mice 
and 60% of artemisone-treated mice). Furthermore, there was an accompanying reduction in the 
chronic burden of tissue cysts in the CNS (Dunay et al., 2009). 
Against N. caninum, artemisinin reduces the intracellular multiplication of tachyzoites at ≥0.1 
µg/ml for 30 hours or 1 µg/ml for 14 days (Kim et al., 2002), and artemether exhibited activity against 
tachyzoite replication with an IC50 of 1.0 µg/ml (Qian et al., 2015). Additionally, artemisone, when 
added prior to infection or in established infection, reduced the number of N. caninum-infected cells 
(Mazuz et al., 2012) with an IC50 of 3 nM, exerting their activity against intracellular parasites, 
causing ultrastructural alterations and switched aberrant gene expression, including bradyzoite 
markers (Muller et al., 2015b). In a gerbil model for acute neosporosis, artemisone increased survival, 
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as 1 out of 8 mice died in the artemisone-treated group, while 8 out 9 mice succumbed in the control 
group (Mazuz et al., 2012). However, in a mouse model of neosporosis, artemiside and artemisone 
had no effect on parasite loads in the brain or in the lungs (Müller et al., 2016). In short, artemiside 
seems to be useful against T. gondii in vitro and in mice models whereas artemisone is less likely to 
be promising for neosporosis in ruminants.  
4.2.2.4. Naphthoquinones  
Naphthoquinone is a class of organic compounds derived from naphthalene. Buparvaquone (2-
((4-tert-butylcyclohexyl)methyl)-3-hydroxy-1,4-naphthoquinone) and atovaquone (trans-2[4-(4-
chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthalenedione) are hydroxynaphthoquinones related to 
parvaquone and were originally developed as anti-malarial compounds (Hudson et al., 1985; Hudson 
et al., 1991). 
Buparvaquone is currently commercially available for use in endemic regions against theileriosis 
in cattle (Wilkie et al., 1998); however, in other regions of the world, e.g., the EU, it is not registered. 
A focus on the parasite mitochondrion as an anti-parasitic target has been a priority in the drug 
development field for decades (Mather and Vaidya, 2008; Sen and Majumder, 2008). 
Hydroxynaphthoquinones are structurally similar to the inner mitochondrial protein ubiquinone (also 
called coenzyme Q), which is an integral component of electron flow in aerobic respiration. 
Ubiquinone accepts electrons from the dehydrogenase enzymes and passes them to the electron 
transport cytochromes (Sun et al., 1992). The passage of electrons from ubiquinone to the cytochrome 
bc1 (complex III) requires the binding of coenzyme Q complex III at the Qo cytochrome domain; it 
is this step that is inhibited by hydroxynaphthoquinones (Fry and Pudney, 1992; Pfefferkorn et al., 
1993; McFadden et al., 2000). The consequence of this inhibition is the collapse of the mitochondrial 
membrane potential (Srivastava et al., 1997). On the one hand, atovaquone inhibited the replication 
of T. gondii tachyzoites in vitro with an IC50 of 64 nM (Romand et al., 1993; Meneceur et al., 2008). 
Moreover, atovaquone is active in vitro against the cyst stage of T. gondii (Huskinson-Mark et al., 
1991), although high concentrations of it are required (Araujo et al., 1991; Araujo et al., 1992). In a 
mouse model of acute toxoplasmosis, atovaquone administration resulted in prolonged survival, with 
a reduction of parasite burdens in the blood and tissues during the course of treatment (Araujo et al., 
1991; Romand et al., 1993). In a mouse model of chronic toxoplasmosis, atovaquone showed a 
decline in the number of tissue cysts and a decrease in the inflammatory response in the brain (Araujo 
et al., 1991; Araujo et al., 1992; Ferguson et al., 1994). Indeed, atovaquone is effective against 
reactivation, as it protected mice against reactivated toxoplasmic encephalitis (Dunay et al., 2004).  
In short term studies, buparvaquone efficiently inhibited the replication of N. caninum tachyzoites 
with an IC50 of 4.9 nM exerting parasiticidal activity after 9 days of culture in 0.5 μM or 6 days in 1 
μM buparvaquone. However, in the long-term studies, the tachyzoites reached an adaption to high 
levels of buparvaquone. Additionally, ultrastructural changes confirm that buparvaquone acted rather 
slowly (Muller et al., 2015a). In a non-pregnant mouse model of neosporosis, buparvaquone reduced 
the mortality and parasite load in the lungs, while the brain parasite load was higher than in untreated 
mice (Muller et al., 2015a); the brain parasite load was lower when a 20-times reduced challenge 
dose was used (Müller et al., 2016). In addition, in a pregnant mouse model of neosporosis, pup 
mortality and the transmission of N. caninum to offspring were strongly reduced by buparvaquone 
treatment of the dams (Müller et al., 2016). In light of these results, atovaquone represents a valuable 
candidate to be tested for toxoplasmosis in ruminants and, although further studies are required to 
improve the efficacy in a mouse model, buparvaquone represents an obvious candidate to be tested 
against neosporosis in ruminants.  
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4.2.2.5. Anticancer agents 
Another example of prospective compounds that provide interesting results is anticancer drugs, as 
parasites have several of the common characteristics of malignant tumours (Klinkert and Heussler, 
2006; Dissous and Grevelding, 2011; Dissous and Grevelding, 2011), sharing a crucial feature of 
living and multiplying in a host organism. Tumour cells are defined by their independence from 
exogenous growth factors, their resistance to programmed cell death (apoptosis), and their infinite 
proliferative capacity. Unlimited proliferation and independence of growth factors are also 
characteristics of many parasites. Although it remains controversial whether apoptosis occurs in 
unicellular parasites (Debrabant et al., 2003), it seems to be clear that intracellular parasites interfere 
with the programmed host cell apoptosis (Lüder et al., 2001). Parasite and cancer cells disseminate 
in immune compromised tissues in order to escape host immune responses. Anticancer drugs may 
affect parasite survival at two completely different levels. Firstly, they might kill the parasite directly, 
if the target molecules of parasite and cancer cell are sufficiently similar. In this case, the original 
cancer drugs may serve as leader compounds and can be modified accordingly to specifically inhibit 
the parasite homologue. Secondly, to kill intracellular parasites successfully, the drug might also act 
on a host cell signalling pathway, which is essential for the parasite's survival. The advantage here is 
that the drug need not be modified, since it is already directed against the target molecule (Klinkert 
and Heussler, 2006). 
Miltefosine (2-[hexadecoxy-oxido-phosphinoyl] oxyethyl-trimethyl-ammonium), an alkyl 
phospholipid and an analogue of the ubiquitous compound phosphatidyl choline found in eukaryotic 
cell membranes, was initially developed as an anticancer agent (Wieder et al., 1999) and widely used 
for Leishmania therapy (Solano-Gallego et al., 2011). It is highly active against extracellular T. gondii 
tachyzoites and exerts its activity by triggering apoptosis (Nyoman and Lüder, 2013). Miltefosine has 
no effect on a mouse model of acute toxoplasmosis after 5 days of treatment, but it shows activity in 
a 15-day treatment against chronic experimental toxoplasmosis, with a 78% reduction in the brain 
cyst burden. Pathological findings showed that the tissue cysts were smaller in size upon 
microscopical examination and that there were ultrastructural changes in the remaining cysts, 
suggesting that miltefosine effectively penetrates the blood-brain barrier (Eissa et al., 2015). Against 
N. caninum, miltefosine showed an IC50 of 5.2 μM in vitro with a parasitostatic effect at 25 μM for 
10 hours and parasiticidal activity after 20 hours. In addition, N. caninum tachyzoites revealed 
ultrastructural changes after miltefosine exposure. In a mouse model of neosporosis, miltefosine 
improved mouse survival and reduced the cerebral parasite burden (Debache and Hemphill, 2012).  
Recently, organometallic ruthenium complexes are object of great attention as antitumor agents 
with acceptable toxicity (Kostova, 2006; Bergamo and Sava, 2011). They also have antibacterial 
activity against some bacteria and parasites (Beckford et al., 2011; Caroli et al., 2012). Earlier studies 
indicated that ruthenium compounds interact with DNA (Schwietert and McCue, 1999), but more 
recent investigations showed that ruthenium compounds bind more strongly to proteins (Ravera et 
al., 2004). Ruthenium compounds (compounds 16 and 18) were reported to exhibit IC50 values of 6–
12 nM for N.caninum and 18-41 nM for T.gondii (Barna et al., 2013). Furthermore, dinuclear thiolato-
bridged arene ruthenium complexes (complex 9, complex 1 and complex 2) showed promising 
activities against T. gondii with IC50 values of 1.2 nM, 34 nM and 62 nM (Basto et al., 2017). 
Therefore, anticancer drug such as miltefosine could be considered as an appropriate drug to be 
evaluated in ruminant model for toxoplasmosis and neosporosis whereas ruthenium complexes need 
to be evaluated in mice models before contemplate the option of testing in ruminants.  
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4.2.2.6. Endochin-like quinolones  
 Endochin is a 4-(1H)-quinolone initially investigated as an antimalarial drug (Salzer et al., 
1948). Subsequently, endochin was active against avian and murine toxoplasmosis (Gingrich and 
Darrow, 1951). Recent 4-(1H)-quinolone derivatives, endochin-like quinolones (ELQ), compounds 
that are analogs of ubiquinone, have been developed and tested against apicomplexan parasites such 
as P. falciparum and T. gondii, as well as other protozoa such as Leishmania parasites (Ortiz et al., 
2016). ELQs exert their activity by inhibit cytochrome c reduction by the cytochrome bc1 complex 
(Winter et al., 2008; Doggett et al., 2012). The cytochrome bc1 complex is a membrane-bound 
enzyme complex located in the inner mitochondrial membrane that contributes to pyrimidine 
biosynthesis and oxidative phosphorylation (Vercesi et al., 1998). 3-alkyl-2-methyl-4(1H)-
quinolones exhibited excellent in vitro activity against P. falciparum (Winter et al., 2011). 4(1H)-
quinolone-3-diarylethers, with improved stable and solubility properties, have been tested against T. 
gondii and ELQ-271 and ELQ-316 showed in vitro IC50 values of 0.1 nM and 0.007 nM, respectively. 
ELQ-271 and ELQ-316 were also efficacious against acute toxoplasmosis in mice when administered 
orally and against the cyst form of T. gondii in mice when administered intraperitoneally (Doggett et 
al., 2012). Against N. caninum, ELQ-400 showed an IC50 value below 10 nM, had an impact on 
intracellular proliferation of tachyzoites and transmission electron microscopy showed that the 
primary target of ELQ-400 was the mitochondrion. In experimentally infected non-pregnant mice, 
ELQ-400 orally showed a reduction in the number of animals with lung and brain infection, as well 
as a reduction in the humoral immune response against N. caninum (Müller et al., 2017a). Thus, ELQ-
316 is a promising starting point for the development of a future toxoplasmosis therapy in ruminants, 
and ELQ-400 showed hopeful results against N. caninum, but further studies are needed to assess 
efficacy in pregnant animal models. 
4.2.2.7. Calcium-dependent protein kinase inhibitors 
Calcium signalling is a very important pathway that regulates diverse cellular processes (Berridge 
et al., 2000). In apicomplexan parasites, this signalling pathway directs motility, cell invasion and 
egression (Lourido et al., 2012). Members of the family of calcium dependent protein kinases 
(CDPK’s) are abundant in certain pathogenic parasites and absent in mammalian cells making them 
strong drug target candidates. Genetic disruption of CDPKs has shown they control a wide range of 
phenotypes in T. gondii including egress (TgCDPK1 and TgCDPK3) (Lourido et al., 2010; Garrison 
et al., 2012; Lourido et al., 2012; McCoy et al., 2012), microneme secretion (TgCDPK1) (Lourido et 
al., 2012), motility (TgCDPK1) (Lourido et al., 2010), or cell division (TgCDPK7) (Morlon‐Guyot 
et al., 2014). Other CDPKs in T. gondii (CDPK4, CDPK4A, CDPK5, CDPK6, CDPK8, and CDPK9) 
were described non essential for the lytic cycle (Wang et al., 2016). CDPKs may are also involved in 
other functions in T. gondii, for example, CDPK2 is essential for bradyzoite development (Uboldi et 
al., 2015) and CDPK4A, CDPK6 and CDPK7A may play roles during sporozoite formation or 
transmission via oocysts (Long et al., 2016). 
Bumped kinase inhibitors (BKIs), a particular class of pyrazolopyrimidine inhibitors of CDPK1, 
have bulky C3 aryl moieties entering a hydrophobic pocket in the ATP binding site. BKIs selectively 
inhibit CDPK1 from apicomplexans in a good structure-activity relationship (Keyloun et al., 2014), 
but they do not inhibit mammalian kinases because they have larger amino acid residues adjacent to 
the hydrophobic pocket, thereby blocking the entry of the bulky C3 aryl group. CDPK1 is found in 
most apicomplexans, and the highly conserved nature of the ATP binding domain shared by 
apicomplexan CDPK homologues could be exploited, to some extent, in the development of potential 
broad-spectrum inhibitors (Keyloun et al., 2014). BKIs were originally developed to combat malaria 
(Ojo et al., 2012), but they have been tested for many apicomplexan parasites (Van Voorhis et al., 
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2017). BKI-1294 acted with an IC50 of 20-220 nM in vitro for different strains of T. gondii (Winzer 
et al., 2015). BKI-1294 was highly effective against acute toxoplasmosis in mice, decreasing the 
numbers of T. gondii tachyzoites in the peritoneal lavage fluid (Doggett et al., 2014) and in a murine 
vertical transmission model of T. gondii (Müller et al., 2017c).  
BKI-1517 showed a 3-times lower IC50 than BKI-1553 and BKI-1294 against N. caninum in vitro 
(Ojo et al., 2014; Müller et al., 2017b). In a pregnant mouse model, BKI-1294, BKI-1517 and, less 
clearly, BKI-1553 achieved protection against the vertical transmission of N. caninum, but BKI-1553 
and more markedly BKI-1517 showed detrimental effects on fertility (Winzer et al., 2015; Müller et 
al., 2017b). Hence, BKI-1294 could be considered a promising drug to be tested in ruminant models 
for toxoplasmosis and neosporosis.   
Since BKIs showed parasitostatic rather than parasiticidal effects, they are appropriated for a 
combined immunization plus treatment protocol. These compounds triggered the formation of 
relatively long-lived multinucleated complexes where parasites are blocked in the process of 
cytokinesis and remain trapped within the host cell but are still viable. These multinucleated 
complexes express specific antigen SAG1 and the bradyzoite marker BAG1 (Winzer et al., 2015; 
Müller et al., 2017b). Thereby, these antigens may be presented to the immune system eliciting stable 
immune responses against tachyzoite as well as bradyzoite stages.  
Apart from CDPK1, the rarity of kinases containing small gatekeeper residues in the apicomplexan 
genome reduces the chance of off-target effects, although intermediate sensitivity is expected for 
kinases containing A, S, or T in the gatekeeper position, thus potentially limiting this approach in 
some cases. However, an interesting strategy based on the exploitation of the kinase gatekeeper 
residue was recently developed to identify parasite CDPKs substrates (Lourido et al., 2013). 
  
4.3. Vaccination  
4.3.1. T. gondii vaccines  
The role of a vaccine against T. gondii would be to prevent parasitaemia and colonization of 
placenta and ideally, prevent formation of tissue cysts which are a source of infection to humans 
(Menzies, 2012). In mice a large number of vaccines based on inactivated antigens, live attenuated 
vaccines, vaccines based on recombinant proteins, DNA vaccines and vector-based vaccines have 
been evaluated (Jongert et al., 2009).  
In sheep, several T. gondii vaccines have been also assessed (Hiszczyńska-sawicka et al., 2014).  
The commercial attenuated live vaccine, Toxovax® (MSD) was designed to limit the incidence of 
abortion in sheep related to T. gondii. It results in a decrease of abortion but does not completely 
eradicate the parasite (Buxton and Innes, 1995). This vaccine is based on the S48 isolate, which was 
originally isolated in New Zealand from an aborted lamb and after over 3000 passages in mice it lost 
the ability to form tissue cysts or oocysts (Buxton et al., 1991; Buxton and Innes, 1995). Following 
subcutaneous inoculation of naïve sheep, the parasite multiplies in the local draining lymph node, 
causing a mild febrile response with peak titres of antibody reached by 6 weeks. The immunity 
induced by this vaccine is likely to involve both CD4+ and CD8+ T cells and IFN-γ (Montoya and 
Liesenfeld, 2004). Vaccination induces immunity that protects against abortion for at least 18 months 
after the initial vaccination (O'Connell et al., 1988; Wilkins et al., 1988; Buxton et al., 1993b). This 
vaccine is only licensed for sheep and the administration of a single shot prior to mating is 
recommended.  
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An attenuated T. gondii isolate was also evaluated as a vaccine to prevent the infection of meat 
animals. It is shown that lambs immunized with oocysts of the relatively avirulent TgME49 isolate, 
and then challenged with a virulent M3 isolate, developed complete prevention of the formation of 
virulent M3 cysts in lamb muscle (Falcon and Freyre, 2009). Another study assessed the effectiveness 
of a mutant isolate lacking the MIC1 and MIC3 genes (Mévélec et al., 2010). Ewes inoculated 
subcutaneously or intraperitoneally, 2 months before mating, with MIC1-3KO tachyzoites developed 
a mild febrile response and serum IgG antibodies, which persisted throughout the experiment. 
Pregnant ewes were challenged orally with sporulated oocysts. All unvaccinated ewes aborted, 
whereas 62-91% of the lambs from vaccinated ewes were viable (Mévélec et al., 2010). Moreover, 
subcutaneous vaccination with MIC1-3KO tachyzoites showed potential for reduction in the 
development of tissue cysts in lambs born to vaccinated ewes. These results are encouraging in respect 
to the prevention of parasite transmission from food animals to humans.  
Only an increase on the humoral and/or cellular immune responses have been elicited in sheep 
by vaccines based on tachyzoite antigens (Lundén, 1995; Stanley et al., 2004), vector vaccines 
expressing GRA1 (Supply et al., 1999) and DNA vaccines encoding GRA, ROP, MAG and MIC 
proteins (Hiszczynska-Sawicka et al., 2010; Hiszczyńska-Sawicka et al., 2010; Hiszczyńska-Sawicka 
et al., 2011a; Hiszczyńska-Sawicka et al., 2011b; Hiszczynska-Sawicka et al., 2012). However, 
immune responses induced by DNA vaccines have not yet been evaluated for their ability to provide 
a protective effect against abortion in pregnant ewes.  
4.3.2. N. caninum vaccines  
An ideal N. caninum vaccine should prevent abortion and vertical transmission of the parasite. For 
several years, a commercial killed vaccine against bovine neosporosis based on a tachyzoite lysate 
(Bovilis Neoguard) was available in some countries (Barling et al., 2003). This vaccine exhibited a 
moderate protection under field conditions, with a reduction of 50% in the abortion (Romero et al., 
2004). However, recent studies have revealed large differences in the efficacy at farm level, showing 
certain degree of protection against horizontal transmission, but no effect on vertical transmission, 
being even suggested that vaccination increased the risk of early foetal death in immunized cows 
(Weston et al., 2012). At present, this vaccine has been withdrawal from the market and, therefore, 
the effort of numerous research groups is focused on the identification of new vaccine targets that 
allow the development of safe and effective vaccines against bovine neosporosis.  
The most promising results have been obtained with the use of live vaccines, due to their ability 
to stimulate the cellular immune response after a natural infection (Innes and Vermeulen, 2006). In 
fact, a high percentage of protection against vertical transmission in mice (Miller et al., 2005; Ellis et 
al., 2008; Marugán-Hernández et al., 2011; Rojo-Montejo et al., 2012) and cattle (Williams et al., 
2007; Hecker et al., 2013; Rojo-Montejo et al., 2013; Weber et al., 2013) were found. The live 
vaccines tested include, the use of isolates attenuated in vitro by irradiation (Ramamoorthy et al., 
2006) or successive passages in cell culture (Bartley et al., 2006; Bartley et al., 2008), genetically 
modified isolates (Marugán-Hernández et al., 2011) or natural isolates with low virulence. Among 
the later, there are low-virulence isolates from asymptomatic animals congenitally infected such as 
the Nc-Nowra isolate (Miller et al., 2002) and the Nc-Spain1H isolate (Rojo-Montejo et al., 2009). 
However, in spite of the good efficacy results (Rojo-Montejo et al., 2013), there are no live vaccines 
commercially available due to the difficulties on large-scale production and the lack of viability in 
the medium-long term (Reichel et al., 2015). Additionally, in the live vaccines, especially in those 
using attenuated parasites, the risk of a possible reversion to virulence is present. Therefore, there is 
a safety problem in immunized animals.  
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Thus, the use of inactivated vaccines arise as an alternative to the live vaccines in terms of safety, 
cost and stability of the final formulation and killed tachyzoites and antigen extracts have been used. 
However, most of the studies evaluating inactivated showed negative or ambiguous results in the 
protection against N. caninum infection (Liddell et al., 1999a; Cho et al., 2005; Ribeiro et al., 2009; 
Innes et al., 2011; Mansilla et al., 2013). This could be due to the lower stimulation of the protective 
immune responses, since there is no intracellular replication of the parasite. This deficiency could be 
counteract with the administration of a booster and the choice of the correct adjuvant (Babiuk, 2002).  
Finally, the study of new generation vaccines is another alternative in the long term, including 
DNA vaccines (Cannas et al., 2003b; Liddell et al., 2003; Jenkins et al., 2004), vector vaccines 
(Nishikawa et al., 2000; Nishikawa et al., 2001; Ramamoorthy et al., 2007) and mainly vaccines 
based on recombinant proteins such as NcSRS2 (Cannas et al., 2003a; Vemulapalli et al., 2007; Tuo 
et al., 2011), MIC proteins (Cannas et al., 2003b; Alaeddine et al., 2005; Srinivasan et al., 2007; 
Monney et al., 2011), NcPDI protein (Debache and Hemphill, 2013) and the NcROP2 and NcROP40 
proteins (Debache et al., 2008; Debache et al., 2009; Debache et al., 2010; Pastor-Fernandez et al., 
2015). In addition, this vaccines could include specific markers allowing vaccinated and infected 
animals differentiation (Hemphill et al., 2013). Unfortunately, the efficacy of the recombinant 
vaccines is low compared to live vaccines in mice and cattle (Monney and Hemphill, 2014; Hemphill 
et al., 2016; Horcajo et al., 2016).  
 
5. Experimental models for toxoplasmosis and neosporosis 
According to the National Research Council in USA, experimental models are a critical part in 
biomedical research and include animals, cell cultures as well as computational and mathematical 
simulations. Experimental models are important substitutes for studies that cannot be conducted in 
the target species and provide particular features or advantages that would otherwise be unavailable. 
In this way, many studies have inestimable worth in the clarification of major issues in different 
diseases and in the development of hypotheses to be tested in the target species (NRC, 1998).  
Apart from that, the scientific world is increasingly aware with welfare and ethics in animal 
experimentation. In this context, research is based on the three R´s principle. This principle was stated 
at the beginning of the 1960s by two English biologists, Russel and Burch, in their book “The 
Principle of Humane Experimental Technique” (Russell et al., 1959). The three R´s refer to 
replacement, reduction and refinement. Replacement alternatives refer to methods to avoid or 
substitute the use of animals. Whenever possible, in vivo procedures should be replaced by alternative 
methods that do not use animals, such as mathematical models or biological systems in vitro. 
Reduction means any strategy which results in the use of the lowest number of animals that allow to 
provide scientifically valid results, as well as maximization of the resulting information in each animal 
and thus, avoid or limit a later use of animals. The improvement of the experimental designs and the 
selection of the most appropriate model contribute to compliance of this principle. Finally, refinement 
alternatives include all the procedures to minimize or avoid suffering, as well as all the enrichment 
methods to ensure animal welfare.  
In toxoplasmosis and neosporosis, experimental models are essential to increase knowledge in 
these diseases. Several in vitro models have been developed to study essential processes in the lytic 
cycle of T. gondii and N. caninum while in vivo models represent the best option to carry out 
therapeutic or vaccine trials, as well as to study pathogenesis, immune responses and outcomes of 
infection.  
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5.1. In vitro models 
In vitro models have allowed to study mainly the infection of the tachyzoites in the host cell, 
simulating the dissemination of the parasite during the acute phase of the disease. In vitro cultivation 
of T. gondii and N. caninum makes possible execution of a large number of valuable experiments for 
the knowledge of the ultrastructural features of the parasites as well as the mechanisms of cell 
adhesion and invasion (Hemphill et al., 2004; Lebrun et al., 2014). Likewise, molecular basis of the 
lytic cycle and the host-parasite interactions have been studied, deepening on the knowledge of 
parasite mechanisms that module host cell response (Hemphill et al., 2006). 
Although in vitro models are not a solid alternative compared to the use of animal models, they 
provide an initial approach, optimizing the use of animals. In vitro models are used to characterize 
isolates, to carry out tachyzoite to bradyzoite conversion and to evaluate drug and vaccine candidates 
(Müller and Hemphill, 2013): 
 Characterization of isolates: Among the parameters assessed, those related with invasion and 
proliferation rates are emphasized. Several comparative studies observed differences on these 
parameters between T. gondii isolates as well as N. caninum isolates. Regarding T. gondii isolates, 
the correlation between T. gondii virulence and growth rate has been extensively described (Kaufman 
et al., 1958; Kaufman et al., 1959). Thus, several studies have noted that type I strains (RH) grow 
faster than type II (ME49) or III strains (VEG) (Radke et al., 2001). Likewise, in vitro differential 
phenotypic characteristics have been observed among type II T. gondii strains (Brenier-Pinchart et 
al., 2010). Concerning N. caninum isolates, comparative studies have been carried out between 
Spanish bovine isolates (Nc-Spain 1H, 2H, 3H, 4H, 5H, 6, 7, 8, 9 y 10) and canine isolates (Nc-Ger2, 
Ger3, Ger6, Nc-6Arg y Nc-Bahia), using the Nc-Liverpool isolates as reference in both studies 
(Regidor-Cerrillo et al., 2011; Dellarupe et al., 2014b). Differences on the invasion and proliferation 
rates were observed, with isolates Nc-Spain4H, 5H, 6, 7, 10, Nc-Ger3, Nc-Bahia y Nc-Liverpool 
showing high virulence (higher invasion and lower time needed for replication). On the other hand, 
Nc-Spain 1H, 2H, 3H, 8, Nc-Ger2 y Ger6 showed a lower virulence (Regidor-Cerrillo et al., 2011; 
Dellarupe et al., 2014b).  
 Tachyzoite to bradyzoite conversion: The development of methods for the tachyzoite to 
bradyzoite conversion in vitro provides an excellent tool to study antigen and protein composition, 
effect of prospective drugs and biology of both stages of the parasites (Lindsay et al., 1993; Risco-
Castillo et al., 2007; Bougdour et al., 2009; Marugán-Hernández et al., 2010; Risco-Castillo et al., 
2011). The conversion to the latency stage has been associated with diverse responses to stress, and 
different methods to induce in vitro conversion has been evaluated. N. caninum tissue cysts have been 
more difficult to obtain using in vitro culture. Protocols developed for T. gondii, have yielded only 
few parasites undergoing stage conversion, showing that the efficiency of the differentiation process 
in vitro is rather low compared to T. gondii (Weiss et al., 1999; Vonlaufen et al., 2002). For tachyzoite 
to bradyzoite conversion in vitro in N. caninum the most effective method is adding to cell culture a 
nitric oxide donor, such as sodium nitroprusside, an apoptosis inducer (Vonlaufen et al., 2002; Risco-
Castillo et al., 2004). For T. gondii, one of the earliest and most effective methods to induce tachyzoite 
to bradyzoite conversion in vitro is culturing infected cells in alkaline culture pH of 8–8.2 for three 
to four days (Skariah et al., 2010). 
 Evaluation of drug and vaccine candidates: In vitro models are gaining importance in recent 
years due to the usefulness in the evaluation of drugs against N. caninum and T. gondii (Doggett et 
al., 2012; Mazuz et al., 2012; Barna et al., 2013; Ojo et al., 2014; Winzer et al., 2015; Müller et al., 
2017c), as well as vaccine candidates (Cho et al., 2005; Staska et al., 2005; Niedelman et al., 2012; 
Alaeddine et al., 2013). These in vitro models allow the evaluation of the impact of the compounds 
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on the parasites, and alterations on the parasites as well as modifications on the lytic cycle such as 
inhibition or slowdown in invasion, replication or egression can be assessed. Altogether, results 
provided using in vitro models allow an initial screening of the efficacy of the compounds, and 
therefore a selection of the best candidates to be tested in animal models.  
 Obtention of antigens: In vitro culture has been also employed to obtain tachyzoites used as 
a source of antigen for diagnostic techniques and vaccine formulations (Alvarez-Garcia et al., 2003; 
Ismael et al., 2003; Aguado-Martínez et al., 2008). For vaccine formulations, it is highlighted the use 
of tachyzoites for extraction of antigens and the expression of certain proteins in vectors for their 
purification and characterization (Garcia et al., 2014; Monney and Hemphill, 2014). 
 
5.2. Animal models of toxoplasmosis and neosporosis 
Animal models are useful when, due to the characteristics of the target species or the objective 
of the study, there is no availability, their use is no practical and ethical, and is economically unviable 
or is not feasible to acquire and maintain a suitable number of animals of these species. Therefore, an 
animal model is a live organism in which it is possible to study a relevant fact that is similar to the 
target species (Wall and Shani, 2008). The choice of the animal model should be based on the 
suitability as analogous to the target species, the transferability of the information, uniformity, 
knowledge of the biological properties, generalization of the results, easy handling and ethical 
implications. However, these criteria with sense from a theorical point of view, not always can be 
considered in practice, due to punctual restrictions of each model.  
Obviously the ideal model to study neosporosis is the bovine model, since it is the main target 
species, from both the veterinary and economic point of view, however, mice and ovine models are 
widely used. Regarding toxoplasmosis, due to the wide range of intermediate hosts, there are a large 
number of animal models in different species, and although the mice models are the most used due to 
the ease of handling, also ovine models have been established to study the disease. The main 
advantages of the use of mice as an experimental model are the small size, ease of handling, low cost, 
accessibility to many immunological reagents and availability of genetically modified animals. All 
these parameters together with the short period of gestation and the high number of pups facilitate 
greatly the generation of results in a short period of time. Therefore, mice models are useful for the 
characterization of isolates and study the pathogenesis of the diseases as well as for testing vaccine 
and drug candidates. Nevertheless, the choice an animal model will depend on the aim proposed, with 
each of them showing inherent pros and cons mainly related to the physiological characteristics of 
the animal species. Regardless the natural susceptibility of each species, and since the main impact 
of toxoplasmosis and neosporosis is the abortion, the physiological differences related to duration of 
gestation and, mainly, the type of placentation, are particularly relevant, since can play a critical role 
in the pathogenesis of toxoplasmosis and neosporosis.  
In a schematic way, the placenta is composed by the maternal side or uterine lining, more or less 
modified, and the foetal side, with villi. The foetal elements of the placental barrier (trophoblast, 
connective tissue and foetal endothelium) are known as chorion. In accordance with morphological 
classification proposed by Strahl (Carter and Mess, 2010), ruminant placenta is multiple or 
cotyledonary, in which grouped villi are formed in small areas of the chorion. These correspond to 
elevations of the uterine lining called caruncles. The junction of the cotyledon (foetal side) and 
caruncle (maternal side) constitutes the placentome. The morphology of these placentomes is slightly 
different in ruminants (Figure 5). While in cow is convex, in sheep is concave and in goat is like a 
flat plateau. In rodents (as well as primates and humans), the placenta is discoidal, being the villi 
Chapter II ~ Background 
 
~ 41 ~ 
grouped in a round or oval area. On the other hand, following the histologic classification proposed 
by Grosser based on extend of the destruction of maternal and foetal elements of the placenta 
(Grosser, 1927), the different species can be classified. Thus, bovine placenta is epitheliochorial since 
there is no destruction of maternal tissues, contacting the uterine epithelium with the chorion. The 
placenta in sheep and goats, despite being very similar to cattle, presents some differences. In this 
case, there is some areas with a syndesmochorial relation, which means a partial destruction of the 
uterine epithelium, attaching to trophoblast. Nevertheless, these areas present poor vascular supply, 
so from a functional point of view, is of low significance. Regarding mice, the placenta is 
hemochorial, with an extensive interaction of the foetuses with the maternal tissues, being in close 
contact the chorion and the maternal blood (Figura 5), therefore with a destruction of the vascular 
endothelium in the dam (Bainbridge, 2000). 
 
 
 
5.3. Animal models of toxoplasmosis 
Since there are many hosts of T. gondii, a large number of animal models of toxoplasmosis have 
been established in very different species and with different purposes (Dubey, 2010). Thus, after the 
discovery of the parasite, the first isolation was conducted in mice (Sabin and Olitsky, 1937), although 
throughout its history, experimental infections have been also carried out in cat, the definitive host 
(Frenkel et al., 1970). 
In general, the purpose of studying T. gondii infection using experimental animal models is to 
obtain a better understanding of the disease in humans. The exception is in veterinary research, where 
it is possible to study experimental toxoplasmosis in the host of interest, e.g. sheep, goats or pigs. In 
this case the results are directly relevant to the disease in these animal species and are also of value 
in human toxoplasmosis. 
T. gondii is capable of infecting all warm blooded animals; however, the consequences of 
infection are very variable between different species. Much of the work has been done using 
experimentally infected mice. While there are many advantages in using this experimental model, 
care should be taken in extrapolating results from mice to other species. Mice are vulnerable to the 
consequences of infection with T. gondii, and their use to further our understanding of congenital 
toxoplasmosis may not be ideal, as foetal infection can occur in successive generations of mice 
(Beverley, 1959). This is not the case in rats or sheep; they are more resistant to the disease and 
therefore may provide a more relevant model for human congenital toxoplasmosis (Innes, 1997). 
However, the correlation between virulence of T. gondii isolates in mice and other hosts remain 
unknown.  
Figure 5 – Morphology and structure of the placenta in ruminants and rodents 
Chapter II ~ Background 
 
~ 42 ~ 
Beside mice, other experimental infections have been carried out in laboratory animals, such as 
rats (Dubey and Frenkel, 1998), rabbits and hares (Gustafsson et al., 1997), chickens (Dubey, 2010), 
pigs (Dubey, 2009a), as well as in non human primates (Furuta et al., 2001), Australian marsupials 
(Bettiol et al., 2000), horses (Tassi, 2007), and ruminants such as sheep (see section 5.3.2 in this 
chapter), goats (Obendorf et al., 1990) and cattle (Dubey, 1983). Finally experimental infections have 
been carried out in cats attempting to elucidate aspects of the enteroepithelial stages (Frenkel et al., 
1970; Dubey, 2001; Dubey, 2006) and other issues (Davidson et al., 1993; Dubey et al., 1995).  
5.3.1. Mice model 
Mice can be infected naturally by T. gondii, and an alarming high rate of T. gondii infection has 
been reported in house mice (Mus musculus)(Marshall et al., 2004; Hughes et al., 2006; Murphy et 
al., 2008; Yan et al., 2014), although much lower rates (0-5%) are more general (Smith et al., 1992; 
Smith and Frenkel, 1995; Kijlstra et al., 2008; Meerburg et al., 2012; Muradian et al., 2012; Hůrková-
Hofmannová et al., 2014). 
Cat and mice are global species and sympatric and it is thought that mice is an evolutionary 
significant host for T. gondii with importance in the transmission of the pathogen (Müller and 
Howard, 2016). Virulence of T. gondii strains in mice varies with the genetic background of the 
parasites. Some genotypes of T. gondii are lethal to all strains of mice regardless of the dose of 
parasites administered, whereas other genotypes are non-lethal with a low dose of inoculation and 
can readily establish chronic infection in mice (Dardé et al., 1992; Sibley and Boothroyd, 1992; Howe 
and Sibley, 1995; Ajzenberg et al., 2002; Khan et al., 2009a; Khan et al., 2009b; Shwab et al., 2016). 
Therefore, virulence of T. gondii for its natural intermediate host, the mouse, appears paradoxical 
from an evolutionary standpoint because death of the mouse before encystment interrupts the parasite 
life cycle (Lilue et al., 2013). 
Many mice models of toxoplasmosis has been established depending on the purposes of the 
study. Thus, the most used mice models are those to evaluate virulence of T. gondii isolates in mice 
and congenital infection, as well as those to study ocular toxoplasmosis (Dukaczewska et al., 2015) 
and cerebral infection (Reichard and Gross, 2007).  
 Model to evaluate virulence of T. gondii isolates in mice 
The house mouse (Mus musculus) has been used as the primary laboratory animal model for 
determining the virulence of T. gondii strains. Thus, virulence of T. gondii strains has been commonly 
defined by the mortality rate in laboratory mice. Type I and most South American isolates are highly 
virulent in mice whereas types II and III show a dose-dependent mortality. However, many factors 
can affect virulence measurements, including route of infection, life stage of the parasite, number of 
passages of the parasite in mice or cell culture, the mouse host line used, and dose. 
 Life stage of the parasite:  
T. gondii has a complex life cycle, and the specific stages of the parasite used for inoculation 
may lead to marked differences in the outcomes of virulence in mice. All three infective forms may 
be used to infect mice, but infection with different forms may have varied results in terms of virulence. 
Among the three infectious stages of the parasite, oocysts in general are more virulent (Dubey and 
Frenkel, 1973; Dubey et al., 1981; Dubey, 2006).  
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 Number of passages of the parasite in mice or cell culture:  
Changes in biological characteristics occur in T. gondii strains after passage in mice or cell 
culture (Jacobs and Melton, 1954; Frenkel et al., 1976; Lindsay et al., 1991; Villard et al., 1997; 
Dubey et al., 1999; Khan et al., 2009b). Several isolates T. gondii isolates were found to have lost the 
capacity to produce oocysts in cats after several passages (30-40) in cell culture and mice (Frenkel et 
al., 1976; Lindsay et al., 1991; Dubey et al., 1999). A variety of phenotypic changes among several 
RH-derived clonal lineages were also observed (Khan et al., 2009b). Differences among these 
lineages included larger plaque formation, enhanced survival outside the cells, faster growth, and 
decreased differentiation. Enhanced virulence in mice for T. gondii strains maintained in cell culture 
for several passages has been reported previously (Frenkel and Ambroise-Thomas, 1996). Genetic 
variability among RH lineages in different laboratories has been reported (Howe and Sibley, 1994); 
however, the cause-effect relationship between genetic variations and phenotypes is unclear. 
Therefore, any comparison of phenotypes among T. gondii isolates should be conducted using the 
original or low passage stocks. 
 Route of infection:  
The three common routes in determining T. gondii virulence in mice include intraperitoneal (IP) 
injection, subcutaneous (SC) injection and per oral inoculation (Dubey and Frenkel, 1973; Johnson, 
1984). The IP injection involves direct deposition of T. gondii parasites into the peritoneal cavity, 
whereas SC injection deposits the parasites below the dermis. In oral infections, parasites are 
deposited into the stomach of mice. Higher infectivity and pathogenicity in mice have been observed 
between IP and oral route of infections with T. gondii compared to SC injection (Dubey and Frenkel, 
1973; Dubey et al., 1981). However, one study showed that mice were highly sensitive to oral 
infection, but resistant to IP injection (Johnson, 1984). As evident from these observations, the route 
of infection has an important effect on T. gondii virulence in mice and thus a standardized inoculation 
method is necessary in order for direct comparisons between different studies. 
 Mouse line:  
A high degree of variation in susceptibility to T. gondii has been observed among different lines 
of laboratory mice (Araujo et al., 1976; Johnson, 1984; McLeod et al., 1989; Suzuki et al., 1993; 
Dubey et al., 2012). Outbred mice were considerably resistant to T. gondii infection (Araujo et al., 
1976). Therefore it is important select the appropriate mouse lines with similar resistance when 
making virulence comparisons. 
 Method of preparing tachyzoites for infection: 
Most studies on T. gondii virulence in laboratory mice have employed the tachyzoites due to its 
relative ease of preparation. The two most common ways of propagating tachyzoites include the use 
of mice and cell culture (Dubey, 2010). For the former, T. gondii bradyzoites, tachyzoites or 
sporozoites can be inoculated into the mice by IP injection. Within a week post infection, tachyzoites 
can be harvested from the peritoneal exudates in the abdominal cavities of mice (Dempster, 1984). T. 
gondii isolates that are highly virulent usually propagate well in mice and release a large amount of 
free tachyzoites within 3-7 days post infection. However, T. gondii strains of low virulence usually 
replicate slowly and free tachyzoites are difficult to obtain. To overcome this problem, it is advisable 
to administer 10 mg/ml dexamethasone phosphate in drinking water, which will suppress the murine 
immune response and facilitate tachyzoites production (Dubey, 2010). In laboratories with access to 
cell culture, T. gondii tachyzoites can be propagated and maintained readily. Tachyzoites can 
proliferate in almost any mammalian cell lines, with fibroblasts being the most commonly used 
Chapter II ~ Background 
 
~ 44 ~ 
(Derouin et al., 1987). Whether obtained from cell culture or mouse peritoneal exudate, tachyzoites 
will often be mixed with a large amount of host cells. Therefore, it is necessary to remove these cells 
and enrich tachyzoites. There are several methods to purify tachyzoites, including density gradients, 
sonication and trypsin digestion, differential centrifugation, hemolysin digestion, filtration through 
glass wool, cellulose columns or sintered glass, and polycarbonate filtration (Dempster, 1984). With 
the exception of sonication and trypsin digestion, all of these methods are capable of removing greater 
than 90% of the mouse leukocytes without altering parasite viability (Dempster, 1984). Recently, a 
comparison of tachyzoite purification by trypsin digestion, filtration by 3-μm polycarbonate 
membrane, filtration by cellulose columns, and separation by percoll solution showed a similar results 
(Wu et al., 2012). Therefore, tachyzoites prepared by trypsin digestion should be avoided for 
virulence testing in mice.  
 Dose:  
Earlier studies of mortality in mice have shown that some T. gondii strains such as those 
belonging to the type I lineage and most South American isolates are highly virulent to mice and kill 
all infected mice within two weeks after infection regardless of inoculation dosage (Dardé et al., 1992; 
Sibley and Boothroyd, 1992). For these acutely virulent T. gondii strains, a single viable parasite is 
lethal to mice, therefore the mortality is dose-independent. In contrast, the majority of T. gondii strains 
can readily establish chronic infection in mice if inoculated at low dosages, and mortality is dose-
dependent, with median lethal doses (LD50) that range from 102 to 105 (Dardé et al., 1992; Sibley and 
Boothroyd, 1992; Howe et al., 1996; Khan et al., 2009a, b). Therefore, to accurately determine the 
virulence of T. gondii isolates, it is necessary to test a series of parasite concentrations ranging from 
low to high inoculation doses. Any single dose inoculation will not be able to appropriately assess the 
virulence of a particular T. gondii isolate. 
Variability among these factors makes it difficult to compare results between different studies in 
different laboratories, so recently it has been established a standardized method to evaluate T. gondii 
virulence in mice (Saraf et al., 2017).  
 Mice model of congenital infection 
Mice are used for model for congenital infection due to the ease of handling and the similarity 
between mouse and human placenta, since both have a hemochorial placenta (Loke, 1982; Darcy and 
Zenner, 1993). As indicated by numerous articles that have appeared during decades, mice have been 
widely used to study congenital toxoplasmosis (Beverley, 1959; Remington et al., 1961; Roberts and 
Alexander, 1992; Roberts et al., 1994) and a review has been accomplished (Vargas-Villavicencio et 
al., 2016). 
 Primoinfection during pregnancy:  
Maternal infection of T. gondii at early and intermediate stages of pregnancy could result in 
severe congenital toxoplasmosis, including foetal death (Hay et al., 1983; Graham et al., 1984; 
Couper et al., 2003; Lahmar et al., 2010; Wang et al., 2011; Müller et al., 2017c) and spontaneous 
cognitive handicap in the offspring (Wang et al., 2011), while the infection at the late stage of 
pregnancy usually results in subclinical toxoplasmosis in the offspring (Cabañas-Cortés et al., 2009; 
Wang et al., 2011).  
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 Recrudescence of the infection:  
Vertical transmission seems to occur during chronic infection and through successive 
generations of mice (Beverley, 1959; Remington et al., 1961). Thus, at first glance the mouse model 
may not be best suited to mimic the situation in humans. However, other findings prove that whether 
transmission to the foetus during a chronic infection of the mother occurs is largely dependent on the 
parasite strain as well as on the mouse strain used – for example, in mice that were latently infected 
with 11 different T. gondii strains, placental transmission succeed with only 6 strains (Werner et al., 
1977), and, indeed, chronically infected BALB/c mice do not allow vertical disease transmission at 
all (Roberts and Alexander, 1992). As a consequence, more recent investigations on congenital 
toxoplasmosis tend to use a BALB/c mouse model rather than models using other inbred or outbred 
mouse strains (Thouvenin et al., 1997; Fux et al., 2000; Elsaid et al., 2001; Abou-Bacar et al., 2004; 
Abou‐Bacar et al., 2004; Beghetto et al., 2005).  
5.3.2. Ovine model 
T. gondii is a main cause of reproductive failure in flocks worldwide, therefore, numerous ovine 
models have been established in order to evaluate the efficacy of drug (Buxton et al., 1988; Buxton 
et al., 1993a; Buxton et al., 1996) and vaccine candidates (Buxton et al., 1991; Buxton et al., 1993b). 
Oocysts are the most frequent used in experimental infections (Dubey, 2009b), and despite not being 
natural routes of infection, tachyzoites (Hartley, 1961; Jacobs and Hartley, 1964; Payne et al., 1988; 
Moraes et al., 2010) and cysts (Jacobs and Hartley, 1964; Beverley et al., 1975; Buxton and 
Finlayson, 1986; Verhelst et al., 2014) have been also used for challenge.  
 Non-pregnant sheep model 
Non-pregnant sheep models have been used to evaluate effect of oocyst dose on clinical signs 
and serology (McColgan et al., 1988), to develop serological techniques (Payne et al., 1988; Verma 
et al., 1989; Tenter et al., 1992), as well as to study parasitaemia (Dubey and Sharma, 1980), parasite 
distribution and immune responses during the acute phase of the infection (Verhelst et al., 2014) and 
lesions (Benavides et al., 2011). Likewise, the protective effect of a primary infection on a subsequent 
infection (Falcon and Freyre, 2009) and the efficacy of toltrazuril on the formation of cysts (Kul et 
al., 2013) have been studied. On the other hand, presence of T. gondii in semen of experimentally 
infected rams have been demonstrated (Teale et al., 1982; Aganga et al., 1988; Lopes et al., 2009).  
 Pregnant sheep model 
Sheep can be easily infected by feeding them sporulated T. gondii oocysts (Table 1). Although 
in some studies there is a generally delay of 4 weeks until the occurrence of the abortion (Munday 
and Dubey, 1986), several experimental studies have defined an unacknowledged clinical 
presentation of ovine toxoplasmosis, where abortions occur during the acute phase of infection, 
between day 7 and 14 post infection (Dubey, 2009b). Most of the experimental infections have been 
carried out at mid-pregnancy, however, in a study comparing infections at early, mid and late 
gestation, early abortions were found regardless of the stage of gestation when ewes were infected 
(Castaño et al., 2016). By contrast, there was a clear influence of the gestational stage over those 
abortions or stillbirths that occurred after 14 dpi. This influence is denoted by the differences in the 
rate and day post infection in which abortions occur, histological lesions and parasite burden (Castaño 
et al., 2016).   
A range of variables, including isolate virulence and infective dose, have been proposed as key 
factors in the development of the early abortions (Benavides et al., 2017). Although early abortions 
in sheep have been observed after infection with type I (GT-1 strain) (Dubey, 1984) and type II (M1, 
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M3, M4 and PRU) isolates (Trees et al., 1989; Buxton et al., 1996; Mévélec et al., 2010; Castaño et 
al., 2014), little is known about the influence of the isolate virulence on this clinical form of the 
disease. Concerning doses of infection, a large range, between 12000 (Buxton et al., 1988) and 50 
oocysts (Castaño et al., 2016), has been evaluated in sheep at mid-pregnancy, however there are only 
three experimental infections in which intermediate-to-high oocyst doses were titrated (Buxton et al., 
1988; Trees et al., 1989; Mévélec et al., 2010). Most of the ewes fed 2000 oocysts or more aborted 
or produced dead foetuses, although 100% abortion were reported in a study after infection with 100 
oocysts (Mévélec et al., 2010) (Table 1).   
Artificial insemination using semen contaminated with 6.5 x 104 and 4 x107 T. gondii tachyzoites 
can also cause reproductive pathology with embryonic reabsorption in 80% and 100% of infected 
ewes (Moraes et al., 2010). Primary infection of pregnant sheep has been also useful to evaluate 
presence and quantity of T. gondii in maternal and foetal tissues (Gutierrez et al., 2010). Although 
the importance of endogenous transplacental transmission of T. gondii in naturally infected sheep 
remains controversial (see section 2.3 above in this chapter), after experimental challenge before 
pregnancy, congenital infection was common (dos Santos et al., 2016).  
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5.4. Animal models of neosporosis 
In the case of neosporosis, the advancement of animal models has been essential, allowing a 
great progress in its knowledge. In fact, shortly after the discovery of N. caninum, the first 
experimental models based on parasite inoculations in mice and rats (Lindsay and Dubey, 1989b; 
Lindsay and Dubey, 1990b) and sheep (Dubey and Lindsay, 1990) begin implementation. Later, 
deeper understanding on the pathogenesis was achieved through experimental infections in mice, 
cattle and sheep (Barr et al., 1994; Lindsay et al., 1995; McAllister et al., 1996b). 
Obviously the ideal model to study neosporosis is the bovine model, however, due to economical 
and logistical limitations, only a few institutions are able to carry out such experiments. Therefore, 
laboratory animals, mainly mice, have become a very attractive alternative for different researchers. 
(Cole et al., 1995; Lindsay et al., 1995; Long and Baszler, 1996; Collantes-Fernández et al., 2006a; 
López-Pérez et al., 2008). Beside mice, other laboratory animals have shown susceptibility to 
experimental N. caninum infection, such as gerbils (Dubey and Lindsay, 2000; Gondim et al., 2001; 
Ramamoorthy et al., 2005; Kang et al., 2009), chickens and pigeons (Furuta et al., 2007; Mineo et 
al., 2008) or rats, the latter present some natural resistance and a immunosuppressive treatment is 
needed to generate infection (Lindsay and Dubey, 1990b). Rabbits have been mainly used to generate 
antibodies against the parasite, although these animals remain clinically healthy even with high 
infectious doses (Lindsay and Dubey, 1989a). Finally, despite not numerous, experimental infections 
have been carried out in dogs attempting to elucidate aspects of the enteroepithelial stages (McAllister 
et al., 1998; Lindsay et al., 1999; Cedillo et al., 2008; Bandini et al., 2011; Cavalcante et al., 2012; 
Munhoz et al., 2013). On the other hand, the use of other ruminants as an alternative model has the 
advantage of being very closely related phylogenetically with cattle. Within these ruminants, buffalos 
(Konrad et al., 2012), goats (Lindsay et al., 1995; Yin et al., 2012; Porto et al., 2016) and sheep have 
been used, being the latter the most frequently used (detailed above).  
5.4.1. Mice model 
Although there are some evidences that rodents can be naturally infected by N. caninum, since 
the parasite has been detected by PCR in mice and rats (Huang et al., 2004; Ferroglio et al., 2007; 
Jenkins et al., 2007; Medina-Esparza et al., 2013), their role in the biological cycle is unknown.  
Along with the low susceptibility of mice to neosporosis, the main disadvantage of this model is the 
marked physiological differences with cattle, the target host. In this sense, immune response and 
different gestation parameters (particularly length of gestation and placental structure) make results 
difficultly extrapolated directly to the targe host. However, mice models are the most used model at 
present. 
Mice models are widely heterogeneous and the most used are the non-pregnant mice models or 
mice models of cerebral infection (Collantes-Fernández et al., 2006a; Pereira García-Melo et al., 
2010) and the pregnant mice models or mice models of congenital infection (López-Pérez et al., 2006; 
López-Pérez et al., 2008; Arranz-Solis et al., 2015a).  
 Non-pregnant mice model:  
In this model, and according to the intraorganic distribution of the parasite, kinetics of the immune 
response and presence and severity of clinical signs, the course of the infection can be separated into 
two phases.  
 Acute phase: during this phase of infection the mice can start to show unespecific clinical signs 
such as inactivity, anorexia, apathy, ruffled coat or dyspnea in the more severe cases (Eperon et al., 
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1999; Rettigner et al., 2004a; Collantes-Fernández et al., 2006a). Usually, except in immunodeficient 
mice, there is no mortality in this phase of infection. 
 
 Chronic phase (cerebral model): in the second week pi, a progressive decrease in the number 
of tachyzoites in the lung is observed, as well as a higher load in the brain (Collantes-Fernández et 
al., 2006a; Pereira García-Melo et al., 2010). Mice can be asymptomatic or show nervous clinical 
signs such as weakness, paralysis of the hindlimb, rounded back, head tilt, ataxia and circular 
movements (Eperon et al., 1999; Rettigner et al., 2004a; Collantes-Fernández et al., 2006a). These 
clinical signs get progressively worse causing death of the animal (Lindsay and Dubey, 1989b; 
Reichel and Ellis, 2009).  
 
 Pregnant mice model:  
The pregnant mice model has proven to be particularly useful to study congenital neosporosis, 
being important to evaluate the safety and the efficacy of vaccines and drugs. In fact, the use of the 
pregnant mice model as a proof of concept before the study in the target host is a more adequate 
alternative than the non-pregnant mice model, since the goal of the compounds is avoid vertical 
transmission of the parasite (Aguado-Martínez et al., 2009; Marugán-Hernández et al., 2011; Rojo-
Montejo et al., 2011; Monney et al., 2012; Debache and Hemphill, 2013; Arranz-Solis et al., 2015a). 
Also, in spite of the physiological differences between both species, most of the results from this 
model have shown a high degree of similarity with those from the bovine model.  
To date, most of the models of congenital neosporosis simulate the exogenous transplacental 
transmission, with a primoinfection during pregnancy (Liddell et al., 1999b; Quinn et al., 2002; 
López-Pérez et al., 2006; López-Pérez et al., 2008; Arranz-Solis et al., 2015a). Concerning 
recrudescence of the infection, the attempts to reproduce endogenous transplacental transmission 
have not been satisfactory (Jiménez-Ruiz et al., 2013a, b).   
5.4.2. Bovine model  
Obviously, the main advantage of the use of the bovine model is that the results are directly 
applicable and transferable to the knowledge and control of neosporosis. Nevertheless, the 
requirements for the experimentation with these animals (high cost, extended time of the experiments, 
hard handling of the animals, appropriate facilities, etc.) make impossible their use in initial tests of 
drug and vaccine candidates. In addition, the analysis of different conditions in the same experiment 
is greatly hampered by the limited number of experimental animals. Thus, the bovine model, as target 
host from both the veterinary and economic point of view, represents de model of choice to study the 
outcomes of infection (Benavides et al., 2014). This model is very useful to study important aspects 
of neosporosis, such as pathogenesis, host-parasite interaction, local and systemic immune responses. 
Furthermore, bovine model is essential for the final evaluation of prospective vaccine and drug 
candidates, as well as new diagnostic tools. In any case, different bovine models, both non-pregnant 
and pregnant, have been established (Benavides et al., 2014).   
 Non-pregnant bovine model:  
Most of the experiments conducted in non-pregnant bovine models have been carried out in order 
to study the N. caninum life cycle and the postnatal modes of transmission. In this sense, it was proven 
the oral mode of transmission between dog and cattle (Gondim et al., 2002).  
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 Pregnant bovine model: 
Although endogenous transplacental transmission has been considered the most common mode 
of transmission and maintenance of neosporosis in the herd (Dubey et al., 2007), to date, the 
reproduction in bovine experimental models has not been achieved (McCann et al., 2007; Benavides 
et al., 2014). Thus, most of the pregnant models currently available are models of primoinfection to 
evaluate exogenous transplacental transmission. In the bovine model of primoinfection, the most 
important parameters to be evaluated are abortion and vertical transmission. 
5.4.3. Ovine model 
Natural N. caninum infection in sheep was first described in a congenitally infected lamb (Dubey 
and Lindsay, 1990). Later, ovine neosporosis has been described in several cases worldwide 
(Kobayashi et al., 2001; Koyama et al., 2001; Hassig et al., 2003; Moore, 2005; West et al., 2006; 
Howe et al., 2012; Moreno et al., 2012; González-Warleta et al., 2014). Nevertheless, traditionally 
T. gondii has been considered the main parasite causing abortion in sheep, with N. caninum being 
much less epidemiologically, clinically and economically relevant compared to cattle (Buxton, 1998; 
Givens and Marley, 2008; Dubey and Schares, 2011). However, recent studies have demonstrated 
that N. caninum could be an important cause of abortion in small ruminants (Moreno et al., 2012), 
and even of reproductive losses in many flocks (West et al., 2006; González-Warleta et al., 2014; 
González-Warleta et al., submitted). Several studies in different countries have shown a highly 
variable N. caninum seroprevalence in sheep. Thus, for example, it has been described a global 
seroprevalence in the world ranging from 2% to 14% (Hassig et al., 2003; Moore, 2005; Howe et al., 
2012). However, in Jordan a seroprevalence rate of 92% has been described (Abo-Shehada and Abu-
Halaweh, 2010), while in Spain a seroprevalence rate of 5% was reported (Díaz et al., 2014). On the 
other hand, N. caninum detection in aborted foetuses has been examined in several studies. For 
example, detection percentage in aborted foetuses was 20% in Switzerland (Hassig et al., 2003), 13% 
in New Zealand (Howe et al., 2012) and 7% in Spain (Moreno et al., 2012), being the detection 
percentage in the latter similar for T. gondii.   
Besides being a natural N. caninum host, ovine model has some advantages over bovine model, 
such as shorter gestation period and easy handling. Furthermore, this model allows the use of a larger 
number of animals. Likewise, ovine placenta is very similar compared to cattle. Thereby, ovine model 
is a good alternative to the use of expensive bovine model and mice model. Nonetheless, despite being 
closely related phylogenetically, there are evidences that N. caninum infections in cattle and sheep 
are not exactly the same (Benavides et al., 2014). However, the results from the ovine model are more 
extrapolable to bovine model than those from the murine model. Thus, ovine model results 
particularly helpful to test vaccines and drugs. Since the discovery of N. caninum, several 
experimental infections in sheep have been carried out, but less compared to bovine and mice 
(Benavides et al., 2014). Most of them are focused on the study of pathogenesis and immune response 
of N. caninum during pregnancy.  
 Non-pregnant sheep model:  
Just like bovine models, most of the studies in non-pregnant sheep aimed to deep the knowledge 
of the N. caninum life cycle (Benavides et al., 2014). Thus, for example, horizontal transmission has 
been demonstrated in sheep after ingestion of oocysts shed by dogs as well as in dogs after feeding 
with tissues from these sheep (Schares et al., 2001). Likewise, sheep model has been used to study 
venereal mode of transmission. In a N. caninum experimental infection of rams, it was demonstrated 
the dose-dependent presence of tachyzoites in the semen after infection, albeit it was no able to infect 
female sheep at mating, similarly to findings in cattle (Syed-Hussain et al., 2013).    
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 Pregnant sheep model:  
Experimental infections in pregnant sheep have shown a similar pattern than bovine neosporosis, 
with abortions, healthy but congenitally infected lambs or lambs showing weakness and neurological 
signs depending on the stage of gestation when infection occurs. Most of the experimental infections 
in pregnant sheep have been carried out at mid-gestation, while those in early and late gestation are 
scarce (Table 2). In these studies it was observed that infections early in gestation usually result in 
abortion (Buxton et al., 1998; Arranz-Solis et al., 2015b), while infections in the last term of gestation 
cause the birth of healthy but congenitally infected lambs (McAllister et al., 1996b; Arranz-Solis et 
al., 2015b; Syed-Hussain et al., 2015a). However, the likelihood of abortion after infection at mid-
pregnancy in sheep is much higher compared to cattle (Dubey and Lindsay, 1990; McAllister et al., 
1996b; Buxton et al., 1998; Buxton et al., 2001; Innes et al., 2001a; Weston et al., 2009; Arranz-Solis 
et al., 2015b). Nevertheless, in sheep it has been also described the birth of congenitally infected 
lambs after infection at mid-pregnancy (McAllister et al., 1996b; Buxton et al., 1998; O'Handley et 
al., 2003).  
Apart from the stage of gestation, several authors revealed the importance of the infection dose, 
with higher percentage of abortions after infection with high doses (Dubey and Lindsay, 1990; Buxton 
et al., 2001; Innes et al., 2001a; Weston et al., 2009), while the infection with low doses reduces 
abortion or not appear despite causing infection (Weston et al., 2009).   
Finally, there is no a model of recrudescence in sheep so far. Several studies have evidenced 
recrudescence of the infection in natural conditions (González-Warleta et al., submitted) or even 
experimentally (Jolley et al., 1999). Despite this, other studies did not detect abortions in sheep 
experimentally infected 3 and 8 weeks before gestation (Buxton et al., 2001; Syed-Hussain et al., 
2015b). However, the latter observed vertical transmission since parasite was detected in more than 
the 50% of healthy lambs (Syed-Hussain et al., 2015b).   
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“La religión es la cultura de la fe, la ciencia es la 
cultura de la duda” 
Richard Feynman (1918-1988) 
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T. gondii and N. caninum are apicomplexan parasites considered to be one of the main infectious 
causes of abortion in sheep and cattle, respectively. Toxoplasmosis and neosporosis are generally 
latent and asymptomatic in non-pregnant sheep/cattle, although the consequences of infection in a 
pregnant sheep/cow can be abortion, birth of weak lambs/calves or birth of clinically healthy but 
persistently infected lambs/calves (Innes et al., 2002). T. gondii and N. caninum show a high 
prevalence rate and important economic losses in ovine and cattle population, respectively. In sheep, 
primoinfection with T. gondii during pregnancy triggered reproductive failure, while the 
recrudescence of a latent infection is rare and seems to play a minor role in transmission of T. gondii 
in sheep (Trees and Williams, 2005). However, reproductive failure in cattle due to N. caninum 
infection can be found after infection during pregnancy or recrudescence of a chronic infection 
(Dubey and Schares, 2011). For the control of toxoplasmosis in sheep there is a commercial attenuated 
live vaccine available, which partially reduced abortions (Buxton and Innes, 1995), while no vaccine 
is available in the market for the prevention of neosporosis in cattle. Concerning treatment, to date, 
no drug is available for the treatment of toxoplasmosis and neosporosis in ruminants. Therefore, the 
improvement and development of control measures is of paramount importance. Indeed, the efforts 
of several research groups are nowadays focused on the search for effective drugs and vaccines 
against ovine toxoplasmosis and bovine neosporosis.  
In this sense, the employment of in vitro models has been a great help to the increase on the 
knowledge of ultrastructural features of the parasite and to gain deeper insight into the processes of 
the tachyzoite lytic cycle (Hemphill et al., 2004; El Hajj et al., 2007). This understanding has allowed 
the use of in vitro models for various assays and assessments. Among these, the obtainment and 
characterization of isolates, the evaluation of putative drugs and the tachyzoite-bradyzoite conversion 
studies stand out. Although in vitro assays does not pose a sound alternative to the employment of 
animal models, they offer an initial approximation in many variables of interest, thus reducing and 
optimising the usage of experimentation with animals (3R´s rule). However, the use of animal models 
is essential for the study of several aspects of the disease, which cannot be analysed by in vitro means. 
In fact, in vivo models have increased and deepened the knowledge of toxoplasmosis and neosporosis 
and have allowed to test potential drugs and vaccine candidates.  
Mice is often used as the preferred animal model to determine the virulence of T. gondii (Saraf 
et al., 2017). Likewise, to evaluate congenital infection, several mice models are available (Vargas-
Villavicencio et al., 2016), since the use of laboratory mice is of advantage in terms of low cost, easy 
handling, short gestation period and litter size. However, structure of the placenta, reproductive 
physiology and immune responses greatly differ between rodents and ruminants, which clearly could 
influence the passing of T. gondii trough the maternofetal interface and the modulation of the host 
immune responses during pregnancy. In sheep, most of the experimental infections during pregnancy 
have been carried out using the M1, M3 and M4 T. gondii type II isolates (Dubey, 2009b; Castaño et 
al., 2014) and the virulence in mice of these strains has not been studied in depth. Therefore, there is 
no information on how T. gondii virulence in mice compare to the outcome of experimental infection 
in pregnant sheep.  
In neosporosis, the interest of pregnant sheep models has arisen in the last years as a valid 
alternative to the costly bovine model and to the poorly comparable murine model. In this sense, 
sheep provide several advantages over cattle as an experimental animal model, such as number of 
animals, ease of handling, length of the experiment and cost. Moreover, sheep are, likewise other 
ruminants, a natural intermediate host of N. caninum (Dubey et al., 2007). In fact, recent studies in 
small ruminants suggest that neosporosis may be a more important cause of reproductive disorders 
than it has been traditionally considered, at least in certain scenarios. Recent evidence has 
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accumulated, which points towards N. caninum as a cause of natural abortion and reproductive failure 
in sheep and goats (West et al., 2006; Moreno et al., 2012; González-Warleta et al., 2014; Benavides 
et al., 2014; González-Warleta et al., submitted). The pathogenesis of ovine neosporosis is poorly 
understood, infection during mid-pregnancy in sheep results in severe clinical outcome, since most 
of the animals abort or, less frequently, produce weak lambs (McAllister et al., 1996b; Arranz-Solis 
et al., 2015b). In pregnant sheep, infective doses of 107– 108 tachyzoites result in a high percentage 
of abortions (Dubey and Lindsay, 1990; Buxton et al., 2001; Innes et al., 2001a; Weston et al., 2009) 
and there is only one study comparing different infective doses (Weston et al., 2009). In the latter, 
the results are difficult to compare since a mixture of isolates was employed (Weston et al., 2009). 
Likewise, although the subcutaneous inoculation closely mimics a natural primary infection as the 
parasite is “processed” through a draining lymph node before circulating in the blood (Dubey et al., 
2006), nowadays, there are no studies comparing the outcome of N. caninum experimental infection 
using different routes of inoculation in pregnant sheep. 
To date, pregnant ruminant models have not been used for assessments of drug efficacy against 
N. caninum infection and vertical transmission. In toxoplasmosis, drugs evaluated in pregnant sheep 
(monensin, folate inhibitors and decoquinate) showed protection against abortion in 10-40% of 
infected ewes, however there is limited or no protection against vertical transmission. Therefore, there 
is lack of effective drugs for the treatment of congenital toxoplasmosis and neosporosis in ruminants. 
Highly promising drugs classes have been tested against T. gondii and N. caninum in vitro and in 
small animal models, such as thiazolides, diamidines, artemisinins, naphthoquinones, anticancer 
agents, endochin-like quinolones and calcium-dependent protein kinase inhibitors (Sánchez-Sánchez 
et al., accepted for publication). Calcium dependent protein kinase 1 (CDPK1) represents a promising 
drug target, as CDPK1 is encoded by the apicoplast DNA, and is thus absent from mammalian hosts 
(Lourido et al., 2010; Murphy et al., 2010; Ojo et al., 2010) and it is conserved among apicomplexan 
parasites (Keyloun et al., 2014). CDPK1 activity is essential for microneme secretion, host cell 
invasion, and egress of T. gondii (Kieschnick et al., 2001; Lourido et al., 2010) and can be effectively 
targeted by a class of ATP-competitive compounds, collectively named bumped kinase inhibitors 
(BKIs). The compound BKI-1294 was effective in vitro against T. gondii and N. caninum and showed 
highly protection against vertical transmission in mice models of congenital toxoplasmosis and 
neosporosis (Winzer et al., 2015; Müller et al., 2017c). Likewise, the compound BKI-1553, with an 
improved bioavailability compared to BKI-1294 (Vidadala et al., 2016) was also effective in vitro 
against N. caninum and in vivo in a pregnant mice model of neosporosis (Müller et al., 2017b).  
In this scenario, the general aim of the present Doctoral Thesis was to standardize pregnant mice 
and sheep models of T. gondii infection and compare the virulence of T. gondii type II isolates 
between mice and sheep, standardize a pregnant sheep model for the study of N. caninum infection, 
and evaluate the safety and efficacy against T. gondii and N. caninum infections of BKI compounds 
in pregnant sheep.  
To this end, in the first place, the in vitro phenotype and in vivo behavior in mice and sheep of 
two type II T. gondii isolates were determined. Secondly, a dose titration of N. caninum and the 
evaluation of the intravenous and subcutaneous routes of administration in pregnant sheep were 
carried out in order to assess the impact on this model. Finally, the safety and efficacy against T. 
gondii and N. caninum infections of BKI-1294 and BKI-1553 compounds, respectively were 
evaluated. 
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 Objective 1. Standardization of pregnant mice and sheep models of T. gondii infection and 
comparison of the virulence of T. gondii type II isolates in mice and sheep. 
This objective included the evaluation of the effects of infection in mice and sheep of a recently 
obtained type II T. gondii isolate (TgShSp1) and the reference type II T. gondii isolate (TgME49) 
with the aim of determine if virulence in mice of T. gondii type II isolates could be a good indicator 
to predict the outcome of experimental infection in pregnant sheep.  
 
 Objective 2. Standardization of the pregnant sheep model of N. caninum infection by a dose-
titration assay and evaluation of different routes of administration of the virulent Nc-Spain7 
isolate. 
This study was conducted to evaluate the effects of various infectious doses and routes of 
administration of a virulent N. caninum isolate (Nc-Spain7) in pregnant sheep, with the aim of 
optimising the challenge dose and route of administration, and thus to contribute to the refinement 
and standardization of the pregnant sheep model for its use in further studies. 
 
 Objective 3. Evaluation of the safety and efficacy against T. gondii and N. caninum of BKI 
compounds in pregnant sheep.  
These studies were carried out to assess the safety of BKI-1294 orally administered and BKI-
1553 subcutaneously administered in pregnant sheep and their efficacy against abortion and vertical 
transmission after experimental infection with T. gondii and N. caninum, respectively, with the aim 
of find therapeutic tools for the control of toxoplasmosis and neosporosis in ruminants.  
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“Para mí, nunca ha habido una mayor 
fuente de honores terrenales o distinción 
mayor que la conexión con los avances 
de la ciencia” 
Isaac Newton (1642-1727)  
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Objetivo 1 
Estandarización de los modelos murino y ovino gestantes de 
infección por T. gondii y comparación de la virulencia de 
aislados tipo II de T. gondii entre ratón y oveja  
 
 
Toxoplasma gondii es un párasito apicomplejo que infecta a casi todos los animales de sangre 
caliente. Se conoce poco acerca de como la virulencia del parásito en ratón se extrapola a otro 
hospedadores relevantes. En el presente estudio, se comparan el fenotipo in vitro y el comportamiento 
in vivo en ratón y en oveja de un aislado tipo II de T. gondii (TgShSp1) y del aislado de tipo II de T. 
gondii de referencia (TgME49). Los resultados de los ensayos in vitro y de la inoculación 
intraperitoneal de taquizoitos en ratones indicaron una virulencia incrementada del aislado de 
laboratorio TgME49 en comparación con el aislado recientemente obtenido TgShSp1. El aislado 
TgShSp1 proliferó menos y presento un retraso en la formación de placas de lisis en comparación con 
el aislado TgME49, pero forma estructuras similares a quistes in vitro. No se observó mortalidad en 
ratones adultos tras la infección con 1-105 taquizoitos por vía intraperitoneal o con 25-2000 ooquistes 
por vía oral del aislado TgShSp1. En ovejas infectadas por vía oral con ooquistes, la infección con el 
aislado TgME49 produjo un incremento ligeramente mayor en las temperaturas rectales y una mayor 
carga parasitaria en los cotiledones de ovejas que paren y en el cerebro sus respectivos corderos, pero 
no se observaron diferencias entre estos dos aislados en la mortalidad perinatal ni en las lesiones o 
número de corderos positivos a T. gondii. La infección congénita tras el desafío a mitad de la gestación 
con el aislado TgShSp1, evaluada mediante la mortalidad perinatal y la transmisión vertical, fue 
diferente en función de la especie desafiada. En ratones, se observó una mortalidad del 50% de las 
crias cuando la madre se desafió con una dosis alta de ooquistes (500 ooquistes del aislado TgShSp1), 
mientras que en ovejas infectadas con la misma dosis de ooquistes se observó la mortalidad de todos 
los fetos. Asimismo una mortalidad del 9% y 27% de las crías se encontró en ratones tras la infección 
con 100 y 25 ooquistes del aislado TgShSp1, respectivamente, mientras que en ovejas, la infección 
con 50 y 10 ooquistes del aislado TgShSp1 desencadenó mortalidad en el 68% y 66% de los 
fetos/corderos. Tan solo se encontraron diferencias en transmisión vertical tras la infección con dosis 
bajas de ooquistes (100% tras la infección con 10 ooquistes del aislado TgShSp1 en ovejas y 37% en 
ratón tras la infección con 25 ooquistes del aislado TgShSp1). En conclusión, la virulencia en ratones 
con aislados tipo II de T. gondii quizás no sea un buen indicador para predecir el resultado de la 
infección en ovejas gestantes.  
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Abstract 
 
Toxoplasma gondii is an apicomplexan parasite that infects almost all warm-blooded animals. 
Little is known about how the parasite virulence in mice extrapolates to other relevant hosts. In the 
current study, in vitro phenotype and in vivo behavior in mice and sheep of a type II T. gondii isolate 
(TgShSp1) were compared with the reference type II T. gondii isolate (TgME49). The results of in 
vitro assays and the intraperitoneal inoculation of tachyzoites in mice indicated an enhanced virulence 
for the laboratory isolate, TgME49, compared to the recently obtained TgShSp1 isolate. TgShSp1 
proliferated at a slower rate and had delayed lysis plaque formation compared to TgME49, but it 
formed more cyst-like structures in vitro. No mortality was observed in adult mice after infection with 
1-105 tachyzoites intraperitoneally or with 25-2000 oocysts orally of TgShSp1. In sheep orally 
challenged with oocysts, TgME49 infection resulted in sporadically higher rectal temperatures and 
higher parasite load in cotyledons from ewes that gave birth and brain tissues of the respective lambs, 
but no differences between these two isolates were found on perinatal mortality or lesions and number 
of T. gondii-positive lambs. The congenital infection after challenge at mid-pregnancy with TgShSp1, 
measured as perinatal mortality and vertical transmission, was different depending on the challenged 
host. In mice, mortality in 50% of the pups was observed when a dam was challenged with a high 
oocyst dose (500 TgShSp1 oocysts), whereas in sheep infected with the same dose of oocysts, 
mortality occurred in all fetuses. Likewise, mortality of 9% and 27% of the pups was observed in 
mice after infection with 100 and 25 TgShSp1 oocysts, respectively, while in sheep, infection with 
50 and 10 TgShSp1 oocysts triggered mortality in 68 and 66% of the fetuses/lambs. Differences in 
vertical transmission in the surviving offspring were only found with the lower oocyst doses (100% 
after infection with 10 TgShSp1 oocysts in sheep and only 37% in mice after infection with 25 
TgShSp1 oocysts). In conclusion, virulence in mice of T. gondii type II isolates may not be a good 
indicator to predict the outcome of infection in pregnant sheep.   
 
Keywords: Toxoplasma gondii; type II; virulence; phenotypic traits; mice; sheep; congenital 
toxoplasmosis
1. Introduction 
 
Toxoplasma gondii is an apicomplexan 
parasite capable of infecting almost all warm-
blooded animals and causing potentially fatal 
disease in humans and some relevant domestic 
species, such as small ruminants (Dubey, 
2010). T. gondii may be transmitted 
horizontally by oral ingestion of infectious 
oocysts from the environment and tissue cysts 
contained in raw and undercooked meat or 
vertically by transplacental transmission of 
tachyzoites (Tenter et al., 2000). T. gondii 
diverges in three main clonal lineages, I, II and 
III, with marked differences in mouse virulence 
(Howe and Sibley, 1995). Type I isolates are 
highly virulent in mice, whereas types II and III 
show a dose-dependent mortality (Saeij et al., 
2006). Laboratory isolates from types I, II and 
III are used in T. gondii research and have been 
maintained in successive passages in cell 
culture and mice. Enhanced virulence 
throughout successive passages in cell culture 
and mice for T. gondii type I isolates (e.g., RH 
isolate) has been widely reported (Villard et al., 
1997; Mavin et al., 2004; Khan et al., 2009b), 
but little is known about the influence of 
continuous passages in type II isolates. 
Likewise, there is little information on how T. 
gondii virulence in mice compares to virulence 
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in other species, particularly in those 
experiencing clinical toxoplasmosis, such as 
sheep and humans.   
Transmission of T. gondii from dams to 
offspring during pregnancy (congenital 
toxoplasmosis) is one of the consequences of 
infection (Innes et al., 2009; McAuley, 2014). 
Many animal experimental models have been 
developed; among them, mouse models are the 
most frequently used due to similarities in 
placental histology between rodents and 
humans (Vargas-Villavicencio et al., 2016). 
However, the structure of the placenta, 
reproductive physiology and immune 
responses greatly differ between rodents and 
ruminants, which clearly could influence the 
passing of T. gondii through the maternofetal 
interface and the modulation of the host 
immune responses during pregnancy (Entrican, 
2002). In sheep, T. gondii is one of the main 
abortifacient agents (Dubey, 2009b). Type II T. 
gondii isolates are the most prevalent in all of 
the hosts in Europe, including sheep (Chessa et 
al., 2014). In most of the experimental studies 
in pregnant sheep, type II isolates M1, M3 and 
M4 have been used (Dubey, 2009b; Castaño et 
al., 2014), but the virulence in mice of these 
isolates was never assessed.  
The aim of this study was to compare the 
phenotype in vitro and the virulence in mice of 
a newly obtained T. gondii type II isolate 
(TgShSp1) with that of the laboratory type II 
reference isolate (TgME49) and to compare 
congenital infection in mice and in sheep.  
2. Materials and methods  
2.1. Ethics statement 
Animal procedures for the T. gondii 
isolation by a mouse bioassay of field samples 
from sheep abortions (PROEX 274/16), for 
evaluation of virulence by intraperitoneal 
inoculation of tachyzoites in non-pregnant 
mice (PROEX 274/16) and for T. gondii 
infection of mice and cats (PROEX 166/14) for 
oocyst production were approved by the 
Animal Welfare Committee of the Community 
of Madrid, Spain, following proceedings 
described in Spanish and EU legislation (Law 
32/2007, R.D. 53/2013, and Council Directive 
2010/63/EU). Animal procedures to 
characterize TgShSp1 oocysts in pregnant mice 
were approved by the Animal Welfare 
Committee of the Canton of Bern (approval No. 
BE 101/17). All sheep handling practices were 
approved by the local government and followed 
the recommendations of the Directive 
2010/63/EU of the European Parliament, the 
Council on the protection of animals used for 
scientific purposes, and the IGM-CSIC Animal 
Experimentation Committee (protocol number 
416-2016). All animals used in this study were 
handled in strict accordance with good clinical 
practices, and all efforts were made to 
minimize suffering.     
2.2. T. gondii isolates, isolation of the 
TgShSp1 and genotyping 
The T. gondii type II ovine isolate TgME49 
(genotype #1) isolated in 1958 from sheep 
muscle (Lunde and Jacobs, 1983) was kindly 
donated by Dr. J.C. Boothroyd and had an 
unknown passage number, but it had been 
routinely maintained in cell culture and mice. 
The T. gondii type II (genotype #3) isolate 
(TgShSp1) was obtained from a T. gondii ovine 
abortion outbreak in a Spanish sheep flock 
(Assaf breed) in the province of Palencia 
(northwest Spain), which suffered abortion in 
30 out of 239 pregnant sheep (12.5%).   
TgShSp1 was isolated by passage in mice 
from a brain of an ovine aborted fetus, in which 
T. gondii infection was confirmed by PCR 
within 24 h after collection as described 
(Regidor-Cerrillo et al., 2008). Briefly, fetal 
brain (6 g) was homogenized in 6 mL of PBS 
containing 2% antibiotic-antimycotic solution 
(Gibco, Thermo Fisher Scientiﬁc, Waltham, 
MA, USA), filtered in sterile gauze, and 
centrifuged at 1350 g for 15 min. The 
supernatant was discarded, and the sediment 
was suspended in 1400 μL of PBS with 
antibiotic-antimycotic solution, and 400 μL 
was inoculated subcutaneously into one 8-
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week-old female CD1 mouse that was followed 
for clinical signs. At day 40 pi, asymptomatic 
mouse were euthanized, and the brain collected 
and tested by PCR (see below). A fraction of 
the PCR-positive mouse brain was 
homogenized in PBS with antibiotics by 
passing through a descending series of needles 
(20 to 25 G) and immediately subcutaneously 
inoculated into two other CD1 mice. At 11 dpi, 
mice were euthanized, and peritoneal flushes 
were used for isolation in MARC-145 cell 
culture (Regidor-Cerrillo et al., 2008) and 
checked for the presence of parasite by PCR.  
The T. gondii isolate obtained was 
genotyped by polymerase chain reaction–
restriction fragment length polymorphism 
(PCR-RFLP) using 12 molecular markers 
(SAG1, 3’-SAG2, 5’-SAG2, Alt.SAG2, SAG3, 
BTUB, GRA6, c22-8, c29-2, L358, PK1 and 
Apico) as previously described Su et al. (2006). 
The digested PCR products were visualized by 
2.5% agarose gel electrophoresis, stained with 
Gel Red® Nucleic Acid Gel Stain (Biotium®, 
Fremont, California, USA), observed under UV 
light, assigned to a T. gondii type and classified 
according to genotypes present in ToxoDB 
(http://toxodb.org/toxo/).  
2.3. In vitro assays 
MARC-145, Vero and Human Foreskin 
Fibroblasts (HFF) cell lines were used for 
studying the tachyzoite-to-bradyzoite 
conversion and proliferation of T. gondii 
isolates in vitro. Cells were routinely 
maintained in DMEM (Gibco, Thermo Fisher 
Scientiﬁc, Waltham, MA, USA) with phenol 
red supplemented with 10% heat-inactivated, 
sterile, ﬁltered fetal calf serum (FCS) (Gibco, 
Thermo Fisher Scientiﬁc, Waltham, MA, 
USA), 2 mM glutamine (Lonza Group, Basel, 
Switzerland) and a mixture of penicillin (100 
U/ml), streptomycin (100 μg/ml) and 
amphotericin B (Lonza Group, Basel, 
Switzerland) at 37 °C in a humidified 
atmosphere of 5% CO2. TgME49 and TgShSp1 
were maintained by serial passages in MARC-
145 and Vero cells in the same culture medium 
with 2% FCS. Tachyzoites used for in vitro 
assays were harvested 3 days pi (TgME49) or 5 
days pi (TgShSp1, passage 10), when the 
majority of parasites were still intracellular and 
purified by a PD-10 column (GE Healthcare, 
Little Chalfont, United Kingdom), as described 
(Regidor-Cerrillo et al., 2011). Tachyzoite 
viability was confirmed by trypan blue 
exclusion, and numbers were determined by 
counting in a Neubauer chamber. All assays 
were carried out in triplicate, including at least 
three replicates in each assay.  
2.3.1. Evaluation of the tachyzoite-to-
bradyzoite differentiation in vitro 
through cyst wall-specific DBL 
staining 
Purified T. gondii parasites of the TgME49 
or TgShSp1 isolate (2 x 103 tachyzoites) were 
added to MARC-145 monolayers grown to 
confluence in 24-well plates. At 24 h, culture 
medium was replaced by DMEM with alkaline 
pH (8-8.2), and plates were incubated at 37°C 
without CO2 supplementation for 3-4 days 
(Skariah et al., 2010). Duplicate plates were 
maintained for 3 days under regular conditions 
(pH 7.2-7.4 and 5% CO2). Tachyzoite-to-
bradyzoite conversion was evaluated at 72-96 h 
by double immunofluorescence staining, in 
fixed cell monolayers with paraformaldehyde 
3% and glutaraldehyde 0.05% using a 
polyclonal mouse-anti T. gondii antiserum at a 
dilution of 1:100 as primary antibody, Alexa 
Fluor® 594 Goat Anti-Mouse IgG (H + L) (Life 
technologies, Carlsbad, CA, USA) at a dilution 
of 1:1000 as secondary antibody for parasite 
staining, and the Dolichos biflorus lectin 
(DBL) (Vector Labs, Burlingame, United 
States) at a dilution of 1:50 for cyst wall 
staining. Cell nuclei were stained with DAPI. 
Finally, the total numbers of DBL-positive 
cysts and DBL-negative structures compatible 
with parasite structures, including lysis 
plaques, were counted using an inverted 
fluorescence microscope (Nikon Eclipse 
TE200) at 200x magnification. The percentage 
of conversion for each well was determined.   
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2.3.2. In vitro intracellular proliferation 
assays 
T. gondii proliferation was evaluated in 
Vero cells by a plaque assay and in HFF 
determining the tachyzoite yield at 48 h pi. For 
this assay, Vero cultures grown to confluence 
in 24-well plates were infected with 5 x 104 
purified tachyzoites of either TgME49 or 
TgShSp1 and further maintained at 37 °C and 
5% CO2 for 4 days and stained with 0.2% 
crystal violet (Alfa Aesar, Haverhill, 
Massachusetts, United States) solution in 2% 
ethanol. (Ufermann et al., 2017). Images were 
captured using a SMZ1000 binocular loupe 
(Nikon®, Tokyo, Japan).   
Tachyzoite yield in HFF was determined by 
quantifying the number of tachyzoites at 48 h 
pi (TY48h) by real-time PCR (qPCR). HFF 
cultures grown to confluence in 24-well plates 
were infected with 105 purified T. gondii 
tachyzoites and maintained for 48 h at 37°C in 
5% CO2 as previously described Regidor-
Cerrillo et al. (2011). Then, the medium was 
removed, and cells were recovered in 150 µL 
lysis buffer and 10 µL proteinase K (Macherey-
Nagel, Düren, Germany) for DNA extraction 
and quantification of parasite genomic DNA by 
qPCR.   
 
2.4. In vivo experimental infections 
2.4.1. Virulence assessment in non-
pregnant mice intraperitoneally 
inoculated with TgShSp1 and 
TgME49 tachyzoites 
TgShSp1 and TgME49 virulence was 
determined in mice following 
recommendations for standardization described 
by Saraf et al. (2017). For the in vivo challenge, 
tachyzoites of TgShSp1 (passage 10) and 
TgME49 (unknown passage number) were 
recovered from Vero cultures when they were 
still largely intracellular (> 80% of undisrupted 
parasitophorous vacuoles) (Regidor-Cerrillo et 
al., 2010), repeatedly passed through a 27-
gauge needle at 4°C and filtered through a 5-
μm polycarbonate filter (IpPORE®, IT4IP, 
Louvain-la-Neuve, Belgium) (Saraf et al., 
2017). The tachyzoite viability was determined 
by Trypan blue exclusion and counted in a 
Neubauer chamber. Tachyzoite 10-fold serial 
dilutions were performed starting from 105 to 1 
tachyzoite(s) suspended in 200 μL of PBS, and 
each dilution was inoculated intraperitoneally 
into five 8-week-old female CD1 mice 
(Janvier-Labs, Laval, France) within 30 min of 
harvesting the parasites from cell culture. Five 
control female mice were inoculated with PBS. 
Mice were observed daily, and clinical signs 
(morbidity) were scored according to the 
description made by Arranz-Solis et al. 
(2015a). Briefly, scores were classified as 0 (no 
alterations), 1 (ruffled coat), 2 (rounded back), 
3 (noticeable loss of body condition/severe 
weight loss) or 4 (nervous signs such as activity 
decrease, hind limb paralysis, walking in 
circles or head tilt). As a humane endpoint, 
mice exhibiting evident loss of body condition 
(score of 3) or nervous signs (score of 4) were 
culled to limit unnecessary suffering. Mice 
with clinical scores of 0, 1 and 2 were 
euthanized at six weeks p.i. Samples of blood 
were collected from mice for serology by IFAT 
and brain and lung for parasite detection by 
PCR. 
2.4.2. Generation, purification and 
sporulation of T. gondii oocysts 
Oocysts of the TgShSp1 isolate were 
obtained through oral infection of cats as 
previously described Müller et al. (2017c). 
Briefly, ten 8-week-old female CD1 mice 
(Janvier-Labs, Laval, France) were inoculated 
intraperitoneally with 105 tachyzoites of 
TgShSp1 (passage 10). At 2 months 
postinoculation, mice were euthanized, and the 
brains were collected. Two twelve-week-old 
kittens free of T. gondii and other relevant 
feline pathogens (Isoquimen S.L., Barcelona, 
Spain) were fed a pool of 5 brains each. Feces 
were collected from kittens daily and examined 
to detect shedding of T. gondii oocysts. 
Unsporulated oocysts were harvested from 
feces and sporulated by resuspending in 2% 
H2SO4 for 4 days at room temperature. 
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Sporulated oocysts were kept at 4 °C until used. 
The same batch of sporulated oocysts of the 
TgME49 and TgShSp1 was used in mouse and 
sheep infections. Sporulated oocysts of 
TgME49 originated from the same batch as 
described earlier (Müller et al., 2017c).   
2.4.3. Assessment of TgShSp1 oocyst 
infection in pregnant mice 
TgShSp1 was evaluated in pregnant mice 
out similarly as previously described for 
TgME49 (Müller et al., 2017c). CD1 females 
(50 mice) and males (25 mice) were purchased 
from Charles River Laboratories (Sulzberg, 
Germany) at the age of 8 weeks and were 
maintained in a common room under 
conventional day/night cycle housing 
conditions. Females at 9 weeks of age were 
synchronized with respect to estrus and were 
distributed into cages, where two females and 
one male were housed together for 3 days 
(during which 3 females died). Subsequently, 
the female mice were orally infected by gavage 
with high doses of oocysts: 2000 oocysts 
(group A, n = 9) and 500 oocysts (group B, n = 
9), an intermediate dose of oocysts: 100 oocysts 
(group C, n = 10) and a low dose of oocysts: 25 
oocysts (group D, n = 10) suspended in 100 μL 
of carboxymethyl cellulose solution (0.5% in 
water) at day 7 postmating. The control group 
(group E, n = 9) received carboxymethyl 
cellulose solution alone. Pregnancy was 
confirmed 2 weeks postmating by weighing, 
and pregnant mice were then allocated into 
single cages to give birth on days 19–22 and to 
rear their pups for an additional 4 weeks. 
During this time, those females that had 
remained non-pregnant were maintained in 
cages of three to five mice. Dams and their 
offspring were evaluated daily from birth to day 
28 postpartum (pp). Despite the numerous 
parameters evaluated, pup mortality (number of 
pups born dead or euthanized due to severe 
clinical signs) and vertical transmission 
(surviving pups being PCR-positive in the 
brain) were the most relevant assessments. 
Data on pregnancy rate (percentage of female 
mice housed with males that became pregnant), 
litter size (number of delivered pups per dam) 
and clinical signs (morbidity) of dams and non-
pregnant mice were recorded during this time 
as described above for intraperitoneal 
inoculation. Neonates were weighed every 
second day from day 14 pp until the end of the 
experiment (day 28 pp) to evaluate morbidity 
in the offspring. Day 14 pp was chosen as a 
starting point for weight monitoring to avoid 
excessive handling of the pups during the first 
2 weeks after birth, which can result in rejection 
by the dams. Dams, non-pregnant mice and 
pups were euthanized in a CO2 chamber at 28 
days pp. Blood from dams and non-pregnant 
mice was recovered by cardiac puncture, and 
sera were obtained to test humoral immune 
responses. Brains and lungs were removed 
from dams and non-pregnant mice and stored at 
-20°C until determination of parasite load. The 
heads of pups that survived were collected and 
stored at -20°C. Subsequently, the frozen heads 
were cleaved and brains were removed. The 
frozen brains from pups were immediately 
processed for DNA purification and then 
parasite quantification. Whenever possible, 
dead pups succumbing to the infection early 
after birth were removed, their heads sampled 
and their brains analyzed.   
2.4.4. Assessment of TgShSp1 and 
TgME49 oocyst infections in 
pregnant sheep 
Fifty-four pure Rasa Aragonesa breed 
female ewes aged 12 months were selected 
from a commercial flock. All animals were 
seronegative for T. gondii, N. caninum, border 
disease virus (BDV), Schmallenberg virus 
(SBV), Coxiella burnetii and Chlamydia 
abortus as determined by enzyme-linked 
immunosorbent assay (ELISA). They were 
estrus-synchronized and mated with pure-bred 
Rasa Aragonesa tups for 2 days, after which the 
rams were separated from the ewes. Pregnancy 
and fetal viability were confirmed by 
ultrasound scanning (US) on day 40 
postmating. Pregnant ewes (n = 37) were 
randomly distributed into seven experimental 
groups and housed at the Instituto de Ganadería 
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de Montaña (CSIC-Universidad de León), 
León, Spain.   
Thirty-three pregnant ewes were orally 
dosed on day 90 of pregnancy with a high dose 
of oocysts (500 sporulated oocysts) of 
TgShSp1 (group 500A, G500A, n=6) or 
TgME49 (group 500B, G500B, n=5), an 
intermediate dose of oocysts (50 oocysts) of 
TgShSp1 (group 50A, G50A, n=6) or TgME49 
(group 50B, G50B, n=5) or a low dose of 
oocysts (10 oocysts) of TgShSp1 (group 10A, 
G10A, n=6) or TgME49 (group 10B, G10B, 
n=5). The four remaining sheep were used as 
negative controls of infection (uninfected) and 
received 50 mL of PBS on day 90 of pregnancy.  
Pregnant ewes were observed daily 
throughout the experimental period. Rectal 
temperatures were recorded daily from day 0 
until 14 days pi and then weekly to evaluate 
morbidity. The physiological range for rectal 
temperatures in sheep was obtained from 
Diffay et al. (2002), and rectal temperatures 
above 40°C were considered hyperthermic. 
Fetal viability was assessed by US monitoring 
of fetal heartbeat and movements twice a week 
after infection. When fetal death occurred, or 
immediately after parturition, dams and lambs 
were first sedated with xylazine (Rompun, 
Bayer, Mannheim, Germany) and then 
euthanized by an intravenous overdose of 
embutramide and mebezonium iodide (T61, 
Intervet, Salamanca, Spain). Animals from the 
uninfected group were examined by US every 
two weeks.   
According to the perinatal survival, sheep 
were classified into three categories: (a) 
suffering early abortions (i.e., between 8 and 11 
dpi); (b) suffering late abortions, which 
occurred from 12 to 50 dpi; and c) sheep 
delivering stillbirths, mummified fetuses or live 
lambs from 51 dpi. Perinatal mortality was 
calculated in each group considering fetal 
mortality during pregnancy and stillbirths 
according to Hubbert et al. (1972). After birth, 
lambs were clinically inspected and then 
sedated and euthanized. Lambs showing 
weakness in relation to all live lambs were used 
to calculate morbidity in the offspring. In spite 
of the numerous parameters evaluated, 
perinatal mortality and vertical transmission in 
live lambs (seropositivity and parasite 
detection in brain or lung) were the most 
relevant assessments.  
Blood samples to evaluate humoral immune 
responses were collected prior to infection, at 
3, 5, 7 and 10 days pi and then weekly by 
jugular blood draw. Precolostral serum was 
collected from lambs immediately after 
delivery from dams. To prevent any 
transmission of colostral antibodies from dams, 
udders were covered with a piece of cloth one 
week before the expected date of delivery as a 
preventive measure, and lambs were separated 
from their mothers immediately after birth. 
Serum samples were stored at −80°C until 
analysis.   
During necropsy, six randomly selected 
placentomes or cotyledons from aborted dams 
and dams that gave birth, respectively, were 
recovered from each placenta, transversally cut 
into 2–3 mm-thick slices, and fixed in 10% 
formalin for histopathological examination, 
whereas the remaining tissues from these 
placentomes/cotyledons were stored at −80°C 
for further DNA extraction and PCR analyses. 
Samples from fetal tissues, including brain and 
lungs, were stored at −80°C for DNA extraction 
or were fixed in 10% formalin for 
histopathology. Thoracic and abdominal fluids 
were also collected from fetuses and stillborn 
lambs from which precolostral sera could not 
be obtained, and maintained at −80°C for 
serology.   
2.5. Serological analyses: IFAT and 
ELISA 
The serum samples from mice used for 
isolation and determination of virulence were 
analyzed by the immunofluorescence antibody 
test (IFAT) for the detection of anti-T. gondii 
IgG as previously described Alvarez-Garcia et 
al. (2003), using an anti-mouse IgG conjugated 
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to FITC (Sigma-Aldrich, Madrid, Spain) 
diluted 1:64 in Evans Blue (Sigma-Aldrich). 
We used the cut-off of 1:25. Serum titers for T. 
gondii in oocyst-infected mice were assessed 
by ELISA as previously described for 
Neospora caninum-infected mice (Debache et 
al., 2008; Debache et al., 2009), except that 
soluble antigen extract from T. gondii 
tachyzoites was used (Alaeddine et al., 2005).  
T. gondii-specific IgG antibody levels in 
sheep were measured using an in-house indirect 
ELISA similarly as previously described 
Castaño et al. (2014). First, 96-well microtiter 
plates (Thermo Fisher Scientific, Waltham, 
USA) were coated with 100 µL soluble T. 
gondii antigen (1.5 µg/mL in 100 mM 
carbonate buffer pH 9.6) overnight at 4°C. 
Plates were blocked, and serum samples were 
diluted 1:100 using 3% bovine serum albumin 
diluted in PBS containing 0.05% Tween 20 
(PBS-T). Subsequently, horseradish 
peroxidase-conjugated protein G (Sigma-
Aldrich, Madrid, Spain) diluted 1:3000 in PBS-
T was added. After that, ABTS (Roche, 
Basilea, Switzerland) was used as substrate. 
The reaction was stopped adding 100 μL of 0.3 
M oxalic acid, and the optical density (OD) was 
read at 405 nm (OD405). For each plate, values 
of the OD were converted into a relative index 
percentage (RIPC) using the following 
formula: RIPC = (OD405 sample – OD405 
negative control)/(OD405 positive control–
OD405 negative control) × 100. A RIPC value 
≥10 indicated a positive result.  
The indirect fluorescent antibody test 
(IFAT) was used to detect specific IgG anti-
Toxoplasma antibodies in fetal fluids and 
precolostral sera, adapting the technique 
previously described for IFAT analysis in N. 
caninum-infected animals (Alvarez-Garcia et 
al., 2003), using an anti-sheep IgG (Sigma-
Aldrich) diluted 1:200 in Evans blue (Sigma-
Aldrich). Fetal fluids and precolostral sera were 
diluted at two-fold serial dilutions in PBS 
starting at 1:8 (for fetal fluids) and 1:50 (for 
precolostral sera) up to the endpoint titer. 
Continuous tachyzoite membrane fluorescence 
at a titer ≥ 8 for fetal fluids or ≥ 50 for 
precolostral sera was considered a positive 
reaction.   
 
2.6. DNA extraction and PCR for parasite 
detection and quantification in tissues 
Genomic DNA from in vitro samples was 
extracted from these samples using the 
NucleoSpin® DNA RapidLyse Kit (Macherey-
Nagel, Düren, Germany) according to the 
manufacturer’s instructions. DNA 
concentrations were adjusted to 20 ng/μL and 
quantified using qPCR with primer pairs for the 
529-bp repeat element for T. gondii for parasite 
quantification and primer pairs for the 28S 
rRNA gene for quantify cell DNA under 
conditions previously described (Castaño et al., 
2016) and (Collantes-Fernández et al., 2002), 
respectively.  
Genomic DNA was extracted from mice 
that were used for isolation and determination 
of virulence out using the commercial 
Maxwell® 16 Mouse Tail DNA Purification 
Kit. The T. gondii DNA detection was carried 
out by an ITS-1 PCR adapted to a single tube 
as previously described Castaño et al. (2014). 
DNA extraction and qPCR analysis from 
oocyst-infected mice were performed as 
previously described Müller et al. (2017c).   
In sheep, genomic DNA was extracted from 
three 50–100 mg samples taken from each 
location: six placentomes in aborted dams or 
six cotyledons in dams that gave birth, as well 
as fetal brain and lung, using the commercial 
Maxwell® 16 Mouse Tail DNA Purification 
Kit. T. gondii DNA detection was carried out 
by an ITS-1 PCR as described above (Castaño 
et al., 2014). DNA that tested positive by 
nested-PCR was adjusted to 20 ng/μL and 
quantified using qPCR as previously described 
Castaño et al. (2014). Parasite number in tissue 
samples (parasite burden) was expressed as 
parasite number/mg ovine tissue. Standard 
curves for T. gondii and sheep DNA showed an 
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average slope of −3.44 and −3.30, respectively, 
and an R2 > 0.99. Parasite-negative DNA 
samples were included in each round of DNA 
extraction and PCR as negative controls.   
2.7. Histological processing  
After fixation for five days, placental and 
fetal sheep tissues were cut coronally, 
embedded in paraffin wax and processed by 
standard procedures for hematoxylin and eosin 
(HE) staining. Conventional histological 
evaluation was carried out on all sections. To 
quantify the lesions in the brain of stillborn 
lambs and live lambs, the number and size of 
glial foci, as well as the total area of lesion in 
the examined tissue, were calculated through a 
computer-assisted morphometric analysis on 
HE-stained sections following the procedure 
described previously (Arranz-Solis et al., 
2015b).  
2.8. Statistical analysis  
The growth rate and percentage of DBL-
positive cysts in vitro of TgME49 and TgShSp1 
were compared using the Mann–Whitney test. 
In pregnant mice, differences in 
seroconversion, pregnancy rates, litter size, pup 
mortality, and parasite presence in tissues were 
analyzed by the χ2 test or Fisher’s exact F-test. 
One-way ANOVA followed by Tukey’s 
multiple comparisons test were employed to 
compare body weights. Parasite burdens and 
anti-T. gondii antibody levels were analyzed 
using the nonparametric Kruskal–Wallis test 
followed by Dunn’s test for comparisons 
between groups, as well as the Mann–Whitney 
test for pairwise comparisons.   
In pregnant sheep, the number of 
fetuses/lambs suffering perinatal mortality and 
the number of weak lambs (morbidity) were 
compared using the χ2 test or Fisher’s exact F-
test. Rectal temperatures and humoral immune 
responses were analyzed using one-way 
ANOVA followed by Tukey’s multiple 
comparisons test until 14 days pi or until the 
end of the experiment. Differences in 
frequency of PCR detection of parasite DNA 
and in the percentage of cases showing lesions 
were evaluated using the χ2 test or Fisher’s 
exact F-test. Differences in parasite burdens 
and histological measurements of lesions were 
analyzed using the nonparametric Kruskal–
Wallis test followed by Dunn’s test for 
comparisons between groups, as well as the 
Mann–Whitney test for pairwise comparisons.  
Differences between mice and sheep in the 
number of fetuses/pups/lambs that died in 
relation to the total number of 
fetuses/pups/lambs or in the number of 
surviving offspring infected with T. gondii in 
relation to all live offspring were assessed using 
the χ2 test or Fisher’s exact F-test. Likewise, a 
categorization of the parameters to evaluate 
congenital infection was done, into high 
(>67%), medium (66-34%), low (<33%) or 
none (0%) of the fetuses/pups/lambs with 
clinical signs, perinatal mortality or vertical 
transmission. Statistical significance for all 
analyses was established at P < 0.05. All 
statistical analyses were performed using 
GraphPad Prism 6.01 software (San Diego, 
CA, USA).   
3. Results 
3.1. Isolation of the T. gondii isolate 
TgShSp1 from a sheep flock in Spain  
On day 40 post-inoculation, one mouse 
inoculated with the brain homogenate of the 
sheep abortion was T. gondii PCR-positive in 
the brain. The peritoneal fluid of one of the 
other two mice inoculated with the positive 
mouse brain was PCR-positive on day 11 pi. 
Four days after inoculating the PCR-positive 
peritoneal flush into cell culture, the isolation 
of TgShSp1 was confirmed. Genotyping 
classified TgShSp1 as type II, genotype #3 
(ToxoDB).   
 
 
Chapter IV ~ Results 
Objective 1: Virulence of T. gondii type II isolates in mice and sheep 
 
~ 72 ~ 
 
3.2. TgShSp1 and TgME49 differ in 
behavior in vitro 
3.2.1. TgShSp1 exhibits a high capacity 
to form cysts in vitro 
At difference in TgME49 free-floating cyst-
like structures was often identified by light 
microscopy in the TgShSp1 infected cultures at 
3 days p.i. in successive passages. TgShSp1 
cultured under regular conditions (at a neutral 
pH) demonstrated spontaneous conversion to 
bradyzoite with a statistically higher number of 
DBL-positive cysts (14%) compared to 
TgME49 (2%) (P < 0.0001). Additionally, after 
induction of bradyzoite development (at a basic 
pH), TgShSp1 formed a higher number of 
DBL-positive cysts (55%) compared to 
TgME49 (33%) (P < 0.0001) (Figure 1A).   
3.2.2. TgME49 shows a higher growth 
rate in vitro than TgShSp1 
Evaluation of parasite growth in Vero cells 
by a lysis plaque assay showed that TgME49 
produced large clear zones due to host cell 
lysis, while during the same period, TgShSp1 
showed essentially an intact monolayer cell 
(Figure 1B). Determination of the TY48h in HFF 
was also assessed to confirm differences in 
parasite growth. The TY48h values for TgME49 
were significantly higher compared to those 
from TgShSp1 (P < 0.0001) (Figure 1C).   
3.3. TgShSp1 and TgME49 differ greatly 
in virulence in mice 
A summary of clinical signs, serology and 
parasite detection in mice is shown in Table S1. 
Most of the mice inoculated with doses from 
105 to 102 tachyzoites of TgShSp1 only 
exhibited a ruffled coat between days 4 and 13 
pi, but they did not have to be euthanized due 
to severe clinical signs (Figure 2A) (Table S1). 
In contrast, upon infection with TgME49, 
several mice had to be euthanized due to 
clinical scores (Figure 2B). The surviving mice 
infected with doses from 105 to 10 tachyzoites 
of TgME49 exhibited clinical signs (rounded 
back) between days 8 and 14 pi (Table S1). The 
LD50 for TgME49 was approximately 103 
tachyzoites vs. > 105 tachyzoites for TgShSp1.   
All mice inoculated with doses from 105 to 
10 tachyzoites of TgShSp1 were seropositive at 
6 weeks pi, with IFAT titers ranging from 1:400 
to 1:3200. Concerning mice infected with 
TgME49, mice euthanized prior to day 24 pi 
were seronegative, while one mouse infected 
with 103 tachyzoites euthanized on day 33 pi 
had an IFAT titer of 1:25. Survivors infected 
with doses from 105 to 10 tachyzoites of 
TgME49 were seropositive at 6 weeks pi, with 
IFAT titers ranging from 1:50 to 1:800 (Table 
S1).    
All mice infected with doses from 105 to 10 
tachyzoites of TgME49 and TgShSp1 were 
PCR-positive in the brain, confirming T. gondii 
infection. Likewise, almost all lung samples 
from mice infected with doses from 105 to 10 
tachyzoites of both isolates were PCR-positive, 
except lung samples from surviving mice 
infected with 10 tachyzoites of TgME49. Mice 
infected with 1 tachyzoite did not show clinical 
signs, they were seronegative, and all tissue 
samples were PCR-negative, identical to 
uninfected mice (Table S1).   
3.4. TgShSp1 shows low virulence in mice 
infected with oocysts but is efficiently 
transmitted to offspring 
3.4.1. Evaluation of TgShSp1 infection 
in dams  
Clinical signs in infected dams were 
generally mild. Therefore, none of the dams 
had to be euthanized due to severe clinical 
signs. At 12 days pi, one out of five dams 
infected with 2000 oocysts (group A) exhibited 
ruffled coat (1), and one out of six dams 
infected with 500 oocysts (group B) displayed 
rounded back (2). No clinical signs were 
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Figure 1-Tachyzoite-to-bradyzoite differentiation, plaque formation and tachyzoite yield in 
vitro of TgME49 and TgShSp1 isolates. (A) In vitro tachyzoite-to-bradyzoite differentiation at 
neutral and alkaline pH. Percentage of events being DBL-positive cysts at pH 7 and pH 8 are 
represented. The rest of nonrepresented events were found to be DBL-negative structures and lysis 
plaques. (****) marks the higher spontaneous and induced differentiation into bradyzoites with the 
TgShSp1 isolate. (B) Plaque formation with TgShSp1 (I) and TgME49 (II) isolates. Plaques are 
visible as clear zones on a crystal violet-stained Vero monolayer background. (C) A column-plot 
graph representing the tachyzoite yield (TY48h) of TgME49 and TgShSp1. Values of replicates from 
experiments performed in triplicate for each isolate. Error bars indicate the SD. (****) marks the 
significantly higher TY48 h values for TgME49 compared to TgShSp1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
observed in dams infected with 100, 25 or 0 
oocysts (groups C, D and E). Pregnancy rates 
ranged from 55 to 66%, with no significant 
differences between them. Similarly, no 
differences between the groups were found in 
litter size (11.8–14.4 delivered pups), 
suggesting that pregnancy was not noticeably 
altered by infection with TgShSp1 oocysts 
(Table 1).   
All infected dams with 2000, 500 and 100 
oocysts (groups A, B and C) developed
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Figure 2 - Survival curve of CD1 mice after infection with T. gondii tachyzoites of TgShSp1 
isolate (A) and TgME49 isolate (B). Five mice per group were infected i.p. with 105, 104, 103, 102, 
10 or 1 tachyzoite of the TgShSp1 isolate. Survival was monitored for 42 days. Each point represents 
the percentage of surviving animals at that day, and downward steps correspond to euthanasia due to 
severe clinical signs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxoplasma-specific humoral immune 
responses at day 28 pp. However, although only 
seroconversion in half of the dams was 
observed in the group infected with 25 oocysts 
(group D), there were no statistically 
significant differences in the number of dams 
showing seroconversion between infected 
groups (Table 1). Anti-T. gondii IgG levels 
were significantly increased in groups infected 
with 2000 (P < 0.05), 500 (P < 0.01) and 100 
oocysts (P < 0.01) in comparison to the 
unchallenged group in which all dams were 
seronegative (Figure S1A). T. gondii DNA was 
detected in the brain of all dams from infected 
groups, with the exception of three dams in the 
group infected with 25 oocysts (group D) 
(Table 1). Quantitative evaluation of parasite 
burdens in brain showed no significant 
differences between infected groups (Figure 
S2A). In the lungs, parasite DNA was detected 
in the 50-83% of the dams from oocyst-infected 
groups, without significant differences in 
parasite detection or parasite load between 
them (Table 1) (Figure S3A). 
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3.4.2. Evaluation of TgShSp1 infection 
in offspring mice 
Most pups were born dead (82/93; 88%), 
although a few pups had to be euthanized due 
to severe clinical signs between day 2 and day 
21 pp (11/93; 12%). Half of the pups in the 
group infected with 2000 oocysts (group A) and 
with 500 oocysts (group B) were born dead or 
had to be euthanized due to severe clinical signs 
and had significantly higher pup mortality 
compared to the uninfected group (P < 0.05) 
(Table 1). In groups infected with 100 oocysts 
(group C) and 25 oocysts (group D), 
respectively, 9% and 27% of pups were born 
dead or had to be euthanized due to severe 
clinical signs. Only one of seventy-two pups 
was born dead in the uninfected group (group 
E) (Table 1). Starting from day 14 pp, offspring 
of the uninfected group (group E) showed 
significantly higher body weight than groups 
infected with 500 (P < 0.0001) and 100 oocysts 
(P < 0.001), and the same was true of those 
infected with 2000 oocysts (group A) from day 
22 pp (P < 0.001). However, no decreased body 
weight was noted in pups infected with 25 
oocysts (group D) (Figure 3A).  
Vertical transmission was detected upon 
PCR analyses in all brains (100%) of surviving 
pups from groups infected with 2000, 500 and 
100 oocysts (groups A, B and C). However, 
parasite was only detected in 37% of the brains 
from pups infected with 25 oocysts (group D), 
with significantly lower parasite detection 
compared to groups infected with 2000, 500 
and 100 oocysts (P < 0.0001) (Table 1). Pups 
infected with 25 oocysts (group D) and with 
100 oocysts showed lower parasite burden 
compared to those infected with 2000 and 500 
oocysts (groups A and B) (P < 0.0001) (Figure 
3B). No T. gondii DNA could be detected in the 
brain of pups that had died on day 0 or 1 pp.   
 
 
 
3.4.3. Evaluation of TgShSp1 oocyst 
infection in non-pregnant mice 
Similarly, to pregnant mice, clinical signs in 
non-pregnant mice infected with oocysts were 
generally mild. Therefore, none of the non-
pregnant mice had to be euthanized due to 
severe clinical signs. Only ruffled coat was 
observed in all mice infected with 2000 oocysts 
(group A), in one out of three mice in the group 
infected with 500 oocysts (group B) and in one 
out of four non-pregnant mice in the group 
infected with 100 oocysts (group C). All 
infected non-pregnant mice infected with 2000, 
500 and 100 oocysts (groups A, B and C) 
developed Toxoplasma-specific humoral 
immune responses at day 28 p.p. that were 
significantly increased in comparison to the 
unchallenged group, with basal IgG levels (P < 
0.05) (Figure S1B). In the group infected with 
25 oocysts (group D), only three of the four 
non-pregnant mice seroconverted (Table 1). 
Further analyses of antibody responses of 
pregnant and non-pregnant mice in each group 
did not reveal any significant differences. T. 
gondii DNA was detected in the brains of all 
non-pregnant mice from infected groups, with 
the exception of one mouse infected with 25 
oocysts (group D) (Table 1). In the lungs, 
parasite DNA was only detected in three out of 
four samples from mice infected with 100 
oocysts (group C). Quantitative evaluation 
showed no significant differences in parasite 
load in non-pregnant mice (Figures S2B and 
S3B). The comparison of parasite load in brain 
and lungs in pregnant mice vs non-pregnant 
mice revealed no significant differences.   
3.5. TgShSp1 and TgME49 oocyst 
infection cause similar perinatal mortality 
and vertical transmission in pregnant 
sheep 
3.5.1. Clinical observations 
No mortality was found in any sheep during 
the experiment. All ewes showed fever after 
infection. Significant increases in body 
temperature were found for three-four days 
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Figure 3 - Effect of oral administration of TgShSp1 oocysts in the mouse pups. (A) Body weight 
progression of neonates born from dams infected on day 7 of pregnancy with 2000 (group A), 500 
(group B), 100 (group C) or 25 (group D) TgShSp1 oocysts and the uninfected group (group E). Each 
point represents the average body weight of all animals per group. (B) Dot-plot graph of T. gondii 
load in brain from surviving pups. Each dot represents individual values of parasite burden (number 
of parasites per μg of DNA), and medians are represented as horizontal lines. (****) indicates P < 
0.0001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
after day 4 p.i. in all infected groups. From day 
14 pi until the end of the experiment, no 
changes were detected in the infected groups. 
Likewise, compared to groups infected with 
500 oocysts, one day of delay in the increase of 
rectal temperature (from day 5 to 6 pi) was 
found in groups infected with 50 and 10 oocysts 
(Figure 4). Differences in temperature increase 
between groups receiving the same dose of 
oocysts of the different T. gondii isolates were
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Figure 4 - Rectal temperatures of ewes infected with TgShSp1 oocysts and the uninfected ones 
(A) and ewes infected with TgME49 oocysts and the uninfected ones (B). From day 7 pi onwards, 
some ewes aborted and were euthanized, and their data are not available. Each point represents the 
mean + S.D. at the different sampling times for each group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generally not found. As an exception, lower 
rectal temperatures were only found on day 8 pi 
in groups infected with 500 and 10 oocysts of 
TgShSp1 compared to groups receiving the 
same doses of TgME49 oocysts (G500A vs 
G10A and G500B vs G10B) (P < 0.05). The 
mean rectal temperature in the uninfected 
group remained below 39.5°C throughout the 
monitoring period.   
Perinatal mortality in groups receiving 500 
oocysts was 100%. In groups receiving 50 and 
10 oocysts, 68% of fetuses/lambs in G50A (in 
6/6 ewes) and 66% in G10A (in 4/6 ewes) died 
after infection with TgShSp1, and 42% (in 2/5 
ewes) of them died in both groups after 
infection with TgME49. Perinatal mortality 
was increased with the oocyst doses. A lower 
perinatal survival rate was found in the group 
infected with 500 TgME49 oocysts compared 
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with that infected 50 oocysts (G500B vs G50B) 
(P < 0.05). In addition, a significantly lower 
perinatal mortality was found in those infected 
with 500 oocysts compared with those infected 
with 10 oocysts for both isolates (G500A and 
G500B compared to G10A and G10B, 
respectively) (P < 0.05). No differences in 
perinatal mortality were found between groups 
infected with 50 and 10 oocysts (G50A and 
G50B compared to G10A and G10B, 
respectively). Comparing groups that received 
the same dose of sporulated oocysts but 
different isolates, no significant differences 
were found in the perinatal survival rate. 
Concerning fetal death during pregnancy, all 
ewes challenged with 500 oocysts (G500A and 
G500B) aborted, and in the groups infected 
with lower doses, abortions were found in 3/6 
and 2/5 pregnant ewes infected with 50 oocysts 
of TgShSp1 and TgME49, respectively, and in 
1/6 and 1/5 pregnant ewes infected with 10 
oocysts of TgShSp1 and TgME49, respectively 
(Table 2). Non-aborted dams gave birth 
between days 143 and 149 of pregnancy, except 
one ewe infected with 50 TgME49 oocysts, 
which gave birth prematurely on day 134. In 
G50A, 1 mummified fetus and 3 stillborn lambs 
were found, and in G50B, G10A and G10B, 
one, eight and one stillborn lambs were 
delivered, respectively. Concerning morbidity 
in lambs born alive, weakness was found in 5 
out of 5 and 1 out of 4 in groups infected with 
50 oocysts, G50A and G50B, respectively, and 
in 2 out of 5 and 0 out of 4 in those infected 
with 10 oocysts, G10A and G10B, respectively. 
Therefore, morbidity in lambs born alive from 
the group infected with 50 TgShSp1 oocysts, 
G50A, was significantly higher than the 
corresponding TgME49 group, G50B (P < 
0.05), whereas no significant differences in the 
number of weak lambs were found between 
lambs from groups infected with 10 oocysts or 
between lambs from groups receiving different 
doses of both isolates. Dams from the 
pregnancy control group gave birth two 
stillborn lambs and six healthy lambs between 
days 147 and 152 of pregnancy.     
3.5.2. Parasite detection and burden in 
placental and fetal tissues  
3.5.2.1. Placental tissues 
In ewes suffering early abortions, no T. 
gondii DNA was detected in placentomes in 
TgME49-infected animals (i.e., G500B, G50B 
and G10B), and in ewes infected with 
TgShSp1, parasite DNA was only detected in 
one ewe infected with 500 oocysts (G500A), 
which aborted on day 9 pi (one positive 
placentome sample out of 30), and in one ewe 
infected with 50 oocysts (G50A), which 
aborted on day 10 pi (one positive placentome 
samples out of 18). In contrast, all placentomes 
from ewes showing late abortion were PCR-
positive. In ewes that delivered stillbirths or 
live lambs, all cotyledons from TgShSp1-
infected animals were PCR-positive. Among 
those challenged with TgME49 oocysts, 100% 
of cotyledon samples were positive in the group 
infected with 500 oocysts (G50B), while 75% 
of cotyledon samples were positive in the group 
infected with 10 oocysts G10B (Table 2) (Table 
S2). Concerning parasite burden (measured as 
the number of tachyzoites per milligram of 
tissue) in cotyledons from ewes that delivered 
stillbirths or live lambs, no differences were 
found between groups infected with 50 and 10 
oocysts in any of the isolates. However, 
comparing both T. gondii isolates, parasite 
loads in cotyledons from ewes that gave birth 
in groups infected with 50 and 10 oocysts of 
TgShSp1 (groups G50A and G10A), both were 
lower compared to those infected with 
TgME49 (G50B and G10B) (P < 0.05) (Figure 
5A).  
3.5.2.2. Fetal tissues 
In tissues from fetuses undergoing early 
abortion upon TgME49 infection, no T. gondii 
DNA was detected. The same was true for 
fetuses from early abortions after challenge 
with TgShSp1 oocysts, except for one positive 
fetal lung sample (1 positive sample out of 20) 
from one ewe that aborted on day 10 pi in one 
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Figure 5 - Dot-plot graphs of T. gondii burdens in cotyledons from ewes that gave birth (A) and 
brain (B) and lung (C) from stillborn lambs and live lambs from T. gondii-infected ewes. Each 
dot represents individual values of parasite burden (number of parasites per milligram of host tissue), 
and medians are represented as horizontal lines. Considering that the T. gondii detection limit by real-
time PCR is 0.1 parasites, negative samples (0 parasites) were represented on the log scale as <0.1 
(i.e., 10−2). The unbroken line is used to indicate differences between isolates, and the dashed line (--
--) is used to indicate differences between doses. For significant differences between infected groups 
in each tissue, (*) indicates P < 0.05 and (**) indicates P < 0.01.  
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group infected with 50 oocysts (G50A) (Table 
2) (Table S2).    
In late abortions, T. gondii DNA was 
detected in every fetus and all organs analyzed 
(Table 2). The percentage of positive samples 
in every individual organ ranged from 33% in 
the brain from one fetus in G10A to 100% in 
the rest of the brains and lungs from late 
abortions (Table S2).   
 
In all stillbirths and live lambs, T. gondii 
DNA was found in at least one of the studied 
organs, except in one stillborn lamb and one 
live lamb born from one ewe infected with 10 
TgME49 oocysts (G10B) in which T. gondii 
DNA was not detected in any analyzed tissue 
(Table S2). Concerning parasite detection in 
the brain of stillbirths/live lambs born from 
ewes infected with TgME49 oocysts, more 
samples were PCR-positive in the group 
infected with 50 oocysts, G50B (91.6%; 11/12; 
4 out of 4 fetuses) compared to the group 
infected with 10 oocysts, G10B (53.3%; 8/15; 
3 out of 5 fetuses) (P < 0.05). In lambs from 
ewes infected with TgShSp1 oocysts, a lower 
number of brain samples were found to be 
PCR-positive in the group infected with 50 
oocysts, G50A (33.3%; 5/15; 7 out of 9 
fetuses), compared to the group infected with 
10 oocysts, G10A (66.6%; 26/39; 13 out of 13 
fetuses) (P < 0.05). Similarly, lower parasite 
burden in brain from lambs was found in the 
group infected with 50 TgShSp1 oocysts 
(G50A vs G10A (P < 0.01). Comparing both 
isolates, parasite detection and parasite burden 
were higher in brain samples from lambs in the 
group infected with 50 oocysts of TgME49 
compared to the corresponding TgShSp1 group 
G50B vs G50A) (P < 0.01), while no 
significant differences were found between 
groups infected with 10 oocysts (G10A vs 
G10B) (Table 2) (Figure 5B) (Table S2). In 
lung tissues from stillbirths/live lambs, all 
samples were PCR-positive in those groups 
infected with 50 oocysts (G50A and G50B). 
Additionally, 100% parasite detection was 
observed in the group infected with 10 oocysts 
of TgShSp1 (G10A), whereas a significantly 
lower parasite detection rate was found in the 
group infected with 10 oocysts of TgME49, 
G10B (60%; 9/15; 3 out of 6 animals) (P < 
0.05). Comparison of the same oocyst dose 
from both isolates revealed no differences in 
parasite detection in lung samples from groups 
infected with 50 oocysts (G50B and G50A), but 
a higher parasite detection rate was found in the 
group infected with 10 TgShSp1 oocysts, 
G10A, compared to the group infected with 10 
TgME49 oocysts, G10B (P < 0.001) (Table 2) 
(Table S2). No differences in parasite burden in 
lungs from lambs were found between different 
doses or isolates (Figure 5C). Likewise, no 
differences in parasite detection or parasite 
burden were found in any fetal tissue between 
stillborn lambs and live lambs (data not 
shown). Samples from fetal tissues exhibiting 
DNA degradation and mummification were 
excluded from PCR analysis.  
3.5.3. Histological lesions and lesion 
quantification 
The only evident histological lesions in the 
studied organs were found in the brain from 
fetuses/lambs and placenta. Only the placenta 
from late abortions detected through US was 
available for histological study. As in those 
cases of early abortions, lambing or delivery of 
stillbirths, it was too autolytic to allow proper 
histological evaluation.   
In early abortions, multifocal areas of 
coagulative necrosis at the white matter 
(leukomalacia) were found in the brain from all 
the fetuses aborted in this period. In addition, 
no evident differences in the severity or number 
of lesions were noted between groups. In late 
abortions, lesions (multifocal necrotic 
placentitis) were found in all placentas studied. 
Likewise, there were brain lesions (multifocal 
nonpurulent encephalitis) in all the fetuses from 
late abortions (Table 2).  
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In stillbirths/live lambs, glial foci with or 
without a central area of necrosis were 
observed in the brain. These lesions were found 
in lambs from all groups, with a prevalence 
between 60% and 100%, depending on the 
group (Table 2). When the percentages of brain 
lesions in lambs from ewes infected with 
TgME49 and TgShSp1 were compared, there 
were no differences between isolates or oocyst 
doses tested. Furthermore, there was no 
difference in the percentage of cases with brain 
lesions between stillbirths and live lambs (data 
not shown). Lesion quantification was carried 
out in brain samples from the stillbirths and live 
lambs, and no significant difference was found 
in the number of lesions, individual focus area 
or percentage of damaged area between groups 
(Figure S4).   
3.5.4. Humoral immune responses 
The Toxoplasma-specific IgG antibody 
responses in dams are shown in Figure 6. No 
increase in IgG level compared to the 
uninfected group and no seroconversion was 
found in any of the ewes showing abortion 
during the acute phase of the infection. 
However, ewes with late abortion or those 
giving birth seroconverted on day 21 pi. In the 
group infected with 500 TgShSp1 oocysts, 
500A, all ewes except one suffered early 
abortions, so this group was excluded from 
statistical analysis. From day 21 pi onwards, 
ewes infected with 50 and 10 oocysts 
seroconverted and exhibited higher IgG 
compared to the control group (P < 0.05). 
When analyzing the IgG levels of animals 
infected with TgShSp1 sporulated oocysts, no 
significant differences were found between 
ewes infected with 50 and 10 oocysts, G50A 
and G10A (Figure 6A). However, in animals 
infected with TgME49 sporulated oocysts, it is 
noteworthy that the group infected with 10 
oocysts, G10B, had higher IgG on day 21 pi 
than the group infected with 50 oocysts, G50B 
(P < 0.01) (Figure 6B). Comparing groups 
receiving the same dose of sporulated oocysts, 
no significant differences in IgG level were 
found between groups infected with 50 oocysts, 
G50A and G50B. However, the group infected 
with 10 oocysts of TgShSp1, G10A, displayed 
lower IgG than that infected with TgME49, 
G10B, from day days 21 to 35 pi (P < 0.01). All 
uninfected control animals exhibited basal IgG 
levels within the reference range throughout the 
experimental study.   
None of the fetuses that were aborted before 
day 11 pi had detectable IgG against T. gondii 
antigen. In contrast, fetuses undergoing late 
abortions were IgG-positive. Of the lambs born 
from TgShSp1-infected ewes, seven out of 
eight and nine out of twelve lambs were 
positive in groups infected with 50 and 10 
TgShSp1 oocysts, G50A and G10A, 
respectively. Similarly, of the lambs born from 
TgME49-infected ewes, two out of three and 
50% of lambs born from those groups infected 
with 50 and 10 TgME49 oocysts, G50B and 
G10B, respectively, were positive (Table S3). 
Specific IgG responses against parasite antigen 
were not detected in lambs from the uninfected 
group.   
3.6. Comparative assessment of congenital 
infection in mice and sheep after infection 
with TgShSp1 oocysts. 
Perinatal mortality after infection with 500 
TgShSp1 oocysts occurred in sheep at a 
statistically higher rate compared to mice (P < 
0.001), since in sheep all fetuses died and in 
mice only 50% of the pups died. Similarly, 
higher perinatal mortality was found in sheep 
compared to mice after infections with 
intermediate (P < 0.0001) and low doses of 
oocysts (P < 0.01), since infection with 50 and 
10 TgShSp1 oocysts triggered mortality in 68 
and 66% of fetuses/lambs, whereas in mice 
mortality of 9% and 27% of the pups was 
observed after infection with 100 and 25 
TgShSp1 oocysts, respectively.  
Since no lambs were born in the group 
infected with 500 TgShSp1 oocysts, offspring 
morbidity in this group could not be assessed. 
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Figure 6 - Kinetics of the antibody production in ewes infected with TgShSp1 oocysts and the 
uninfected ones (A) and ewes infected with TgShSp1 oocysts and the uninfected ones (B). From 
day 7 pi onwards, some ewes aborted and were euthanized, and their data are not available. Each 
point represents the mean + S.D. at the different sampling times for each group. Serum levels of total 
IgG antibodies against T. gondii are expressed as a relative index percent (RIPC), according to the 
formula: RIPC = (OD405 sample – OD405 negative control)/(OD405 positive control – OD405 
negative control) × 100. 
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However, in mice infected with 500 TgShSp1 
oocysts, a decrease in pup body weight was 
found from day 14 pi onwards. Offspring from 
mice infected with 100 TgShSp1 oocysts 
showed a decrease in bodyweight from day 14 
pi onwards, and all lambs born alive from ewes 
infected with 50 TgShSp1 exhibited weakness 
at birth. At low doses of oocysts, no body 
weight decrease was noted in pups born from 
mice infected with 25 TgShSp1 oocysts; 
however, 2 out 5 live lambs from ewes infected 
with 10 TgShSp1 oocysts were born with 
obvious weakness and impaired health.   
All (100%) of the surviving mouse pups 
were PCR-positive in the brain, and 100% live 
lambs were seropositive or with a PCR-positive 
result in at least one tissue after infection with 
intermediate doses of oocysts (100 TgShSp1 
oocysts in mice and 50 TgShSp1 oocysts in 
sheep). Additionally, 100% of the surviving 
pups were PCR-positive in the brain after 
infection with 500 TgShSp1 oocysts (high dose 
of oocysts). However, a statistically higher 
number of T. gondii-positive offspring were 
found in sheep compared to mice after infection 
with low doses of oocysts (P < 0.05), since 
100% lambs were seropositive or with a PCR-
positive result in at least one tissue after 
infection with 10 TgShSp1 oocysts and only 
37% of the surviving pups were PCR-positive 
in the brain after infection with 25 TgShSp1 
oocysts (Table 3).   
4. Discussion  
T. gondii is an apicomplexan parasite that is 
distributed worldwide (Dubey, 2010). In 
Europe and North America, T. gondii isolates 
display a clonal population structure, with the 
vast majority of T. gondii isolates being 
grouped into three lineages, namely, types I, II 
and III (Howe and Sibley, 1995). Type II T. 
gondii is the most prevalent in all hosts in 
Europe, including sheep (Dumètre et al., 2006; 
Halos et al., 2010a; Su et al., 2010). Previous 
studies in Europe have shown that T. gondii 
type II is associated with ovine abortion (Owen 
and Trees, 1999; Jungersen et al., 2002; Chessa 
et al., 2014). In Spain, type II is the most 
prevalent genotype in wild animals and cats 
(Montoya et al., 2008; Calero-Bernal et al., 
2015), as well as in previously obtained ovine 
isolates (Fuentes, 1999). The TgShSp1 isolate 
belongs to genotype #3 (a type II variant, II for 
nine alleles/I for Apico), sharing genotype with 
the Prugniaud (PRU) isolate.  
T. gondii PRU isolates exhibit a similar 
genetic pattern to the T. gondii type II reference 
isolate, TgME49 (genotype #1) (Su et al., 
2012). In addition, both type II isolates, 
TgME49 and PRU, activate the host cell 
transcription factor NF-κB, an integral 
component of the immune response to T. 
gondii, and they display identical GRA15 gene 
sequences, which is involved in NF-κB 
activation (Rosowski et al., 2011). TgME49 
was isolated from sheep muscle in 1958 (Lunde 
and Jacobs, 1983) and has since then undergone 
long-term passaging in cell culture and mice 
(Sibley et al., 2002). Previous studies have 
demonstrated changes in biological 
characteristics of T. gondii isolates after 
passages in mice and cell culture (Frenkel et al., 
1976; Lindsay et al., 1991; Harmer et al., 1996; 
Saraf et al., 2017). This fact has been widely 
studied in T. gondii type I isolates (Cesbron and 
Sabin, 1994; Villard et al., 1997; Dubey et al., 
1999; Mavin et al., 2004; Khan et al., 2009b). 
However, whether these changes also occur in 
type II isolates, and how they compare to 
recently obtained isolates, remains unknown. 
Increased growth in vitro can be found after 
repeated passages (Yano et al., 1987). The 
dramatic differences observed during in vitro 
growth of TgME49 and TgShSp1 might reflect 
the highly different passage history of the two 
isolates. Plaque formation is commonly used to 
measure growth of T. gondii, and this process 
is the result of several events, including 
invasion, growth, egress, and migration (Roos 
et al., 1995). Notably, TgME49 tachyzoites 
formed plaques at 4 days pi, but TgShSp1 did 
not. The finding that TgShSp1 did not form  
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plaques in vitro could have resulted from the 
limited growth rate, associated with a higher 
capacity of bradyzoite conversion, as 
previously described Khan et al. (2009b). This 
was confirmed by monitoring spontaneous cyst 
formation through labeling with the fluorescent 
lectin DBL, demonstrating tissue cyst 
formation under standard cell culture 
procedures in TgShSp1 that was greater than 
TgME49. Due to its high passage number in 
cell culture or mice, our TgME49 isolate may 
not accurately represent natural virulence traits 
of the type II lineage, which suggests that 
comparisons of phenotypes between T. gondii 
isolates should be conducted using low-passage 
stocks.    
Traditionally, mouse models are utilized to 
evaluate virulence by monitoring survival after 
experimental infection. Type I isolates are 
highly virulent in mice (LD100 of 1 tachyzoite), 
whereas types II and III exhibit median lethal 
doses (LD50) that range from 102 to 105 (Saeij 
et al., 2006). Conventionally, TgME49 is a 
cystogenic type II isolate with low virulence in 
mice (Ferreira et al., 2001; Gavrilescu and 
Denkers, 2001; Oliveira et al., 2016). 
Intraperitoneal inoculation of 103 and 5 x 104 
TgME49 tachyzoites intraperitoneally has not 
caused mortality (Ferreira et al., 2001; Oliveira 
et al., 2016). However, in this study, TgME49 
displayed a LD50 of 103, so the virulence of our 
TgME49 could be considered stronger than 
previous descriptions (Ferreira et al., 2001; 
Oliveira et al., 2016). Enhanced virulence in 
mice for T. gondii strains maintained for 
several passages has also been reported 
previously (Shimizu et al., 1967; Sibley and 
Boothroyd, 1992; Frenkel and Ambroise-
Thomas, 1996). Hence, it seems logical to 
speculate that results from studies using 
laboratory isolates should be validated with 
more recent isolates before they can be 
extrapolated as general features of the 
respective lineage. In contrast to TgME49, 
mice inoculated with tachyzoites of the recently 
obtained type II isolate TgShSp1 exhibited only 
moderate, low-level clinical signs, but no 
mortality (LD50 > 105), similar to what was 
described earlier after intraperitoneal 
inoculation of Swiss Webster mice with 103 
tachyzoites of a PRU isolate (Wang et al., 
2013). In addition, although oocysts are 
considered more virulent than tachyzoites in 
mice (Dubey and Frenkel, 1973), no mortality 
in adult mice was found after infection with 
oocysts of TgShSp1 in pregnant and non-
pregnant mice, suggesting very low virulence 
in mice.    
In the present work, we also investigated 
congenital toxoplasmosis in pregnant mice by 
inoculating them orally with different doses of 
TgShSp1 oocysts. The risk of congenital 
toxoplasmosis depends on the virulence of the 
parasite (Tenter et al., 2000). Based on the 
previously established toxoplasmosis model 
using TgME49 oocysts (Müller et al., 2017c), 
we infected mice at day 7 postmating, which 
represents the beginning of the second term of 
gestation. Few mice infected with TgShSp1 
oocysts showed mild clinical signs, contrary to 
the large number of mice succumbing to 
infection after the same oocyst doses of 
TgME49 (Müller et al., 2017c). There is a 
possibility that there has been a selection 
towards increased virulence within TgME49 
due to the successive passages, as explained 
above but also due to the sulfadimidine 
treatment that was applied in mice used for 
infection of cats to generate TgME49 oocysts 
used in this study (Müller et al., 2017c). This 
sulfonamide treatment could act as a bottleneck 
in selecting tachyzoites with a faster replication 
and therefore increasing the virulence in mice 
of the final TgME49 parasites. Unlike what was 
observed for TgME49 (Müller et al., 2017c), 
with which a clear effect on pregnancy rate was 
found after infection with 2000 oocysts and on 
litter size after infection with 500 oocysts, 
infection with TgShSp1 oocysts did not result 
in alteration of pregnancy rate or litter size. 
Likewise, while 92% of the pups died after 
infection of dams with 25 TgME49 oocysts 
(Müller et al., 2017c), a significant decrease in 
pup survival was found only after infection 
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with 2000 and 500 TgShSp1 oocysts, where 
there was mortality in 50% of the pups. It has 
been proposed that immune modulation in 
pregnant mice (Athanassakis and Iconomidou, 
1996) generally renders them more susceptible 
to infection, but in this study, infection with 
TgShSp1 oocysts did not show differences in 
cerebral or lung infection between pregnant and 
non-pregnant mice. In conclusion, infection of 
mice with TgShSp1 oocysts at mid-pregnancy 
did not generate severe clinical signs in adult 
mice, but infection doses of 2000 and 500 
oocysts in the dams resulted in mortality of 
50% of the pups and decreased body weight in 
surviving pups, and 100% vertical transmission 
occurred with doses of up to 100 oocysts.  
Sheep are a relevant host of the parasite and 
could suffer abortions when primo infected 
during gestation (Vargas-Villavicencio et al., 
2016). In this study, although rectal 
temperatures in sheep were similarly increased 
in TgME49 and TgShSp1, ewes infected with 
500 and 10 TgME49 oocysts exhibited higher 
rectal temperature on day 8 pi compared to 
same doses of TgShSp1 oocysts. Perinatal 
mortality was similar for both isolates. 
However, those ewes infected with 10 and 50 
TgME49 oocysts and that delivered 
stillbirths/live lambs exhibited higher parasite 
load in cotyledons than those infected with the 
same doses of TgShSp1 oocysts. Similarly, a 
higher parasite load was found in the brain from 
lambs born in the group infected with 50 
TgME49 oocysts compared to the 
corresponding TgShSp1 group. Therefore, it is 
tempting to hypothesize that the enhanced 
virulence of our TgME49 contributed to the 
abovementioned effects. Comparing different 
doses of infection, pregnant ewes challenged 
with 50 and 10 oocysts showed one day of 
delay in the increase of rectal temperature 
compared to ewes infected with 500 oocysts in 
both isolates, similar to what was described by 
Buxton et al. (1991) and Mévélec et al. (2010). 
Likewise, there is a correlation between the 
dose of infection and the rate of early abortions, 
as previously suggested (Mévélec et al., 2010; 
Benavides et al., 2017). Infection with 500 
oocysts triggered abortion in all fetuses, similar 
to previous experimental infections in pregnant 
sheep at mid-pregnancy using 2000 oocysts 
(Owen et al., 1998a; Castaño et al., 2014). 
After infection with 50 TgShSp1 oocysts or 50 
TgME49 oocysts, 68 and 42% of fetuses/lambs 
died, respectively, similar to what was 
previously reported after infection with 50 M4 
oocysts (Castaño et al., 2014). The occurrence 
of abortions after infection with 10 oocysts was 
low, but large numbers of stillbirths and weak 
lambs were found, mainly in the 10 TgShSp1 
oocysts group. There seems to be a correlation 
between the presence of the parasite and the 
occurrence of stillbirths, since stillbirths from 
the group infected with 10 TgShSp1 oocysts 
exhibited higher parasite detection and load in 
the brain than those in the group infected with 
50 TgShSp1 oocysts. Regardless of the isolate 
or dose, no differences were found in the 
congenital infection of lambs born, since 
vertical transmission was found in all them 
except in one stillborn lamb and one live lamb 
born from one ewe infected with 10 TgME49 
oocysts. Likewise, no differences were found 
between doses or isolates with respect to brain 
lesion presence and lesion severity in lambs 
born.  
Most of the experimental studies in pregnant 
sheep carried out so far used M1, M3 and M4 
T. gondii type II isolates for infection (Dubey, 
2009b; Castaño et al., 2014). However, 
although numerous experimental infections 
were also carried out in mice with these isolates 
(Nicoll et al., 1997; Owen et al., 1998a; 
Hamilton et al., 2018), their virulence in mice 
models has not been studied in depth. 
Therefore, the correlation between virulence in 
mice and outcome of experimental infections in 
pregnant sheep has not been elucidated. 
Despite the clear differences in body weight 
between mice and sheep, in the current study, 
similar doses of oocysts were used to compare 
both hosts. None of the adult mice challenged 
with 25 TgShSp1 oocysts exhibited clinical 
signs, whereas all ewes challenged with 10 
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TgShSp1 oocysts had fever. Therefore, 
morbidity in sheep seems to be higher than in 
mice. In addition, no mortality was observed in 
adult mice or sheep infected with TgShSp1 
oocysts. When comparing the congenital 
infection after challenge at mid-pregnancy 
between both hosts, 50% mortality was caused 
in mice by infection with 500 TgShSp1 
oocysts, whereas in sheep infection with the 
same oocyst dose caused mortality in all 
fetuses. In brief, mice seem to be less 
susceptible to perinatal mortality than sheep, 
despite the fact that vertical transmission was 
similar in both species. High vertical 
transmission and low offspring mortality could 
be an evolutionary strategy of the parasite to 
generate a large infected offspring group in 
mice, one of the most relevant hosts of T. gondii 
(Müller and Howard, 2016).  
 
There are several differences between mice 
and sheep that could underlie the differences 
found in this study. The histological structure 
of the placenta is very different between mice 
and sheep (Entrican, 2002), and although 
maternal blood and fetal tissue are closer in 
mice, allowing an easy crossing of tachyzoites 
but also of antibodies, the longer period of 
gestation, the lack of maternal antibodies 
crossing the placental barrier and fewer fetuses 
may facilitate vertical transmission in sheep. In 
addition, host genetics are likely important in 
determining susceptibility and severity of 
infection (Howe et al., 1996; Müller and 
Howard, 2016). Small rodents, natural 
intermediate hosts, are often exposed to a 
higher dose and more virulent parasites than 
other groups of mammals. It may therefore be 
that Toll-Like-Receptors (TLR)11 and TLR12 
and the polymorphism of immunity-related 
GTPases (IRG proteins) have been positively 
selected in rodents, because of their critical 
importance in host resistance against high 
infection loads or more virulent clones of T. 
gondii. In mice, TLR11 and TLR12 on 
dendritic cells detect the apicomplexan actin-
binding protein profilin leading to the secretion 
of interleukin 12 (IL12), which can 
subsequently induce production of IFNγ by T 
cells. IFNγ induces a variety of parasiticidal 
mechanisms, which in mice are dominated by 
upregulation of the IRGs. IRGs can destroy the 
vacuole in these parasites live and subsequently 
the parasite itself (Gazzinelli et al., 2014). 
Considering the ubiquity of T. gondii in nature, 
it is intriguing that genes encoding TLR11, 
TLR12, and IRG proteins are not found in 
many mammalian species (Gazzinelli et al., 
2014). Although further studies are needed, and 
despite the influence of genetic polymorphisms 
in ovine abortions (Darlay et al., 2011), this fact 
could render sheep less resistant. Similarly, 
differences in immune cell populations may 
influence the pathogenesis of toxoplasmosis in 
these hosts. γδ T cells, which rapidly recognize 
and respond to nonprocessed antigens and seem 
to have an important role in T. gondii infection 
(Egan et al., 2005), represent a relevant subset 
of circulating T cells in sheep compared to mice 
(Holderness et al., 2013). Further studies are 
needed to characterize the cellular and 
molecular bases contributing to transmission 
dynamics and disease in different hosts of T. 
gondii (Dubremetz and Lebrun, 2012; Hunter 
and Sibley, 2012).    
 
In conclusion, we have demonstrated that 
infection with tachyzoites and oocysts of the 
type II T. gondii isolate TgShSp1 in mice does 
not cause mortality, but this isolate is 
efficiently vertically transmitted in pregnant 
mice, and compared to sheep, it triggers lower 
offspring mortality and morbidity. Thus, at 
least for this isolate, the disease caused in 
pregnant mice and offspring is not a reliable 
predictor/indicator for disease caused in 
pregnant sheep at mid-gestation. Whether this 
conclusion is also valid for other type II T. 
gondii strains needs to be addressed in future 
studies. In addition, our results suggest that the 
laboratory isolate TgME49 exhibits an 
enhanced virulence due to successive passages 
in cell culture and mice. Thus, virulence traits 
may have been modified, and it might be 
advisable to use low-passage isolates in 
experimental studies, as these probably provide 
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a more realistic picture of the true nature of the 
parasite biology in the field. 
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Table S1 - Clinical signs, serological titres and parasite detection in mice intraperitoneally 
infected with TgME49 and TgShSp1 tachyzoites.    
Dose of tachyzoites 
Mice 
ref. 
Clinical signs 
(dpi)* 
IFAT titre 
PCR 
Brain Lung 
105 TgShSp1  
1 1 (4) 1:400 + - 
2 1 (5) 1:800 + + 
3 1 (7) 1:1600 + + 
4 1 (9) 1:800 + + 
5 1 (10) 1:1600 + + 
105 TgME49  
1 3 (11)T Negative + + 
2 3 (8)T NA + + 
3 2 (8) 1:800 + + 
4 2 (8) 1:800 + + 
5 2 (8) 1:400 + + 
104 TgShSp1 
1 2 (10) 1:800 + + 
2 1 (8) 1:800 + + 
3 1 (8) 1:1600 + + 
4 1 (9) 1:800 + + 
5 0 1:400 + - 
104 TgME49 
1 3 (10)T Negative + + 
2 2 (9) 1:200 + - 
3 3 (14)T Negative + + 
4 2 (9) 1:200 + + 
5 2 (9) 1:800 + - 
103 TgShSp1 
1 1 (6) 1:800 + - 
2 1 (6) 1:400 + + 
3 1 (7) 1:400 + + 
4 1 (9) 1:1600 + + 
5 1 (9) 1:800 + - 
103 TgME49  
1 4 (33)T 1:25 + + 
2 4 (13)T Negative + + 
3 2 (10) 1:400 + + 
4 2 (10) 1:400 + - 
5 3 (14)T NA + + 
102 TgShSp1 
1 1 (7) 1:800 + - 
2 1 (8) 1:1600 + + 
3 1 (8) 1:1600 + + 
4 1 (9) 1:3200 + + 
5 1 (13) 1:800 + + 
102 TgME49  
1 2 (14) 1:200 + + 
2 4 (13)T Negative + + 
3 2 (14) 1:100 + + 
4 2 (14) 1:100 + + 
5 2 (14) 1:200 + - 
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Table S1 – Continued.  
Dose of tachyzoites 
Mice 
ref. 
Clinical signs 
(dpi)* 
IFAT titre 
PCR 
Brain Lung 
10 TgShSp1 
1 1 (7) 1:800 + + 
2 0 1:800 + + 
3 0 1:800 + + 
4 0 1:800 + + 
5 0 1:1600 + + 
10 TgME49  
1 2 (14) 1:100 + - 
2 2 (14) 1:100 + - 
3 4 (24)T Negative + + 
4 2 (14) 1:100 + - 
5 2 (14) 1:50 + - 
1 TgShSp1 
1 0 Negative - - 
2 0 Negative - - 
3 0 Negative - - 
4 0 Negative - - 
5 0 Negative - - 
1 TgME49 
1 0 Negative - - 
2 0 Negative - - 
3 0 Negative - - 
4 0 Negative - - 
5 0 Negative - - 
 
* Clinical signs compatible with toxoplasmosis. Scores of 0 (no alterations), 1 (ruffled coat), 2 (rounded back), 
3 (noticeable loss of body condition/severe weight loss) or 4 (nervous signs such as activity decrease, hind limb 
paralysis, walking in circles or head tilt). In brackets, day post infection when mice exhibited clinical signs. 
T Mice showing clinical scores of 3 or 4 were euthanized to limit unnecessary suffering.  
NA: not available 
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Figure S1 - Box-plots showing IgG serum titers generated in dams (A) and non-pregnant mice 
(B) infected with TgShSp1 oocysts and the uninfected group. Graphs represent the median 
percentage, the lower and upper quartiles (boxes) and minimum and maximum values (whiskers).     
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Figure S2 - Dot-plot graphs of T. gondii burdens in brain from dams (A) and non-pregnant mice 
(B). Each dot represents individual values of parasite burden (number of parasites per microgram of 
DNA), and medians are represented as horizontal lines.      
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Figure S3 - Dot-plot graphs of T. gondii burdens in lung from dams (A) and non-pregnant mice 
(B). Each dot represents individual values of parasite burden (number of parasites per microgram of 
DNA), and medians are represented as horizontal lines.       
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Table S2 - Individual frequency of parasite DNA detection in infected animals.    
 
Group 
Ewe 
ref. 
Foetal 
death 
(dpi)a 
Placentomes/
cotyledonsb 
Foetal/    
lamb      
ref 
Foetal tissues 
Brain Lung 
G500A 
(500 
TgShSp1 
oocysts) 
500A.1 9 + 500A.1F1 - - 
500A.2 36 +++ 500A.2F1 +++ +++ 
500A.3 8 - 500A.3F1 - - 
500A.4 9 - 500A.4F1 - - 
   500A.4F2 - - 
   500A.4F3 - - 
500A.5 8 - 500A.5F1 - - 
500A.6 8 - 500A.6F1 - - 
   500A.6F2 - - 
   500A.6F3 - - 
   500A.6F4 - - 
   500A.6F5 - - 
G500B 
(500 
TgME49 
oocysts) 
 
500B.1 8 - 500B.1F1 - - 
   500B.1F2 - - 
500B.2 9 - 500B.2F1 - - 
   500B.2F2 - - 
   500B.2F3 - - 
 
500B.3 8 - 500B.3F1 - - 
   500B.3F2 - - 
500B.4 9 - 500B.4F1 - - 
500B.5 9 - 500B.5F1 - - 
   500B.5F2 - - 
G50A 
(50 
TgShSp1 
oocysts)  
50A.1 a +++ 50A.1F1 - +++ 
   50A.1F2 γ γ 
   50A.1F3 β β 
50A.2 10 + 50A.2F1 - + 
   50A.2F2 - - 
   50A.2F3 - - 
50A.3 9 - 50A.3F1 - - 
   50A.3F2 - - 
50A.4 a +++ 50A.4F1 ++ +++ 
   50A.4F2 ++ +++ 
50A.5 a  50A.4F3 γ γ 
  +++ 50A.5F1 - +++ 
   50A.5F2 + +++ 
 50A.6 10 - 50A.6F1 - - 
    50A.6F2 - - 
G50B 
(50 
TgME49 
oocysts) 
50B.1 35 +++ 50B.1F1 +++ +++ 
50B.2 a NA 50B.2F1 +++ +++ 
50B.3 11 - 50B.3F1 - - 
50B.4 a +++ 50B.4F1 +++ +++ 
   50B.4F2 +++ +++ 
50B.5 a +++ 50B.5F1 ++ +++ 
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Table S2 – Continued. 
Group 
Ewe 
ref. 
Foetal 
death 
(dpi)a 
Placentomes/
cotyledonsb 
Foetal/    
lamb      
ref 
Foetal tissues 
Brain Lung 
G10A (10 
TgShSp1 
oocysts) 
 
10A.1 49 +++ 10A.1F1 γ γ 
   10A.1F2 + +++ 
10A.2 a +++ 10A.2F1 ++ +++ 
   10A.2F2 + +++ 
10A.3 a +++ 10A.3F1 +++ +++ 
   10A.3F2 ++ +++ 
   10A.3F3 ++ +++ 
10A.4 a +++ 10A.4F1 +++ +++ 
   10A.4F2 ++ +++ 
10A.5 a +++ 10A.5F1 + +++ 
   10A.5F2 + +++ 
 10A.6 a +++ 10A.6F1 +++ +++ 
    10A.6F2 ++ +++ 
    10A.6F3 + +++ 
    10A.6F4 +++ +++  
G10B (10 
TgME49 
oocysts) 
10B.1 11 - 10B.1F1 - - 
   10B.1F2 - - 
10B.2 a +++ 10B.2F1 ++ +++ 
10B.3 a - 10B.3F1 - - 
   10B.3F2 - - 
10B.4 a +++ 10B.4F1 +++ +++ 
10B.5 a +++ 10B.5F1 +++ +++ 
 
a Day post-challenge when foetal death was detected by ultrasonography. The remaining ewes (a) delivered 
stillbirths/live lambs. 
b Placentomes in ewes that aborted and cotyledons in ewes that gave birth;  
γ Samples from foetal tissues exhibiting DNA degradation were excluded. 
β Mummified foetuses were not evaluated.  
dpi: days post-infection 
NA: not available 
Plus (+++, ++, +) and minus (-) signs represent PCR detection in >67%, 66-34%, <33% and 0% of samples 
analysed, respectively.   
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Figure S4 - Dot-plots showing number of lesions (A), individual focus area (B) and percentage 
of damaged area (C) in the brains from stillborn lambs and live lambs. Each dot represents 
individual, and medians are represented as horizontal lines.        
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Table S3 - Individual serological titers in fetuses/lambs from infected ewes.    
 
Group 
Ewe 
ref. 
Foetal death 
(dpi)a 
Foetus/Lambs 
ref. 
FL or Sera 
titre 
G500A 
(500 TgShSp1 
oocysts) 
500A.1 9 500A.1F1 - 
500A.2 36 500A.2F1 1:64 
500A.3 8 500A.3F1 - 
500A.4 9 
 
500A.4F1 - 
500A.4F2 - 
500A.4F3 - 
500A.5 8 500A.5F1 - 
500A.6 8 500A.6F1 - 
500A.6F2 - 
500A.6F3 - 
  500A.6F4 - 
  500A.6F5 - 
G500B                                  
(500 TgME49 
oocysts) 
500B.1 8 500B.1F1 - 
  500B.1F2 - 
500B.2 9 500B.2F1 - 
  500B.2F2 - 
  500B.2F3 - 
 500B.3 8 500B.3F1 - 
   500B.3F2 - 
 500B.4 9 500B.4F1 - 
 500B.5 9 500B.5F1 - 
   500B.5F2 - 
       50A.1 a      50A.1F1 - 
   50A.1F2 1:8^ 
   50A.1F3 NA 
 50A.2 10 50A.2F1 - 
   50A.2F2 - 
   50A.2F3 - 
 50A.3 9 50A.3F1 - 
G50A (50 TgShSp1 
oocysts)   
  50A.3F2 - 
 50A.4 a 50A.4F1 1:800 
   50A.4F2 1:100 
   50A.4F3 1:16^ 
 50A.5 a 50A.5F1 1:100 
   50A.5F2 1:100 
   50A.5F3 1:16^ 
 50A.6 10 50A.6F1 - 
   50A.6F2 - 
G50B                                  
(50 TgME49 oocysts)  
50B.1 35 50B.1F1 1:128 
50B.2 a 50B.2F1 -^  
50B.3 11 50B.3F1 - 
50B.4 a 50B.4F1 1:400 
  50B.4F2 1:200 
50B.5 a 50B.5F1 NA* 
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Table S3 – Continued. 
 
Group 
Ewe 
ref. 
Foetal death 
(dpi) 
Foetus/Lambs 
ref. 
FL or Sera 
titre 
 10A.1 49 10A.1F1 - 
G10A                                 
(10 TgShSp1 oocysts) 
  10A.1F2 1:64 
10A.2 
 
a 10A.2F1 1:100 
 10A.2F2 1:100 
10A.3 
 
a 10A.3F1 1:200 
 10A.3F2 - 
  10A.3F3 1:100 
10A.4 a 10A.4F1 -^  
10A.5 a 
10A.4F2 1:16^ 
10A.5F1 1:200 
10A.5F2 NA* 
10A.6 a 10A.6F1 1:200 
  10A.6F2 1:100 
   10A.6F3 1:800 
   10A.6F4 - 
G10B                                  
(10 TgME49 oocysts) 
10B.1 11 10B.1F1 - 
  10B.1F2 - 
10B.2 a 10B.2F1 1:50 
10B.3 a 10B.3F1 - 
  10B.3F2 -^ 
10B.4 a 10B.4F1 NA* 
10B.5 a 10B.5F1 1:50 
 
a Day post-challenge when foetal death was detected by ultrasonography. The remaining ewes (a) delivered 
stillbirths/live lambs 
^ thoracic or abdominal fluids were analysed in stillborn lambs of which it was unable to obtain precolostral 
sera. 
 * suckling before serum sampling. dpi: days post-infection; FL: foetal liquid; NA: not available. 
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Objetivo 2 
Estandarización de un modelo ovino gestante de infección con el 
aislado Nc-Spain7 de N. caninum mediante la evaluación de la 
influencia de la dosis y la via de administración 
 
 
Las infecciones experimentales en ovejas gestantes se han centrado en el estudio del efecto que 
tiene el momento del desafío en el resultado de la infección por N. caninum, mientras que el impacto 
de la dosis y la vía de desafío no han sido estudiadas en profundidad. Asi pues, el resultado de la 
infección, la respuesta immune, la detección y carga del parásito y la gravedad de las lesiones en 
tejidos placentarios y cerebros fetales fueron investigadas en ovejas inoculadas por vía intravenosa 
en día 90 de gestación con 105, 104, 103 o 102 taquizoitos o por vía subcutánea con 104 taquizoitos del 
aislado virulento Nc-Spain7. Comparando las dosis de desafio, las ovejas desafiadas por vía 
intravenosa con 105 taquizoitos fueron las únicas que mostraron un 100% de aborto. Asimismo, los 
niveles de IFNγ en las ovejas desafíadas con 105 taquizoitos por vía intravenosa se incrementaron 
antes que en aquellas desafiadas por vía intravenosa con menos dosis, y los niveles de IgG en día 21 
postinfección fueron mayores en las ovejas infectadas con 105 taquizoitos que en el resto de ovejas 
desafiadas por vía intravenosa con dosis menores. En relación a la transmisión vertical, las ovejas 
desafiadas con 105 taquizoitos por vía intravenosa mostraron una mayor carga parasitaria en el cerebro 
de los fetos que aquellas desafiadas con 104 y 103 taquizoitos por vía intravenosa. Comparando las 
vías de administración, no se observaron diferencias en la mortalidad fetal ni en la carga parasitaria 
de los cerebros de los fetos. Aunque las ovejas desafiadas con 104 taquizoitos por vía intravenosa 
mostraron mayores niveles de IFNγ que aquellas desafiadas con 104 taquizoitos por vía subcutánea, 
no se vieron diferencias en las respuestas immunes humorales. Dado que el resultado del desafio por 
vía intravenosa con 105 taquizoitos es similar al observado en un estudio previo tras la infección por 
vía intravenosa con 106 taquizoitos (100% de aborto y transmisión vertical), se concluye que quizás 
sea razonable el uso de 105 taquizoitos por vía intravenosa en futuros experimentos que evalúen 
candidatos farmacológicos y vacunales.  
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Abstract  
 
Experimental infections in pregnant sheep have been focused on studying the effect of the time of 
challenge on the outcome of N. caninum infection, whereas the impact of the dose and route of 
challenge has not been studied in depth. Therefore, clinical outcome, immune responses, parasite 
detection and burden, and lesion severity in placental tissues and foetal brains were investigated in 
90-day-pregnant sheep inoculated intravenously with 105 (G1), 104 (G2), 103 (G3), or 102 (G4) 
tachyzoites or subcutaneously with 104 (G5) tachyzoites of the virulent Nc-Spain7 isolate and an 
uninfected group (G6). Comparing challenge doses, G1 was the only group that showed 100% 
abortion. Likewise, IFNγ levels in G1 increased earlier than those in other intravenously infected 
groups, and IgG levels on day 21 post-infection (pi) were higher in G1 than those in other 
intravenously infected groups. Concerning vertical transmission, G1 showed a higher parasite burden 
in the foetal brain than did G2 and G3. Comparing routes of administration, no differences in foetal 
survival rate or parasite load in the foetal brain were found. Although G2 showed higher IFNγ levels 
than G5 on day 10 pi, no differences were found in humoral immune responses. Because the outcome 
after intravenous infection with 105 tachyzoites is similar to that observed after intravenous infection 
with 106 tachyzoites used in a previous work (100% abortion and vertical transmission), we conclude 
that it may be reasonable to use 105 tachyzoites administered by the intravenous route in further 
experiments when assessing drugs or vaccine candidates.    
Keywords: Neospora caninum, pregnant sheep model, Nc-Spain7, dose titration, route of 
administration, abortion, vertical transmission 
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1. Introduction 
Neospora caninum is an obligate 
intracellular apicomplexan parasite considered 
one of the leading infectious causes of abortion 
in cattle worldwide (Dubey et al., 2007; 
Reichel et al., 2013; Dubey et al., 2017). 
Recent studies suggest that N. caninum could 
also be a relevant abortifacient in some small 
ruminant management systems (Moreno et al., 
2012) or even the main cause of reproductive 
losses in some flocks (West et al., 2006; 
González-Warleta et al., 2014). The 
pathogenesis of ovine neosporosis is poorly 
understood and, in contrast to the clinical 
outcome in cattle, infection during mid-
pregnancy in sheep resulted in severe clinical 
outcome, as most of the animals aborted or, less 
frequently, produced weak lambs (McAllister 
et al., 1996b; Buxton et al., 1998; Arranz-Solis 
et al., 2015b).  
In pregnant sheep, infective doses of 107-108 
tachyzoites resulted in a high percentage of 
abortions (Dubey and Lindsay, 1990; Buxton et 
al., 2001; Innes et al., 2001a; Weston et al., 
2009). In a study comparing different infective 
doses, a strong relationship between the 
challenge dose of Nc-NZ1, Nc-NZ2 and Nc-
NZ3 N. caninum tachyzoites and the clinical 
outcome was found in pregnant sheep at mid-
gestation (Weston et al., 2009). To date, there 
are no studies comparing the outcome of N. 
caninum experimental infection using different 
routes of inoculation in pregnant sheep, 
although, in cattle, it was crucial because 
intravenous inoculation was associated with a 
more severe clinical presentation than 
subcutaneous inoculation (Macaldowie et al., 
2004). Likewise, there are clear differences 
concerning the outcome of the infection among 
parasite isolates (Benavides et al., 2014). The 
Nc-Spain7 isolate (Regidor-Cerrillo et al., 
2008) is a very well-characterized virulent 
isolate tested so far in three experimental 
ruminant models, sheep (Arranz-Solis et al., 
2015b), goats (Porto et al., 2016) and cattle 
(Caspe et al., 2012; Regidor-Cerrillo et al., 
2014; Almería et al., 2016).  
Recently, the Nc-Spain7 isolate has been 
evaluated at different times during gestation in 
pregnant sheep, suggesting that the time of 
infection plays a key role in the pathogenesis of 
the disease (Arranz-Solis et al., 2015b).  
Therefore, the aim of this study was to 
investigate the effect of challenge dose and 
route of administration in the outcome of 
experimental infection in ewes at mid-term of 
gestation using the Nc-Spain7 isolate. The 
effect of parasite dose and route of 
administration on the clinical course of disease, 
cellular and humoral immune responses, lesion 
development and parasite detection and burden 
in placental and foetal tissues were evaluated. 
This experiment allowed the refinement and 
standardization of an exogenous transplacental 
transmission model for ovine neosporosis.  
2. Material and methods 
2.1. Ethics statement 
All protocols involving animals were 
approved by the Animal Welfare Committee of 
the Community of Madrid, Spain following 
procedures described in Spanish and EU 
legislations (PROEX 93/14, Law 32/2007, 
R.D. 53/2013, and Council Directive 
2010/63/EU). All animals used in this study 
were handled in strict accordance with good 
clinical practices, and all efforts were made to 
minimize suffering.  
2.2. Animals and experimental design  
Forty Rasa Aragonesa breed female lambs 
aged 3 months were selected from a 
commercial flock after checking their 
seronegativity for T. gondii, N. caninum, 
Border disease virus (BDV), Schmallenberg 
virus (SBV), Coxiella burnetii and Chlamydia 
abortus by ELISA. Animals were maintained 
in isolation at Zaragoza University (Spain) 
facilities and at 12 months old were oestrus 
synchronized by insertion of intravaginal 
progestogen-impregnated sponges 
(Chronogest® 20 mg fluorogestone acetate, 
MSD Animal Health, Salamanca, Spain) for 14 
days. At the time of removal, 480 UI of 
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pregnant mare serum gonadotrophin (PMSG) 
(Foligon® 6000 UI, MSD Animal Health, 
Salamanca, Spain) was administered to each 
ewe through intramuscular injection as 
previously described Abecia et al. (2011). After 
48 hours, ewes were mated with breed Rasa 
Aragonesa tups for 2 days, after which, the 
rams were removed from the ewes. Pregnancy 
and foetal viability were confirmed by 
ultrasound scanning (US) on day 40 after 
mating, and twenty-seven pregnant sheep were 
selected for the experiment. Pregnant ewes 
(n=27) were randomly distributed into six 
experimental groups at Clinical Veterinary 
Hospital facilities of Complutense University 
of Madrid (Spain). Twenty-four ewes were 
inoculated intravenously into the jugular vein at 
90 days of gestation (dg) with 105 (group 1, G1; 
n=6), 104 (group 2, G2; n=5), 103 (group 3, G3; 
n=5), 102 (group 4, G4; n=4) tachyzoites; or 
subcutaneously over the left prefemoral lymph 
node with 104 tachyzoites (group 5, G5; n=4) of 
the Nc-Spain7 bovine isolate (Regidor-Cerrillo 
et al., 2008). The three remaining pregnant 
ewes were allocated to group 6 (G6; n=3), acted 
as uninfected controls and received an 
intravenous inoculum of phosphate-buffered 
saline (PBS) at 90 dg (Table 1).     
 
2.3. Parasite culture and dose preparation 
Tachyzoites of the Nc-Spain7 isolate were 
routinely maintained in cultured MARC-145 
cells as described previously (Regidor-Cerrillo 
et al., 2010). For the challenge, tachyzoites 
(passage 19) were recovered from culture 
flasks when they were still largely intracellular 
(>80% of undisrupted parasitophorous 
vacuoles), and infected cells were repeatedly 
passed through a 25-gauge needle at 4ºC. The 
number of viable tachyzoites was determined 
by Trypan blue exclusion (typically 95–99%) 
followed by counting the viable tachyzoites in 
a Neubauer chamber. Subsequently, the 
concentration of viable tachyzoites was 
adjusted to the required dose (105, 104, 103 and 
102) by dilution in PBS in a final volume of 1 
mL. Tachyzoites were administered to pregnant 
ewes within 30 min of harvesting from cell 
culture. 
2.4. Clinical monitoring and collection of 
samples  
Pregnant ewes were observed daily 
throughout the entire experimental period. 
Rectal temperatures were recorded daily from 
day 0 until 14 days pi and then weekly. Animals 
were considered febrile when the rectal 
temperature was over 40ºC (Diffay et al., 
2002).   
In G5, which was subcutaneously 
inoculated with Nc-Spain7 tachyzoites, 
changes in the left prefemoral lymph node 
compared to the right prefemoral lymph node 
by palpation were recorded daily until its 
resolution. The left prefemoral lymph node was 
regarded as enlarged if its size exceeded that of 
the right prefemoral lymph node by at least 
50%.       
Blood samples to evaluate immune 
responses were collected before infection, on 
days 3, 5, 7 and 10 pi and then weekly by 
jugular venipuncture into 5 mL Vacutainer 
tubes (Becton Dickinson and Company, 
Plymouth, UK) with lithium heparin as 
anticoagulant and without anticoagulant. Tubes 
without anticoagulant were allowed to clot and 
centrifuged to obtain serum, and samples were 
stored at −80°C until analysis.  
Foetal viability was assessed by 
transabdominal ultrasonography (US) to 
monitor foetal heartbeat and movements once 
weekly for the first two weeks post-infection 
(pi) and then twice weekly until detection of 
foetal death. When foetal death was detected in 
any of the foetuses or 24 hours after parturition, 
dams and lambs were first sedated with  
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Table 1 - Experimental design. 
 
IV: intravenous route 
SC: subcutaneous route 
 
xylazine (Rompun, Bayer, Mannhein, 
Germany) and then immediately euthanized by 
an IV overdose of embutramide and 
mebezonium iodide (T61, Intervet, Salamanca, 
Spain).  
At necropsy, six randomly selected 
placentomes were recovered from each 
placenta of aborted dams, were transversally 
cut into slices of 2–3 mm thickness and were 
stored in 10% formalin for histopathological 
examinations. The rest of the placentomes were 
stored at −80 °C for further parasite DNA 
detection by PCR. In dams that gave birth, six 
randomly selected cotyledons were recovered 
and stored at -80 ºC for further parasite DNA 
detection by PCR. From foetuses, the foetal 
brain was stored at −80°C for DNA extraction 
and fixation in 10% formalin. Foetal thoracic 
and abdominal fluids or precolostral serum 
were also collected from aborted foetuses or 
newborn lambs, respectively, and maintained at 
−80°C for serology.  
Lambs were weighed and sampled for blood 
at birth and were euthanized 24 hours after 
birth. To avoid any accidental suckling from 
lambs born overnight, udders were covered 
with a piece of cloth one week before the 
expected date of delivery as a preventive 
measure. 
2.5. Peripheral blood stimulation assay 
and interferon-gamma (IFNγ) production 
analysis 
Peripheral blood stimulation assay was 
carried out and interferon-gamma (IFNγ) 
production was evaluated as previously 
described Sánchez-Sánchez et al. (2018). 
Briefly, heparinised blood was cultured in 24-
well flat-bottom plates in the presence of either 
soluble N. caninum antigens or concanavalin A 
(ConA, Sigma-Aldrich, Madrid, Spain), both at 
final concentrations of 5 μg/mL. Plates were 
incubated in a 5% CO2/37°C/100% humidity 
atmosphere for 24 h. They were then 
centrifuged at 1000 x g for 10 min at 4°C, and 
culture supernatants were assayed for IFN-γ 
detection using a commercial bovine enzyme 
Group 
Number of 
pregnant 
ewes 
Number of 
foetuses 
Ratio 
foetuses/dam 
Inoculum  
Route of 
inoculation 
G1 6 12 2 
Nc-Spain7 
105 tachyzoites  
IV 
G2 5 11 2.20 
Nc-Spain7 
104 tachyzoites 
IV 
G3 5 13 2.60 
Nc-Spain7 
103 tachyzoites 
IV 
G4 4 7 1.75 
Nc-Spain7 
102 tachyzoites  
IV 
G5 4 8 2 
Nc-Spain7 
104 tachyzoites 
SC 
G6 3 5 1.66 PBS IV 
Chapter IV ~ Results 
Objective 2: Pregnant sheep model of neosporosis  
 
~ 106 ~ 
 
immunoassay kit with a capture monoclonal 
antibody (MT17.1) showing cross-reactivity 
with ovine IFNγ (Mabtech AB, Sweden) as 
previously described Arranz-Solis et al. 
(2015b).  
 
2.6. Serological analyses: ELISA and 
IFAT 
Neospora caninum-specific IgG antibody 
levels were measured using an in-house 
indirect enzyme-linked immunosorbent assay 
(ELISA) as previously described Sánchez-
Sánchez et al. (2018). Briefly, 96-well 
microtiter plates (Thermo Fisher Scientific, 
Waltham, USA) were coated with 100 µL 
soluble N. caninum antigen (1 µg/mL in 100 
mM carbonate buffer pH 9.6) overnight at 4°C 
(Alvarez-Garcia et al., 2003). Plates were 
blocked and serum samples were diluted 1:100 
using 3% bovine serum albumin diluted in PBS 
containing 0.05% Tween 20 (PBS-T). 
Subsequently, horseradish peroxidase-
conjugated protein G (Sigma-Aldrich, Madrid, 
Spain) diluted 1:2000 in PBS-T was added and 
after that, ABTS (Roche, Basilea, Switzerland) 
was used as substrate. The reaction was stopped 
by 0.3 M oxalic acid and the optical density 
(OD) was read at 405 nm (OD405). For each 
plate, values of the OD were converted into a 
relative index percent (RIPC) using the 
following formula: RIPC = (OD405 sample – 
OD405 negative control)/(OD405 positive 
control–OD405 negative control) × 100. A 
RIPC value ≥10 indicates a positive result.  
 
An indirect fluorescent antibody test (IFAT) 
was used to detect specific IgG anti-Neospora 
antibodies in foetal fluids and precolostral sera, 
according to the technique described by 
Alvarez-Garcia et al. (2003) and used in 
previous studies (Sánchez-Sánchez et al., 
2018).   
 
2.7. Histopathology and lesion scoring 
After fixation in formalin for five days, 
formalin-fixed samples were cut, embedded in 
paraffin wax, and processed by standard 
procedures for haematoxylin and eosin (HE) 
staining. Conventional histological evaluation 
was carried out on all the sections. The analysis 
was based on the observation of lesions 
according to previous descriptions (Arranz-
Solis et al., 2015b), and lesions were classified 
as none detected/unrelated (-), mild lesions (+) 
(in the placentome, 0-33.3% of the placentome 
showed lesions; in the foetal brain, presence of 
local encephalitis), moderate lesions (++) (in 
the placentome, 33.3-66.6% of the placentome 
showed lesions; in the foetal brain, presence of 
diffuse encephalitis) and severe lesions of 
ovine neosporosis (+++) (in the placentome, 
66.6-99.9% of the placentome showed lesions; 
in the foetal brain, presence of diffuse 
encephalitis and necrosis). 
 
2.8. DNA extraction and PCR for parasite 
detection and quantification in tissues 
Genomic DNA was extracted from 50–100 
mg of maternal and foetal tissue samples using 
the commercial Maxwell® 16 Mouse Tail DNA 
Purification Kit, developed for the automated 
Maxwell® 16 System (Promega, Wisconsin, 
USA), following the manufacturer’s 
recommendations. The concentration of DNA 
for all samples was determined by 
spectrophotometry and adjusted to 50–100 
ng/μL.  
PCR was carried out on six placentome 
samples from aborted dams or cotyledons in 
dams that gave birth and three foetal brain 
samples. Parasite DNA detection was carried 
out by nested PCR adapted to a single tube as 
previously described Buxton (1998) and 
Regidor-Cerrillo et al. (2014). Each reaction 
was performed in a final volume of 25 μL with 
5 μL of sample DNA. Samples from the 
uninfected group (G6) were included in each 
round of DNA extraction and PCR as negative 
controls. Positive PCR controls with N. 
caninum genomic DNA equivalent to 10, 1 and 
0.1 tachyzoites in 100 ng of sheep DNA were 
also included in each batch of amplifications. 
Ten microlitre aliquots of the PCR products 
were visualized under UV light in a 1.5% 
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agarose/ethidium bromide gel to detect the N. 
caninum-specific 247 bp amplification product. 
Placenta and foetal brain samples that tested 
positive by nested-PCR were adjusted to 20 ng 
DNA/μL, and the parasite load was quantified 
using real-time PCR. Primer pairs from the N. 
caninum Nc-5 sequence (Collantes-Fernández 
et al., 2002) were used for parasite 
quantification, and primers from the β-actin 
gene (Gutierrez et al., 2012) were used for the 
quantification of host DNA. Amplification 
reactions were performed as described by 
Sánchez-Sánchez et al. (2018). 
 
2.9. Statistical analysis  
The occurrence of foetal death was analysed 
by the Kaplan–Meier survival method. Foetal 
survival curves were then compared by the 
Log-rank (Mantel-Cox) test, and the median 
foetal survival time, i.e., the day at which 50% 
of the foetuses aborted, was calculated. Weight 
of the lambs and antibody responses in foetuses 
and lambs were compared using the non-
parametric Kruskal–Wallis test followed by 
Dunn’s test for comparisons between groups 
and the Mann–Whitney test for pairwise 
comparisons. Rectal temperatures were 
analysed using a two-way ANOVA of repeated 
measures test until 14 days pi and a one-way 
ANOVA test afterwards. Humoral and cellular 
immune responses for each experimental group 
were analysed using a two-way ANOVA of 
repeated measures test until 28 days pi and a 
one-way ANOVA test afterwards. However, 
cellular immune responses in G1 were analysed 
using one-way ANOVA test. Differences in 
PCR detection of parasite DNA were evaluated 
using the χ2 or Fisher Exact F-test. Differences 
in parasite burdens and lesion severity were 
analysed using the non-parametric Kruskal–
Wallis test followed by Dunn’s test for 
comparisons between groups and the Mann–
Whitney test for pairwise comparisons. 
Statistical significance for all analyses was 
established at P < 0.05. Differences that 
showed P values ≥ 0.05 and ≤ 0.18 were 
considered to be trending towards statistical 
signification. All statistical analyses were 
carried out using GraphPad Prism 6.01 
software (San Diego, CA, USA).  
 
3. Results 
3.1. Clinical observations 
Foetal death was detected from 32-44 days 
pi by US in 6 out of 6 pregnant ewes in G1 
(median abortion day 38), 4 out of 5 pregnant 
ewes in G2 (median abortion day 34), 3 out of 
5 pregnant ewes in G3 (median abortion day 
42), 2 out of 4 pregnant ewes in G4 (median 
abortion day 38) and 3 out of 4 pregnant ewes 
in G5 (median abortion day 35) (Table 2). The 
median survival times were 38, 37, 44, 51 and 
36 days for G1, G2, G3, G4 and G5, 
respectively (Figure 1). All aborted dams in G3 
and G4, one aborted dam in G1 and one aborted 
dam in G5 had twin pregnancies, and they 
showed, before being euthanized, foetal death 
in one of the foetuses and foetal heartbeat and 
movements by US in the other. One 
mummified foetus in G1 and three mummified 
foetuses in G2 were found at necropsy (Table 
2). All dams from the uninfected group (G6) 
gave birth, and a significant difference was 
found in the foetal survival rate compared to 
that in G1 (P < 0.05). Regarding challenge 
doses, compared to G1, a higher foetal survival 
rate was found in G3 (P < 0.05), and in G4, the 
statistical difference (P = 0.06) showed a trend 
towards significance (Figure 1A). Regarding 
routes of administration, no significant 
differences in the foetal survival rate between 
G2 and G5 were found (Figure 1B). Non-
aborted dams in G3, G4 and G5 gave birth 
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Figure 1 - Kaplan–Meier survival curves for foetuses from intravenously challenged dams and 
the uninfected group (A) and intravenously and subcutaneously challenged pregnant ewes with 
104 Nc-Spain7 tachyzoites and the uninfected group (B). Each point represents the percentage of 
surviving animals on that day, and downward steps correspond to observed deaths. Foetal survival 
curves were compared by the log-rank (Mantel-Cox) test. For significant differences between foetal 
survival curves of infected groups, (*) indicates P < 0.05.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
prematurely between days 132 and 141 of 
pregnancy. Stillborn lambs and lambs 
exhibiting weakness, recumbency and 
unresponsiveness to external stimuli and dying 
within 24 after birth were found in 7 of 7 lambs 
in G3, 2 of 3 lambs in G4 and G5. In contrast, 
non-aborting dams in G2 and dams in G6 gave 
birth to healthy lambs between days 144 and 
150 of pregnancy. A significant decrease in the 
weight of the lambs from G3 (1511.5 ± 85.5 g) 
(P < 0.01), G4 (2429 ± 447.4 g) (P < 0.05) and 
G5 (2213.3 ± 528.7 g) (P < 0.05) was found 
compared to that in G6 (4037.4 ± 354.7 g), 
whereas no statistical analysis was performed 
in G2 since only one lamb was born (2919 g).  
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Concerning rectal temperatures, all 
intravenously challenged animals showed fever 
(rectal temperature above 40ºC) at some time 
point until day 14 pi. Compared to the 
uninfected group (G6), a significant increase in 
rectal temperature was found from day 5 pi (P 
< 0.01) to day 8 pi (P < 0.0001) in G1, from day 
6 pi (P < 0.001) to day 9 pi (P < 0.001) in G2, 
from day 7 pi (P < 0.001) to day 10 pi (P < 
0.0001) in G3 and from day 9 pi (P < 0.001) to 
day 11 pi (P < 0.001) in G4, with maximum 
mean rectal temperature on day 7 pi in G1 and 
G2, on day 8 pi in G3 and on day 10 pi in G4 
(Figure 2A). Likewise, in the subcutaneously 
challenged group (G5), a significant increase in 
rectal temperature on day 8 pi (P < 0.05) was 
found when compared to that in the uninfected 
group (G6); moreover, significant increases in 
rectal temperatures on days 4 (P < 0.05), 5 (P < 
0.05) and 9 pi (P < 0.05) were found compared 
to that on day 14 pi in G5. 
 
Figure 2 - Rectal temperatures of intravenously challenged pregnant ewes and the uninfected 
group (A) and intravenously and subcutaneously challenged pregnant ewes with 104 Nc-Spain7 
tachyzoites and the uninfected group (B). Each point represents the mean + SD at different times 
for each group. Rectal temperatures represented in the figure were analysed using two-way ANOVA 
of repeated measures. 
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In contrast to the intravenously infected groups, 
no mean rectal temperature above 40ºC was 
found in the subcutaneously challenged group 
(G5) at any time, and only a few animals 
showed fever (one ewe on days 4, 5, 8 and 10 
pi and two ewes on day 9 pi) (Figure 2B). 
Comparing rectal temperatures between 
aborting ewes and ewes that gave birth, 
significant differences were found only in G4 
since aborting ewes showed higher rectal 
temperatures on days 8 (P < 0.05) and 9 pi (P < 
0.001) than ewes that gave birth. Likewise, in 
G4, aborting ewes showed fever on days 9 and 
10 pi, whereas ewes that gave birth showed 
fever on day 11 pi. The mean rectal temperature 
in the uninfected group (G6) remained below 
39.5ºC throughout the monitoring period. From 
day 14 pi until the end of the experiment, no 
changes were found in rectal temperatures in 
the infected groups. 
 
In G5, enlargement of the left prefemoral 
lymph node was observed in all pregnant sheep 
between days 2 and 14 pi.  
3.2. Cellular and humoral immune 
responses 
IFNγ levels in supernatants recovered 24 
hours after N. caninum antigen stimulation are 
shown in Figure 3. IFNγ values increased on 
day 7 pi in G1 (P < 0.05) and on day 10 pi in 
G2 (P < 0.0001), G3 (P < 0.0001) and G5 (P < 
0.05), whereas G4 did not show a significant 
increase in IFNγ at any time pi compared to the 
uninfected group (G6). Regarding challenge 
doses, on day 10 pi, G2 showed higher IFNγ 
than G4 (P < 0.0001) (Figure 3A). Regarding 
routes of administration, on day 10 pi, G2 
showed higher IFNγ than G5 (P < 0.001) 
(Figure 3B). The ewe that gave birth in G2 
showed higher IFNγ on day 10 pi than those 
that aborted (P < 0.01), but ewes that gave birth 
in G3 showed lower IFNγ than those that 
aborted (P < 0.001). In G4, aborting ewes 
showed higher IFNγ on day 10 pi than those 
that gave birth (P < 0.05); however, ewes that 
gave birth showed higher IFNγ on day 14 pi (P 
< 0.05) than those that aborted. No significant 
differences between ewes that gave birth and 
aborting ewes were found in G5. No significant 
differences between groups were found in IFNγ 
levels from days 14 to 28 pi. Likewise, all 
infected groups maintained low IFNγ levels 
from day 28 pi onwards (data not shown). None 
of the uninfected animals (G6) showed IFNγ 
levels above basal levels recorded prior to 
inoculation throughout the experimental study.     
 
The N. caninum-specific IgG antibody 
response in dams is shown in Figure 4. When 
compared to those in the uninfected group 
(G6), IgG levels increased significantly from 
day 21 pi in G1 (P < 0.0001), G2 (P < 0.01) and 
G5 (P < 0.05) and from day 28 pi in G3 (P < 
0.001) and G4 (P < 0.05). Moreover, when 
challenge doses were compared, G1 showed 
higher IgG values on day 21 pi than all other 
intravenously infected groups (P < 0.0001) and 
on day 28 pi than G3 (P < 0.0001) and G4 (P < 
0.0001). Likewise, G2 showed higher IgG 
values than G4 on days 21 and 28 pi (P < 0.05) 
(Figure 4A). From day 28 pi until foetal 
death/birth occurred, G1 showed higher IgG 
values than G2 (P < 0.01), G3 (P < 0.01) and 
G4 (P < 0.01) (data not shown). When routes of 
administration were compared, no significant 
differences in IgG serum levels were found 
between G2 and G5 at any time (Figure 4B). 
Likewise, no significant differences were found 
between aborting ewes and ewes that gave birth 
in any of the infected groups. Seroconversion 
in all animals from infected groups was 
observed at the time of abortion/birth. All 
uninfected animals (G6) showed basal IgG 
levels throughout the experimental study.   
The Neospora-specific IgG response in 
foetal fluids from aborted foetuses and stillborn 
lambs or precolostral sera collected from lambs 
is summarized in Table 2. Seropositive titres 
were detected in all aborted foetuses from 
infected groups, ranging from 1:32 to 1:1024. 
IFAT titre medians in aborted foetuses were 
1:128 for G2, 1:256 for G1, G3 and G5, and 
1:512 for G4 without significant differences 
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Figure 3 - IFNγ response in the supernatants of intravenously challenged pregnant ewes and 
the uninfected group (A) and pregnant ewes intravenously and subcutaneously challenged with 
104 Nc-Spain7 tachyzoites and the uninfected group (B). Each point represents the mean + SD at 
the different sampling times for each group. IFNγ levels from G1 on day 10 pi are not available due 
to problems in antigen stimulation assays of the peripheral blood. Data beyond day 28 pi are not 
included because several animals did not maintain pregnancy and were therefore sacrificed. 
Concentrations of IFNγ are expressed in pg/mL. The cellular immune response represented in the 
figure was analysed using two-way ANOVA of repeated measures. For significant differences 
between infected groups, (***) indicates P < 0.001, and (****) indicates P < 0.0001.  
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Figure 4 - IgG response in the serum of intravenously challenged pregnant ewes and the 
uninfected group (A) and pregnant ewes intravenously and subcutaneously challenged with 104 
Nc-Spain7 tachyzoites and the uninfected group (B). Each point represents the mean + SD at the 
different sampling times for each group. Data beyond day 28 pi are not included because several 
animals did not maintain pregnancy and were therefore sacrificed. Serum levels of total IgG 
antibodies against N. caninum are expressed as a relative index percent (RIPC), according to the 
formula: RIPC = (OD405 sample– OD405 negative control)/(OD405 positive control–OD405 
negative control) × 100. The humoral immune response shown in the figure was analysed using two-
way ANOVA of repeated measures. For significant differences between infected groups, (*) indicates 
P < 0.05 and (****) indicates P < 0.0001.  
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among challenge doses or routes of 
administration. Precolostral sera yielded 
positive titres ranging from 1:200 to 1:800 in 
all lambs born from infected groups. IFAT titre 
medians were 1:800 in G2 and G5 and 1:400 in 
G3 and G4, without significant differences 
among challenge doses (no statistical analysis 
was performed in G2 because only one lamb 
was born). Specific IgG responses against 
parasite antigen were not detected in lambs 
from the uninfected group (G6).  
 
3.3. Pathology and lesion quantification 
Placentas from aborting ewes showed 
multifocal non-purulent necrotic placentitis 
consisting of foci of necrosis in the 
placentomes mainly located in the caruncular 
septa. Several of these foci showed 
mineralization of the necrotic core area. No 
significant differences among challenge doses 
or routes of administration were found in the 
lesion severity in placentomes (Table 2).    
 
A multifocal nonpurulent necrotizing 
encephalitis characterized by the presence of 
randomly distributed glial foci surrounded by 
mononuclear cells was observed in foetal 
brains from all infected groups. Concerning 
challenge doses, lesion severity in the foetal 
brain was higher in G1 compared to those in G2 
(P < 0.05), G3 (P < 0.01) and G4 (P < 0.05). 
By contrast, concerning routes of 
administration, no differences in lesion severity 
in the foetal brain were found between G2 and 
G5 (Table 2). Although aborted foetuses in G1 
showed higher lesion severity in the foetal brain 
compared to those in G2 (P < 0.05), no 
significant differences in lesion severity in the 
foetal brain were found between lambs born in 
any of the infected groups or between aborted 
foetuses and lambs born in each group. No 
histopathological findings were found in the 
uninfected group (G6).  
 
 
 
3.4. Parasite detection and burden in 
placental tissues and foetal brain  
A few samples from placental tissues and 
foetal brain exhibited DNA degradation mainly 
due to mummification and were excluded from 
parasite detection and/or parasite load analysis 
(Table 2). Neospora DNA was detected in 
100% of placentomes from ewes that aborted in 
G1 (36/36), G2 (24/24), G3 (18/18), G4 (12/12) 
and G5 (18/18),  100% of cotyledons from ewes 
that gave birth in G2 (4/4), G4 (12/12) and G5 
(6/6) and 91.7% of cotyledons from ewes that 
gave birth in G3 (11/12) (Table 2). No 
significant differences in parasite detection in 
placentomes and cotyledons were found among 
challenge doses or between routes of 
administration. Analysing the mean parasite 
burden, measured as the number of tachyzoites 
per mg of tissue, no significant differences in 
parasite load in placentomes were found among 
challenge doses or between routes of 
administration (Figure 5A-B) (Table 2). 
Despite the low number of samples available, 
comparing challenge doses, parasite burden in 
cotyledons was significantly lower in G3 
compared to those in G2 (P < 0.01) and G4 (P 
< 0.001) (Figure 6A). Likewise, comparing 
routes of administration, G2 showed a higher 
parasite load in cotyledons, with a trend 
towards significance compared to G5 (P = 
0.13) (Figure 6B) (Table 2).        
 
Parasite DNA in foetal brains was detected 
in 81.8% of samples in G1 (27/33), 91.7% in 
G2 (22/24), 66.7% in G3 (26/39), 90.5% in G4 
(19/21) and 87.5% in G5 (21/24) (Table 2). 
Concerning challenge doses, significantly 
lower parasite detection was found in G3 
compared to that in G2 (P < 0.05), and a trend 
towards significance was found compared to 
those in G1 (P = 0.18) and G4 (P = 0.06). 
Concerning routes of administration, no 
significant differences in parasite detection in 
the foetal brain were found between G2 and G5. 
Additionally, significantly lower parasite 
detection was found in aborted foetuses in G3 
(12/18) than in aborted foetuses in G2 (20/21) 
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Figure 5 - Dot-plot graphs of N. caninum burdens in placentomes from intravenously challenged 
pregnant ewes (A) and pregnant ewes intravenously and subcutaneously challenged with 104 
Nc-Spain7 tachyzoites and the uninfected group (B). Each dot represents individual values of 
parasite burden (number of parasites per mg of host tissue), and medians are represented as horizontal 
lines. Considering that the N. caninum detection limit by real-time PCR is 0.1 parasites, negative 
samples (0 parasites) were represented on the log scale as <0.1 (i.e., 10−2). Parasite burdens were 
analysed using the non-parametric Kruskal–Wallis test followed by Dunn’s test for comparisons 
between groups, as well as the Mann–Whitney test for pairwise comparisons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(P < 0.05), and a trend towards significance 
was found compared to that in G4 (12/12) (P = 
0.05). Likewise, aborted foetuses from G1 
(27/33) showed lower parasite detection 
compared to aborted foetuses from G4 (12/12) 
(P < 0.05). However, no significant differences 
in parasite detection were found among lambs 
born in any of the infected groups or among 
aborted foetuses or lambs born in each group. 
Parasite DNA was not detected in one aborted 
foetus in G1, in two aborted foetuses belonging 
to different dams in G3 (these three aborted 
foetuses were from twin pregnancies with 
foetal death and parasite detection in only one 
of the foetuses) or in one lamb in G3 (from a 
quadruplet pregnancy with parasite detection in 
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Figure 6 - Dot-plot graphs of N. caninum burdens in cotyledons from intravenously challenged 
pregnant ewes (A) and pregnant ewes intravenously and subcutaneously challenged with 104 
Nc-Spain7 tachyzoites and the uninfected group (B). Each dot represents individual values of 
parasite burden (number of parasites per mg of host tissue), and medians are represented as horizontal 
lines. Considering that the N. caninum detection limit by real-time PCR is 0.1 parasites, negative 
samples (0 parasites) were represented on the log scale as <0.1 (i.e., 10−2). Parasite burdens were 
analysed using the non-parametric Kruskal–Wallis test followed by Dunn’s test for comparisons 
between groups, as well as the Mann–Whitney test for pairwise comparisons. (**) indicates P < 0.01, 
(***) indicates P < 0.001, and (ρ) indicates a trend towards significant differences among infected 
groups in each tissue.   
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three of the four lambs). Furthermore, when 
different challenge doses were compared, the 
parasite burden in the foetal brain was lower in 
G2 (P < 0.05) and G3 (P < 0.001) compared to 
that in G1 and G4. Likewise, G2 showed a 
higher parasite load in the foetal brain 
compared to G3, with a trend towards 
significance (P = 0.06) (Figure 7A). 
Nevertheless, when routes of administration 
were compared, no significant differences 
between parasite load in the foetal brain were 
found between G2 and G5 (Figure 7B) (Table 
2). 
 
Figure 7 - Dot-plot graphs of N. caninum burdens in foetal brain from intravenously challenged 
pregnant ewes (A) and pregnant ewes intravenously and subcutaneously challenged with 104 
Nc-Spain7 tachyzoites and the uninfected group (B). Each dot represents individual values of 
parasite burden (number of parasites per mg of host tissue), and medians are represented as horizontal 
lines. Considering that the N. caninum detection limit by real-time PCR is 0.1 parasites, negative 
samples (0 parasites) were represented on the log scale as <0.1 (i.e., 10−2). Parasite burdens were 
analysed using the non-parametric Kruskal–Wallis test followed by Dunn’s test for comparisons 
between groups, as well as the Mann–Whitney test for pairwise comparisons. (*) indicates P < 0.05, 
(***) indicates P < 0.001, and (ρ) indicates a trend towards significant differences among infected 
groups in each tissue.   
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In addition, a lower parasite load in the foetal 
brain from aborted foetuses in G2 (G1, P < 
0.05; G4, P < 0.01) and G3 (G1, P < 0.05; G4, 
P < 0.01) was found compared to that in G1 and 
G4. Additionally, a higher parasite load in the 
foetal brain from lambs born in G4 was found 
compared to that in G3, with a trend towards 
significance (P = 0.13). However, no 
significant differences in parasite load in the 
foetal brain were found between aborted 
foetuses or lambs in each group. As expected, 
all placental and foetal samples from G6 were 
negative.       
 
4. Discussion  
Ruminant challenge models are critical to 
the evaluation of vaccine and drug candidates 
to help tackle ruminant neosporosis and to 
study pathogenesis and host responses to 
infection (Benavides et al., 2014). As an 
experimental animal model, sheep exhibit 
several advantages over cattle in terms of cost, 
space and infrastructure required, ease of 
handling of the animals and shorter duration of 
gestation. The pathogenesis of ovine 
neosporosis is not well known, and in contrast 
to the clinical outcome in cattle, infection 
during mid-pregnancy in sheep leads to 
abortion in most animals (McAllister et al., 
1996b; Buxton et al., 1998; Weston et al., 
2009; Arranz-Solis et al., 2015b). The impact 
of dose and route of challenge in abortion and 
vertical transmission of N. caninum in pregnant 
sheep has been studied little so far, and the 
results are difficult to compare. Recently, 
infection of 90-day-pregnant sheep with 106 
tachyzoites of the Nc-Spain7 isolate caused 
abortion in all of them (Arranz-Solis et al., 
2015b; Sánchez-Sánchez et al., 2018). 
Therefore, the aim of this study was to test 
different challenge doses and routes of 
administration in ewes infected at mid-term of 
gestation using the Nc-Spain7 isolate and 
establish an exogenous transplacental 
transmission model for ovine neosporosis that 
mimics natural N. caninum infections.   
How the dose of tachyzoites equates to the 
ingestion of sporulated oocysts from definitive 
hosts and what level of environmental 
contamination is required to produce a similar 
outcome through natural exposure is not known 
(Weston et al., 2009). It is possible that the 
doses of tachyzoites used in previous 
experiments (even up to 108) have been 
excessively aggressive for the infected sheep. 
This suggestion is supported by the fact that 
previous studies employing lower doses 
obtained more variable outcomes, ranging from 
a few aborted foetuses to the birth of weak or 
healthy lambs (McAllister et al., 1996b; 
Weston et al., 2009). Since intravenous 
infection of pregnant sheep using 106 
tachyzoites of the Nc-Spain7 isolate at mid-
gestation resulted in 100% abortion and 
parasite detection in the foetal brain in 83% of 
aborted foetuses (Arranz-Solis et al., 2015b; 
Sánchez-Sánchez et al., 2018), the challenge 
doses tested intravenously in the present study 
were less than the 106 tachyzoites previously 
assayed; tachyzoites were diluted 1:10 to a 
minimum concentration of 102 tachyzoites, 
similar to those evaluated by (Weston et al., 
2009). Subcutaneous inoculation closely 
mimics a natural primary infection as the 
parasite is ‘‘processed’’ through a draining 
lymph node before circulating in the blood 
(Dubey et al., 2006). In cattle, it was reported 
that subcutaneous infection resulted in a foetal 
mortality that was 50% reduced compared to 
intravenous infection (Macaldowie et al., 
2004). Hence, in this study we aimed to 
investigate the outcome of N. caninum 
infection after subcutaneous inoculation in 
pregnant ewes using one of the intravenously 
tested doses. The dose of 104 tachyzoites was 
chosen for the subcutaneous administration 
since it is an intermediate-to-high dose between 
those tested by the intravenous route and also, 
because in a previous study, intravenous 
inoculation of 5 x 103 tachyzoites of New 
Zealand isolates at mid-gestation resulted in 
abortion in 50% of the ewes (Weston et al., 
2009). 
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With regard to clinical observations, foetal 
viability is the most significant parameter to be 
evaluated in an abortion model of neosporosis 
(Benavides et al., 2014). Infection of cattle at 
mid-term gestation with 107 tachyzoites of the 
Nc-Spain7 isolate caused foetal death in 50% 
of infected animals after an experimental 
period of 6 weeks (Almería et al., 2016). All 
pregnant ewes intravenously infected with 105 
tachyzoites (G1) aborted in the same way as 
pregnant ewes intravenously infected with a 
10-fold higher dose (106 tachyzoites) (Arranz-
Solis et al., 2015b; Sánchez-Sánchez et al., 
2018). The intravenous dose causing abortion 
in 50% of the infected animals was 102 
tachyzoites (G4), and the foetal survival rate 
was higher compared to G1 (105, IV) with a 
trend towards significance possibly due to the 
lower number of animals in this group. It is 
remarkably lower than the intravenous dose of 
5 x 103 causing abortion in 50% of the infected 
animals in the dose-titration study at mid-
gestation using Nc-NZ1, Nc-NZ2 and Nc-NZ3 
isolates (Weston et al., 2009), suggesting 
higher virulence of Nc-Spain7 than New 
Zealand isolates in pregnant sheep. Likewise, 
intravenous infection at mid-gestation with 105 
tachyzoites of the Nc-Spain7 isolate (G1) 
resulted in abortion of all pregnant ewes, 
whereas intravenous infection of pregnant ewes 
at mid-gestation with 1.7 x 105 tachyzoites of a 
mixture of the Nc-2 and Nc-Liverpool isolates 
caused abortion in 67% of the pregnant ewes 
(McAllister et al., 1996b). However, because 
(McAllister et al., 1996b) and (Weston et al., 
2009) used a mixture of different isolates 
within the same inoculum to assure infection, it 
is difficult to establish comparisons with these 
studies (Benavides et al., 2014). The median 
number of abortion days in our study was 
similar to the time range of abortions in 
previous N. caninum experimental infections in 
pregnant sheep at mid-gestation (McAllister et 
al., 1996a; Buxton et al., 1998; Buxton et al., 
2001; Arranz-Solis et al., 2015b). As reported 
by Weston et al. (2009) regarding the 
differences in the average time between 
abortion and parturition found after infection 
with decreasing doses, in the present study, the 
median survival times in G3 (103, IV) and more 
markedly in G4 (102, IV) were prolonged 
compared to those in G1 (105, IV), G2 (104, IV) 
and G5 (104, SC). In all aborting dams from G3 
(103, IV) and G4 (102, IV), the coexistence at 
the time of euthanasia of live foetuses and dead 
foetuses in twin pregnancies suggests lower 
foetal damage in these groups because this 
observation was only found in one aborting 
dam in G1 (105, IV) and one aborting dam in 
G5 (104, SC). Mummified foetuses found in G1 
(105, IV) and G2 (104, IV) have already been 
described after N. caninum experimental 
infection at mid-gestation in pregnant sheep 
(Buxton et al., 1997). In G3 (103, IV), G4 (102, 
IV) and G5 (104, SC), pregnant ewes gave birth 
prematurely, similar to some pregnant ewes 
infected with 5 x 103 N. caninum tachyzoites 
(Weston et al., 2009). Consequently, in G3 
(103, IV), G4 (102, IV) and G5 (104, SC), 
stillborns and lambs died soon after birth 
showed a significant decrease in their 
bodyweight, as previously described Buxton et 
al. (1998). Likewise, a more significant 
decrease in lamb weight in G3 (103, IV) was 
found because it is known that with increasing 
litter size, the weight of the lambs is lower 
(Gardner et al., 2007). The presence of a large 
number of stillborn lambs and weak lambs 
dying within 24 hours after birth could be 
explained by the absence of differences in 
parasite detection, parasite load and lesion 
severity from the foetal brain between aborted 
foetuses and lambs that gave birth in each 
group.  
 
Another clinical parameter associated with 
infection is rectal temperature, and its increase 
is probably associated with the first replication 
cycles of the parasite in tissues and organs 
(Benavides et al., 2014). Moreover, different 
temperature responses have been associated 
with the dose of parasite inoculums (Buxton et 
al., 1997; Maley et al., 2001; Maley et al., 
2003; Weston et al., 2009). Intravenously 
challenged groups showed a unique fever peak 
after infection, although a dose-dependent 
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delay in the time of rectal temperature increase 
was found compared to the infection with 106 
tachyzoites of the Nc-Spain7 isolate (Sánchez-
Sánchez et al., 2018), suggesting delayed 
parasite replication as lower infection doses 
were applied. However, as reported with 106 
tachyzoites of the Nc-Spain7 isolate (Sánchez-
Sánchez et al., 2018), G1 (105, IV), G2 (104, 
IV) showed maximum rectal temperature on 
day 7 pi. Whereas the increase in rectal 
temperature persisted for 4 days in G1 (105, 
IV), G2 (104, IV) and G3 (103, IV), a less 
prolonged period with 3 days of rectal 
temperature increase was found in G4 (102, IV). 
Similar to different temperature responses 
found between intravenous and subcutaneous 
N. caninum challenge in cattle (Macaldowie et 
al., 2004), after subcutaneous challenge in G5 
(104, SC), a lower rectal temperature increase 
was found compared to intravenous challenge 
in G2 (104, IV). Likewise, a similar temperature 
response was found in G5 (104, SC) compared 
to the infection in sheep with the same dose 
(104 tachyzoites) of the Nc-Liverpool isolate 
(Buxton et al., 1997). The biphasic temperature 
response found in the subcutaneous challenge 
group (G5) had been previously described after 
subcutaneous challenge in sheep (Buxton et al., 
1997; Buxton et al., 1998; Buxton et al., 2001) 
and cattle (Maley et al., 2003; Benavides et al., 
2012). Previous studies in cattle have described 
differences in rectal temperatures between 
aborting and non-aborting dams (Almería et al., 
2010; Almería et al., 2016) in the same way as 
observed in G4 (102, IV) in the present study.  
 
Prefemoral lymph nodes were chosen as 
inoculation sites in G5 (104, SC) because they 
have been widely used for subcutaneous N. 
caninum challenge in cattle (Innes et al., 2001b; 
Maley et al., 2001; Maley et al., 2003; 
Macaldowie et al., 2004; Wiengcharoen et al., 
2011; Benavides et al., 2012) and sheep 
(Buxton et al., 1997; Buxton et al., 1998; 
Buxton et al., 2001). The clinical evaluation in 
G5 (104, SC) revealed enlargement of the left 
prefemoral lymph node as previously described 
Maley et al. (2001), Maley et al. (2003), 
Macaldowie et al. (2004) and Rocchi et al. 
(2011) after subcutaneous N. caninum 
challenge in cattle.  
 
Intracellular protozoan parasites usually 
induce and are controlled by cellular immune 
responses. IFNγ plays a relevant role in 
controlling early N. caninum dissemination 
(Entrican, 2002; Hemphill et al., 2006) and 
protecting against abortion in naturally infected 
cows (Lopez-Gatius et al., 2007). Very short-
lived IFNγ levels were produced in antigen-
specific stimulation analyses at the end of the 
first and during the second week following 
infection with N. caninum and prior to 
mounting a specific IgG response. Similar 
IFNγ kinetics have been described in previous 
reports carried out in cattle upon stimulation of 
peripheral blood mononuclear cells (PBMCs) 
(Regidor-Cerrillo et al., 2014) or in sheep 
serum (Arranz-Solís et al., 2016). In G1 (105, 
IV), IFNγ released upon stimulation increased 
on day 7 pi in the same way that  intravenous 
infection with 106 tachyzoites of the Nc-Spain7 
isolate (Sánchez-Sánchez et al., 2018). 
Nevertheless, the time course of IFNγ showed 
a delay until day 10 pi for IFNγ release after 
intravenous challenge in G2 (104, IV) and G3 
(103, IV) and subcutaneous challenge in G5 
(104, SC), although large individual variations 
were observed as previously described 
Rettigner et al. (2004b). Likewise, no 
significant increase in IFNγ was observed in G4 
(102, IV) compared to the uninfected group 
(G6), which might have led to lower initial 
control of parasitaemia at the peripheral level, 
allowing a higher number of parasites to reach 
the placenta (Entrican, 2002; Innes, 2007). In 
fact, no differences in parasite load in the foetal 
brain between G4 (102, IV) and G1 (105, IV) 
could be due to the absence of a significant 
increase in IFNγ levels in pregnant ewes from 
G4 (102, IV) because a threshold IFNγ response 
is required to be beneficial against N. caninum 
(Almeria et al., 2014; Almería and López-
Gatius, 2015). Recently, it has been shown that 
the immune response appears to lead to 
superior priming of a cell-mediated immune 
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response in dams carrying live foetuses versus 
dams carrying dead foetuses (Bartley et al., 
2012; Darwich et al., 2016). In this way, ewes 
that gave birth in G2 (104, IV) showed higher 
IFNγ levels on day 10 pi than those that 
aborted. Although no significant differences 
were found in IFNγ levels in G4 (102, IV) 
compared to the uninfected group (G6), a delay 
in the IFNγ peak was detected in ewes that gave 
birth. That, along with differences in rectal 
temperatures between aborting ewes and ewes 
that gave birth could suggest decreased early-
stage replication of the parasite in ewes that 
gave birth in G4 (102, IV).        
 
After intravenous infection of pregnant 
sheep at mid-gestation with 106 tachyzoites of 
the Nc-Spain7 isolate, IgG levels increased 
from day 12-14 pi (Arranz-Solís et al., 2016; 
Sánchez-Sánchez et al., 2018), whereas IgG 
levels increased from day 21 pi in G1 (105, IV). 
Furthermore, G1 (105, IV) exhibited higher IgG 
levels than those found with lower doses, 
possibly due to exposure to more abundant 
antigen and increased lymphoid stimulation 
similar to that reported by (Buxton et al., 1997; 
Maley et al., 2001; Bartley et al., 2004; Weston 
et al., 2009). In this study, all challenged 
animals showed seroconversion by ELISA, 
whereas the lower dose tested (50 tachyzoites 
of Nc-NZ1, Nc-NZ2 and Nc-NZ3 isolates) by 
(Weston et al., 2009) revealed one seronegative 
animal at parturition by IFAT.     
 
Concerning offspring, all aborted foetuses 
and lambs from the infected groups showed 
seropositive IFAT titres with no significant 
differences between challenge doses or routes 
of administration. Altogether, this finding 
indicates that once infection is established, it 
cannot be cleared from the host, and vertical 
transmission of the parasite occurred in all 
infected animals. In contrast, in a previous 
dose-titration study, none of the lambs and only 
3 out of 5 lambs born from pregnant ewes 
intravenously infected with 50 and 5 x 103 N. 
caninum tachyzoites (Nc-NZ1, Nc-NZ2 and 
Nc-NZ3 isolates), respectively, were 
seropositive by IFAT (Weston et al., 2009).  
Because immune responses are not accurate 
enough to be used as indicators for disease or 
protection (Benavides et al., 2014), parasite 
detection and quantification and 
histopathological assessment are essential. All 
placentomes from infected ewes were PCR 
positive, and no significant differences in 
parasite load or lesion severity were found, so 
immune responses were unsuccessful in 
preventing the colonization and multiplication 
of N. caninum in the placentomes of aborting 
ewes. No difference was found in parasite 
detection between placentomes from 
intravenously infected ewes at mid-gestation 
with 106 tachyzoites of the Nc-Spain7 isolate 
(PCR-positive samples from 83% to 100%)   
(Arranz-Solis et al., 2015b; Sánchez-Sánchez 
et al., 2018) and placentomes from 
intravenously infected aborting ewes in this 
study. N. caninum DNA was also widely 
detected in cotyledons from ewes that gave 
birth with no significant differences in parasite 
detection, similar to that reported by (Weston et 
al., 2009), which found all PCR-positive 
cotyledons in ewes infected with 5 x 103 N. 
caninum tachyzoites. However, lower parasite 
loads were found in cotyledons from ewes that 
gave birth in G3 (103, IV), which, along with 
lower IFNγ levels detected, could suggest mild 
infection in these animals. When routes of 
administration were compared, no significant 
differences were identified in parasite 
detection, parasite load or lesion severity in 
placentomes, however, cotyledons from the 
subcutaneously infected group (G5) showed 
lower parasite burden compared to G2 (104, IV) 
with a trend towards significance, maybe 
influenced by the lower number of animals in 
this group.   
 
In transplacental transmission models for 
ruminant neosporosis, it is crucial to evaluate 
parasite presence, parasite load and lesions in 
foetal tissues (Benavides et al., 2014). The 
central nervous system has been described as 
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the target tissue in foetuses from N. caninum 
infection of cattle (Almería et al., 2016) and 
sheep (Arranz-Solis et al., 2015b) at mid-
pregnancy. Concerning infective doses, 
detection percentages in foetal brains from G1 
(105, IV), G2 (104, IV) and G4 (102, IV) showed 
no significant differences among them, nor 
when they were compared to detection in foetal 
brains after intravenous infection of pregnant 
ewes with 106 tachyzoites of the Nc-Spain7 
isolate at mid-gestation (94% of PCR-positive 
samples) (Sánchez-Sánchez et al., 2018). These 
results are not in accordance with differences in 
the proportion of positive brains in 
foetuses/lambs of a dose-titration study in 
pregnant sheep at mid-gestation using other 
isolates (Weston et al., 2009). Conversely, the 
lower detection percentage in foetal brains 
from G3 (103, IV) could be because of the 
higher number of foetuses per dam in this 
group; fewer parasites that cross the placental 
barrier reach each foetus. Brain-negative 
foetuses arising from multiple pregnancies 
have already been reported in ewes infected at 
mid-gestation with 106 tachyzoites of Nc-
Spain7 (Arranz-Solis et al., 2015b). Foetuses 
and lamb showing PCR-negative brains in this 
study were seropositive by IFAT in the same 
way as in (Porto et al., 2016), and brain lesions 
were identified, suggesting the presence of very 
low parasite load in their brain.  
 
We hereby describe the outcome of N. 
caninum infection in pregnant sheep at mid-
gestation by performing experimental 
infections using different numbers of 
tachyzoites of the virulent Nc-Spain7 isolate 
and different routes of inoculation. Intravenous 
infection with 105 tachyzoites was sufficient to 
trigger 100% abortion in the same way as 106 
tachyzoites previously assayed. In addition, 
intravenous infection with 105 tachyzoites 
showed distinct immune responses and parasite 
load in the foetal brain. Surprisingly, the 
differences between the highest and the lowest 
intravenous doses were much smaller than 
expected, and we here demonstrate that 
experimental infection with as few as 100 
tachyzoites could induce abortion in 50% of the 
ewes, and parasite load in the foetal brain was 
similar to that with the highest dose. Regarding 
the routes of inoculation, subcutaneous 
infection with 104 tachyzoites showed similar 
abortion rates and vertical transmission to 
intravenous infection.  
 
In conclusion, with the doses and routes of 
administration evaluated, we propose that 
future studies using an abortion model for ovine 
neosporosis should be carried out using the 
intravenous route of administration and a 
challenge dose of 105 tachyzoites (100% 
abortion and vertical transmission), which will 
then allow to obtain more accurate and realistic 
conclusions in studies testing vaccine and drug 
candidates. However, further studies are 
necessary to evaluate the outcome of infection 
with 105 tachyzoites by the subcutaneous route 
of administration.  
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Objetivo 3 
Evaluación de la seguridad y eficacia de los compuestos 
inhibidores de la CPDK1 (BKI) frente a T. gondii y N. caninum 
en ovejas gestantes 
 
T. gondii y N. caninum son parasitos apicomplejos muy relacionados filogenéticamente y 
considerados como unos de los principales agentes causantes de aborto infeccioso en pequeños 
rumiantes y ganado vacuno respectivamente. Actualmente no hay fármacos disponibles en el mercado 
para el tratamiento de la toxoplamosis y neosporosis en rumiantes. Los inhibidores de proteinas 
quinasas que compiten por el sitio de unión del ATP en la proteína quinasa dependiente de calcio tipo 
1 (CDPK1) de los parásitos apicomplejos (BKIs) han mostrado ser altamente eficaces in vitro y en 
modelos de animales de laboratorio frente a numerosos parásitos apicomplejos. Para la consecución 
de este objetivo las ovejas gestantes se dosificaron por vía oral con el BKI-1294 (5 dosis de 100 mg/kg 
cada 48 horas) o por vía subcutánea con el BKI-1553 (con dos pautas de dosificación: 1ª dosis de 35 
mg/kg y una semana después una 2ª dosis de 10 mg/kg ó 7 dosis de 10 mg/kg cada 48 horas). Se 
evaluó la eficacia de estos fármacos administrados a las 48 horas de la infección por vía oral con 
ooquistes del aislado TgShSp1 (BKI-1294) o por vía intravenosa con taquizoitos del aislado Nc-
Spain7 (BKI-1553). La seguridad de estos fármacos se evaluó mediante la monitorización de las 
temperaturas rectales y la viabilidad fetal, el estudio de los parámetros hematológicos y bioquímicos 
asi como mediante la observación de la consistencia fecal (tras la administración oral) o de las 
reacciones locales adversas (tras la administración subcutánea). La eficacia de los inhibidores de la 
CDPK1 fue evaluada mediante la monitorización clínica, el estudio de la respuesta inmune y de las 
lesiones y la determinación de la presencia y carga de los parásitos en placenta y/o tejidos fetales 
diana. Además, fueron determinados los niveles plasmáticos del BKI-1294 y BKI-1553 en ovejas asi 
como los del BKI-1553, tras la administración de una única dosis de 10 mg/kg, tanto en los fetos 
como en las ovejas. Tras la administración subcutánea del BKI-1553 y oral del BKI-1294 las ovejas 
gestantes presentan niveles terapéuticos de fármaco en plasma con concentraciones máximas de 11 
μM y 2 μM y mínimas de 4 μM y 0.4 μM para el BKI-1553 y BKI-1294 respectivamente. Además, 
el BKI-1553 fue capaz de atravesar la barrera placentaria ya que se encontraron niveles terapéuticos 
en plasma fetal de 1 μM. Sin embargo, el BKI-1553 y de forma más acusada el BKI-1294 presentaron 
un rápido aclaramiento plasmático. En relación a la seguridad, tanto el BKI-1294 como el BKI-1553 
parecen seguros ya que no se observaron alteraciones en la temperatura, en los parámetros 
hematológicos y bioquímicos ni en la gestación o daño local asociado con estos fármacos. Sin 
embargo, se observó diferente seguridad para cada una de las rutas de administración utilizadas. 
Mientras que la administración oral no incrementó la temperatura rectal ni modificó la consistencia 
fecal, la administración subcutánea desencadenó la formación de nódulos dérmicos asociados a un 
incremento de temperatura y monocitosis. 
La administración del BKI-1294 a ovejas infectadas con T. gondii o del BKI-1553 a ovejas 
infectadas con N. caninum hizo que fuera menor el incremento de las temperaturas asociado a la 
infección probablemente debido a una menor replicación de los parásitos. Los estudios in vitro han 
puesto de manifiesto la presencia de complejos intracelulares multinucleados inducidos por el BKI-
1294 y BKI-1553, con una sobreexpresión del antigeno de taquizoitos SAG1 y del marcador de 
bradizoito SAG1. Estos complejos multinucleados se componen de multiples prezoitos incapaces de 
separarse y formar taquizoitos y podrían influir sobre la respuesta inmune celular y humoral frente a 
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T. gondii y N. caninum ya que se la administración de estos fármacos desencadena un incremento de 
la producción de IFNγ y la presencia de anticuerpos anti-T. gondii SAG1. En modelos ovinos 
gestantes en los cuales todas las ovejas sin tratar abortaron, el tratamiento con el BKI-1294 en ovejas 
infectadas con T. gondii desencadenó el nacimiento de un 76% de corderos sanos y el tratamiento con 
el BKI-1553 en ovejas infectadas con N. caninum confirió una protección del 37-50% frente al aborto. 
En relación a la transmisión vertical, mientras que el BKI-1553 no protegió frente a la transmisión 
vertical de N. caninum, aunque disminuyó los efectos de la infección reduciendo las lesiones y la 
presencia del parásito y la carga en cerebro fetal, el BKI-1294 fue capaz de prevenir la transmisión 
vertical de T. gondii en el 53% de los corderos. 
 
 
 
 
 
 ~ 127 ~ 
Bumped kinase inhibitor BKI-1294 is safe and produces 
high rates of protection against abortion and vertical 
transmission in sheep experimentally infected with 
Toxoplasma gondii during pregnancy 
 
Roberto Sánchez-Sáncheza, Ignacio Ferrea, Michela Rea,b, Luis Miguel Ferrerc, Javier Regidor-
Cerrilloa, Manuel Pizarro Díazb, Marta González-Huecasb, Enrique Tabanerab, Julio Benavidesd, 
Andrew Hemphille, Matthew A. Hulversonf, Lynn K. Barrettf, Ryan Choif, Grant R. Whitmanf, 
Kayode K. Ojof, Wesley C. Van Voorhisf, Luis Miguel Ortega-Moraa    
 
 
aSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of 
Madrid, Ciudad Universitaria s/n, 28040 Madrid, Spain. 
 
bDepartment of Animal Medicine and Surgery, Faculty of Veterinary Sciences, Complutense 
University of Madrid, Ciudad Universitaria s/n, 28040 Madrid, Spain.  
 
cDepartamento de Patología Animal. Facultad de Veterinaria C/ Miguel Servet 177, 50013 Zaragoza, 
Spain 
 
dInstituto de Ganadería de Montaña (CSIC-Universidad de León), León, Spain 
 
eInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Länggass-Strasse 122, CH-3012 
Berne, Switzerland. 
 
fCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and 
Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA. 
 
 
To be submitted to Journal of Antimicrobial Chemotherapy 
 
  
 
 
 
 
 
 
 
 
 
Chapter IV ~ Results 
Objective 3: Safety and efficacy of BKI compounds in pregnant sheep 
 
~ 128 ~ 
 
Abstract 
 
Toxoplasma gondii is one of the main abortifacient in sheep, causing important economic losses. 
Previous studies on drug efficacy using monensin, folate inhibitors and decoquinate showed moderate 
protection against abortion and vertical transmission of T. gondii in pregnant sheep. Although a live-
attenuated vaccine is available to protect against abortion in T. gondii infected sheep, at present no 
labelled drugs are marketed. Bumped kinase inhibitors (BKIs), which are ATP-competitive inhibitors 
of calcium dependent protein kinase 1 (CDPK1), showed to be highly efficacious against several 
apicomplexan parasites in vitro and in laboratory animal models. We present here the 
pharmacokinetics, safety and efficacy of 5 doses at 100 mg/kg orally of BKI-1294 in a pregnant sheep 
model of T. gondii infection. BKI-1294 showed systemic exposure in pregnant ewes, with maximum 
concentrations of 2 μM and trough concentrations of 0.4 μM at 48 hours after each dose. Oral 
administration of BKI-1294 in sheep at mid-pregnancy wa safe since no variation on fecal 
consistency, rectal temperatures and haematological and biochemical parameters or abortions were 
found. In ewes infected with a T. gondii oocyst dose 100% lethal for the foetuses, BKI-1294 treatment 
resulted in a decrease on rectal temperatures upon infection, a strong IFNγ production, a low humoral 
immune response to soluble tachyzoite antigens but high levels of anti-SAG1 antibodies and a 
decrease of 76% in the perinatal mortality. In addition, none of the lambs born alive showed lesions 
and vertical transmission was prevented in 53% of them. These results provide a proof of concept for 
the therapeutic use of BKIs in ovine toxoplasmosis.  
 
Keywords: Toxoplasma gondii; sheep; treatment; pregnancy; abortion; vertical transmission; protein 
kinase inhibitor; BKI-1294 
1. Introduction 
Toxoplasma gondii is an apicomplexan 
parasite, being one of the main abortifacient in 
sheep and, therefore causing important 
economic losses due to abortions after primo-
infection of pregnant sheep (Dubey, 2010). 
Congenital transmission of T. gondii mainly 
occurs after primoinfection, through ingestion 
of oocysts during pregnancy (Innes et al., 
2009). Infection during the early and mid-
pregnancy is usually associated with the 
occurrence of abortion, while infection in late 
pregnancy would produce a congenitally 
infected but viable lamb (Buxton et al., 2007). 
Once the infection occurs, there is a generally 
delay of 4 weeks until the occurrence of the 
abortion (Dubey, 2010). However, in a number 
of experimental studies, oral inoculation of 
sheep with sporulated oocysts resulted in 
earlier abortion between days 7 and 14 pi 
(Trees et al., 1989; Owen et al., 1998b; Castaño 
et al., 2014; Castaño et al., 2016).   
For the control of ovine toxoplasmosis, 
different measures have been suggested; 
however, the combination of different 
approaches is known to be the optimal strategy 
(Dubey, 2009b). The implementation of farm 
biosecurity protocols, hygienic measures and 
management practices should be adopted in all 
farms, for reducing the level of environmental 
contamination with T. gondii oocysts via cat 
faeces. Despite being properly designed and 
meticulously practised, globally, these control 
measures alone are not cost-viable or 
completely effective in eliminating 
toxoplasmosis from a flock, and it is necessary 
to complement them with an immune-
chemotherapeutical approach (Sánchez-
Sánchez et al., accepted for publication). To 
date, the control of ovine toxoplasmosis is 
primarily based on preventing its horizontal 
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transmission and on the establishment of a 
vaccination programme with a live attenuated 
S48 strain (Toxovax™, MSD) (Buxton et al., 
1991; Buxton et al., 1993b). The benefits are 
associated with protection against abortions 
induced by T. gondii during pregnancy and a 
decrease in tissue cyst development (Innes et 
al., 2009). Although experimental studies have 
revealed effectiveness of several drugs in vitro 
and in laboratory animal models (Sánchez-
Sánchez et al., accepted for publication), only 
monensin (Buxton et al., 1987; Buxton et al., 
1988), folate inhibitors (Buxton et al., 1993a) 
and decoquinate (Buxton et al., 1996) have 
been evaluated against T. gondii in pregnant 
sheep. In these studies, protection against 
abortion was found in 20-40% of infected ewes 
(Buxton et al., 1988; Buxton et al., 1996), 
however there is limited or no protection 
against vertical transmission (Buxton et al., 
1987; Buxton et al., 1988; Buxton et al., 1993a; 
Buxton et al., 1996). Therefore, currently there 
is no a labelled drug available against ovine 
toxoplasmosis in the market.   
 
Anti-parasitic drug development based on 
targeting kinase enzymes is a well-established 
approach (Rotella, 2012). Calcium dependent 
protein kinase 1 (CDPK1) represents a 
promising drug target, as CDPK1 is encoded by 
the apicoplast DNA, and is thus absent from 
mammalian hosts (Lourido et al., 2010; 
Murphy et al., 2010; Ojo et al., 2010; Cardew 
et al., 2018).  
CDPK1 activity is essential for microneme 
secretion, host cell invasion, and egress of T. 
gondii (Kieschnick et al., 2001; Lourido et al., 
2010; Lourido et al., 2012) and can be 
effectively targeted by a class of ATP-
competitive compounds, collectively named 
bumped kinase inhibitors (BKIs). BKIs have a 
broad-spectrum activity that affects many 
apicomplexan parasites (Van Voorhis et al., 
2017). BKI-1294 was effective against T. 
gondii in vitro (Winzer et al., 2015), and in vivo 
against acute (Lourido et al., 2013; Doggett et 
al., 2014) and chronic toxoplasmosis in mice 
(Lourido et al., 2013) as well as against vertical 
transmission in a pregnant mice model of 
toxoplasmosis (Müller et al., 2017c). We report 
here on the safety and efficacy of BKI-1294 
treatment in pregnant sheep experimentally 
infected with T. gondii oocysts at mid-
gestation.   
2. Materials and methods    
2.1. Ethics statement 
All protocols involving animals were 
approved by the Animal Welfare Committee of 
the Community of Madrid, Spain (PROEX 
166/14), following proceedings described in 
Spanish and EU legislation (Law 32/2007, R.D. 
53/2013, and Council Directive 2010/63/EU). 
All animals used in this study were handled in 
strict accordance with good clinical practices, 
and all efforts were made to minimize 
suffering.     
2.2. Animals and experimental design  
Thirty-five pure Rasa Aragonesa breed 
female ewes aged 12 months were selected 
from a commercial flock. All animals were 
seronegative for T. gondii, N. caninum, Border 
disease virus (BDV), Schmallenberg virus 
(SBV), Coxiella burnetii and Chlamydia 
abortus as determined by enzyme linked 
immunosorbent assay (ELISA). They were 
oestrus-synchronized and mated with pure-
breed Rasa Aragonesa tups for 2 days. 
Pregnancy and foetal viability were confirmed 
by ultrasound scanning (US) on day 40 post-
mating, and twenty-five pregnant sheep were 
selected for the experiment. Pregnant ewes (n = 
25) were randomly distributed into four 
experimental groups (see Table 1) and housed 
at the animal facilities of the Animal Health 
Department in the Faculty of Veterinary 
Sciences (Complutense University of Madrid, 
Spain). Fifteen ewes were allocated into groups 
1 (G1; n=7) and 2 (G2; n=8), which were dosed 
orally with 1000 T. gondii sporulated oocysts 
of the type II (genotype #3) T. gondii isolate 
TgShSp1 (Sánchez-Sánchez et al., submitted) 
at day 90 of gestation (dg). The ten remaining 
Chapter IV ~ Results 
Objective 3: Safety and efficacy of BKI compounds in pregnant sheep 
 
~ 130 ~ 
 
pregnant ewes were allocated to groups 3 (G3; 
n=5) and 4 (G4; n=5), which received 50 mL of 
phosphate-buffered saline (PBS) at 90 dg.     
BKI-1294 was synthesized by WuXi and 
further purified in the Department of Chemistry 
of the University of Washington. The drug 
formulation was prepared by dissolving the 
compound in 60% PHOSAL® 53 MCT 
(LIPOID GmbH, Ludwigshafen, Germany), 
30% Polyethyleneglycol 400 (PEG-400) 
(Sigma-Aldrich, Madrid, Spain) and 10% 
Ethanol 96º (Panreac, Barcelona, Spain) by 
heating at 37°C and shaking for 3 hours at a 
final concentration of 45 mg/ml. Starting at 48 
hours post-infection (pi), BKI-1294 was 
administered orally through an oro-ruminal 
probe to G1 and G3, both groups at 100 mg/kg 
bodyweight, 5 doses every other day. Each ewe 
from G1 and G3 received 146.16 ± 20.41 mL 
for each dose. In addition, ewes from G4 
received 5 doses (139.79 ± 7.76 mL), every 
other day, of vehicle alone. Ewes from G3 
(non-infected, treated) and G4 (non-infected, 
vehicle alone) were kept alive until the end of 
the experiment. Safety of BKI-1294 was 
evaluated by clinical monitoring of rectal 
temperatures, fecal consistency and foetal 
viability and evaluation of haematological and 
biochemical parameters. Efficacy of this 
compound against congenital toxoplasmosis in 
sheep was assessed by the presence of perinatal 
mortality (foetal death during pregnancy and 
stillbirths) and vertical transmission in live 
lambs (seropositivity and parasite 
detection/lesion in brain or lungs) according to 
Sánchez-Sanchez et al. (submitted). 
 
2.3. Clinical monitoring 
Pregnant ewes were observed daily 
throughout the entire experimental period. 
Foetal viability was assessed post-infection by 
US monitoring of foetal heartbeat and 
movements once a week. Rectal temperatures 
were recorded daily from day 0 until 14 days pi 
and then weekly. Animals were considered 
febrile when the rectal temperatures was over 
40°C (Diffay et al., 2002). 
When foetal death occurred, or 48 hours 
after parturition, dams and lambs were first 
sedated with xylazine (Rompun, Bayer, 
Mannhein, Germany) and then euthanized by 
an intravenous overdose of embutramide and 
mebezonium iodide (T61, Intervet, Salamanca, 
Spain). Deliveries up to day 140 of pregnancy 
were considered premature. Lambs born from 
day 141 onwards were weighed immediately 
after birth. Lambs born alive were clinically 
inspected for 48 hours after birth.     
2.4. Collection of blood samples 
Blood samples to evaluate peripheral 
immune responses were collected from G1 and 
G2 (both infected) and G4 (uninfected/vehicle 
alone) prior to infection, at 3, 5, 7 and 10 days 
pi and then weekly by jugular venipuncture into 
5 mL vacutainer tubes (Becton Dickinson and 
Company, Plymouth, UK) with and without 
lithium heparin as anticoagulant.  
In addition, in G3 (uninfected/BKI-1294 
treated) and G4 (uninfected/vehicle alone) 
haematological and biochemical parameters 
before (day 0 pi) and after treatment (4 days 
after the 5th BKI-1294 dose) were assessed in 
blood samples collected into 5 mL vacutainer 
tubes (Becton Dickinson and Company, 
Plymouth, UK), with 
ethylenediaminetetraacetic acid (EDTA) as 
anticoagulant and into 5 mL vacutainer tubes 
(Becton Dickinson and Company, Plymouth, 
UK) without anticoagulant. Tubes without
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Table 1 - Experimental design  
 
  P.O.: per os, orally 
 
anticoagulant were allowed to clot and were 
centrifuged to obtain serum samples that were 
stored at −80°C until analysis.  
To determine BKI-1294 exposure, blood 
samples from the treated groups G1-G3 were 
collected at multiple time points by jugular 
venipuncture into 1 mL tubes (Aquisel, 
Barcelona, Spain) containing lithium heparin. 
From G1 and G3, blood was collected: prior to 
BKI-1294 administration; 1, 2, 4, 8, 12, 24, 30 
and 48 hours after the 1st dose; 8, 12, 24, 30 and 
48 hours after the 2nd , 3th, 4th and 5th doses; and 
finally, daily until 7 days after the 5th dose. 
Heparinised blood samples were centrifuged at 
805 x g for 30 min at 4°C, and plasma samples 
were stored at -20°C until analysis by liquid 
chromatography tandem mass spectrometry 
(LCMS/MS).   
Precolostral serum was collected from 
lambs born in G1, G2 and G4 and maintained 
at −80°C for subsequent serological analysis. 
To avoid any accidental suckling from lambs 
born overnight, udders were covered with a 
piece of cloth 1 week before the expected date 
of delivery as a preventive measure.  
 
2.5. Post-mortem collection of tissue and 
body fluid samples 
To evaluate vertical transmission of the 
parasite, brains and lungs from foetuses in G1, 
G2 and G4 were stored at −80°C for DNA 
extraction and fixed in 10% formalin for 
histopathological examination. Foetal thoracic 
and abdominal fluids were also collected from 
foetuses in G1, G2 and G4 and maintained at 
−80°C for serology.  
2.6. BKI-1294 pharmacokinetics 
BKI-1294 was extracted from the plasma 
samples taken from groups G1 and G3 using 
acetonitrile / 0.1% formic acid with an internal 
standard. A standard curve was prepared for 
comparison and quantification. BKI-1294 was 
measured with an Acquity ultra performance 
liquid chromatography (UPLC) system in 
tandem with a Xevo TQ-S mass spectrometer 
(Waters, Milford, MA, USA). Calculations of 
maximum concentration (Cmax) for each dose, 
and area-under-the-curve (AUC) were 
determined using Prism (GraphPad, San Diego, 
CA).  
 
Group 
Number of 
pregnant ewes 
Number of 
foetuses/lambs 
Challenge (P.O.) Treatment (P.O.) 
G1 7 17 
1000 TgShSp1 
sporulated oocysts   
BKI-1294, 5 doses at 100 mg/kg 
bodyweight every other day  
 
G2 8 17 
1000 TgShSp1 
sporulated oocysts   
None 
 
G3 5 8 PBS 
BKI-1294, 5 doses at 100 mg/kg 
bodyweight every other day  
 
G4 5 7 PBS 
Vehicle alone, 5 doses every 
other day  
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2.7. Haematological and biochemical 
analyses   
As previously described Sánchez-Sánchez 
et al. (2018), complete blood counts (CBCs) 
were determined in whole blood using the 
automated laser-based haematology analyser 
Advia 120 (Siemens, Healthcare Diagnostics 
GmbH, Eschborn, Germany). Biochemical 
parameters were measured in serum using the 
sequential automatic autoanalyzer Konelab 30 
(Thermo Fisher Scientific, Waltham, USA). 
Ions were assessed in serum using a Microlyte 
3 (Beckman Coulter, Brea, USA). Reference 
values were obtained from Antón and Mayayo 
(2007). 
2.8. Peripheral blood cell stimulation 
assay and assessment of interferon-gamma 
(IFNγ) production  
Peripheral blood stimulation assay and 
assessment of IFNγ production were carried out 
as previously described Sánchez-Sánchez et al. 
(2018), but using T. gondii soluble antigen for 
stimulation.   
 
2.9. Serological analyses: ELISA and 
IFAT 
T. gondii-specific IgG antibody levels in 
sheep were measured using an in-house indirect 
ELISA similarly as previously described 
Castaño et al. (2014). 96-well microtiter plates 
(Thermo Fisher Scientific, Waltham, USA) 
were coated with 100 µL soluble T. gondii 
antigen (1.5 µg/mL in 100 mM carbonate 
buffer pH 9.6) overnight at 4°C. Plates were 
blocked and serum samples were diluted 1:100 
using 3% bovine serum albumin diluted in PBS 
containing 0.05% Tween 20 (PBS-T). 
Subsequently, horseradish peroxidase-
conjugated protein G (Sigma-Aldrich, Madrid, 
Spain) diluted 1:6000 in PBS-T was added and 
after that, ABTS (Roche, Basilea, Switzerland) 
was used as substrate. The reaction was stopped 
by adding 100 μL of 0.3 M oxalic acid and the 
optical density (OD) was read at 405 nm 
(OD405). For each plate, values of the OD were 
converted into a relative index percent (RIPC) 
using the following formula: RIPC = (OD405 
sample – OD405 negative control)/(OD405 
positive control–OD405 negative control) × 
100. A RIPC value ≥10 indicates a positive 
result. 
 
In addition, anti-T. gondii SAG1 (p30) 
antibodies were measured using a commercial 
ELISA “ID Screen Toxoplasmosis Indirect 
Multi species” (IDvet, Grabels, France). 
Following manufacturer´s instructions, for 
each sample, values of the OD were converted 
into the S/P percentage (S/P %) using the 
following formula: S/P % = (OD450 sample – 
OD450 negative control)/(OD450 positive 
control–OD450 negative control) × 100. A S/P 
% ≥50 indicates a positive result. 
 
Indirect fluorescent antibody test (IFAT) 
was used to detect specific IgG anti-
Toxoplasma antibodies in foetal fluids and 
precolostral sera, adapting the technique 
previously described for IFAT analysis in N. 
caninum infected animals (Alvarez-Garcia et 
al., 2003), using an anti-sheep IgG (Sigma-
Aldrich), diluted 1:200 in Evans Blue (Sigma-
Aldrich). Foetal fluids and precolostral sera 
were diluted at two-fold serial dilutions in PBS 
starting at 1:8 (for foetal fluids) and 1:50 (for 
precolostral sera) up to the endpoint titre. 
Continuous tachyzoite membrane fluorescence 
at a titre ≥ 8 for foetal fluids or ≥ 50 for 
precolostral sera was considered a positive 
reaction.   
 
2.10. Histopathology 
After fixation for five days, brains and lungs 
from foetuses were cut coronally, embedded in 
paraffin wax and processed by standard 
procedures for haematoxylin and eosin (HE) 
staining. Conventional histological evaluation 
was carried out on all sections. 
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2.11. DNA extraction and PCR for parasite 
detection  
Genomic DNA was extracted from 50–100 
mg of brain and lung samples from foetuses 
using the commercial Maxwell® 16 Mouse Tail 
DNA Purification Kit, developed for the 
automated Maxwell® 16 System (Promega, 
Wisconsin, USA), following the 
manufacturer’s recommendations. The 
concentration of DNA for all samples was 
determined by spectrophotometry and adjusted 
to 50–100 ng/μL. T. gondii DNA detection was 
carried out by an ITS-1 PCR adapted to a single 
tube as previously described Castaño et al. 
(2014). Samples from the group receiving 
vehicle alone (G4) were included in each round 
of DNA extraction and PCR as negative 
controls. 
 
2.12. Statistical analysis  
Occurrence of perinatal mortality in ewes 
was analysed by the Kaplan–Meier survival 
method and perinatal survival curves were then 
compared by the Log-rank (Mantel-Cox) test. 
Comparison of the number of foetuses/lambs 
suffering perinatal mortality was done using the 
χ2 or Fisher’s exact F-test. Rectal temperatures 
were analysed using One-way ANOVA 
followed by Tukey’s multiple test until 14 days 
pi. Cellular immune responses were analysed 
using Two-way ANOVA of repeated measures 
until day 7 pi. Weights of the lambs were 
compared using the non-parametric Kruskal–
Wallis test followed by Dunn’s test for 
comparisons between groups, as well as the 
Mann–Whitney test for pairwise comparisons. 
Cmax and AUC for ewes infected (G1) and 
uninfected (G3) as well as within G1 for ewes 
suffering perinatal mortality vs ewes that gave 
birth and for ewes with at least one positive 
lamb vs those ewes with no positive offspring  
were evaluated using the Mann–Whitney test 
for pairwise comparisons. Statistical 
significance for all analyses was established at 
P < 0.05. All statistical analyses were 
performed using GraphPad Prism 6.01 software 
(San Diego, CA, USA).  
 
3. Results 
3.1. Pharmacokinetics 
In G1, at 8-24 hours after BKI-1294 
administration, Cmax of 2.2 ± 0.8 µM after the 
1st, 2nd and 3rd doses and of 3.5 ± 0.7 µM after 
the 4th and 5th doses were reached. Likewise, 
trough plasma concentrations of 1.1 ± 0.6 µM 
48 hours after the 1st, 2nd and 3rd doses and of 
2.4 ± 0.8 µM 48 hours after the 4th and 5th doses, 
and detectable drug levels until 6-7 days after 
the last dose were found (Figure 1). In G3, Cmax 
of 2 ± 0.3 µM were reached 8-24 hours after 
each dose, with trough plasma concentrations 
of 0.4 ± 0.1 µM 48 hours after 1st, 2nd, 3rd, 4th 
and 5th dose and detectable drug levels until 3-
4 days after the last dose (Figure 1).  
 
There were significant differences observed 
between the AUCs (P < 0.05) and Cmax at both 
the 4th (P < 0.05) and 5th (P < 0.05) doses for 
the infected sheep in G1 and the uninfected 
sheep in G3. No significant differences were 
observed for the Cmax or AUCs between the 
ewes that suffered perinatal mortality and those 
that gave birth in G1. There were also no 
significant differences for Cmax or AUC for the 
ewes from G1 with at least one positive lamb 
compared to those ewes with no positive 
offspring.   
 
3.2. Clinical observations 
In sheep that remained uninfected but 
received BKI-1294 treatment (G3) or vehicle 
alone (G4), when analysing the recorded rectal 
temperatures, no significant increase was found 
throughout 12 days after treatment (Figure 2). 
In addition, no alterations on the faecal 
consistency was found. Likewise, no perinatal 
mortality was detected in uninfected but BKI-
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Figure 1 - BKI-1294 plasma concentrations in infected and uninfected ewes. Values from infected 
ewes (G1) and uninfected ewes (G3) dosed with BKI-1294. Each point represents the mean + S.D. at 
the different sampling times for each group.   
 
 
 
 
 
 
 
 
 
 
1294 treated group (G3) and ewes gave birth 
healthy lambs between 146 and 150 days of 
pregnancy. Dams from the uninfected group 
but dosed with vehicle alone (G4) gave birth 
healthy lambs between days 146 and 150 of 
pregnancy (Figure 3) (Additional file 1).  
Concerning the infected groups, statistically 
significantly increased rectal temperatures 
were found between days 4 (P < 0.05) and 8 pi 
(P < 0.001) in the untreated G2 compared to 
G4. However, compared to G4, increased rectal 
temperatures were found in treated G1 between 
days 5 (P < 0.0001) and 8 pi (P < 0.05). 
Comparing both infected groups, a significant 
decrease was observed in G1 on days 5 (P < 
0.001) and 7 pi (P < 0.001) (Figure 2). Severely 
reduced voluntary food intake was found in T. 
gondii infected animals from 6 to 11 days pi. 
From day 14 pi until the end of the experiment, 
no changes were found in rectal temperatures 
or voluntary food intake.    
 
Perinatal mortality was detected in 2 out of 
7 ewes from infected and BKI-1294 treated 
group (G1). One ewe aborted three foetuses on 
day 17 pi and a one ewe gave birth prematurely 
a stillbirth on day 140 of pregnancy (50 days 
pi). Therefore, perinatal mortality was found in 
4 out 17 foetuses/lambs. However, in infected 
but untreated group (G2), 8 out of 8 pregnant 
ewes suffered early abortions (on days 8 and 9 
pi), thus, during the acute phase of the disease. 
Significant differences were found in the 
perinatal survival curve between G1 and G2 (P 
< 0.001) (Figure 3) and also in the number of 
lambs born in G1 and G2 (P < 0.0001) 
(Additional file 1). The remaining dams from 
infected and BKI-1294 treated group (G1) gave 
birth to 11 healthy and 2 dead lambs due to 
dystocia (in a quadruplet pregnancy) on days 
144 and 150 of pregnancy.   
 
The birthweight of the lambs born from sole 
pregnancies was 4631.66 ± 347.55 g in G3 and 
4504.66 ± 585.27 g in G4. In twin pregnancies, 
birthweight of the lamb born was 3217 ± 
340.61 g in G1, 3867.5 ± 682.35 g in G3 and 
3962 ± 487.29 in G4. Finally, in triplet and 
quadruplet pregnancies, birthweight of the 
lambs born was 2918.57 ± 398.27 g in G1 and 
3228.33 ± 154.94 g in G3. The only significant 
difference was the lower birthweight of lambs 
born from twin pregnancies in G1 compared to 
birthweight of lambs born from twin
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Figure 2 - Rectal temperatures of infected (G1 and G2) and uninfected groups (G3 and G4). In 
infected groups, G1 received BKI-1294 treatment and G2 did not. In uninfected groups, G3 were 
dosed with BKI-1294 while G4 received vehicle alone. Each point represents the mean + S.D. for 
each group. Rectal temperatures were analysed using one-way ANOVA followed by Tukey’s 
multiple test. For significant differences, (***) indicates P < 0.001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pregnancies in G4 (P < 0.05).  However, no 
significant differences on the birthweight were 
found in G1 between PCR-positive lambs and 
PCR-negative lambs in the brain.   
 
3.3. Haematology and biochemistry 
 
Means and standard deviations for each 
group and reference values for haematological 
and biochemical parameters at initial and final 
time points are shown in Table 2. Mean values 
for haematological and biochemical parameters 
were in the physiological range at initial and 
final time points. The only exception concerned 
the CK in G4 at final time point, which showed 
a mean value above the reference.   
 
3.4. Cellular and humoral immune 
responses 
IFNγ levels in supernatants of blood cell 
cultures recovered 24 hours after T. gondii 
antigen stimulation were significantly 
increased in samples from G1 isolated on day 7 
pi (P < 0.01) compared to G2 and G4, with the 
maximum IFNγ levels on day 10 pi. 
Furthermore, IFNγ levels in G1 maintained a 
100-fold increase compared to G4 at the end of 
the sampling period. In G2, despite no 
significant increase was found compared to G4, 
a 10-fold increase was found on the IFNγ levels 
on days 5 and 7 pi. In contrast, blood cell 
cultures from uninfected and untreated animals 
(G4) showed IFNγ levels throughout the entire 
experimental study that corresponded to the 
basal levels recorded prior to inoculation 
(Figure 4).   
 
The Toxoplasma-specific IgG responses in 
dams are shown in Figure 5. In G1, ewe aborted 
on day 17 pi were seronegative by both 
ELISAs. The remaining ewes were seropositive 
by the SAG1 commercial ELISA (2 dams were 
seropositive from day 21 pi, 1 dam was 
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Figure 3 - Kaplan–Meier survival curves for foetuses in the infected groups (G1 and G2) and 
uninfected groups (G3 and G4). In infected groups, G1 received BKI-1294 treatment and G2 did 
not. In uninfected groups, G3 were dosed with BKI-1294 while G4 received vehicle alone. Each point 
represents the percentage of surviving animals at that day, and downward steps correspond with 
observed deaths. Foetal survival curves were compared by the Log-rank (Mantel-Cox) test. For 
significant differences between foetal survival curves of infected groups, (***) indicates P < 0.001.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
seropositive from day 28 pi and the remaining 
3 dams in this group were seropositive from 
day 35 pi) (Figure 5A). However, only the ewe 
that gave birth a stillborn lamb and 2 ewes that 
gave birth healthy but congenitally infected 
lambs were seropositive on days 42-49 pi by 
ELISA based on T. gondii soluble antigen 
(Figure 5B). All animals from G2 and G4 were 
seronegative by both ELISAs throughout the 
experimental study.  
Aborted foetuses in G1 and G2, as well as 
lambs born alive in G1, were all seronegative, 
except the stillbirth detected in G1 with an 
IFAT titre of 1:256 (Table 3) (Additional file 
1). Specific IgG responses against parasite 
antigen were not detected in foetuses/lambs 
from the group receiving vehicle alone (G4).  
 
3.5. Histopathological examination 
Multifocal non purulent encephalitis was 
only found in the brain from the stillborn lamb 
found in G1. This lesion was characterized by 
diffuse congestion in the white matter and 
several glial foci with central area of necrosis 
randomly distributed in the brain. The brains 
from foetuses aborted on day 17 pi were too 
autolytic to allow proper histological 
evaluation. No significant lesion was found in 
the brain of the lambs born healthy in G1. 
Likewise, no significant lesion was found in the 
lungs from the foetuses aborted, the stillborn 
lamb and the lambs born healthy in G1.  
In G2, the brain from foetuses were too 
autolytic to allow proper histological 
evaluation. No significant lesions were found 
in the lungs from these foetuses. Finally, no 
histopathological findings were found in the 
uninfected group (G4). 
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Table 2 - Haematological and biochemical parameters at initial and final time points.   
 
 
3.6. Parasite detection in foetal tissues 
In G1, T. gondii DNA was detected in all 
brain samples from the stillbirth and in 66% of 
the brain samples from one of the three foetuses 
aborted on day 17 pi. However, T. gondii DNA 
was not detected in the lung samples from the 
aborted foetus or the stillbirth. In seven out of 
thirteen lambs born healthy in G1 T. gondii was 
not detected in the brain or lung samples. Two 
dams gave birth all the lambs with no detection 
of T. gondii in the brain. However, 33% and 
66% of brain positive samples were detected in 
five and one of the thirteen lambs born healthy, 
respectively (Table 3) (Additional file 1). In 
G2, T. gondii DNA was not detected in any of 
the foetal brain samples and only in 2/51 (4%) 
of foetal lung samples (Additional file 1). As 
expected, all foetal samples from G4 were 
negative.   
 
4. Discussion  
Previous studies on drugs against T. gondii 
in pregnant sheep showed low efficacy against 
abortion and/or vertical transmission (Buxton 
et al., 1987; Buxton et al., 1988; Buxton et al., 
1993a; Buxton et al., 1996). Therefore, studies 
on efficacy of drug target candidates against T. 
gondii are needed (Müller and Hemphill, 
2013). This study reports on BKI-1294 drug 
levels in plasma of pregnant sheep, and the 
safety and anti-parasitic efficacy of BKI-1294 
treatment in a pregnant sheep model of 
toxoplasmosis. The efficacy was assessed with 
respect to the clinical course of disease, cellular 
and humoral immune responses and parasite 
detection and lesions in foetal tissues.   
Compared to other BKIs, such as BKI-1553, 
BKI-1294 showed lower plasma concentrations 
in mice (Schaefer et al., 2016; Vidadala et al., 
2016).
Parameter (units) 
Reference 
values 
G3 (uninfected/treated) G4 (uninfected/ vehicle alone) 
Initial Final Initial  Final 
Erythrocytes (x106) 9-14 10.68 ± 0.67 9.26 ± 0.57 10,74 ± 0.55 9,04 ± 0.66 
Haemoglobin (g/dL) 8-15 11.78 ± 0.40 10.36 ± 0.78 12.24 ± 1.04 10.38 ± 0.86 
Packed cell volume (%) 28-40 32.74 ± 1.96 28.52 ± 1.49 32.94 ± 2.01 27.94 ± 1.89 
Platelets (x103)  250-750 394.20 ± 97.85 533.80 ± 121.61 583.4 ± 73.67 615 ± 114.58 
Leukocytes (x103) 4-12 4.85 ± 1.12 4.84 ± 0.63 7,21 ± 1.42 6.53 ± 1.98 
Segment neutrophils (%) 10-50 38.72 ± 4.86 41.50 ± 12.58 45.3 ± 5.13 38.24 ± 9.39 
Lymphocytes (%) 40-75 51.44 ± 4.04 46.84 ± 13.13 45 ± 5.77 51.48 ± 11 
Monocytes (%) 1-6 3.70 ± 1.04 5.28 ± 1.99 4.12 ± 1.14 4.46 ± 1.47 
Eosinophils (%) 0-15 3.62 ± 1.47 4.04 ± 2.43 1.88 ± 0.94 2.38 ± 1.73 
Proteins (g/dL) 6-8 6.42 ± 0.34 6.56 ± 0.26 6.8 ± 0.36 6.96 ± 0.32 
AST (UI/L) 70-210 97.80 ± 27.34 82.60 ± 27.27 97.4 ± 15.24 119 ± 39.05 
GGT (UI/L) 36-93 56.60 ± 9.65 61.80 ± 12.07 66 ± 11.95 64 ± 7.71 
ALP (UI/L) 44-355 191.40 ± 62.79 221.80 ± 64.61 304.2 ± 60.60 266.4 ± 77.18 
CK (UI/L)  50-180 91.75 ± 4.78 143.75 ± 60.11 170.66 ± 47.81 301 ± 151.70 
Urea (mg/dL) 8.4-30.8 12.08 ± 1.60 15.36 ± 3.46 15.46 ± 1.16 12.02 ± 4.18 
Creatinine (mg/dL) 0.9-1.7 0.98 ± 0.04 0.9 ± 0.04 1 ± 0.07     1.22 ± 0.08 
Calcium (mg/dL) 7.1-9.8 9.80 ± 0.68 10.24 ± 0.75 10.22 ± 0.50     9.76 ± 0.50 
Phosphorus (mg/dL) 3.5-7.3 4.98 ± 1.03 7.18 ± 0.95 6.06 ± 0.35     5.9 ± 0.38 
Sodium (mEq/L) 139-152 147.20 ± 0.83 150 ± 2 148.8 ± 1.30     146 ± 1.22 
Potassium (mEq/L) 3.9-5.2 4.64 ± 0.24 4.94 ± 0.33 4.7 ± 0.46      4.92 ± 0.18 
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Figure 4 - IFNγ in supernatants of peripheral blood cell cultures. Values from infected groups 
(G1 and G2) and group receiving vehicle alone (G4). Each point represents the mean + S.D. at the 
different sampling times for each group. Concentrations of IFNγ are expressed in pg/mL. Cellular 
immune responses represented in the figure were analysed using two-way ANOVA of repeated 
measures until day 7 pi. For significant differences between infected groups, (**) indicates P < 0.01.  
 
However, BKI-1294 showed levels of 0.75 μM 
after oral administration of 10 mg/kg in mice 
(Schaefer et al., 2016; Hulverson et al., 2017). 
After oral multidoses in mice at 40 mg/kg of 
BKI-1294 orally, 3 times a day for 4 
consecutive days, plasma levels of 2-6.3 μΜ 
were found (Ojo et al., 2013). In calves, 
administration of BKI-1294 at 10 mg/kg 
resulted in plasma levels of 1 μM until 24 hours 
after treatment (Schaefer et al., 2016). In this 
experiment, after administration of 100 mg/kg 
of BKI-1294 in pregnant sheep, maximum 
concentrations of 2 μM, with trough plasma 
concentrations of 0.4-1 μM at 48 hours after 
treatment were detected. However, after the 4th 
and 5th doses in infected and treated group (G1), 
higher plasma concentrations were detected, 
most likely due to increased absorption derived 
from the decreased food intake (associated with 
T. gondii fever peak) as previously described 
Hennessy et al. (1995) for treatment of 
gastrointestinal nematodes in sheep with 
albendazole. Detectable drug levels were found 
until 13-17 days after the first dose. Previous 
studies addressing the in vitro efficacy of BKI-
1294 against the reference type II T. gondii 
isolate (TgME49) reported a half-
maximal inhibitory concentration (IC50) of 
0.22 ± 0.06 µM (Winzer et al., 2015). Thus, 
plasma concentrations of BKI-1294 in pregnant 
ewes were higher than the IC50 for T. gondii, 
perhaps indicating adequate exposure that 
could translate into good efficacy in the 
pregnant sheep model of toxoplasmosis.  
BKI-1294 at 100 mg/kg twice daily for 5 
days in mice did not show any signs of toxicity 
such as weight loss or alterations in tissue 
histology, metabolic enzymes, and complete 
blood counts (Ojo et al., 2013). Concerning 
safety during pregnancy, decrease by half on 
fertility was found in pregnant CD1 mice 
treated with BKI-1294 at 50 mg/kg for 5 days 
(Müller et al., 2017c), however, no detrimental
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Figure 5 - IgG responses in sera by ELISA T. gondii SAG1 protein (A) or soluble antigen (B). 
Values from infected groups (G1 and G2) and group receiving vehicle alone (G4). Each point 
represents the mean + S.D. at the different sampling times for each group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
effect on fertility was found using BALB/c 
mice (Winzer et al., 2015). In calves, BKI-
1553, related to BKI-1294, was safe with no 
toxicity observed after oral administration 
(Vidadala et al., 2016). In this study, BKI-1294 
did not show increase on rectal temperature nor 
alterations on the hematological and 
biochemical parameters. The only exception 
was an increase on CK values in G4 at final 
time point, although increased CK values can 
typically appear in late pregnancy (Yokus et al., 
2006). In spite of the decrease by the half on 
fertility in mice, no abortions were found in 
pregnant sheep treated with BKI-1294 and all 
lambs born healthy with no decrease on 
birthweight. Concerning local toxicity, no 
alterations on the faecal consistency was found. 
Therefore, administration in sheep at mid-
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pregnancy of 5 oral doses of BKI-1294 at 100 
mg/kg (formulated in 60% PHOSAL® 53 MCT, 
30% Polyethyleneglycol 400 and 10% Ethanol 
96º) seems to be safe. 
Previous drugs tested against T. gondii in 
pregnant sheep were dosed starting 10 days 
before the infection until parturition (Buxton et 
al., 1987; Buxton et al., 1988; Buxton et al., 
1996). However, initiation of BKI-1294 
treatment 48 h after infection was scheduled 
based on experience with BKI therapy of 
toxoplasmosis in mice (Doggett et al., 2014; 
Huang et al., 2015; Müller et al., 2017c). 
Hence, when a robust infection and 
dissemination of the parasite in the sheep has 
already taken place. Since type II T. gondii 
isolates are the most frequent in sheep 
worldwide (Sharif et al., 2017), challenge was 
carried out with a type II (genotype #3) T. 
gondii isolate, TgShSp1, isolated from an ovine 
abortion outbreak (Sánchez-Sánchez et al., 
submitted). Although 500 sporulated oocysts of 
TgShSp1 isolate triggered 100% abortion 
(Sánchez-Sánchez et al., submitted), infection 
with 2000 sporulated oocysts of TgShSp1 
resulted in 5 aborted ewes and 1 ewe that gave 
birth (unpublished data). In consequence, to 
have a large number of abortions in the 
untreated ewes, 1000 sporulated oocysts were 
applied at 90 days of pregnancy. In this 
experiment, pregnant ewes infected but not 
treated showed 100% perinatal mortality as 
previously described Sánchez-Sánchez et al. 
(submitted). Clinical observations in the BKI-
1294 treated group revealed a high protection 
against perinatal mortality, as 13 out of 17 
foetuses/lambs (76%) were born, with 
statistically improved perinatal survival rates 
compared to infected but not treated group. 
Also, a notable delay from day 8-9 pi (acute 
abortions in infected but untreatred ewes) to 
days 17-50 pi was found on the time in which 
perinatal mortality occurred in 2 infected and 
treated ewes. Although previous drugs tested 
orally against T. gondii in pregnant sheep were 
dosed starting 10 days before the infection until 
parturition, allowing better chance to control T. 
gondii infection, in this study, treatment with 5 
doses of BKI-1294 initiated 48 hours after 
infection resulted in higher protection against 
perinatal mortality (76%) compared to studies 
using monensin (38% of increase in live lambs) 
(Buxton et al., 1988) and decoquinate (22% of 
protection against abortions) (Buxton et al., 
1996). Likewise, contrary to this study in which 
100% perinatal mortality was found in infected 
but untreated pregnant ewes, only 53-55% of 
perinatal mortality was detected in infected but 
untreated pregnant ewes from studies testing 
monensin and decoquinate (Buxton et al., 
1988; Buxton et al., 1996), indicating less 
aggressive infection. Protection against 
perinatal mortality in this study is also higher 
than this achieved with BKI-1553 (37-50% of 
protection against abortion) in a pregnant sheep 
model of neosporosis (Sánchez-Sánchez et al., 
2018). In previous studies, a decreased 
birthweight has been described in lambs born 
form T. gondii infected ewes (Buxton et al., 
1996). In this study, lambs born from twin 
pregnancies in group infected and treated 
exhibited slightly lower birthweights compared 
to uninfected group receiving vehicle alone, but 
since no significant differences were found 
between lambs PCR-positive and PCR-
negative in the brain, is likely that this lower 
growth of the foetuses could be consequence of 
a severely decrease on the food intake in the 
dams from infected and treated group for 6 days 
(from 96 to 101 days of pregnancy, associated 
to marked fever peak due to T. gondii infection) 
as previously described Gardner et al. (2007). 
Likewise, all lambs born healthy while in 
previous studies using TgShSp1 in pregnant 
sheep, weak lambs were often observed 
(Sánchez-Sánchez et al., submitted). Rectal 
temperatures in pregnant ewes infected but 
non-treated increased from day 4 to day 8 pi, 
likely as a consequence of tachyzoite 
multiplication and the first cycles of parasite 
replication in host tissues, similar to previously 
reported results in sheep experimentally 
infected with 500 oocysts of  the TgShSp1 
isolate (Sánchez-Sánchez et al., submitted). 
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Table 3 - Parasite detection and serology of foetuses/lambs from ewes infected with T. gondii 
and treated with BKI-1294. 
 
 
 
 
 
a Number of ewes with at least one foetus/lamb positive by serology or PCR/total number of ewes. 
b Number of foetuses/lambs being T. gondii seropositive by IFAT/total number of foetuses or lambs. 
In brackets, the positive IFAT titres.   
c Number of foetuses/lambs with at least one positive sample by PCR/total number of foetuses or 
lambs. In brackets, the parasite detection (PCR-positive samples/total number of samples analyzed) 
 
The rectal temperatures from infected and 
treated pregnant ewes were lower than infected 
but untreated pregnant ewes on days 5 and 7 pi, 
suggesting that the drug had an impact on 
parasite replication. Likewise, one day of delay 
on the onset of rectal temperature increase was 
found in infected and treated ewes compared to 
those infected but untreated. Decreased rectal 
temperatures and/or delay in on the onset of 
rectal temperatures increase have also been 
described in experiments testing monensin 
(Buxton et al., 1988) or decoquinate (Buxton et 
al., 1996) against toxoplasmosis in pregnant 
ewes. 
IFNγ is known to be important in inhibiting 
the intracellular multiplication of T. gondii and 
in addition will create the appropriate cytokine 
microenvironment for the priming of the 
adaptive immune response towards a Th-1 type 
pro-inflammatory immune response (Innes and 
Vermeulen, 2006). Analysis of the peripheral 
immune responses in pregnant ewes at different 
time points demonstrated a significant increase 
on the IFNγ release in stimulated peripheral 
blood cultures from infected and treated group 
on day 7 pi compared to infected but not treated 
group and uninfected group receiving vehicle 
alone. Likewise, infected and treated group 
showed a peak of IFNγ release on day 10 pi as 
well as 100-fold increased levels until delivery. 
In vitro studies showed that BKI-1294 induced 
the formation of intracellular multinucleated 
complexes composed of multiple pre-zoites 
unable to separate and form tachyzoites, but 
remaining viable for extended periods of time. 
These multinucleated complexes exhibit 
increased tachyzoite specific antigen1 (SAG1) 
expression, and also increased expression of 
the bradyzoite marker BAG1, with an overall 
heavily distorted parasite ultrastructure 
(Winzer et al., 2015). If such complexes are 
also formed in vivo, they are unlikely to evade 
immune responses, but would be increasingly 
exposed to antigen-presenting cells, which 
would then result in higher IFNγ levels in 
treated animals, as previously found (Sánchez-
Sánchez et al., 2018) after treatment with BKI-
1553 of N. caninum experimentally infected 
pregnant ewes. The SAG1 molecule is an 
immunodominant surface protein found on 
tachyzoites and is one of the most extensively 
studied antigens as it is able of inducing a T cell 
response with parasiticidal activity for 
extracellular T. gondii tachyzoites (Khan et al., 
1988). Therefore, and similarly to the enhanced 
to potency of drugs against T. gondii observed 
in vitro (Radke et al., 2018) and in vivo (Araujo 
and Remington, 1991) in the presence of IFNγ, 
the effect of BKI-1294 on T. gondii could act 
Perinatal 
viability                 
Ewes with T. gondii 
positive offspringa 
Foetuses/lambs 
IFATb PCRc 
 Brain Lung 
Abortion  1/1 0/3 1/3 (2/9) 0/3 (0/9) 
Stillbirths  1/1 1/1 (1:256) 1/1 (3/3) 0/1 (0/3) 
Live lambs 3/5 0/13 6/13 (7/39) 0/13 (0/39) 
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synergistically with IFNγ response. The 
increased levels of IFNγ in infected and treated 
group might have led to greater initial control 
of parasitaemia at the peripheral level, 
diminishing the numbers of parasites reaching 
and invading the placenta (Entrican, 2002).  
Concerning humoral immune responses, all 
animals infected and treated (G1) were 
seropositive using SAG1 antigen except one 
ewe that aborted on day 17 pi. However, by the 
ELISA based on T. gondii soluble antigens only 
one ewe that gave birth a stillborn lamb and two 
dams that gave healthy lambs seroconverted, 
while the remaining ewes were seronegative at 
the end of the sampling period. Since soluble 
antigens are exposed to the immune system 
during replication (Joiner and Roos, 2002), and 
since much lower humoral immune response to 
soluble antigens was found compared to ewes 
infected with lower oocyst doses (Sánchez-
Sánchez, et al., submitted), it suggests low 
replication of the parasite throughout the 
experiment. Presence of SAG1 antibodies 
maybe derived from SAG1 expression in 
multinucleated complexes found in vitro after 
BKI-1294 treatment of T. gondii infected 
cultures (Winzer et al., 2015). Likewise, it is 
known that the SAG1 antigen triggers an 
antibody response with an inhibitory effect on 
invasion (Mineo et al., 1993).     
In previous studies testing drugs against 
congenital toxoplasmosis in pregnant sheep, 
vertical transmission was evaluated through 
foetal serology and microscopic observation of 
lesions in placental tissues and foetal brains, 
with around 50% less of animals with vertical 
transmission after treatment with monensin 
(Buxton et al., 1988), or only by evaluating 
placental tissues with 50% less of placentas 
showing lesions using decoquinate (Buxton et 
al., 1996), albeit around 12% of infected and 
untreated sheep did not show placental lesions 
(Buxton et al., 1988; Buxton et al., 1996) or 
seropositive offspring (Buxton et al., 1988). 
However, the study evaluating 
sulphamezathine/pyrimethamine showed 
100% vertical transmission in untreated 
animals and 50% reduction on the placentas 
with lesions, but not differences on foetal 
serology in treated ones (Buxton et al., 1993a). 
In the present study we evaluated transplacental 
transmission of the parasite through foetal 
serology and parasite detection and histological 
lesions in foetal tissues.  In all the lambs born 
after infection with a 100-fold lower TgShSp1 
oocyst dose than used in this study, T. gondii 
was detected in all their brains and lungs and 
lesions was found in most of the brains 
(Sánchez-Sánchez et al., submitted). However, 
in lungs from lambs born in BKI-1294 treated 
group, known as a predilection site for T. gondii 
(Gutierrez et al., 2010), no significant lesions 
or parasites were detected. Likewise, in foetal 
brains parasites were not detected in 7 lambs 
born healthy and slightly detected in the brain 
of 6 of the 13 lambs born healthy (53% of 
protection against vertical transmission in 
lambs born), while no lesions in the brain were 
found in any of them. Therefore, there was a 
slight dissemination of the parasite in the lambs 
with no antibodies detected by IFAT, although 
this technique could suffer of low sensitivity 
(Castaño et al., 2016). These results are 
consistent with those from a pregnant mouse 
model of toxoplasmosis, in which 100% 
protection against perinatal mortality and 93% 
of protection against vertical transmission in 
the surviving offspring were accomplished 
with BKI-1294 (Müller et al., 2017c). The 
higher protection of BKI-1294 in pregnant 
mice compared to pregnant sheep could be 
explained by the lower perinatal mortality and 
vertical transmission of T. gondii type II 
isolates in mice compared to sheep (Sánchez-
Sánchez et al., submitted). Since BKI-1294 
triggers formation of multinucleated complexes 
in T. gondii infected cultures (Winzer et al., 
2015), maybe in vivo, is likely that some 
tachyzoites trapped within the host cell could 
restart their replication and therefore induce 
perinatal mortality or vertical transmission. In 
fact, in some ewes the parasites reached the 
foetus, but since it is likely that therapeutic 
concentrations of BKI-1294 might have been 
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reached in the foetus, similarly to the BKI-1553 
(Sánchez-Sánchez et al., 2018), the 
dissemination of the parasite could be 
controlled. However, probably the central 
nervous system penetration of the drug did not 
allow drug levels above IC50 in the foetal brain, 
which resulted in replication of the parasite in 
some cases.  
In conclusion, BKI-1294 treatment in T. 
gondii infected dams resulted in a decrease on 
rectal temperatures upon infection, a strong 
IFNγ production, a low humoral immune 
response to soluble antigens but high levels of 
SAG1 antibodies and a decrease of 76% in the 
perinatal mortality. In the offspring, BKI-1294 
prevented vertical transmission in 53% of 
lambs born. Results of protection against 
abortion and vertical transmission of BKI-1294 
are very similar to those reported 
experimentally after immunization with the 
commercial live vaccine (Buxton et al., 1991), 
and also to those found with the Mic1-3 
Knockout of T. gondii (Mévélec et al., 2010). 
In the light of these findings, BKI-1294 
exhibits a therapeutic systemic exposure in 
pregnant ewes, is safe and confers high 
protection against abortion and vertical 
transmission of the parasite in a pregnant sheep 
model of toxoplasmosis. Further studies are 
necessary to improve efficacy of BKI-1294, by 
applying alternative formulations and using 
other routes of administration, drug dosages 
and dosing regimes. In addition, other members 
of the BKI class of compounds under 
development could be tested in the near future 
against ruminant toxoplasmosis.     
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Additional file 1 - Individual serological titres in foetuses/lambs and detection of parasite DNA 
in foetal tissues.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Day post-challenge when foetal death was detected by ultrasonography. The remaining 
foetuses lived until the end of the experiment.  
b IFAT IgG antibody titres in foetal body fluids and in precolostral serum collected after birth 
in lambs born alive. 
c Parasite DNA detection; plus (+++, ++, +) and minus (-) signs represent PCR detection in 
>67%, 66-34%, <33% and 0% of samples analysed, respectively.   
* Premature delivery with a stillborn lamb. Thoracic liquid was assessed by IFAT.  
# Lambs dead due to dystocia. 
NA: not available. 
Group 
Ewe 
ref. 
Foetal death 
(days p.i)a 
Foetus/lamb 
ref. 
IFATb 
Parasite detectionc 
Foetal brain Foetal lung 
Group 1 
1.1  1.1 F1 - - - 
  1.1 F2 - + - 
  1.1 F3 - ++ - 
1.2  1.2 F1 - + - 
  1.2 F2 - + - 
  1.2 F3
#
 - - - 
  1.2 F4
#
 - - - 
1.3  1.3 F1 - - - 
  1.3 F2 - - - 
1.4  1.4 F1 - + - 
  1.4 F2  - + - 
1.5 17 1.5 F1 NA - - 
  1.5 F2 NA - - 
  1.5 F3 - ++ - 
1.6  1.6 F1 - - - 
  1.6 F2 - - - 
1.7 50 (140 dg)* 1.7 F1 1:256 +++ - 
 2.1 9 2.1F1 - - - 
   2.1F2 - - - 
   2.1F3 - - - 
Group 2 
2.2 8 2.2 F1 - - - 
2.3 8  2.3 F1 - - - 
  2.3 F2 - - - 
  2.3 F3 - - + 
2.4 9  2.4 F1 - - - 
  2.4 F2 - - - 
2.5 8  2.5 F1 - - - 
2.6  8 2.6 F1 - - - 
  2.6 F2 - - + 
2.7 8  2.7 F1 - - - 
  2.7 F2 - - - 
  2.7 F3 - - - 
2.8  8 2.8 F1 - - - 
   2.8 F2 - - - 
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Abstract 
 
Neospora caninum is one of the main causes of abortion in cattle, and recent studies have highlighted 
its relevance as an abortifacient in small ruminants. Vaccines or drugs for the control of neosporosis 
are lacking. Bumped kinase inhibitors (BKIs), which are ATP-competitive inhibitors of calcium 
dependent protein kinase 1 (CDPK1), were shown to be highly efficacious against several 
apicomplexan parasites in vitro and in laboratory animal models. We here present the 
pharmacokinetics, safety and efficacy of BKI-1553 in pregnant ewes and foetuses using a pregnant 
sheep model of N. caninum infection. BKI-1553 showed exposure in pregnant ewes with trough 
concentrations of approximately 4 µM, and of 1µM in foetuses. Subcutaneous BKI-1553 
administration increased rectal temperatures shortly after treatment, and resulted in dermal nodules 
triggering a slight monocytosis after repeated doses at short intervals. BKI-1553 treatment decreased 
fever in infected pregnant ewes already after two applications, resulted in a 37-50% reduction in foetal 
mortality, and modulated immune responses; IFNγ levels were increased early after infection and IgG 
levels were reduced subsequently. N. caninum was abundantly found in placental tissues; however, 
parasite detection in foetal brain tissue decreased from 94% in the infected/untreated group to 69-
71% in the treated groups. In summary, BKI-1553 confers partial protection against abortion in a 
ruminant experimental model of N. caninum infection during pregnancy. In addition, reduced parasite 
detection, parasite load and lesions in foetal brains were observed.   
Keywords: Neospora caninum; sheep; pregnancy; treatment; protein kinase inhibitor; BKI-1553 
Highlights:  
BKI-1553 showed excellent exposure in pregnant ewes and foetuses.  
BKI-1553 confers partial protection against abortion in N. caninum infected ewes. 
Treatment reduces parasite detection, parasite load and lesions in foetal brains. 
1. Introduction 
 
Neospora caninum (Apicomplexa: 
Eimeriina: Sarcocystidae) is an obligate 
intracellular parasite, known to be one of the 
most important infectious causes of abortion in 
cattle worldwide (Dubey and Schares, 2011; 
Dubey et al., 2017). Since its discovery, N. 
caninum has been identified in various species 
of livestock, including cattle, sheep, goats, 
horses and deer (Dubey et al., 2007). Cattle can 
become infected by horizontal transmission via 
the ingestion of oocysts, or by vertical 
transmission (i.e., transplacentally) as a result 
of either a primary infection of the dam by 
oocysts (exogenous transplacental 
transmission) or recrudescence of a chronic 
infection (endogenous transplacental 
transmission) during pregnancy, with different 
clinical and epidemiological consequences 
(Williams et al., 2009).   
The clinical and economic importance of 
neosporosis in small ruminants has historically 
been considered much less relevant compared 
to infection by Toxoplasma gondii, which is 
one of the most common causative agents of 
abortion in sheep and goats (Dubey, 2009b). 
However, recent evidence suggests that N. 
caninum is also an important abortifacient in 
small ruminants (Moreno et al., 2012) and may 
even be the main cause of reproductive losses 
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in some flocks (West et al., 2006; González-
Warleta et al., 2014). Experimental infections 
in pregnant sheep (McAllister et al., 1996b; 
Buxton et al., 1998; Weston et al., 2009; 
Arranz-Solis et al., 2015b) have shown that 
they are highly susceptible, and as in cattle, 
abortion and vertical transmission are the main 
consequences of infection.     
 
Many control measures have been proposed 
to reduce N. caninum infection in cattle, 
including embryo transfer, artificial 
insemination of seropositive dams, culling of 
infected animals and replacement by healthy 
heifers, drug treatment and vaccination (Dubey 
et al., 2007). The latter two options have been 
identified as economically viable, provided 
suitable targets and efficacious drugs can be 
made available (Häsler et al., 2006a; Häsler et 
al., 2006b). Although experimental studies 
have revealed potent effects of several drugs in 
vitro and in laboratory animal models (Müller 
and Hemphill, 2011; Hemphill et al., 2016), 
only triazinon derivatives, such as ponazuril 
(Kritzner et al., 2002) and toltrazuril (Haerdi et 
al., 2006; Syed-Hussain et al., 2015a), and the 
polyether ionophore antibiotic monensin 
(Vanleeuwen et al., 2011) have been tested in 
ruminants experimentally infected with N. 
caninum, but results remained ambiguous. To 
date, pregnant ruminant models of neosporosis 
have not been used for assessments of drug 
efficacy against N. caninum infection and 
vertical transmission. 
 
Anti-parasitic drug development based on 
targeting kinase enzymes is a well-established 
approach (Rotella, 2012). Calcium dependent 
protein kinase 1 (CDPK1) represents a 
promising drug target, as CDPK1 is encoded by 
the apicoplast DNA, and is thus absent from 
mammalian hosts (Lourido et al., 2010; 
Murphy et al., 2010; Ojo et al., 2010). CDPK1 
activity is essential for microneme secretion, 
host cell invasion, and egress of T. gondii 
(Kieschnick et al., 2001; Lourido et al., 2010) 
and can be effectively targeted by a class of 
ATP-competitive compounds, collectively 
named bumped kinase inhibitors (BKIs).  
BKIs have a broad-spectrum activity that 
affects many apicomplexan parasites (Van 
Voorhis et al., 2017). BKI-1294, BKI-1517 and 
BKI-1553 were all effective against N. 
caninum in vitro and strongly interfered with 
transplacental transmission in a pregnant 
mouse model of neosporosis (Ojo et al., 2014; 
Winzer et al., 2015; Müller et al., 2017b). BKI-
1553 has been developed based on a variant on 
the naphthalinyl-pyrazolopyrimidine scaffold 
of BKI-1294. BKI-1553 is highly efficacious 
against T. gondii in vitro. It exhibits a low 
human ether-a-go-go-related gene (hERG) ion 
channel inhibition, excellent systemic 
exposure, crosses the blood-brain barrier in 
mice when administered orally, and BKI-1553 
treatment lead to reduced parasite burden in the 
brain, lungs and liver of T. gondii infected mice 
(Vidadala et al., 2016). We here report on the 
safety and efficacy of BKI-1553 treatment in 
pregnant sheep experimentally infected with N. 
caninum tachyzoites at mid-gestation, drug 
levels in foetuses, and its impact on vertical 
transmission.  
2. Materials and methods    
2.1. Ethics statement 
All protocols involving animals were 
approved by the Animal Welfare Committee of 
the Community of Madrid, Spain, following 
proceedings described in Spanish and EU 
legislation (PROEX 166/14 -experiment 1- and 
PROEX 064/15 -experiment 2-, Law 32/2007, 
R.D. 53/2013, and Council Directive 
2010/63/EU). All animals used in this study 
were handled in strict accordance with good 
clinical practices, and all efforts were made to 
minimize suffering.     
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2.2. Experiment 1: pharmacokinetics, 
safety and efficacy of BKI-1553 in a 
pregnant sheep model of neosporosis 
2.2.1. Animals and experimental design  
Fifty-four pure Rasa Aragonesa breed 
female lambs aged 3 months were selected 
from a commercial flock. All animals were 
seronegative for T. gondii, N. caninum, Border 
disease virus (BDV), Schmallenberg virus 
(SBV), Coxiella burnetii and Chlamydia 
abortus as determined by enzyme linked 
immunosorbent assay (ELISA). Animals were 
maintained in isolation in Zaragoza University 
(Spain) facilities until 12 months of age. They 
were oestrus-synchronized and mated with 
pure-breed Rasa Aragonesa tups for 2 days, 
after which the rams were removed from the 
ewes. Pregnancy and foetal viability were 
confirmed by ultrasound scanning (US) on day 
40 post-mating, and thirty-seven pregnant 
sheep were selected for the experiment. 
Pregnant ewes (n = 37) were randomly 
distributed into six experimental groups (see 
Table 1) and housed at the Clinical Veterinary 
Hospital facilities (Complutense University of 
Madrid, Spain). Twenty-four ewes were 
allocated into groups 1 (G1; n=8), 3 (G3; n=8) 
and 5 (G5; n=8), which were inoculated 
intravenously with 106 tachyzoites of the 
bovine isolate Nc-Spain7 (Regidor-Cerrillo et 
al., 2008) at day 90 of gestation (dg). The 
thirteen remaining pregnant ewes were 
allocated to groups 2 (G2; n=5), 4 (G4; n=5) 
and 6 (G6; n=3), which received an intravenous 
inoculum of phosphate-buffered saline (PBS) 
at 90 dg.  
BKI-1553 was synthesized by Sundia Inc. 
(Shijiazhuang, China) and further purified in 
the Department of Chemistry of the University 
of Washington. The drug formulation was 
prepared by dissolving the compound in 70% 
Tween 80 (Sigma-Aldrich, Madrid, Spain) and 
30% Ethanol 96º (Panreac, Barcelona, Spain) 
by heating at 60°C and shaking for 3 hours at a 
final concentration of 69 mg/ml. Starting at 48 
hours post-infection, BKI-1553 was 
administered subcutaneously to G1 (1st dose: 
35 mg/kg bodyweight, 2nd dose: 10 mg/kg 
bodyweight a week later) and G3 (10 mg/kg 
bodyweight, 7 doses every other day). G2 and 
G4, which represented the corresponding non-
infected treatment controls, received the same 
doses as G1 and G3, respectively. Ewes from 
G1 and G2 groups were dosed in their armpits 
with 13.12 ± 0.70 ml for the 1st dose and 8.37 ± 
0.93 ml for the 2nd dose. Ewes from groups G3 
and G4 were dosed in their armpits and inguinal 
regions with 8.37 ± 0.20 ml per dose. Ewes 
from the non-infected groups G2 and G4 were 
culled around the time when abortion occurred 
in the respective Neospora-infected groups G1 
and G3, providing a negative control for further 
analyses (see below). Ewes from G6 (non-
infected, no drug) were kept alive until the end 
of the experiment.  
 
2.2.2. Parasites  
Tachyzoites of the Nc-Spain7 isolate were 
routinely maintained in cultured MARC-145 
cells as described previously (Regidor-Cerrillo 
et al., 2010). For the in vivo challenge, 
tachyzoites (passage 14) were recovered from 
culture flasks when they were still largely 
intracellular (>80% of undisrupted 
parasitophorous vacuoles), and infected cells 
were repeatedly passed through a 25-gauge 
needle at 4°C. Tachyzoite numbers were 
determined by Trypan blue exclusion followed 
by counting in a Neubauer chamber, and 
parasites were resuspended in PBS at the 
required dose of 106 tachyzoites in a final 
volume of 1 mL. Infection of ewes was carried 
out within 30 min of harvesting the parasites 
from cell culture.
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Table 1 - Experimental design  
 
i.v.: intravenous route 
s.c.: subcutaneous route 
 
2.2.3. Clinical monitoring 
Pregnant ewes were observed daily 
throughout the entire experimental period. 
Foetal viability was assessed by US monitoring 
of foetal heartbeat and movements once a week 
during the first 14 days post-infection (pi) and 
then twice weekly until detection of foetal 
death. Rectal temperatures were recorded daily 
from day 0 until 14 days pi and then weekly. 
The physiological range for rectal temperatures 
in sheep was obtained from Antón and Mayayo 
(2007), and rectal temperatures above 40°C 
were considered hyperthermic. Skin lesions 
after subcutaneous BKI-1553 administration 
were recorded daily until their resolution. 
When foetal death occurred, or immediately 
after parturition, dams and lambs were first 
sedated with xylazine (Rompun, Bayer, 
Mannhein, Germany) and then euthanized by 
an intravenous overdose of embutramide and 
mebezonium iodide (T61, Intervet, Salamanca, 
Spain). In G2 and G4, at least one ewe was 
culled for each of the three ewes that aborted in 
G1 and G3 as close as possible to the average 
day of abortion. Animals from G6 were 
examined by US every two weeks. Lambs were 
clinically inspected and weighed immediately 
after birth and then euthanized.      
 
2.2.4. Collection of blood samples 
Blood samples to evaluate peripheral 
immune responses were collected prior to 
infection and then weekly by jugular 
venipuncture into 5 mL vacutainer tubes 
(Becton Dickinson and Company, Plymouth, 
UK) with and without lithium heparin as 
anticoagulant. In addition, haematological and 
biochemical parameters before (day 0 pi) and 
after treatment (13 days pi for G1, G2, G5 and 
G6, and 18 days pi for G3 and G4) were 
assessed in blood samples collected into 10 mL 
vacutainer tubes (Becton Dickinson and 
Company, Plymouth, UK), with 
ethylenediaminetetraacetic acid (EDTA) as 
anticoagulant and into 5 mL vacutainer tubes 
(Becton Dickinson and Company, Plymouth, 
Group 
Number of 
pregnant ewes 
Number of 
foetuses/lambs 
Inoculum (i.v.) Treatment (s.c.) 
G1 8 14 
Nc-Spain7 
106 tachyzoites  
BKI-1553, 1st dose: 35 mg/kg 
bodyweight; a week later, a 2nd 
dose at 10 mg/kg bodyweight 
 
G2 5 7 PBS 
BKI-1553, 1st dose: 35 mg/kg 
bodyweight; a week later, a 2nd 
dose at 10 mg/kg bodyweight 
 
G3 8 13 
Nc-Spain7 
106 tachyzoites 
BKI-1553, 7 doses at 10 mg/kg 
bodyweight every other day  
 
G4 5 9 PBS 
BKI-1553, 7 doses at 10 mg/kg 
bodyweight every other day  
 
G5 8 13 
Nc-Spain7 
106 tachyzoites  
None  
G6 3 5 PBS None  
Chapter IV ~ Results 
Objective 3: Safety and efficacy of BKI compounds in pregnant sheep 
 
~ 150 ~ 
 
UK) without anticoagulant. Tubes without 
anticoagulant were allowed to clot and were 
centrifuged to obtain serum samples that were 
stored at −80°C until analysis. 
To determine BKI-1553 exposure, blood 
samples from the treated groups G1-G4 were 
collected at multiple time points by jugular 
venipuncture into 2 mL tubes (Aquisel, 
Barcelona, Spain) containing lithium heparin. 
From G1 and G2, blood was collected prior to 
BKI-1553 administration, after the 35 mg/kg 
bodyweight dose at 12 hours, 48 hours and 7 
days, and after the 10 mg/kg bodyweight dose 
at 12 and 48 hours and 4, 5, 6, 7, 10, 14 and 21 
days. From G3 and G4, blood samples were 
collected prior to BKI-1553 administration, 12 
and 48 hours after the first and second doses, 
48 hours after the fourth and sixth doses and 
finally, 12 and 48 hours and 4, 5, 6, 7, 10, 14 
and 21 days after the seventh dose. Heparinised 
blood samples were centrifuged at 805 x g for 
30 min at 4°C, and plasma samples were stored 
at -20°C until analysis by liquid 
chromatography tandem mass spectrometry 
(LCMS/MS).  
Precolostral serum was collected from 
lambs and maintained at −80°C for subsequent 
serological analysis. To prevent any 
transmission of colostral antibodies from dams, 
lambs were separated from their mothers 
immediately after birth, sampled for blood and 
euthanized.  
2.2.5. Post-mortem collection of tissue 
and body fluid samples 
Six randomly selected placentomes or 
cotyledons from aborted/euthanized dams and 
dams that gave birth, respectively, were 
recovered from each placenta, transversally cut 
into 2–3 mm-thick slices, and fixed in 10% 
formalin for histopathological examination, 
whereas remaining tissues from these 
placentomes/cotyledons were stored at −80°C 
for further DNA extraction. Foetal brains were 
stored at −80°C for DNA extraction and fixed 
in 10% formalin for histopathological 
examination. Foetal thoracic and abdominal 
fluids were also collected from foetuses and 
maintained at −80°C for serology.   
2.2.6. BKI-1553 pharmacokinetics 
BKI-1553 was extracted from the plasma 
samples using acetonitrile/0.1% formic acid 
with an internal standard. A standard curve was 
prepared for comparison and quantification. 
BKI-1553 was quantified by analysis on a 6460 
series triple quadrupole LC-MS/MS (Agilent, 
Santa Clara, CA). For both doses in groups G1 
and G2, and for the first and seventh doses in 
groups G3 and G4, phamacokinetic (PK), 
calculations of maximum concentration (Cmax), 
and area-under-the-curve (AUC) were 
determined using Pharsight Phoenix 
WinNonlin software (Certara, St. Louis, MO). 
2.2.7. Haematological and biochemical 
analyses   
Complete blood counts (CBCs), including 
erythrocytes, haemoglobin, packed cell volume 
(PCV), platelets, leukocytes, segmented 
neutrophils, lymphocytes, monocytes and 
eosinophils, were determined in whole blood 
using the automated laser-based haematology 
analyser Advia 120 (Siemens, Healthcare 
Diagnostics GmbH, Eschborn, Germany). 
Concerning biochemical parameters, proteins, 
aspartate aminotransferase (AST), gamma-
glutamyltransferase (GGT), alkaline 
phosphatase (ALP), creatine kinase (CK), urea 
and creatinine levels were measured in serum 
using the sequential automatic autoanalyzer 
Konelab 30 (Thermo Fisher Scientific, 
Waltham, USA). Ions such as calcium, 
phosphorus, sodium and potassium were 
assessed in serum using a Microlyte 3 
(Beckman Coulter, Brea, USA). Reference 
values were obtained from Antón and Mayayo 
(2007).    
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2.2.8. Peripheral blood cell stimulation 
assay and assessment of 
interferon-gamma (IFNγ) 
production  
To ensure that blood cells retained the 
capacity to respond to stimulation and to 
secrete IFNγ, heparinized blood samples were 
processed within 2 h of collection by mixing 
500 µL blood with 500 µL RPMI 1640 medium 
(Gibco, Paisley, UK) supplemented with 10% 
foetal bovine serum (FBS; Thermo Fisher 
Scientific, Waltham, USA) and 100X 
antibiotic/antimycotic solution (Lonza, 
Belgium). Blood cells were cultured in 24-well 
flat-bottom plates (Thermo Fisher Scientific, 
Waltham, USA) in the presence of either 
soluble N. caninum antigens or concanavalin A 
(ConA, Sigma-Aldrich, Madrid, Spain), both at 
final concentrations of 5 μg/mL. All 
experiments were performed in duplicate. 
Plates were incubated in a 5% CO2/37°C/100% 
humidity atmosphere for 24 h. They were then 
centrifuged at 1000 x g for 10 min at 4°C, and 
cell-free culture supernatants were stored at 
−80°C for IFNγ analyses. IFNγ was detected 
using a commercial bovine enzyme 
immunoassay kit with a capture monoclonal 
antibody (MT17.1) showing cross-reactivity 
with ovine IFNγ (Mabtech AB, Sweden) as 
previously described Arranz-Solís et al. (2016). 
Mean optical density (OD) for each 
experimental animal was calculated as the 
mean OD obtained from each supernatant from 
the N. caninum antigen-stimulated cells divided 
by the mean OD of the same cells incubated 
with medium alone (negative control). 
Afterwards, the mean OD was calculated for 
each experimental group. Supernatant from 
ConA-stimulated cells was processed in a 
similar way as a positive control for stimulation 
but was not included in the subsequent analysis.  
  
 
 
2.2.9. Serological analyses: ELISA and 
IFAT 
Neospora caninum-specific IgG antibody 
levels were measured using an in-house 
indirect ELISA. Soluble N. caninum antigen 
was prepared according to (Alvarez-Garcia et 
al., 2003). 96-well microtiter plates (Thermo 
Fisher Scientific, Waltham, USA) were coated 
with 100 µL soluble N. caninum antigen (1 
µg/mL in 100 mM carbonate buffer pH 9.6) 
overnight at 4°C. Subsequently, nonspecific 
binding was blocked by adding 300 μL of 3% 
bovine serum albumin diluted in PBS (pH 7.4) 
containing 0.05% Tween 20 (PBS-T). After 2 h 
incubation at room temperature (RT), plates 
were washed three times with PBS-T. Serum 
samples were diluted 1:100 in blocking 
solution, and 100 μL of this dilution was added 
to each well and incubated during 1 h at 37°C. 
In each plate, samples of the same positive and 
negative control sera were included. 
 
After three washes in PBS-T, 100 μL of 
horseradish peroxidase-conjugated protein G 
(Sigma-Aldrich, Madrid, Spain) diluted 1:2000 
in PBS-T was added and incubated for 1 h at 
37°C. Plates were washed as above before the 
addition of 100 μL per well of ABTS substrate 
(Roche, Basilea, Switzerland). The reaction 
was stopped after 14 min at RT by the addition 
of 100 μL of 0.3 M oxalic acid, and the optical 
density (OD) was read at 405 nm (OD405). For 
each plate, values of the OD were converted 
into a relative index percent (RIPC) using the 
following formula: RIPC = (OD405 sample – 
OD405 negative control)/(OD405 positive 
control–OD405 negative control) × 100. A 
RIPC value ≥10 indicates a positive result.  
 
Indirect fluorescent antibody test (IFAT) 
was used to detect specific IgG anti-Neospora 
antibodies in foetal fluids and precolostral sera 
as previously described Alvarez-Garcia et al. 
(2003). Foetal fluids and precolostral sera were 
diluted at two-fold serial dilutions in PBS 
starting at 1:8 (for foetal fluids) and 1:50 (for 
precalostral sera) up to the endpoint titre. 
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Continuous tachyzoite membrane fluorescence 
at a titre ≥ 8 for foetal fluids or ≥ 50 for 
precolostral sera was considered a positive 
reaction.   
 
2.2.10. Histopathology and lesion 
scoring 
After fixation in formalin for five days, 
tissue samples were processed for histological 
evaluation. Foetal brain samples were 
subjected to measurement of histological lesion 
characteristics through software-assisted 
analysis of digital pictures as previously 
described Arranz-Solis et al. (2015b). Briefly, 
the number (foci/cm2) and average size of 
lesion foci (ASF), as well as the total area of the 
lesion (%LES), were calculated. 
   
2.2.11. DNA extraction and PCR for 
parasite detection and 
quantification in tissues 
Genomic DNA was extracted from 50–100 
mg of maternal and foetal tissue samples using 
the commercial Maxwell® 16 Mouse Tail 
DNA Purification Kit, developed for the 
automated Maxwell® 16 System (Promega, 
Wisconsin, USA), following the 
manufacturer’s recommendations. The 
concentration of DNA for all samples was 
determined by spectrophotometry and adjusted 
to 50–100 ng/μL.  
Parasite DNA detection was carried out by 
a nested-PCR adapted to a single tube from the 
internal transcribed spacer (ITS1) region of N. 
caninum, using the external primers TgNN1-
TgNN2 and internal primers NP1–NP2 as 
previously described Buxton (1998) and 
Regidor-Cerrillo et al. (2014). Each reaction 
was performed in a final volume of 25 μL with 
5 μL of sample DNA.   
PCR analysis was performed for six samples 
of the placentomes in aborted dams or 
cotyledons in dams that gave birth and three 
samples of foetal brain tissues. Moreover, both 
reactions without a template and DNA samples 
from the uninfected groups (G2, G4 and G6) 
were included in each round of DNA extraction 
and PCR as negative controls. Positive PCR 
controls with N. caninum genomic DNA 
equivalent to 10, 1 and 0.1 tachyzoites in 100 
ng of sheep DNA were also included in each 
batch of amplifications. Ten μL aliquots of the 
PCR products were visualized under UV light 
in 1.5% agarose/ethidium bromide gel to detect 
the N. caninum-specific 247 bp amplification 
product.  
 
Placenta and foetal brain samples that had 
tested positive by nested-PCR were adjusted to 
20 ng DNA/μL and the parasite load was 
quantified using real-time PCR. Primer pairs 
from the N. caninum Nc-5 sequence (Collantes-
Fernández et al., 2002) were used for parasite 
quantification, and primers from the β-actin 
gene (Gutierrez et al., 2012) were used for the 
quantification of host DNA. Amplification 
reactions were performed as described by 
Collantes-Fernández et al. (2002) with slight 
modifications in a final volume of 20 μL using 
Go Taq® qPCR Master Mix (Promega, 
Wisconsin, USA), 20 pmol of each primer and 
100 ng of DNA in an ABI 7300 Real Time PCR 
System (Applied Biosystems, California, 
USA). The N. caninum tachyzoite numbers 
were calculated by interpolating the average Ct 
values on two standard curves: 1) one curve 
equivalent to 105 to 10−1 tachyzoites with 10-
fold serial dilutions in a solution of ovine 
genomic DNA, and 2) a curve of 320, 160, 80, 
40, 20, 10, and 5 ng of genomic DNA for ovine 
DNA quantification. Parasite numbers in tissue 
samples (parasite burden) were expressed as 
parasite number/mg ovine tissue. Standard 
curves for N. caninum and sheep DNA showed 
an average slope of −3.45 and −3.33, 
respectively, and a R2 > 0.99.   
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2.3. Experiment 2: foetal 
pharmacokinetics of BKI-1553 
2.3.1. Animals and experimental design  
Seven pure Churra breed sheep aged 12 
months were selected, oestrus-synchronized 
and mated as described for Experiment 1. 
Pregnancy and foetal viability were confirmed 
by US on day 40 post-mating, and three 
pregnant sheep at 125 ± 9 days of gestation 
were selected for the experiment.  
2.3.2. Foetal catheterization and clinical 
monitoring 
Pregnant ewes were pre-medicated with 
flunixin meglumine (Fluvex, SP Veterinaria, 
Spain), benzylpencillin (Penilevel, ERN 
Laboratorios, Barcelona, Spain) and 
gentamicin (Gentamicin 60%, Braun, 
Barcelona, Spain) following the 
manufacturer´s recommendations. After 24 
hours of fasting, pregnant ewes were induced 
for general anaesthesia, maintained under 
inhalation anaesthesia with isofluorane (Isovet, 
Braun, Barcelona, Spain) and monitored for 
physiological parameters. After hysterotomy 
and location of the hind limb of one of the 
foetuses (Herrera et al., 2012), foetal 
catheterization of the saphenous vein was 
performed with the catheter Prowler® 
Select® Plus, 2,8 F/150 cm (Cordis, California, 
USA). The catheter was fixed to the abdominal 
skin of the pregnant ewes. Pregnant ewes were 
observed, and foetal viability was assessed by 
US monitoring foetal heartbeat and 
movements, on a daily basis. At the end of the 
experiment, pregnant ewes were sedated and 
euthanized as described above (subsection 
2.2.3).    
 
2.3.3. Drug administration  
Upon recovery from anaesthesia, BKI-1553 
formulated as described in subsection 2.2.1 was 
administered to pregnant sheep subcutaneously 
into the right armpit at 10 mg/kg bodyweight.  
2.3.4. Collection of samples  
Pregnant ewes and one of their foetuses 
were sampled by jugular venipuncture into 2 
mL tubes (Aquisel, Barcelona, Spain) 
containing lithium heparin as an anticoagulant. 
Samples were collected prior to BKI-1553 
administration, 1, 2, 4, and 8 hours after 
administration and, if possible, 24 and 30 hours 
after administration. Heparinised blood 
samples were processed as described in 
subsection 2.2.6 to determine BKI-1553 
exposure.   
2.3.5. Statistical analysis  
Occurrence of foetal death was analysed by 
the Kaplan–Meier survival method. Foetal 
survival curves were then compared by the 
Log-rank (Mantel-Cox) test, and the median 
foetal survival time, i.e., the day at which 50% 
of the foetuses aborted, was calculated. Areas 
of the skin lesions, weights of the lambs and 
antibody responses in foetuses and lambs were 
compared using the non-parametric Kruskal–
Wallis test followed by Dunn’s test for 
comparisons between groups, as well as the 
Mann–Whitney test for pairwise comparisons. 
Rectal temperatures were analysed using Two-
way ANOVA of repeated measures testing 
until 14 days pi and One-way ANOVA test 
afterwards. Haematological and biochemical 
parameters were compared between groups 
using One-way ANOVA testing at each time 
point. Humoral and cellular immune responses 
for each experimental group were analysed 
using Two-way ANOVA of repeated measures 
testing until 21 days pi and One-way ANOVA 
test afterwards. Differences in Cmax and AUC 
for infected versus non-infected and aborted 
versus non-aborted ewes within the different 
treatments were evaluated using the Mann–
Whitney test for pairwise comparisons.   
Differences in frequency of PCR detection of 
parasite DNA were evaluated using the χ2 or 
Fisher’s exact F-test. Differences in parasite 
burdens and histological measurements of 
lesions were analysed using the non-parametric 
Kruskal–Wallis test followed by Dunn’s test 
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for comparisons between groups, as well as the 
Mann–Whitney test for pairwise comparisons. 
Statistical significance for all analyses was 
established at P < 0.05. All statistical analyses 
were performed using GraphPad Prism 6.01 
software (San Diego, CA, USA).   
 
3. Results 
3.1. Experiment 1: plasma concentrations, 
safety and efficacy of BKI-1553 in a 
pregnant sheep model of neosporosis 
3.1.1. Pharmacokinetics 
Cmax for groups treated weekly (G1 and G2) 
reached 11.7 ± 5.2 µM at 12 hours after the first 
dose administration (35 mg/kg) and 9.0 ± 3.7 
μM at 12 hours after the second dose (10 
mg/kg), with trough plasma concentrations of 
4.2 ± 2.9 µM after the first dose and 1.5 ± 1.2 
µM at the end of the sampling period, 21 days 
after the final dose. Cmax for groups treated at 
10 mg/kg every 48 hours (G3 and G4) reached 
5.7 ± 2.8 μM at 12 hours after the first dose and 
7.7 ± 4.7 μM at 12 hours after the final dose, 
with trough plasma concentrations of 3.6 ± 2.4 
μM after the first dose and 2.2 ± 2.1 μM at the 
end of the sampling period, 21 days after the 
final dose.   
 
No significant differences were observed 
between the infected and uninfected animals in 
groups receiving equivalent treatments for Cmax 
or AUCs. For infected ewes receiving weekly 
treatment (G1), there was no significant 
difference between the aborted and not-aborted 
ewes for the AUCs or the Cmax for the first or 
second dose. In infected ewes receiving 
treatment every 48 hours (G3), there was no 
significant difference between the aborted and 
not-aborted ewes for AUC or Cmax of the first 
or final dose.    
 
3.1.2. Clinical observations 
In sheep that remained uninfected but 
received treatment (G2 and G4), when 
analysing the recorded rectal temperatures in 
relation to G6, a significant increase in G2 was 
found on day 1 (P < 0.05) and day 2 (P < 
0.0001) after treatment, and in G4 on day 1 
after treatment (P < 0.05). Mean rectal 
temperatures in G2 on day 2 were slightly 
above 40°C (Figure 1A). Foetuses from G2 and 
G4 remained alive just prior to the euthanasia 
of two dams on days 41 and 47 pi in G2 and of 
a dam on day 41 pi in G4. The remaining dams 
gave birth to 5 healthy lambs in G2 and 7 
healthy lambs and 1 dead lamb due to dystocia 
in G4 between days 145 and 147 of pregnancy.    
 
Concerning the infected groups, statistically 
significantly increased rectal temperatures 
were found between days 4 (P < 0.05) and 7 pi 
(P < 0.0001) in the untreated G5 compared to 
G6. Furthermore, compared to G5, rectal 
temperatures were significantly increased in 
G1 (P < 0.0001) and G3 (P <0.001) on day 3 pi 
(day 1 after treatment), and a significant 
decrease was observed in G1 on days 5 (P < 
0.0001) and 6 pi (P < 0.05). Maximum mean 
rectal temperatures were measured on day 7 pi 
in all infected groups (Figure 1B). No 
significant differences in rectal temperatures 
were found between aborting and non-aborting 
ewes from G1 and G3. From day 14 pi until the 
end of the experiment, no changes were found 
in rectal temperatures.  
 
Dermal nodules at the sites of drug 
administration were observed 24 hours after 
application of BKI-1553 in all dams from the
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Figure 1 - Rectal temperatures of uninfected groups G2, G4 and G6 (A) and infected groups 
G1, G3 and G5 and the uninfected/untreated group G6 (B). Each point represents the mean + S.D. 
for each group. Rectal temperatures represented in the figure were analysed using Two-way ANOVA 
of repeated measures. For significant differences, (*) indicates P < 0.05, (***) indicates P < 0.001 
and (****) indicates P < 0.0001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
treated groups, with areas of 108.8 ± 57.5 cm2 
in G1, 102.1 ± 76.1 cm2 in G2, 99.6 ± 67.3 cm2 
in G3 and 140.1 ± 66.9 cm2 in G4, without 
significant differences between them. These 
nodules eventually resolved over the course of 
the experiment.    
Foetal death was detected by US between 
23-46 days pi in 5 out of 8 pregnant ewes in G1 
(median day 39 pi), 4 out of 8 pregnant ewes in 
G3 (also median day 39 pi) and in all pregnant 
ewes in G5 (median day 36 pi). Median foetal 
survival times were 42, 51 and 36 days for G1, 
G3 and G5, respectively. Significant 
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differences were found in the foetal survival 
rate between G3 and G5 (P < 0.05). No foetal 
death was detected in uninfected groups. Dams 
from the pregnancy control group (G6) gave 
birth healthy lambs between days 146 and 150 
of pregnancy, and the foetal survival rate in G6 
was significantly different from G5 (P < 0.01) 
(Figure 2). The remaining dams from G1 gave 
birth to 6 healthy and 1 dead lamb on days 145 
and 146 of pregnancy, whereas the remaining 
dams in G3 gave birth to 7 healthy and 2 dead 
lambs on days 142 (premature), 144 and 145 of 
pregnancy.   
 
Albeit lower, the birthweight of the lambs 
from G1 (2821.6 ± 360.3 g), G2 (3323 ± 720.6 
g) and G4 (2885.8 ± 566.8 g) did not show 
statistically significant differences compared to 
G6 (4037.4 ± 354.7 g), while a significant 
decrease in the birthweight in G3 (1845 ± 434.3 
g) was found when compared to G6 (P < 0.01) 
or to G4 (P < 0.05).  
 
3.1.3. Haematology and biochemistry 
Means and standard deviations for each 
group and reference values for haematological 
and biochemical parameters at initial and final 
time points are shown in Table 2. Mean values 
for haematological parameters were in the 
physiological range or showed no significant 
differences when values from the different 
groups at initial and final time points were 
compared. The only exceptions concern the 
lymphocyte percentage, which showed a 
significant increase (P < 0.01) at the final time 
point in G5 compared to G3, and the monocyte 
percentage, which showed a significant 
increase (P < 0.05) at the final time point in G3 
compared to G1.
 
Figure 2 - Kaplan–Meier survival curves for foetuses in the infected groups G1 and G3 treated 
with BKI-1553, infected group G5, and the non-infected groups. Each point represents the 
percentage of surviving animals at that day, and downward steps correspond with observed deaths. 
Foetal survival curves were compared by the Log-rank (Mantel-Cox) test. For significant differences 
between foetal survival curves of infected groups, (*) indicates P < 0.05.   
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Biochemical parameters in the serum such 
as total proteins were not different from each 
other in all groups. Regarding liver function 
parameters, AST showed a significant increase 
(P < 0.01) in G5 compared to the other groups 
at the final time point, but was still within the 
normal range. GGT levels were in the 
physiological range in all groups, ALP mean 
values were above the normal range in most 
cases, and in G2 significantly higher values 
were noted at initial (P < 0.05) and final (P < 
0.01) time points compared to the other groups. 
Concerning renal function parameters, urea 
levels were normal in all groups, but 
statistically lower in G1 compared to G3 at the 
final time point (P < 0.05). For all groups 
creatinine showed mean values within a normal 
range at initial time points, but these values 
decreased to below the normal range at final 
time points. CK, an early marker of myocardial 
damage, was 2-fold higher, thus above the 
normal physiological range in sheep initially 
and at the final time points in all groups. Levels 
of phosphorus, sodium and potassium were in 
the physiological range in all groups 
throughout the experiment, whereas calcium 
levels were slightly above the physiological 
range, and statistically elevated levels were 
noted in G5 at the final time point compared to 
the other groups (P < 0.05).   
 
3.1.4. Humoral and cellular immune 
responses 
The N. caninum-specific IgG antibody 
responses in dams analysed by ELISA are 
shown in Figure 3A. All uninfected control 
animals in G2, G4 and G6 exhibited basal IgG 
levels within the reference range throughout the 
experimental study. In contrast, compared to 
the control groups (G2 + G4 + G6), IgG levels 
increased significantly from day 14 pi in G5 (P 
< 0.05), and continued rising until day 21 pi, 
whereas in G1 and G3, significantly different 
IgG levels were only found from day 21 pi (P 
< 0.0001). On day 21 pi, G3 exhibited 
significantly lower IgG levels compared to G1 
(P < 0.05) and G5 (P < 0.0001). On day 21 pi, 
IgG levels were also compared between 
aborted ewes and ewes that gave birth. No 
significant differences were found in G3, but 
lower IgG levels were observed in ewes that 
gave birth in G1 compared to those that aborted 
(P < 0.01). From day 21 pi until foetal 
death/birth occurred, IgG levels in G1 and G3 
remained at similar values, but significantly 
lower values were noted in these two groups in 
relation to G5 (P < 0.0001) (data not shown).   
Aborted foetuses in G1, G3 and G5 were all 
similarly seropositive, with titres ranging from 
1:32 to 1:1024. Median values of the IFAT 
titres were calculated as 1:128 for G1 and G3, 
whereas G5 showed a median IFAT titre of 
1:256. Precolostral sera collected from lambs 
born in G1 and G3 yielded positive titres 
ranging from 1:200 to 1:6400, with no 
significant differences, and median IFAT titres 
of 1:1600 in both groups (Additional file 1). 
Specific IgG responses against parasite antigen 
were not detected in foetuses/lambs from the 
three non-infected control groups (G2, G4 and 
G6).   
 
IFNγ levels in supernatants of blood cell 
cultures recovered 24 hours after N. caninum 
antigen stimulation were significantly 
increased in samples from G1, G3 and G5 
isolated on day 7 pi (P < 0.0001) and in cultures 
from G3 on day 14 pi (P < 0.001). In contrast, 
blood cell cultures from non-infected control 
animals (G2, G4 and G6) showed IFNγ levels 
that corresponded to the basal levels recorded 
prior to inoculation throughout the entire 
experimental study. The increased IFNγ levels 
observed in G1, G3 and G5 culture 
supernatants decreased from day 21 pi onwards 
and remained at low levels. Comparisons 
between infected groups showed significantly 
increased IFNγ levels on day 7 pi in G1 and G3 
cultures compared to G5 (P < 0.01) and on day 
14 pi in G3 compared to G1 (P < 0.05) (Figure 
3B). When IFNγ values of stimulated cultures 
from aborting and non-aborting ewes were 
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Figure 3 - IgG response in sera (A) and IFNγ in supernatants of peripheral blood cell cultures 
(B). Values from infected (G1, G3 and G5) and uninfected (G2+G4+G6) pregnant ewes are 
represented. Each point represents the mean + S.D. at the different sampling times for each group. 
Data beyond day 21 pi are not shown, since several animals did not maintain pregnancy and were 
therefore sacrificed. Sera levels of total IgG antibodies against N. caninum are expressed as a relative 
index percent (RIPC), according to the formula: RIPC = (OD405 sample – OD405 negative 
control)/(OD405 positive control – OD405 negative control) × 100. Concentrations of IFNγ are 
expressed in pg/mL. Humoral and cellular immune responses represented in the figure were analysed 
using two-way ANOVA of repeated measures. For significant differences between infected groups, 
(*) indicates P < 0.05, (**) indicates P < 0.01 and (****) indicates P < 0.0001.  
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compared, no significant differences on day 7 
pi were found in G1, but in G3 the cultures from 
aborting ewes produced significantly more 
IFNγ compared to cultures from non-aborting 
ewes (P < 0.01).   
 
3.1.5. Pathology and lesion 
quantification 
No histopathological lesions were found in 
the uninfected and treated groups (G2 and G4) 
or in the uninfected and untreated group (G6) 
(Figure 4A-C).  Foci of necrosis with variable 
degrees of infiltration of inflammatory cells, 
primarily lymphocytes and macrophages, were 
found in all placentomes from all aborted ewes 
in infected groups (Figure 4B). Cotyledons 
from ewes that gave birth were too autolytic to 
permit proper histological evaluation. In foetal 
brains from infected sheep, lesions were found 
in 79%, 83% and 92% in G1, G3 and G5, 
respectively. In aborted foetuses from G1 and 
G3, 100% of foetal brains exhibited lesions, 
whereas 57% and 75% of foetal brains from 
lambs born in G1 in G3 showed lesions, 
respectively. Histological lesions were 
characterized by necrotic glial foci with 
random distribution in the neuropile (Figure 
4D). The number of foci, average area of the 
lesions, and the percentages of damaged area 
showed no significant differences between 
infected groups (Additional file 1). However, 
within G1 and G3, when comparing the lesions 
found in aborted foetuses with those found in 
lambs, significant differences were found 
regarding the number of foci and percentage of 
damaged area. In G1, foetal brain from lambs 
born showed lower numbers of foci (P < 0.05) 
and percentages of damaged area (P < 0.01) 
compared to aborted foetuses. Similarly, foetal 
brains from lambs born in G3 showed lower 
numbers of foci (P < 0.01) and percentages of 
damaged area (P < 0.05) compared to aborted 
foetuses (Figure 5). No differences in those 
parameters were seen when aborted foetuses 
from different groups were compared, and 
when lambs from different groups were 
analysed.
 
Figure 4 - Hemotoxylin and eosin staining. A) Interdigitate area of the placentome of an uninfected 
sheep with no evident lesion. B) Foci of necrosis and scant inflammatory infiltration at the 
interdigitated area of the placentome of an infected sheep. C) Foetal brain from an uninfected sheep 
with no evident lesion. D) Glial foci with central necrosis at the foetal brain from an infected sheep. 
Bar: 200 μm. 
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Figure 5 - Box-plots showing number of lesions (A), average size of focus (B) and lesion rates 
(C) in foetal brains from G1 and G3. Graphs represent the median percentage, the lower and upper 
quartiles (boxes) and minimum and maximum values (whiskers). Histological measurements of 
lesions were analysed using the non-parametric Kruskal–Wallis test followed by Dunn’s test for 
comparisons between groups, as well as the Mann–Whitney test for pairwise comparisons. For 
significant differences between infected and treated groups, (*) indicates P < 0.05 and (**) indicates 
P < 0.01.  
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Figure 6 - Dot-plot graphs of N. caninum burdens in placentomes (A), cotyledons (B) and foetal 
brain (C) from G1, G3 and G5. Each dot represents individual values of parasite burden (number 
of parasites per mg of host tissue), and medians are represented as horizontal lines. Considering that 
the N. caninum detection limit by real-time PCR is 0.1 parasites, negative samples (0 parasites) were 
represented on the log scale as <0.1 (i.e., 10−2). Parasite burdens were analysed using the non-
parametric Kruskal–Wallis test followed by Dunn’s test for comparisons between groups, as well as 
the Mann–Whitney test for pairwise comparisons. For significant differences between infected groups 
in each tissue, (**) indicates P < 0.01 and (****) indicates P < 0.0001. 
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3.1.6. Parasite detection and burden in 
placental tissues and foetal brain  
Neospora DNA was detected in 
placentomes or cotyledons from all ewes in the 
three infected groups, with 100% positive 
samples of the placentomes (30/30) or 
cotyledons (18/18) in G1, 96% positive 
samples of the placentomes (23/24) and 100% 
positive samples of the cotyledons (24/24) in 
G3 and 100% positive samples of the 
placentomes (48/48) in G5, with no statistical 
significances between them. The mean parasite 
burden (measured as the number of tachyzoites 
per mg of tissue) in placentomes from aborting 
ewes in G3 was higher compared to G5 (P < 
0.01), and no significant differences were 
found compared to G1 (Figure 6A). Likewise, 
parasite burdens in cotyledons from ewes that 
gave birth were significantly lower in G1 than 
G3 (P < 0.0001) (Figure 6B).             
A significantly higher percentage of 
Neospora positive foetal brains was detected in 
G5 (37/39) compared to G1 (30/42) (P < 0.05) 
and G3 (27/39) (P < 0.05) (Additional file 1). 
In G1 and G3, no significant differences were 
found for the percentage of detection in foetal 
brains between aborted foetuses and lambs 
born. In aborted foetuses of G1, a significantly 
higher number of foetal brain samples (19/21) 
was Neospora PCR positive compared to 
samples obtained from lambs born (11/21) (P < 
0.05). However, no significant differences were 
found when comparing aborted foetuses 
(10/12) and lambs born (17/27) in G3. 
Furthermore, the overall parasite burden in the 
brains of aborted foetuses in G5 was 
significantly higher compared to G3 (P < 0.01) 
(Figure 6C) (Additional file 1). When 
comparing brain parasite burdens between 
infected groups, no significant differences were 
found in foetal brains between aborted foetuses 
or between lambs born. However, aborted 
foetuses in G5 showed higher brain parasite 
loads than lambs born from G1 (P < 0.0001) 
and G3 (P < 0.001). Additionally, significant 
differences were observed between aborted 
foetuses and lambs born in G1 when comparing 
brain parasite burdens (P < 0.0001). As 
expected, all placental and foetal samples from 
G2, G4 and G6 were negative.   
 
3.2. Experiment 2: BKI-1553 plasma 
levels in foetal blood 
The Cmax was 5.9 ± 3.2 μM for pregnant 
ewes and 1.6 ± 0.2 μM for foetuses, resulting in 
a ratio between foetuses and pregnant ewes of 
0.27 ± 0.10 (Figure 7). The AUC was 2608 ± 
1469 μM*min for pregnant ewes and 603 ± 61 
μM*min for foetuses, resulting in a ratio 
between foetuses and pregnant ewes of 0.23 ± 
0.12.    
4. Discussion  
This study reports on BKI-1553 drug levels 
in plasma of pregnant sheep and foetuses, and 
the safety and anti-parasitic efficacy of BKI-
1553 treatment in a pregnant sheep model of 
neosporosis. The efficacy was assessed with 
respect to the clinical course of disease, 
immune responses, lesion development and 
parasite detection and load in placental tissues 
and foetal brains. To our knowledge, this is the 
first evaluation of a therapeutic drug candidate 
in a pregnant ruminant model of neosporosis.   
 
Compared to previously developed BKIs, 
BKI-1553 has shown greatly improved 
bioavailability based on mouse 
pharmacokinetic data, with systemic levels 
>30-fold higher than BKI-1294 (Vidadala et 
al., 2016). Consequently, BKI-1553 has been 
tested in calves, resulting in successful 
systemic exposure after a single dose with 
maximum concentrations 12 hours after 
administration (Schaefer et al., 2016; Vidadala 
et al., 2016), or multiple-doses with steady state 
plasma concentrations 25-fold higher than 
BKI-1294 (Schaefer et al., 2016). Here, BKI-
1553 demonstrated excellent exposure in 
pregnant ewes after multiple subcutaneous  
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Figure 7 - Plasma concentrations of BKI-1553 in pregnant ewes and foetuses after single 10 
mg/kg subcutaneous dose. Each point represents the mean + S.D. at the different sampling times for 
pregnant ewes and foetuses.   
 
 
 
 
 
 
 
 
 
 
applications. Maximum concentrations > 5 µM 
were reached at 12 hours after administration. 
Trough concentrations of approximately 4 µM 
were found, with > 1 µM in most of the 
pregnant ewes until the end of the sampling 
period. Because neosporosis greatly affects the 
foetus, foetal blood levels of BKI-1553 was 
evaluated in pregnant ewes. BKI-1553 
application resulted in foetal plasma 
concentrations of 1.6 ± 0.2μM, which 
corresponded to approximately 20-30% of the 
systemic exposure in pregnant ewes over 24 to 
30 hours post dose. Different sheep breeds were 
used in experiments 1 and 2. However, since 
very similar Cmax were found in both 
experiments when the drug was applied at 10 
mg/kg, it is conceivable that potential 
differences associated with the use of different 
sheep breeds in the two experiments can be 
discarded. Previous studies addressing the in 
vitro efficacy of BKI-1553 against N. caninum 
reported a half-maximal inhibitory 
concentration (IC50) of 0.18 ± 0.03 µM (Müller 
et al., 2017b). Plasma concentrations of BKI-
1553 in pregnant ewes and their foetuses were 
higher than the IC50 for N. caninum, perhaps 
indicating adequate exposure that could 
translate into good efficacy in the pregnant 
sheep model of neosporosis. We did not find a 
significant association between individual 
levels of BKI-1553 and the outcome of foetal 
infection.   However, the number of animals 
used here are small, and the variability in 
outcome may have been more affected by the 
actual drug concentrations in target tissues, 
which were not assessed. The concentration of 
free BKI-1553 in target tissues probably 
determines efficacy, and >90% of BKI-1553 is 
plasma protein bound, suggesting the levels of 
free drug may not have been completely 
adequate to achieve 100% efficacy (Vidadala et 
al., 2016). In addition, some target tissues, such 
as foetal brain, may not have obtained 
sufficient drug levels to achieve complete 
efficacy (see below).    
BKI-1553 treatment in mice did not cause 
any adverse side effects leading to toxicity, and 
complete blood counts and serum biochemical 
profiles were within normal ranges, suggesting 
that the compound was safe. However, 
although no gross abnormalities upon necropsy 
were found, histological examination revealed 
inflammation in the spleen and liver in several 
treated mice (Vidadala et al., 2016). When 
BKI-1553 was applied to pregnant mice daily 
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at 20 mg/kg bodyweight for 5 days, it caused 
high neonatal mortality; this did not occur after 
administration at 20 mg/kg bodyweight 3 times 
with one-day intervals after each drug 
treatment (Müller et al., 2017b). Likewise, 
BKI-1553 was safe in calves, with no toxicity 
observed after administration (Schaefer et al., 
2016; Vidadala et al., 2016). In the present 
study, dermal nodules were found 24 hours 
after drug application at the sites of 
administration in all treated dams. Similar 
dermal nodules were found after vehicle (70% 
Tween 80 and 30% Ethanol 96º) administration 
in sheep (data not shown), indicating that the 
dermal nodules could be formed due to the 
vehicle. A formulation comprised of 7% Tween 
80, 3% ethanol 96º and 90% normal saline has 
been already used in mice for oral 
administration of BKI-1294 (Ojo et al., 2013) 
and in rats for oral and intravenous 
administration of antimalarial drugs (Van 
Voorhis et al., 2007). In this study, higher 
percentage of Tween 80 and ethanol 96º was 
chosen as drug vehicle to achieve drug 
concentration that would allow the volume be 
administered subcutaneously. The much higher 
percentages of Tween 80 and Ethanol 96º could 
have triggered the appearance of mild dermal 
nodules. Concerning systemic side effects, 
non-infected pregnant ewes treated with BKI-
1553 (G2 and G4) exhibited an increase in 
rectal temperatures on days 1 and 2 post-
treatment start in G2 and on day 1 in G4; there 
were no associated abortions, and dams gave 
birth to healthy lambs without significant 
decreased birthweights. Furthermore, no 
microscopic lesions were found in placental 
and foetal tissues examined from these groups.     
The haematological assessments in G2 and 
G4 showed no alterations in red and white 
blood cell counts (RBCs and WBCs, 
respectively). In contrast, in the infected 
groups, a minor monocytosis was found in G3, 
and an increase in lymphocyte percentages 
(still within the normal range) was detected in 
G5 at the final time point. Thus, due to normal 
monocyte percentages in G5 after infection, the 
minor monocytosis found in G3 could have 
been derived from dermal nodules arising after 
7 BKI-1553 administrations over short 
intervals. Additionally, it was suggested that 
monocyte levels increase during the recovery 
period during inflammation (Weiss and 
Perman, 1992). Biochemical parameters in G2 
and G4 to evaluate liver function, such as GGT 
and AST, were consistently in the 
physiological range at all time points. ALT 
displayed irrelevant higher values in G2; 
increased concentrations normally appear 
during late pregnancy in sheep (Yokus et al., 
2006). The apparent lack of liver toxicity is 
important because liver metabolism is 
hypothesized to be predominant for BKI-1294 
in mice (Ojo et al., 2013) and might also occur 
for BKI-1553, since it is also based on the 
naphthalinyl-pyrazolopyrimidine scaffold. 
Despite only 1% of BKI-1294 being excreted 
in urine (Ojo et al., 2013), renal function 
parameters are essential for toxicity evaluation. 
In this study, no remarkable abnormalities were 
found for urea and creatinine values in G2 and 
G4. CK showed levels above the physiological 
range, although increased concentrations can 
typically appear in late pregnancy (Yokus et al., 
2006). CK and AST values have been 
previously described as valuable for 
investigating cardiotoxicity of drugs in lambs 
(Ekici and Isik, 2011). In contrast to BKI-1294, 
which was shown to be a potent human ether-
a-go-go-related gene (hERG) inhibitor, BKI-
1553 does not have a hERG liability (Vidadala 
et al., 2016). Myocardial damage in sheep was 
not identified, since the corresponding markers 
AST and CK were not altered in G2 and G4 
after BKI-1553 administration. No notable 
disorders related to minerals were observed 
after BKI-1553 administration, and the 
observed calcium levels slightly above the 
basal range may have been due to calcium 
regulation disruption associated with foetal 
demands in late pregnancy (Kovacs and 
Kronenberg, 1997). 
 
Initiation of BKI-1553 treatment 48 h after 
infection was scheduled based on experience 
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with BKI therapy in murine neosporosis 
(Winzer et al., 2015; Müller et al., 2017b) and 
toxoplasmosis models (Doggett et al., 2014; 
Huang et al., 2015; Müller et al., 2017c). The 
pregnant sheep model of neosporosis with 
infection on day 90 of pregnancy had been 
standardized to the extent that all pregnant ewes 
aborted between 34-48 days pi (Arranz-Solis et 
al., 2015b). In this experiment, pregnant ewes 
from G5 displayed the same pattern, although a 
different breed was used. Clinical observations 
in the BKI-1553 treated groups revealed a 
partial protection against abortion, as 37 and 50 
percent of the pregnant ewes gave birth in G1 
and G3 respectively, with statistically 
improved foetal survival rates and median 
foetal survival times in G3. However, lambs in 
group G3 exhibited lower birthweights 
compared to uninfected lambs, regardless of 
treatment, which indicates that infection, but 
not the treatment, impacted on the weight in 
this group.  Rectal temperatures in pregnant 
ewes in G5 increased from day 4 to day 7 pi, 
likely as a consequence of tachyzoite 
multiplication and the first cycles of parasite 
replication in host tissues, similar to previously 
reported results in cattle and goats 
experimentally infected with the Nc-Spain7 
isolate (Regidor-Cerrillo et al., 2014; Porto et 
al., 2016). The rectal temperatures from 
pregnant ewes in G1 were lower than G5 on 
days 5 and 6 pi, suggesting that the drug had an 
impact on parasite replication. A decrease in 
rectal temperatures has also been described in 
experiments testing toltrazuril against 
neosporosis in calves (Kritzner et al., 2002) and 
monensin (Buxton et al., 1988) or decoquinate 
(Buxton et al., 1996) against toxoplasmosis in 
pregnant ewes. Additionally, since AST 
typically increases after T. gondii infection, 
indicating liver injury (Yeo et al., 2016), the 
increased AST in G5 and not in G1 and G3 at 
the final time point might indicate that treated 
pregnant ewes exerted better control of N. 
caninum infection.   
Analysis of the peripheral immune 
responses in pregnant ewes at different time 
points demonstrated an increase in IFNγ release 
in stimulated peripheral blood cultures from G5 
obtained at day 7 pi, showing similar kinetics 
to IFNγ in sera (Arranz-Solís et al., 2016). 
Several reports have shown that a Th1-biased 
immune response against N. caninum is 
required to control tachyzoite proliferation 
(Entrican, 2002; Innes, 2007). IFNγ levels were 
higher on day 7 pi in G1 and G3 and on day 14 
pi in G3, compared to G5. In vitro studies 
showed that BKI-1553 exhibited parasitostatic 
rather than parasiticidal effects, and induced 
the formation of intracellular multinucleated 
complexes composed of multiple pre-zoites 
unable to separate and form tachyzoites, but 
remaining viable for extended periods of time 
(Müller et al., 2017b). These multinucleated 
complexes exhibit increased tachyzoite specific 
antigen1 (SAG1) expression, and also 
increased expression of the bradyzoite marker 
BAG1, with an overall heavily distorted 
parasite ultrastructure (Winzer et al., 2015; 
Müller et al., 2017b). If such complexes are 
also formed in vivo, they are unlikely to evade 
immune responses, but would be increasingly 
exposed to antigen-presenting cells, which 
would then result in higher IFNγ levels in 
treated animals. Likewise, increased IFNγ 
levels in G3 on day 14 pi might be caused by 
extended BKI-1553 administration in this 
group, although IFNγ levels were not elevated 
in the corresponding uninfected group G4. The 
increased levels of IFNγ in G1 and G3 might 
have led to greater initial control of 
parasitaemia at the peripheral level, 
diminishing the numbers of parasites reaching 
and invading the placenta (Entrican, 2002; 
Innes, 2007).   
Concerning humoral immune responses, the 
levels of IgG started to increase in G5 on day 
14 pi, which was in accordance to previously 
described results (Arranz-Solís et al., 2016). 
However, antibody responses in the treated 
groups were delayed. As explained above, 
lymphocyte counts showed an increase in G5 at 
day 13 pi, and it is likely that this also includes 
B cells. On day 21 pi, significantly decreased 
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IgG levels were found in G1 and G3, but G3 
showed lower IgG values than the other two 
infected groups G1 and G5. Similarly 
decreased antibody responses have been 
previously reported during treatments of N. 
caninum infected calves with toltrazuril 
(Kritzner et al., 2002) and monensin (Buxton et 
al., 1988) or decoquinate (Buxton et al., 1996) 
treatment trials against toxoplasmosis in 
pregnant ewes. In treated groups, the delay at 
day 14 pi and lower antibody responses from 
day 21 pi onwards may have been due to higher 
IFNγ levels in the early stage of infection, as 
previously described Lopez-Gatius et al. 
(2007) under natural conditions. Likewise, 
longer IFNγ responses in G3 could contribute 
to reduced IgG levels on day 21 in this group.  
In contrast, on day 21 pi, IgG levels from 
pregnant ewes that aborted in G1 were higher 
than those that gave birth, suggesting that 
higher antibody responses occurred in animals 
that aborted their foetuses, as previously 
described Almería et al. (2016). 
 
At approximately mid-gestation in pregnant 
ewes, the foetal immune system is undergoing 
development, according to specific antibodies 
detected in foetal fluids (Arranz-Solis et al., 
2015b). While BKI-1553 treatment had a 
beneficial impact on offspring survival, the 
drug did not prevent transplacental 
transmission. All foetuses/lambs were 
seropositive as assessed by IFAT. However, 
lower median IFAT titres were found in aborted 
foetuses from the treated groups G1 and G3, 
which is indicative for decreased antigen 
stimulation and thus enhanced control of N. 
caninum infection. To quantify the efficacy of 
BKI-1553 against transplacental transmission 
of N. caninum, microscopic lesions, detection 
and burden of N. caninum in placental tissues 
and foetal brains were investigated. In placental 
tissues N. caninum was widely detected in 
infected groups, as well as lesions in all 
placentomes from aborting ewes. In foetal 
brains, known as a predilection site for N. 
caninum (Collantes-Fernández et al., 2006), 
parasites were less abundant, and the 
percentage of foetal brains with histological 
lesions was reduced in the treated groups. This 
is likely due to the efficacious BKI-1553 
concentrations present in the foetuses. These 
results are consistent with those from a 
pregnant mouse model of neosporosis, in which 
reduced transplacental transmission to 
offspring was accomplished (Müller et al., 
2017b). In the treated groups, histopathological 
analysis revealed a lower percentage of foetal 
brains with lesions, lower numbers of foci, and 
lower percentage of damaged areas in lambs 
that were born compared to aborted foetuses, 
which is in accordance to previously described 
studies (Macaldowie et al., 2004). 
Additionally, the parasite burden in foetal 
brains was reduced in G3 but not in G1, and in 
G1, but not G3, a higher parasite load was 
found in aborted foetuses compared to lambs 
born. Thus, the treatment undergone in G3 
appeared to show higher efficacy in terms of 
controlling brain infection in the offspring. In 
both G1 and G3, cerebral parasite loads in 
lambs born were found to be lower compared 
to cerebral parasite loads in aborted foetuses in 
G5. Central nervous system (CNS) penetration 
by BKI-1553 could possibly explain why, 
despite a lack of difference in systemic 
exposures, some foetuses aborted and others 
were protected. CNS penetration of BKI-1553 
was previously found to be approximately 33% 
compared to plasma exposure in mice 
(Vidadala et al., 2016). If this is similar in 
sheep, then BKI-1553 concentrations in foetal 
brains would be ≤ 2 fold above the N. canimum 
IC50 level at the troughs for all dose 
concentrations. Such rather low concentrations 
would most likely only offer incomplete 
protection at this infection site in foetuses.  
In conclusion, BKI-1553 treatment in N. 
caninum infected dams resulted in decreased 
rectal temperature upon infection, triggered an 
increase in peripheral IFNγ levels and a 
reduction in IgG responses, and achieved a 
reduced abortion rate due to neosporosis. In 
foetuses, BKI-1553 treatment did not prevent 
vertical transmission, but partially alleviated 
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the effects of infection, by reducing lesions, 
parasite presence and parasite loads in foetal 
brains. In the light of these findings, BKI-1553 
exhibits an excellent systemic exposure in 
pregnant ewes and their foetuses, a tolerable 
safety profile and confers partial protection 
against abortion and foetal dissemination of the 
parasite in a pregnant sheep model of 
neosporosis. However, the reduction in terms 
of parasite detection in foetal brain was only 
25%, which indicates a rather low efficacy of 
this particular treatment regime.  Further 
studies are necessary to explore efficacy of 
BKI-1553, by applying alternative 
formulations and using other routes of 
administration, drug dosages and dosing 
regimes. In addition, other members of the BKI 
class of compounds under development could 
be tested in the near future against ruminant 
neosporosis.     
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Additional file 1 - Individual serological titres in foetuses/lambs, measurement of histological 
lesions and detection of parasite DNA and parasite load in foetal brain.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group 
Ewe 
ref. 
Foetal death 
(days p.i)a 
Foetus/lamb 
ref. 
IFATb 
Foetal brain 
Histopathology 
DNAf qPCRg 
NFc ASFd % Lese 
Group 1 
1.1 28 
1.1 F1 1:128 46 43130 0,39 +++ 6.17 ± 5.24 
1.1 F2 1:128 67 35650 0,38 +++ 38.23 ± 17 
1.1 F3 1:64 37 54159 0,37 +++ 63.76 ± 51.53 
1.2 44 1.2 F NA 9 64245 0,09 ++ 0.14 ± 0.13 
1.3  
1.3 F1 1:3200 5 53386 0,03 +++ 1.31 ± 0.97 
1.3 F2 1:1600 4 34239 0,02 +++ 0.23 ± 0.18 
1.4  
1.4 F1 1:1600 1 30191 0,01 ++ 0.06 ± 0.05 
1.4 F2 1:1600 0 0 0 + 0.08 ± 0.12 
1.4 F3 1:1600 0 0 0 - 0.01 
1.5  1.5 F 1:128 27 38173 0,2 +++ 12.90 ± 11.64 
1.6  
1.6 F1 1:1600 0 0 0 + 4.68 ± 8.10 
1.6 F2 1:256* 2 43278 0,01 + 0.15 ± 0.24 
1.7 41 1.7 F NA 10 26710 0,05 ++ 0.18 ± 0.15 
1.8 23 1.8 F 1:64 3 15426 0,02 +++ 27.13 ± 27.06 
Group 3 
3.1 42 3.1 F 1:512 28 49651  0.16 +++ 0.35 ± 0.18 
3.2   
3.2 F1 1:512* 7 105205 0.13 - 1.16 ± 1.99 
3.2 F2 1:6400 0 0 0 +++ 2.02 ± 1.41 
3.3   
3.3 F1 1:3200 0 0 0 +++ 0.66 ± 0.65 
3.3 F2 1:3200 3 20212  0.01 ++ 0.70 ± 1.01 
3.4   
3.4 F1 1:200 3 15901 0.01 ++ 1.66 ± 1.77 
3.4 F2 1:800 5 16094  0.01 ++ 6.33 ± 10.41 
3.4 F3 1:128* NA NA NA ++ 0.41 ± 0.46 
3.5  40 3.5 F 1:128 23 18814 0.05 ++ 0.18 ± 0.15 
3.6   
3.6 F1 1:1600 2 99271  0.02 - 0.06 ± 0.10 
3.6 F2 1:200 1 13254  0.00 + 0.09 ± 0.13 
3.7  30 3.7 F 1:128 29 33035  0.15 +++ 19.73 ± 12.76 
3.8 39 3.8 F 1:128 10 44310 0.06 ++ 1.05 ± 1.03 
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Additional file 1 - Continued.  
 
a Day post-challenge when foetal death was detected by ultrasonography. The remaining foetuses lived until 
the end of the experiment.  
b IFAT IgG antibody titres in foetal body fluids and in precolostral serum collected after birth in lambs born 
alive. 
c Number of foci (number of lesions/cm2).  
d Average size focus (µm2). 
e Percentage of damaged area. 
f Parasite DNA detection; plus (+++, ++, +) and minus (-) signs represent PCR detection in >67%, 66-34%, 
<33% and 0% of samples analysed, respectively.   
g Mean parasite load (tachyzoites/mg tissue) and standard deviation (S.D.). Taking into account that the N. 
caninum detection limit by real-time PCR is 0.1 parasites, negative samples (0 parasites) were represented as 
0.01. 
* Lamb dead at birth.  
NA: not available.  
 
 
 
 
 
 
Group 
Ewe 
ref. 
Foetal death 
(days p.i)a 
Foetus/lamb 
ref. 
IFATb 
Foetal brain 
Histopathology 
DNAf qPCRg 
NFc ASFd % Lese 
Group 5 
5.1 42 5.1 F NA 21 21305  0.06 ++ 0.18 ± 0.15 
5.2 30 5.2 F 1:512 50 37769  0.38 +++ 121.47 ± 72.90 
5.3 29 
5.3 F1 1:128 27 40015  0.11 +++ 0.16 ± 0.11 
5.3 F2 1:256 18 26902  0.13 +++ 0.59 ± 0.71 
5.3 F3 1:256 2 47219  0.05 +++ 16.28 ± 8.82 
5.3 F4 1:32 0 0 0 +++ 8.67 ± 4.39 
5.4 46 5.4 F 1:512 1 24360  0.01 +++ 0.23 ± 0.06 
5.5 29 5.5 F 1:512 20 42148  0.09 +++ 6.82 ± 2.02 
5.6 45 5.6 F 1:1024 1 68851  0.05 +++ 0.28 ± 0.02 
5.7 42 
5.7 F1 NA 9 22249  0.08 ++ 1.85 ± 3 
5.7 F2 1:256 6 16883  0.03 +++ 20.66 ± 19.23 
5.8 29 
5.8 F1 1:64 27 30493  0.20 +++ 37.53 ± 25.67 
5.8 F2 1:512 25 28526  0.18 +++ 11.04 ± 10.69  
  
 
  
 
 
 
 
 
CAPÍTULO V 
DISCUSIÓN GENERAL 
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“La ciencia nunca resuelve un problema 
sin crear otros 10 más” 
George Bernard Shaw (1856-1950)  
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T. gondii and N. caninum are apicomplexan parasites considered to be the one of the main 
infectious causes of abortion in sheep (Dubey, 2009b) and cattle (Dubey and Schares, 2011), 
respectively. Thereby, toxoplasmosis and neosporosis deserve special attention since they entail 
severe economic losses in ovine (Innes et al., 2009) and cattle population (Trees et al., 1999; Reichel 
et al., 2013), respectively. For the control of toxoplasmosis and neosporosis different measures have 
been suggested, including management practices, chemotherapy and vaccination (Dubey et al., 2007; 
Dubey, 2009b). In bovine neosporosis, the use of drugs and vaccines are considered the best control 
strategies to avoid reactivation (Reichel and Ellis, 2006). However, in toxoplasmosis, the same tools 
should be preferable applied if there is a likely environmental contamination with oocysts or during 
an abortion outbreak to avoid the clinical manifestation of the disease. A commercial attenuated live 
vaccine based on a modified strain (S48), with no capacity to form tissue cysts and oocysts, is 
available for ovine toxoplasmosis, allowing an increase of around 60% in the number of live lambs 
(Buxton et al., 1991). However, despite the great effort on developing a vaccine against neosporosis, 
there is no vaccine available in the market (Hemphill et al., 2016; Horcajo et al., 2016). Likewise, 
unfortunately, there are no drugs registered for the treatment of toxoplasmosis and neosporosis in 
ruminants (Sánchez-Sánchez et al., accepted for publication). Therefore, there is an urgent need to 
develop drugs and vaccines aimed at preventing their transmission, as well as reducing severity of 
these diseases. In this sense, a large amount of research focuses its efforts on the development of new 
candidates that may be effective in protecting against abortion and vertical transmission. For that 
purpose, both in vitro and in vivo models have served as steps in the process of testing safety and 
efficacy of new products. In vitro assays offer a reduction in the usage of animals for experimentation, 
and provide high throughput screening of drugs or antibodies directed against potential vaccine 
targets (Müller and Hemphill, 2013). However, animal models are essential for the study of several 
aspects that otherwise could not be assessed by means of in vitro culture. Apart from being of great 
utility for studies related to host-parasite relationship, immune response or pathogenesis, 
experimental animal models of infection are essential tools for an adequate evaluation of efficacy of 
vaccines or drugs developed against toxoplasmosis and neosporosis (Jongert et al., 2009; Reichel and 
Ellis, 2009).  
T. gondii presents three different clonal lineages classified as I, II and III (Howe and Sibley, 
1995). Laboratory mice are generally sensitive to T. gondii infection and are often used as the 
preferred animal model to determine the virulence of the parasite (Saraf et al., 2017). Type I and most 
South American isolates are highly virulent in mice whereas types II and III show a dose-dependent 
mortality (Saeij et al., 2006). Enhanced virulence throughout successive passages in cell culture and 
mice for T. gondii type I isolates (RH isolate) has been widely reported (Villard et al., 1997; Mavin 
et al., 2004; Khan et al., 2009b), however, little is known about influence of continuous passages in 
type II isolates. Likewise, mice have been widely used as animal model for congenital toxoplasmosis 
due similarities in placental histology of rodents and humans. In addition, mice offer several 
advantages such as the small size, ease of handling, low cost, short period of gestation and high 
number of pups. However, structure of the placenta, reproductive physiology and immune responses 
greatly differ between rodents and ruminants, which clearly could influence the passing of T. gondii 
trough the maternofetal interface and the modulation of the host immune responses during pregnancy 
(Entrican, 2002). In sheep, most of experimental studies during pregnancy have been carried out using 
M1, M3 and M4 T. gondii strains (Dubey, 2009b; Castaño et al., 2014) and the congenital infection 
in mice of these strains has not been studied in depth.  
On the other hand, despite the broad usage of the mice model for the study of neosporosis and 
for “proof-of-concept” assays of vaccine and drug candidates, the obvious physiological and size 
differences between rodents and ruminants render the results obtained in mice poorly reliable. In this 
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sense, the employment of other animal models of neosporosis more proximate to cattle could serve 
as a good alternative. Besides being a natural host of N. caninum, sheep offer several advantages over 
cattle in terms of number and size of animals, handling, costs and timing of experiments. Therefore, 
it would seem suitable as a model for further research. Moreover, even though the epidemiological, 
clinical and economic relevance of the parasite for reproductive failure in small ruminants has 
remained elusive, recent studies suggest that neosporosis may be a more important cause of 
reproductive disorders than it has traditionally been considered, at least in certain scenarios (West et 
al., 2006; Howe et al., 2012; Moreno et al., 2012; González-Warleta et al., 2014; Gonzalez-Warleta, 
submitted). In pregnant sheep, infective doses of 107–108 tachyzoites results in a high percentage of 
abortions (Dubey and Lindsay, 1990; Buxton et al., 2001; Innes et al., 2001a; Weston et al., 2009) 
and there is only one study comparing different infective doses (Weston et al., 2009). Likewise, to 
date, there are no studies comparing the outcome of N. caninum experimental infection using different 
routes of inoculation in pregnant sheep.   
To date, pregnant ruminant models of neosporosis have not been used for assessments of drug 
efficacy against N. caninum infection and vertical transmission. In toxoplasmosis, drugs evaluated in 
pregnant sheep (monensin, folate inhibitors and decoquinate) showed moderate protection against 
abortion and limited or no protection against vertical transmission. Therefore, there is lack of effective 
drugs for the treatment of congenital toxoplasmosis and neosporosis in ruminants. Highly promising 
drugs candidates have been tested against T. gondii and N. caninum in vitro and in small animal 
models, such as thiazolides, diamidines, artemisinins, naphthoquinones, anticancer agents, endochin-
like quinolones and calcium-dependent protein kinase inhibitors (Sánchez-Sánchez et al., accepted 
for publication). Calcium dependent protein kinase 1 (CDPK1) represents a promising drug target, as 
CDPK1 is encoded by the apicoplast DNA, and is thus absent from mammalian hosts (Lourido et al., 
2010; Murphy et al., 2010; Ojo et al., 2010) and it is conserved among apicomplexan parasites 
(Keyloun et al., 2014). CDPK1 activity is essential for microneme secretion, host cell invasion, and 
egress of T. gondii (Kieschnick et al., 2001; Lourido et al., 2010) and can be effectively targeted by 
a class of ATP-competitive compounds, collectively named bumped kinase inhibitors (BKIs). The 
compound BKI-1294 was effective in vitro against N. caninum and T. gondii and showed highly 
protection against vertical transmission in mice models of congenital toxoplasmosis and neosporosis 
(Winzer et al., 2015; Müller et al., 2017c). Likewise, the compound BKI-1553, with an improved 
bioavailability compared to BKI-1294 in mice and calves (Schaefer et al., 2016; Vidadala et al., 2016) 
was also effective in vitro against N. caninum and in vivo in a pregnant mice model of neosporosis 
(Müller et al., 2017b). However, the safety of BKI compounds in pregnant sheep and their efficacy 
in pregnant sheep models of toxoplasmosis and neosporosis are unknown.  
Taking all of this into consideration, the present Doctoral Thesis addresses three main objectives: 
the standardization of pregnant mice and sheep models of T. gondii infection and the comparative 
assessment of virulence of T. gondii type II isolates in mice and sheep (Objective 1), the 
standardization of a well-defined pregnant sheep model of neosporosis (Objective 2) and the 
evaluation of safety and efficacy against T. gondii and N. caninum of BKIs in experimentally infected 
pregnant sheep (Objective 3).  
Standardization of pregnant mice and sheep models of T. gondii infection and comparative 
assessment of virulence of T. gondii type II isolates in mice and sheep 
For the attainment of the first objective, the phenotype in vitro, virulence in mice and congenital 
infection in mice and sheep were compared between a newly obtained T. gondii type II isolate 
(TgShSp1) and the laboratory type II reference isolate (TgME49).  
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In Europe and North America, T. gondii isolates display a clonal population structure, with the 
vast majority of T. gondii isolates being grouped into three lineages, namely, types I, II and III (Howe 
and Sibley, 1995). Type II T. gondii is the most prevalent in all hosts in Europe, including sheep 
(Dumètre et al., 2006; Halos et al., 2010a; Su et al., 2010). Previous studies in Europe have shown 
that T. gondii type II is associated with ovine abortion (Owen and Trees, 1999; Jungersen et al., 2002; 
Chessa et al., 2014). The TgShSp1 isolate belongs to genotype #3 (a type II variant, II for nine alleles/I 
for Apico), sharing genotype with the Prugniaud (PRU) isolate.   
T. gondii PRU isolates exhibit a similar genetic pattern to the T. gondii type II reference isolate, 
TgME49 (genotype #1) (Su et al., 2012). In addition, both type II isolates, TgME49 and PRU, activate 
the host cell transcription factor NF-κB, an integral component of the immune response to T. gondii, 
and they display identical GRA15 gene sequences, which is involved in NF-κB activation (Rosowski 
et al., 2011). TgME49 was isolated from sheep muscle in 1958 (Lunde and Jacobs, 1983) and has 
since then undergone long-term passaging in cell culture and mice (Sibley et al., 2002). Previous 
studies have demonstrated changes in biological characteristics of T. gondii isolates after passages in 
mice and cell culture (Frenkel et al., 1976; Lindsay et al., 1991; Harmer et al., 1996; Saraf et al., 
2017). This fact has been widely studied in T. gondii type I isolates (Cesbron and Sabin, 1994; Villard 
et al., 1997; Dubey et al., 1999; Mavin et al., 2004; Khan et al., 2009b). However, whether these 
changes also occur in type II isolates, and how they compare to recently obtained isolates, remains 
unknown. Increased growth in vitro can be found after repeated passages (Yano et al., 1987). The 
dramatic differences observed during in vitro growth of TgME49 and TgShSp1 might reflect the 
highly different passage history of the two isolates. Plaque formation is commonly used to measure 
growth of T. gondii, and this process is the result of several events, including invasion, growth, egress, 
and migration (Roos et al., 1995). Notably, TgME49 tachyzoites formed plaques at 4 days pi, but 
TgShSp1 did not. The finding that TgShSp1 did not form plaques in vitro could have resulted from 
the limited growth rate, associated with a higher capacity of bradyzoite conversion, as previously 
described Khan et al. (2009b). This was confirmed by monitoring spontaneous cyst formation through 
labeling with the fluorescent lectin DBL, demonstrating tissue cyst formation under standard cell 
culture procedures in TgShSp1 that was greater than TgME49. Due to its high passage number in cell 
culture or mice, our TgME49 isolate may not accurately represent natural virulence traits of the type 
II lineage, which suggests that comparisons of phenotypes between T. gondii isolates should be 
conducted using low-passage stocks.    
Traditionally, mouse models are utilized to evaluate virulence by monitoring survival after 
experimental infection. Conventionally, TgME49 is a cystogenic type II isolate with low virulence in 
mice (Ferreira et al., 2001; Gavrilescu and Denkers, 2001; Oliveira et al., 2016). Intraperitoneal 
inoculation of 103 and 5 x 104 TgME49 tachyzoites intraperitoneally has not caused mortality 
(Ferreira et al., 2001; Oliveira et al., 2016). However, in this study, TgME49 displayed a LD50 of 103, 
so the virulence of our TgME49 could be considered higher than previous descriptions (Ferreira et 
al., 2001; Oliveira et al., 2016). Enhanced virulence in mice for T. gondii strains maintained for 
several passages has also been reported previously (Shimizu et al., 1967; Sibley and Boothroyd, 1992; 
Frenkel and Ambroise-Thomas, 1996). Hence, it seems logical to speculate that results from studies 
using laboratory isolates should be validated with more recent isolates before they can be extrapolated 
as general features of the respective lineage. In contrast to TgME49, mice inoculated with tachyzoites 
of the recently obtained type II isolate TgShSp1 exhibited only moderate, low-level clinical signs, but 
no mortality (LD50 > 105), similar to what was described earlier after intraperitoneal inoculation of 
Swiss Webster mice with 103 tachyzoites of a PRU isolate (Wang et al., 2013). In addition, although 
oocysts are considered more virulent than tachyzoites in mice (Dubey and Frenkel, 1973), no 
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mortality in adult mice was found after infection with oocysts of TgShSp1 in pregnant and non-
pregnant mice, suggesting very low virulence in mice.    
We also investigated congenital toxoplasmosis in pregnant mice by inoculating them orally with 
different doses of TgShSp1 oocysts. The risk of congenital toxoplasmosis depends on the virulence 
of the parasite (Tenter et al., 2000). Few mice infected with TgShSp1 oocysts showed mild clinical 
signs, contrary to the large number of mice succumbing to infection after the same oocyst doses of 
TgME49 (Müller et al., 2017c). There is a possibility that there has been a selection towards increased 
virulence within TgME49 due to the successive passages, as explained above but also due to the 
sulfadimidine treatment that was applied in mice used for infection of cats to generate TgME49 
oocysts (Müller et al., 2017c). This sulfonamide treatment could act as a bottleneck in selecting 
tachyzoites with a faster replication and therefore increasing the virulence in mice of the final 
TgME49 parasites. Unlike what was observed for TgME49 (Müller et al., 2017c), with which a clear 
effect on pregnancy rate was found after infection with 2000 oocysts and on litter size after infection 
with 500 oocysts, infection with TgShSp1 oocysts did not result in alteration of pregnancy rate or 
litter size. Likewise, while 92% of the pups died after infection of dams with 25 TgME49 oocysts 
(Müller et al., 2017c), a significant decrease in pup survival was found only after infection with 2000 
and 500 TgShSp1 oocysts, where there was mortality in 50% of the pups.  
In sheep, although rectal temperatures were similarly increased in TgME49 and TgShSp1, ewes 
infected with 500 and 10 TgME49 oocysts exhibited higher rectal temperature on day 8 pi compared 
to same doses of TgShSp1 oocysts. Perinatal mortality was similar for both isolates. However, those 
ewes infected with 10 and 50 TgME49 oocysts and that delivered stillbirths/live lambs exhibited 
higher parasite load in cotyledons than those infected with the same doses of TgShSp1 oocysts. 
Similarly, a higher parasite load was found in the brain from lambs born in the group infected with 
50 TgME49 oocysts compared to the corresponding TgShSp1 group. Therefore, it is tempting to 
hypothesize that the enhanced virulence of our TgME49 contributed to the abovementioned effects. 
Comparing different doses of infection, pregnant ewes challenged with 50 and 10 oocysts showed 
one day of delay in the increase of rectal temperature compared to ewes infected with 500 oocysts in 
both isolates, similar to what was described by Buxton et al. (1991) and Mévélec et al. (2010). 
Likewise, there is a correlation between the dose of infection and the rate of early abortions, as 
previously suggested (Mévélec et al., 2010; Benavides et al., 2017). Infection with 500 oocysts 
triggered abortion in all fetuses, similar to previous experimental infections in pregnant sheep at mid-
pregnancy using 2000 oocysts of M1 and M4 isolates (Owen et al., 1998a; Castaño et al., 2014). After 
infection with 50 TgShSp1 oocysts or 50 TgME49 oocysts, 68 and 42% of fetuses/lambs died, 
respectively, similar to what was previously reported after infection with 50 M4 oocysts (Castaño et 
al., 2014). The occurrence of abortions after infection with 10 oocysts was low, but large numbers of 
stillbirths and weak lambs were found, mainly in the 10 TgShSp1 oocysts group. There seems to be 
a correlation between the presence of the parasite and the occurrence of stillbirths, since stillbirths 
from the group infected with 10 TgShSp1 oocysts exhibited higher parasite detection and load in the 
brain than those in the group infected with 50 TgShSp1 oocysts. Regardless of the isolate or dose, no 
differences were found in the congenital infection of lambs born, since vertical transmission was 
found in all them except in one stillborn lamb and one live lamb born from one ewe infected with 10 
TgME49 oocysts. Likewise, no differences were found between doses or isolates with respect to brain 
lesion presence and lesion severity in lambs born.   
Despite the clear differences in body weight between mice and sheep, similar doses of oocysts 
were used to compare both hosts. None of the adult mice infected with 25 TgShSp1 oocysts exhibited 
clinical signs, whereas all ewes infected with 10 TgShSp1 oocysts had fever. Therefore, morbidity in 
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sheep seems to be higher than in mice. In addition, no mortality was observed in adult mice or sheep 
infected with TgShSp1 oocysts. When comparing the congenital infection between both hosts, 50% 
mortality was caused in mice by infection with 500 TgShSp1 oocysts, whereas in sheep infection with 
the same oocyst dose caused mortality in all fetuses. In brief, mice seem to be less susceptible to 
perinatal mortality than sheep, despite the fact that vertical transmission was similar in both species. 
High vertical transmission and low offspring mortality could be an evolutionary strategy of the 
parasite to generate a large infected offspring group in mice, one of the most relevant hosts of T. 
gondii (Müller and Howard, 2016).  
There are several differences between mice and sheep that could underlie the differences found in 
this study. The histological structure of the placenta is very different between mice and sheep 
(Entrican, 2002), and although maternal blood and fetal tissue are closer in mice, allowing an easy 
crossing of tachyzoites but also of antibodies, the longer period of gestation, the lack of maternal 
antibodies crossing the placental barrier and fewer fetuses may facilitate vertical transmission in 
sheep. In addition, host genetics are likely important in determining susceptibility and severity of 
infection (Howe et al., 1996; Müller and Howard, 2016). Small rodents, natural intermediate hosts, 
are often exposed to a higher dose and more virulent parasites than other groups of mammals. It may 
therefore be that Toll-Like-Receptors (TLR)11 and TLR12 and the polymorphism of immunity-
related GTPases (IRG proteins) have been positively selected in rodents, because of their critical 
importance in host resistance against high infection loads or more virulent clones of T. gondii. In 
mice, TLR11 and TLR12 on dendritic cells detect the apicomplexan actin-binding protein profilin 
leading to the secretion of interleukin 12 (IL12), which can subsequently induce production of IFNγ 
by T cells. IFNγ induces a variety of parasiticidal mechanisms, which in mice are dominated by 
upregulation of the IRGs. IRGs can destroy the vacuole in these parasites live and subsequently the 
parasite itself. Considering the ubiquity of T. gondii in nature, it is intriguing that genes encoding 
TLR11, TLR12, and IRG proteins are not found in many mammalian species (Gazzinelli et al., 2014). 
Although further studies are needed, and despite the influence of genetic polymorphisms in ovine 
abortions (Darlay et al., 2011), this fact could render sheep less resistant. Similarly, differences in 
immune cell populations may influence the pathogenesis of toxoplasmosis in these hosts. γδ T cells, 
which rapidly recognize and respond to nonprocessed antigens and seem to have an important role in 
T. gondii infection (Egan et al., 2005), represent a relevant subset of circulating T cells in sheep 
compared to mice (Holderness et al., 2013). Further studies are needed to characterize the cellular 
and molecular bases contributing to transmission dynamics and disease in different hosts of T. gondii 
(Dubremetz and Lebrun, 2012; Hunter and Sibley, 2012).  
In conclusion, we have demonstrated that infection with tachyzoites and oocysts of the type II T. 
gondii isolate TgShSp1 in mice does not cause mortality, but this isolate is efficiently vertically 
transmitted in pregnant mice, and compared to sheep, it triggers lower offspring mortality and 
morbidity. Thus, at least for this isolate, the disease caused in pregnant mice and offspring is not a 
reliable predictor/indicator for disease caused in pregnant sheep at mid-gestation. Whether this 
conclusion is also valid for other type II T. gondii strains needs to be addressed in future studies. 
Because sheep have neither TLR11/12 nor the IRGs and are reported to express the “human” rather 
than the “murine” type of TLR members (Nalubamba et al., 2007), we hypothesize that sheep can 
serve as a better animal model to study Toxoplasma-host interactions that are relevant for humans 
and farm animals.  
 
 
Chapter V ~ General discussion 
 
  ~ 181 ~ 
Standardization of a well-defined pregnant sheep model of neosporosis 
Regarding the pregnant sheep model of neosporosis, there is only one study comparing different 
infective doses (Weston et al., 2009) and, to date, there are no studies comparing the outcome of N. 
caninum experimental infection using different routes of inoculation in pregnant sheep. 
Consequently, the second objective of the present Doctoral Thesis was to optimise the challenge dose 
of N. caninum and route of administration in pregnant sheep and, therefore standardize the pregnant 
sheep model of neosporosis for its use in further studies. For the attainment of the second objective, 
a dose titration of N. caninum tachyzoites by the intravenous route of administration as well as an 
evaluation of the subcutaneous route of administration were carried out in pregnant sheep at mid-
pregnancy by assessing clinical course of disease, cellular and humoral immune responses, lesion 
development and parasite detection and burden in placental and foetal tissues. The Nc-Spain7 isolate 
(Regidor-Cerrillo et al., 2008) used in this experiment is a very well-characterized virulent isolate 
tested so far in three experimental ruminant models, such as sheep (Arranz-Solis et al., 2015b), goats 
(Porto et al., 2016) and cattle (Caspe et al., 2012; Regidor-Cerrillo et al., 2014; Almería et al., 2016). 
Since intravenous infection of pregnant sheep using 106 tachyzoites of the Nc-Spain7 isolate at mid-
gestation resulted in 100% abortion and parasite detection in the foetal brain in 83% of aborted 
foetuses (Arranz-Solis et al., 2015b; Sánchez-Sánchez et al., 2018), the challenge doses tested 
intravenously in the present study were less than the 106 tachyzoites previously assayed; tachyzoites 
were diluted 1:10 to a minimum concentration of 102 tachyzoites, similar to those evaluated by 
(Weston et al., 2009). Subcutaneous inoculation closely mimics a natural primary infection as the 
parasite is “processed” through a draining lymph node before circulating in the blood (Dubey et al., 
2006). In cattle, it was reported that subcutaneous infection resulted in a foetal mortality that was 
50% reduced compared to intravenous infection (Macaldowie et al., 2004). Hence, in this study we 
investigated the outcome of N. caninum infection after subcutaneous inoculation in pregnant ewes 
using one of the intravenously tested doses. The dose of 104 tachyzoites was chosen for the 
subcutaneous administration since it is an intermediate-to-high dose between those tested by the 
intravenous route and also, because in a previous study, intravenous inoculation of 5x103 tachyzoites 
of New Zealand isolates at mid-gestation resulted in abortion in 50% of the ewes (Weston et al., 
2009). 
In this study, all pregnant ewes intravenously infected with 105 tachyzoites aborted in the same 
way as pregnant ewes intravenously infected with a 10-fold higher dose (106 tachyzoites) (Arranz-
Solis et al., 2015b; Sánchez-Sánchez et al., 2018). The intravenous dose causing abortion in 50% of 
the infected animals was 102 tachyzoites. It is remarkably lower than the intravenous dose of 5x103 
causing abortion in 50% of the infected animals in the dose-titration study at mid-gestation using Nc-
NZ1, Nc-NZ2 and Nc-NZ3 isolates (Weston et al., 2009), suggesting higher virulence of Nc-Spain7 
than New Zealand isolates in pregnant sheep. Likewise, intravenous infection at mid-gestation with 
105 tachyzoites of the Nc-Spain7 isolate resulted in abortion of all pregnant ewes, whereas intravenous 
infection of pregnant ewes at mid-gestation with 1.7x105 tachyzoites of a mixture of the Nc-2 and 
Nc-Liverpool isolates caused abortion in 67% of the pregnant ewes (McAllister et al., 1996b). 
However, because (McAllister et al., 1996b) and (Weston et al., 2009) used a mixture of different 
isolates within the same inoculum to assure infection, it is difficult to establish comparisons with 
these studies (Benavides et al., 2014). The median number of abortion days in our study was similar 
to the time range of abortions in previous N. caninum experimental infections in pregnant sheep at 
mid-gestation (McAllister et al., 1996b; Buxton et al., 1998; Buxton et al., 2001; Arranz-Solis et al., 
2015b). As reported by Weston et al. (2009) regarding the differences in the average time between 
abortion and parturition found after infection with decreasing doses, in the present study, the median 
survival times in ewes infected intravenously with 103 tachyzoites and more markedly in ewes 
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intravenously infected with 102 tachyzoites were prolonged compared to those infected intravenously 
with 105 tachyzoites and 104 tachyzoites and to those subcutaneously challenged with 104 tachyzoites. 
In all aborting dams from groups infected intravenously with 103 and 102 tachyzoites, the coexistence 
at the time of euthanasia of live foetuses and dead foetuses in twin pregnancies suggests lower foetal 
damage in these groups because this observation was only found in one aborting dam in the group 
infected with 105 tachyzoites and one aborting dam in the group subcutaneously infected with 104 
tachyzoites. Mummified foetuses found in group intravenously challenged with 105 and 104 
tachyzoites have already been described after N. caninum experimental infection at mid-gestation in 
pregnant sheep (Buxton et al., 1997). In groups intravenously infected with 103 and 102 tachyzoites 
and in the group subcutaneously challenged with 104 tachyzoites, pregnant ewes gave birth 
prematurely, similar to some pregnant ewes infected with 5x103 N. caninum tachyzoites (Weston et 
al., 2009). Consequently, in groups intravenously infected with 103 and 102 tachyzoites and in the 
group subcutaneously challenged with 104 tachyzoites, stillborns and lambs that died soon after birth 
show a significant decrease in their bodyweight, as previously described Buxton et al. (1998). 
Likewise, a more significant decrease in lamb weight in the group intravenously challenged with 103 
tachyzoites was found because it is known that with increasing litter size, the weight of the lambs is 
lower (Gardner et al., 2007). The presence of a large number of stillborn lambs and weak lambs dying 
within 24 h after birth could be explained by the absence of differences in parasite detection, parasite 
load and lesion severity from the foetal brain between aborted foetuses and lambs that gave birth in 
each group. 
Traditionally, different temperature responses have been associated with the dose of parasite 
inoculums (Buxton et al., 1997; Maley et al., 2001; Maley et al., 2003; Weston et al., 2009). 
Intravenously challenged groups show a unique fever peak after infection, although a dose-dependent 
delay in the time of rectal temperature increase was found compared to the infection with 106 
tachyzoites of the Nc-Spain7 isolate (Sánchez-Sánchez et al., 2018), suggesting delayed parasite 
replication as lower infection doses were applied. However, as reported with 106 tachyzoites of the 
Nc-Spain7 isolate (Sánchez-Sánchez et al., 2018), the groups intravenously infected with 105 and 104 
tachyzoites show maximum rectal temperature on day 7 pi. Whereas the increase in rectal temperature 
persisted for 4 days in the groups intravenously infected with 105, 104 and 103 tachyzoites a less 
prolonged period with 3 days of rectal temperature increase was found in the group intravenously 
challenged with 102 tachyzoites. Similar to different temperature responses found between 
intravenous and subcutaneous N. caninum challenge in cattle (Macaldowie et al., 2004), after 
subcutaneous challenge with 104 tachyzoites, a lower rectal temperature increase was found compared 
to intravenous challenge with the same dose. Likewise, a similar temperature response was found in 
group subcutaneously challenged with 104 tachyzoites compared to the infection in sheep with the 
same dose (104 tachyzoites) of the Nc-Liverpool isolate (Buxton et al., 1997). The biphasic 
temperature response found in the subcutaneous challenge group had been previously described after 
subcutaneous challenge in sheep (Buxton et al., 1997; Buxton et al., 1998; Buxton et al., 2001) and 
cattle (Maley et al., 2003; Benavides et al., 2012). Previous studies in cattle have described 
differences in rectal temperatures between aborting and non-aborting dams (Almería et al., 2010; 
Almería et al., 2016) in the same way as observed in the group intravenously challenged with 102 
tachyzoites in the present study. The clinical evaluation in the group subcutaneously challenged with 
104 tachyzoites revealed enlargement of the left prefemoral lymph node as previously described 
Maley et al. (2001), Maley et al. (2003), Macaldowie et al. (2004) and Rocchi et al. (2011) after 
subcutaneous N. caninum challenge in cattle.  
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Regarding cellular immune response, similar IFNγ kinetics, with very short lived  IFNγ levels, 
have been described in previous reports carried out in cattle upon stimulation of peripheral blood 
mononuclear cells (PBMCs) (Regidor-Cerrillo et al., 2014) or in sheep serum (Arranz-Solís et al., 
2016). In the group intravenously challenged with 105 tachyzoites, IFNγ released upon stimulation 
increased on day 7 pi in the same way that intravenous infection with 106 tachyzoites of the Nc-Spain7 
isolate (Sánchez-Sánchez et al., 2018). Nevertheless, the time course of IFNγ shows a delay until day 
10 pi for IFNγ release after intravenous challenge in the groups intravenously challenged with 104 
and 103 tachyzoites and in the group subcutaneously challenge with 104 tachyzoites. Likewise, no 
significant increase in IFNγ was observed in the group intravenously challenged with 102 tachyzoites 
which might have led to lower initial control of parasitaemia at the peripheral level, allowing a higher 
number of parasites to reach the placenta (Entrican, 2002; Innes, 2007). In fact, no differences in 
parasite load in the foetal brain between the groups intravenously challenged with 102 and 105 
tachyzoites could be due to the absence of a significant increase in IFNγ levels in pregnant ewes from 
the group intravenously challenged with 102 tachyzoites because a threshold IFNγ response is 
required to be beneficial against N. caninum (Almeria et al., 2014; Almería and López-Gatius, 2015). 
Recently, it has been shown that the immune response appears to lead to superior priming of a cell-
mediated immune response in dams carrying live foetuses versus dams carrying dead foetuses 
(Bartley et al., 2012; Darwich et al., 2016). In this way, ewes that gave birth in the group intravenously 
challenged with 104 tachyzoites had higher IFNγ levels on day 10 pi than those that aborted. Although 
no significant differences were found in IFNγ levels in the group intravenously challenged with 102 
tachyzoites, a delay in the IFNγ peak was detected in ewes that gave birth. That, along with differences 
in rectal temperatures between aborting ewes and ewes that gave birth could suggest decreased early-
stage replication of the parasite in ewes that gave birth in the group intravenously challenged with 
102 tachyzoites.  
After intravenous infection of pregnant sheep at mid-gestation with 106 tachyzoites of the Nc-
Spain7 isolate, IgG levels increased from day 12–14 pi (Arranz-Solís et al., 2016; Sánchez-Sánchez 
et al., 2018), whereas IgG levels increased from day 21 pi in the group intravenously challenged with 
105 tachyzoites. Furthermore, the group intravenously infected with 105 tachyzoites exhibited higher 
IgG levels than those found with lower doses, possibly due to exposure to more abundant antigen and 
increased lymphoid stimulation similar to that reported by others (Buxton et al., 1997; Maley et al., 
2001; Bartley et al., 2004; Weston et al., 2009). In this study, all challenged animals show 
seroconversion by ELISA, whereas the lower dose tested (50 tachyzoites of Nc-NZ1, Nc-NZ2 and 
Nc-NZ3 isolates) by (Weston et al., 2009) revealed one seronegative animal at parturition by IFAT. 
Concerning offspring, all aborted foetuses and lambs from the infected groups had seropositive IFAT 
titres with no significant differences between challenge doses or routes of administration. Altogether, 
this finding indicates that once infection is established, it cannot be cleared from the host, and vertical 
transmission of the parasite occurred in all infected animals. In contrast, in a previous dose-titration 
study, none of the lambs and only 3 out of 5 lambs born from pregnant ewes intravenously infected 
with 50 and 5x103 N. caninum tachyzoites (Nc-NZ1, Nc-NZ2 and Nc-NZ3 isolates), respectively, 
were seropositive by IFAT (Weston et al., 2009).  
Because immune responses are not accurate enough to be used as indicators for disease or 
protection (Benavides et al., 2014), parasite detection and quantification and histopathological 
assessment are essential. All placentomes from infected ewes were PCR positive, and no significant 
differences in parasite load or lesion severity were found, so immune responses were unsuccessful in 
preventing the colonization and multiplication of N. caninum in the placentomes of aborting ewes. 
No difference was found in parasite detection between placentomes from intravenously infected ewes 
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at mid-gestation with 106 tachyzoites of the Nc-Spain7 isolate (PCR-positive samples from 83 to 
100%) (Arranz-Solis et al., 2015b; Sánchez-Sánchez et al., 2018) and placentomes from 
intravenously infected aborting ewes in this study. N. caninum DNA was also widely detected in 
cotyledons from ewes that gave birth with no significant differences in parasite detection, similar to 
that reported by (Weston et al., 2009), which found all PCR-positive cotyledons in ewes infected with 
5x103 N. caninum tachyzoites. However, lower parasite loads were found in cotyledons from ewes 
that gave birth in the group intravenously challenged with 103 tachyzoites, which, along with lower 
IFNγ levels detected, could suggest mild infection in these animals. When routes of administration 
were compared, no significant differences were identified in parasite detection, parasite load or lesion 
severity in placentomes, however, cotyledons from the subcutaneously infected group showed lower 
parasite burden compared to the corresponding group intravenously infected with a trend towards 
significance, maybe influenced by the lower number of animals in this group.  
As for transplacental transmission, no significant differences were not found between doses 
among detection percentages in foetal brains from groups intravenously challenged with 105, 104 and 
102 tachyzoites, nor when they were compared to detection in foetal brains after intravenous infection 
of pregnant ewes with 106 tachyzoites of the Nc-Spain7 isolate at mid-gestation (94% of PCR-positive 
samples) (Sánchez-Sánchez et al., 2018). These results were not in accordance with differences in the 
proportion of positive brains in foetuses/lambs of a dose-titration study in pregnant sheep at mid-
gestation using other isolates (Weston et al., 2009). Conversely, the lower detection percentage in 
foetal brains from the group intravenously challenged with 103 tachyzoites could be because of the 
higher number of foetuses per dam in this group; fewer parasites that cross the placental barrier reach 
each foetus. Brain-negative foetuses arising from multiple pregnancies have already been reported in 
ewes infected at mid-gestation with 106 tachyzoites of Nc-Spain7 (Arranz-Solis et al., 2015b). 
Foetuses and lambs showing PCR-negative brains in this study were seropositive by IFAT in the same 
way as in (Porto et al., 2016), and brain lesions were identified, suggesting the presence of very low 
parasite load in their brains.  
In brief, after intravenous infection with 105 tachyzoites foetal death is induced in all infected 
animals in the same way as 106 tachyzoites previously assayed. In addition, intravenous infection 
with 105 tachyzoites shows distinct immune responses and parasite load in the foetal brain. 
Surprisingly, the differences between the highest and the lowest intravenous doses were much smaller 
than expected, and we here demonstrate that experimental infection with as few as 100 tachyzoites 
could induce abortion in 50% of the ewes, and parasite load in the foetal brain was similar to that with 
the highest dose. Regarding the routes of inoculation, subcutaneous infection with 104 tachyzoites 
shows similar abortion rates and vertical transmission to intravenous infection. In light of these 
results, we propose that future studies using an abortion model for ovine neosporosis should be carried 
out using the intravenous route of administration and a challenge dose of 105 tachyzoites (100% 
abortion and vertical transmission), which will then allow to obtain more accurate and realistic 
conclusions in studies testing vaccine and drug candidates. However, further studies would be 
desirable to evaluate the outcome of infection with 105 tachyzoites by the subcutaneous route of 
administration. 
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Evaluation of safety and efficacy of BKI compounds in pregnant sheep experimentally infected 
with T. gondii and N. caninum 
At present, there is lack of effective drugs for the treatment of congenital toxoplasmosis and 
neosporosis in ruminants (Sánchez-Sánchez et al., accepted). BKI compounds have emerged as 
promising drugs with tested efficacy against T. gondii and N. caninum in vitro and in laboratory 
animal models and also against other apicomplexan parasites (Van Voorhis et al., 2017). However, 
their safety in pregnant ruminants and their efficacy in pregnant ruminant models of toxoplasmosis 
and neosporosis have not been assessed. For this reason, the third objective of the present Doctoral 
Thesis was to test the safety in pregnant sheep of BKI-1294 and BKI-1553 and their efficacy against 
abortion and vertical transmission after experimental infection with T. gondii and N. caninum, 
respectively. For the achievement of the third objective, pregnant ewes were orally dosed with BKI-
1294 (5 doses of 100 mg/kg every other day) or subcutaneously dosed with BKI-1553 (with two 
different dosages: 1st dose of 35 mg/kg and a week later and a 2nd dose at 10 mg/kg or 7 doses at 10 
mg/kg every other day). The efficacy of these drugs administered 48 hours after infection was 
evaluated in pregnant ewes infected orally with TgShSp1 oocysts (BKI-1294) or intravenously with 
Nc-Spain7 tachyzoites (BKI-1553). Safety of BKI compounds was assessed by clinical monitoring 
of rectal temperatures and foetal viability, evaluation of haematological and biochemical parameters 
and monitoring of fecal consistency (after oral administration) and local side effects (after 
subcutaneous administration). The efficacy was assessed with respect to the clinical course of disease, 
immune responses, lesion development and parasite presence in placental and/or target foetal tissues. 
In addition, drug levels of BKI-1294 and BKI-1553 in sheep plasma samples and in the fetal plasma 
samples after single administration of BKI-1553 at 10 mg/kg were determined.  
In mice, BKI-1553 showed concentrations around 13 μM after oral administration of 10 mg/kg 
(Schaefer et al., 2016; Vidadala et al., 2016), however, BKI-1294 showed only levels of 0.75 μM 
using the same dose (Schaefer et al., 2016; Hulverson et al., 2017). In calves, BKI-1553 resulted in 
successful systemic exposure after a single oral dose of 10 mg/kg, with maximum concentrations of 
10 μM (Schaefer et al., 2016; Vidadala et al., 2016), however, BKI-1294 resulted in plasma levels of 
1 μM using the same dose (Schaefer et al., 2016). In pregnant sheep, after subcutaneous 
administration of BKI-1553 at 10 and 35 mg/kg, maximum concentrations of >5 μM and trough 
concentrations of approximately 4 μM were found, however, oral administration of 100 mg/kg of 
BKI-1294 showed maximum concentrations of 2 μM, with trough plasma concentrations of 0.4-1 
μM. Therefore, BKI-1553 has shown greatly improved bioavailability compared to BKI-1294 in 
different species. In addition, because toxoplasmosis and neosporosis greatly affects the foetus, foetal 
blood levels of BKI-1553 was evaluated in pregnant ewes. BKI-1553 application resulted in foetal 
plasma concentrations of 1.6 ± 0.2 μM, which corresponded to approximately 20–30% of the systemic 
exposure in pregnant ewes over 24-30 h post dosing. Previous studies addressing the in vitro efficacy 
of BKI-1553 against N. caninum, a half-maximal inhibitory concentration (IC50) of 0.18 ± 0.03 μM 
was reported (Müller et al., 2017b). Therefore, plasma concentrations of BKI-1553 in pregnant ewes 
and their foetuses were higher than the IC50 for N. caninum, perhaps indicating adequate exposure that 
could translate into good efficacy in the pregnant sheep model of neosporosis, since in vitro efficacy 
against T. gondii has not been assessed. Regarding the in vitro studies of BKI-1294 against the 
reference type II T. gondii isolate (TgME49) and the Nc-Spain7 isolate reported a half-
maximal inhibitory concentration (IC50) of 0.22 ± 0.06 µM and 0.27 ± 0.02, respectively (Winzer et 
al., 2015). Thus, plasma concentrations of BKI-1294 in pregnant ewes were higher than the IC50 for 
T. gondii and N. caninum, perhaps indicating adequate exposure that could translate into good efficacy 
in the pregnant sheep models of toxoplasmosis and neosporosis.   
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Regarding safety, BKI-1553 at 100 mg/kg twice daily for 5 days in mice did not cause any 
adverse side effects leading to toxicity, and complete blood counts and serum biochemical profiles 
were within normal ranges, suggesting that the compound was safe. However, although no gross 
abnormalities upon necropsy were found, histological examination revealed inflammation in the 
spleen and liver in several treated mice (Vidadala et al., 2016). Similarly, BKI-1294 at 100 mg/kg 
twice daily for 5 days in mice did not show any signs of toxicity or weight loss, and no alterations in 
tissue histology, metabolic enzymes, and complete blood counts were found (Ojo et al., 2013). 
Concerning safety during pregnancy, when BKI-1553 was applied to pregnant mice daily at 20 mg/kg 
bodyweight for 5 days, it caused high neonatal mortality; this did not occur after administration at 20 
mg/kg bodyweight 3 times with one-day intervals after each drug treatment (Müller et al., 2017b). 
When BKI-1294 at 50 mg/kg for 5 days (Müller et al., 2017c) was applied, decrease by half on mice 
fertility was found (Müller et al., 2017c), however, no detrimental effect on fertility was found using 
BALB/c mice (Winzer et al., 2015). In calves, BKI-1553 and BKI-1294 did not show toxicity after 
oral administration of 10 mg/kg (Schaefer et al., 2016; Vidadala et al., 2016). In pregnant ewes treated 
subcutaneously with BKI-1553, dermal nodules were found 24 h after drug application at the sites of 
administration in all of them. Similar dermal nodules were found after vehicle (70% Tween 80 and 
30% Ethanol 96°) administration in sheep, indicating that the dermal nodules could be formed due to 
the vehicle. A formulation comprised of 7% Tween 80, 3% ethanol 96° and 90% normal saline has 
been already used in mice for oral administration of BKI-1294 (Ojo et al., 2013) and in rats for oral 
and intravenous administration of antimalarial drugs (Van Voorhis et al., 2007).  In this study, higher 
percentage of Tween 80 and ethanol 96° was chosen as drug vehicle to achieve drug concentration 
that would allow the volume be administered subcutaneously. The much higher percentages of Tween 
80 and Ethanol 96° could have triggered the appearance of mild dermal nodules. In pregnant ewes 
treated orally with BKI-1294 no alterations on the faecal consistency was found. Therefore, 5 doses 
orally of BKI-1294 at 100 mg/kg (formulated in 60% PHOSAL® 53 MCT, 30% Polyethyleneglycol 
400  and 10% Ethanol 96º) seems to be safe in pregnant ewes.  
Concerning systemic side effects, BKI-1294 by the oral route did not show increase on rectal 
temperature. By contrast, non-infected pregnant ewes treated subcutaneously with BKI-1553 
exhibited an increase in rectal temperatures on day 1-2 posttreatment. Ewes treated with BKI-1294 
and BKI-1553 did not show alterations on the hematological parameters, except a minor monocytosis 
found in group infected and treated subcutaneously with 7 doses of BKI-1553, which could have been 
derived from dermal nodules arising after 7 BKI-1553 administrations over short intervals. 
Additionally, it was suggested that monocyte levels increase during the recovery period during 
inflammation (Weiss and Perman, 1992). Biochemical parameters such as GGT, AST and ALT were 
consistently in the physiological range or irrelevantly increased in pregnant ewes treated with BKI-
1294 and BKI-1553. The apparent lack of liver toxicity is important because liver metabolism is 
hypothesized to be predominant for BKI-1294 in mice (Ojo et al., 2013) and might also occur for 
BKI-1553, since it is also based on the naphthalinyl-pyrazolopyrimidine scaffold. Despite only 1% 
of BKI-1294 being excreted in urine (Ojo et al., 2013), renal function parameters are essential for 
toxicity evaluation. No remarkable abnormalities were found for urea and creatinine values after 
treatment with BKI-1294 and BKI-1553. CK showed levels above the physiological range in some 
treated groups with BKI-1294 and BKI-1553, although increased concentrations can typically appear 
in late pregnancy (Yokus et al., 2006). CK and AST values have been previously described as 
valuable for investigating cardiotoxicity of drugs in lambs (Ekici and Isik, 2011). In contrast to BKI-
1294, which was shown to be a potent human ether-ago-go-related gene (hERG) inhibitor, BKI-1553 
does not have a hERG liability (Vidadala et al., 2016). Myocardial damage in sheep treated with BKI-
1294 and BKI-1553 was not identified, since the corresponding markers AST and CK were not 
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altered. No notable disorders related to minerals were observed after BKI-1294 and BKI-1553 
administration. In spite of the decrease on fertility in mice by BKI-1294 and BKI-1553, no abortions 
were found in pregnant sheep treated with BKI-1294 and BKI-1553 and all lambs born healthy with 
no decrease on birthweight.  
Regarding efficacy of BKI-1294 against T. gondii infection in pregnant sheep, although previous 
studies testing drugs orally administered started 10 days before the infection until parturition, 
(allowing better chance to control T. gondii infection), in our study with a shorter time window, 
treatment with 5 doses of BKI-1294 initiated 48 hours after infection resulted in higher protection 
against perinatal mortality (76%) compared to studies using monensin (46% of increase in live lambs) 
(Buxton et al., 1988) and decoquinate (61% of protection against acute abortions) (Buxton et al., 
1996). Likewise, contrary to this study in which 100% perinatal mortality was found in infected but 
untreated pregnant ewes, only 53-55% of perinatal mortality was detected in infected but untreated 
pregnant ewes from studies testing monensin and decoquinate (Buxton et al., 1988; Buxton et al., 
1996), indicating not so aggressive infection. In previous studies, a decreased birthweight has been 
described in lambs born form T. gondii infected ewes (Buxton et al., 1996). In our study, lambs born 
from twin pregnancies in group infected and treated with BKI-1294 exhibited slightly lower 
birthweights compared to uninfected group receiving vehicle alone, but since no significant 
differences were found between lambs PCR-positive and PCR-negative in the brain, is likely that this 
lower growth of the foetuses could be consequence of a severely decrease on the food intake in the 
dams from infected and treated group for 6 days (from 96 to 101 days of pregnancy, associated to 
marked fever peak due to T. gondii infection) as previously described Gardner et al. (2007). Likewise, 
all lambs born healthy while in previous studies presented here using TgShSp1 in pregnant sheep, 
weak lambs were often observed. The rectal temperatures from T. gondii infected and BKI-1294 
treated pregnant ewes were lower than infected but untreated pregnant ewes on days 5 and 7 pi, 
suggesting that the drug had an impact on parasite replication. Likewise, one day of delay on the onset 
of increase on rectal temperature was found in infected and treated ewes compared to those infected 
but untreated. Decreased rectal temperatures and/or delay in on the onset of rectal temperatures 
increase have also been described in experiments testing monensin (Buxton et al., 1988) or 
decoquinate (Buxton et al., 1996) against toxoplasmosis in pregnant ewes. 
IFNγ is known to be important in inhibiting the intracellular multiplication of T. gondii and in 
addition will create the appropriate cytokine microenvironment for the priming of the adaptive 
immune response towards a Th-1 type pro-inflammatory immune response (Innes and Vermeulen, 
2006). Analysis of the peripheral immune responses in pregnant ewes at different time points 
demonstrated a significant increase on the IFNγ release in stimulated peripheral blood cultures from 
infected and treated group on day 7 pi compared to infected but not treated group and uninfected 
group receiving vehicle alone. Likewise, infected and treated group showed a peak of IFNγ release 
on day 10 pi as well as 100-fold increased levels until delivery. In vitro studies showed that BKI-
1294 induced the formation of intracellular multinucleated complexes composed of multiple pre-
zoites unable to separate and form tachyzoites, but remaining viable for extended periods of time. 
These multinucleated complexes exhibit increased SAG1 expression, and also increased expression 
of the bradyzoite marker BAG1, with an overall heavily distorted parasite ultrastructure (Winzer et 
al., 2015). If such complexes are also formed in vivo, they are unlikely to evade immune responses, 
but would be increasingly exposed to antigen-presenting cells, which would then result in higher IFNγ 
levels in treated animals. The SAG1 molecule is an immunodominant surface protein found on 
tachyzoites and is one of the most extensively studied antigens as it is able of inducing a T cell 
response with parasiticidal activity for extracellular T. gondii tachyzoites (Khan et al., 1988). 
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Therefore, and similarly to the enhanced to potency of drugs against T. gondii observed in vitro 
(Radke et al., 2018) and in vivo (Araujo and Remington, 1991) in the presence of IFNγ, the effect of 
BKI-1294 on T. gondii could act synergistically with IFNγ response. The increased levels of IFNγ in 
infected and treated group might have led to greater initial control of parasitaemia at the peripheral 
level, diminishing the numbers of parasites reaching and invading the placenta (Entrican, 2002). 
Concerning humoral immune responses, all animals infected with T. gondii and treated with BKI-
1294 were seropositive using SAG1 antigen except one ewe that aborted on day 17 pi. However, by 
the ELISA based on T. gondii soluble antigens only one ewe that gave birth a stillborn lamb and two 
dams that gave healthy lambs seroconverted, while the remaining ewes were seronegative at the end 
of the sampling period. Since soluble antigens are exposed to the immune system during replication 
(Joiner and Roos, 2002), and since much lower humoral immune response to soluble antigens was 
found compared to ewes infected with lower oocyst doses (Sánchez-Sánchez, et al., submitted), it 
suggests low replication of the parasite throughout the experiment. Presence of SAG1 antibodies 
maybe derived from SAG1 expression in multinucleated complexes found in vitro after BKI-1294 
treatment of T. gondii infected cultures (Winzer et al., 2015). Likewise, it is known that the SAG1 
antigen triggers an antibody response with an inhibitory effect on invasion (Mineo et al., 1993).  
In previous studies testing drugs against congenital toxoplasmosis in pregnant sheep, vertical 
transmission was evaluated through foetal serology and microscopic observation of lesions in 
placental tissues and foetal brains, with around 50% less of animals with vertical transmission after 
treatment with monensin (Buxton et al., 1988), or only by evaluating placental tissues with 50% less 
of placentas showing lesions using decoquinate (Buxton et al., 1996), albeit around 12% of infected 
and untreated sheep did not show placental lesions (Buxton et al., 1988; Buxton et al., 1996)or 
seropositive offspring (Buxton et al., 1988). However, the study evaluating 
sulphamezathine/pyrimethamine showed 100% vertical transmission in untreated animals and 50% 
reduction on the placentas with lesions, but not differences on foetal serology in treated ones (Buxton 
et al., 1993a). In our study testing efficacy of BKI-1294 against T. gondii infection, we evaluated 
transplacental transmission of the parasite through foetal serology and parasite detection and 
histological lesions in foetal tissues. In all the lambs born after infection with a 100-fold lower 
TgShSp1 oocyst dose than used in BKI-1294 efficacy experiment, T. gondii was detected in all their 
brains and lungs and lesions was found in most of the brains as described in the objective 1 of the 
present Doctoral Thesis. However, in lungs from lambs born in BKI-1294 treated group, known as a 
predilection site for T. gondii (Gutierrez et al., 2010), no significant lesions or parasites were detected. 
Likewise, in foetal brains, parasites were not detected in 7 lambs born healthy and slightly detected 
in the brain of 6 of the 13 lambs born healthy (53% of protection against vertical transmission in 
lambs born), while no lesions in the brain were found in any of them. Therefore, there was a slight 
dissemination of the parasite in the lambs with no antibodies detected by IFAT, although this 
technique could show low sensitivity (Castaño et al., 2016). These results are consistent with those 
from a pregnant mouse model of toxoplasmosis, in which 100% protection against pup mortality and 
93% of protection against vertical transmission in the surviving offspring were accomplished with 
BKI-1294 (Müller et al., 2017). The higher protection of BKI-1294 in pregnant mice compared to 
pregnant sheep could be explained by the lower perinatal mortality and vertical transmission of T. 
gondii type II isolates in mice compared to sheep as described in the objective 1 of the present 
Doctoral Thesis. Since BKI-1294 triggers formation of multinucleated complexes in T. gondii 
infected cultures (Winzer et al., 2015), maybe in vivo, is likely that some tachyzoites trapped within 
the host cell could restart their replication and therefore induce perinatal mortality or vertical 
transmission. In fact, in some ewes the parasites reach the foetus, but since is likely that therapeutic 
concentrations of BKI-1294 might have been reached in the foetus, similarly to the results described 
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above for BKI-1553, the dissemination of the parasite could be controlled. However, it could happens 
that the central nervous system penetration of the drug did not allow drug levels above IC50 in the 
foetal brain, which resulted in replication of the parasite in some cases. 
As for efficacy of BKI-1553 against N. caninum infection in pregnant sheep, clinical 
observations in the BKI-1553 treated groups revealed a partial protection against abortion, as 37 and 
50 percent of the pregnant ewes gave birth in group infected and treated twice and group infected and 
treated seven times, respectively, with statistically improved foetal survival rates and median foetal 
survival times in the group infected and treated seven times. However, lambs in group infected but 
treated seven times with BKI-1553 exhibited lower birthweights compared to uninfected and 
untreated lambs, therefore since no decrease in birthweights was found in the corresponding treated 
group but uninfected, the infection, but not the treatment, impacted on the weight in this group. The 
rectal temperatures from pregnant ewes in the group infected and treated twice with BKI-1553 were 
lower than uninfected and untreated group on days 5 and 6 pi, suggesting that the drug had an impact 
on parasite replication. A decrease in rectal temperatures has also been described in experiments 
testing toltrazuril against neosporosis in calves (Kritzner et al., 2002). Additionally, since AST 
typically increases after T. gondii infection, indicating liver injury (Yeo et al., 2016), the increased 
AST in infected but untreated group and not in both groups infected and treated at the final time point 
might indicate that treated pregnant ewes exerted better control of N. caninum infection. IFNγ levels 
were higher on day 7 pi in both groups infected with N. caninum and treated with BKI-1553 and on 
day 14 pi in the group infected and treated seven times with BKI-1553, compared to group infected 
but not treated. Likewise, increased IFNγ levels in group infected and treated 7 times on day 14 pi 
might be caused by extended BKI-1553 administration in this group. The increased levels of IFNγ in 
both groups infected and treated with BKI-1553, similarly to animals infected with T. gondii and 
treated with BKI-1294 might have led to greater initial control of parasitaemia at the peripheral level, 
diminishing the numbers of parasites reaching and invading the placenta (Entrican, 2002; Innes, 
2007). Concerning humoral immune responses, antibody responses in the treated groups were 
delayed. Also, on day 21 pi, significantly decreased IgG levels were found in both groups infected 
and treated with BKI-1553, but group infected and treated seven times with BKI-1553 showed lower 
IgG values than the other two infected groups. Similarly decreased antibody responses have been 
previously reported during treatments of N. caninum infected calves with toltrazuril (Kritzner et al., 
2002) and monensin (Buxton et al., 1988) or decoquinate (Buxton et al., 1996) treatment trials against 
toxoplasmosis in pregnant ewes. In treated groups, the delay at day 14 pi and lower antibody 
responses from day 21 pi onwards may have been due to higher IFNγ levels in the early stage of 
infection, as previously described Lopez-Gatius et al. (2007) under natural conditions. Likewise, 
longer IFNγ responses in the group infected and treated seven times with BKI-1553 could contribute 
to reduced IgG levels on day 21 in this group. In contrast, on day 21 pi, IgG levels from pregnant 
ewes that aborted in the group infected and treated twice with BKI-1553 were higher than those that 
gave birth, suggesting that higher antibody responses occurred in animals that aborted their foetuses, 
as previously described Almería et al. (2016).  
While BKI-1553 treatment had a beneficial impact on offspring survival of N. caninum infected 
ewes, the drug did not prevent transplacental transmission. All foetuses/lambs were seropositive as 
assessed by IFAT. However, lower median IFAT titres were found in aborted foetuses from the 
treated groups, which is indicative for decreased antigen stimulation and thus enhanced control of N. 
caninum infection. To quantify the efficacy of BKI-1553 against transplacental transmission of N. 
caninum, microscopic lesions, detection and burden of N. caninum in placental tissues and foetal 
brains were investigated. In placental tissues N. caninum was widely detected in infected groups, as 
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well as lesions in all placentomes from aborting ewes. In foetal brains, known as a predilection site 
for N. caninum (Collantes-Fernández et al., 2006), parasites were less abundant, and the percentage 
of foetal brains with histological lesions was reduced in the treated groups. This is likely due to the 
efficacious BKI-1553 concentrations present in the foetuses. These results are consistent with those 
from a pregnant mouse model of neosporosis, in which reduced transplacental transmission to 
offspring was accomplished (Müller et al., 2017b). In the treated groups, histopathological analysis 
revealed a lower percentage of foetal brains with lesions, lower numbers of foci, and lower percentage 
of damaged areas in lambs that were born compared to aborted foetuses, which is in accordance to 
previously described studies (Macaldowie et al., 2004). Additionally, the parasite burden in foetal 
brains was reduced in the group infected and treated seven times with BKI-1553, but not in the group 
infected and treated twice. However, in aborted foetuses in the group infected and treated twice, but 
not in the group infected and treated seven times, a higher parasite load in the brain was found 
compared to lambs born. Thus, the treatment with BKI-1553 seven times appeared to show higher 
efficacy in terms of controlling brain infection in the offspring. In both infected and treated groups, 
cerebral parasite loads in lambs born were found to be lower compared to cerebral parasite loads in 
aborted foetuses in the group infected but not treated. Central nervous system (CNS) penetration by 
BKI-1553 could possibly explain why, despite a lack of difference in systemic exposures, some 
foetuses aborted and others were protected. CNS penetration of BKI-1553 was previously found to 
be approximately 33% compared to plasma exposure in mice (Vidadala et al., 2016). If this is similar 
in sheep, then BKI-1553 concentrations in foetal brains would be ≤2 fold above the N. canimum IC50 
level at the troughs for all dose concentrations. Such rather low concentrations would most likely only 
offer incomplete protection at this infection site in foetuses.  
To sum up, BKI-1294 and BKI-1553 reduced in 37-76% the foetal mortality after experimental 
infections with T. gondii and N. caninum, in which all the untreated animals aborted. Likewise, in 
dams, both BKI compounds decreased rectal temperature upon infection and triggered an increase in 
peripheral IFNγ levels. In the offspring, BKI-1294 prevented vertical transmission in 53% of lambs 
born from ewes infected with T. gondii, while BKI-1553 treatment did not prevent vertical 
transmission, but partially alleviated the effects of N. caninum infection, by reducing lesions, parasite 
presence and parasite loads in foetal brains. Looking ahead, other members of the BKI class of 
compounds under development with improved biovailability in mice and hERG liability, but also 
highly efficacious in vitro and in non-pregnant and pregnant mice models could be tested in the near 
future against toxoplasmosis and neosporosis in ruminants. In addition, since pregnant sheep model 
of toxoplasmosis may closely mimics the human infection with T. gondii, as explained above, the 
results obtained in sheep with this BKI compounds could be extrapolable to humans.  
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Objetivo 1. Normalización de los modelos murino y ovino gestantes de infección por T. 
gondii y comparación de la virulencia de aislados tipo II de T. gondii en ratones y ovejas 
Primera. Se observa mayor crecimiento y formación de quistes in vitro con el aislado TgME49 
y mayor mortalidad de las crías y transmisión vertical tras la infección de ratones gestantes con el 
aislado TgME49 en comparación con el aislado recientemente obtenido TgShSp1. Estos resultados 
sugieren un incremento en la virulencia del aislado TgME49, probablemente debido a los pases 
sucesivos en cultivo celular y en ratones. Por lo tanto, se recomienda el uso de pases bajos en futuros 
estudios que comparen características fenotípicas entre aislados de T. gondii.  
Segunda. La baja morbilidad y la ausencia de mortalidad en ratones no gestantes ni en gestantes 
inoculados por vía intraperitoneal con taquizoitos o por vía oral con ooquistes del aislado TgShSp1 
sugieren una baja patogenicidad de este aislado para ratones adultos.  
Tercera. En ovejas desafiadas a mitad de gestación con ooquistes no se encuentran diferencias 
en la mortalidad perinatal ni en las lesiones ni en el número de corderos positivos a T. gondii entre 
los aislados TgME49 y TgShSp1. 
Cuarta. La inoculación de ratones y ovejas a mitad de la gestación con dosis similares de 
ooquistes del aislado TgShSp1 ocasionan una mayor mortalidad perinatal en ovejas que en ratones. 
Todas crias de ratones que sobreviven tras la infección durante la gestación con 100 ooquistes del 
aislado TgShSp1 fueron positivas a T. gondii al igual que todos los corderos mortinatos y nacidos 
vivos de ovejas desafiadas con 50 ooquistes del aislado TgShSp1. Sin embargo, mientras que todos 
los corderos mortinatos y nacidos vivos de ovejas desafiadas con 10 ooquistes del aislado TgShSp1 
fueron positivos, tan solo el 37% de las crias de ratones que sobreviven a la infección durante la 
gestación con 25 ooquistes del aislado TgShSp1 fueron positivas a T. gondii. Por lo tanto, la virulencia 
en ratones con aislados de tipo II no es un buen indicador para predecir las consecuencias de la 
infección en ovejas gestantes.  
Objetivo 2. Normalización de un modelo ovino gestante de infección con N. caninum 
mediante una titulación de dosis y evaluación de diferentes vías de administración del aislado 
virulento Nc-Spain7 
Primera. Tan solo las ovejas desafíadas con la mayor dosis por vía intravenosa testada (105 
taquizoitos) muestran 100% de aborto. Estas ovejas presentan un incremento más temprano de la 
temperatura rectal y de los niveles de IFN-gamma y una mayor respuesta inmune humoral. Además, 
su carga parasitaria en el cerebro fetal en comparación con aquellas ovejas desafiadas por vía 
intravenosa con dosis menores es también mayor.  
Segunda. Las ovejas desafiadas por vía subcutánea con 104 taquizoitos muestran menor 
temperatura rectal y niveles de IFN-gamma en comparación con aquellas ovejas desafiadas por vía 
intravenosa con la misma dosis de taquizoitos, sin embargo no se observan diferencias entre ambas 
vías de administración en la respuesta inmune humoral ni la mortalidad fetal ni en la transmisión 
vertical.  
Tercera. Se propone un modelo ovino gestante de primoinfección con N. caninum basado en la 
administración intravenosa de 105 taquizoitos. Esta dosis, 10 veces menor que la estudiada 
anteriormente, y esta vía de administración parecen ser suficientes para provocar el 100% de aborto. 
Esta modificación permitirá obtener resultados más precisos en ensayos de candidatos terapeúticos y 
vacunales.  
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Objetivo 3. Evaluación de la seguridad y eficacia frente a T. gondii y N. caninum de los 
compuestos BKI en ovejas gestantes. 
Primera. La administración oral del BKI-1294 y la administración subcutánea del BKI-1553 en 
ovejas gestantes a las pautas de dosificación estudiadas da lugar a concentraciones plasmáticas 
terapéuticas para T. gondii y N. caninum respectivamente. Sin embargo, el BKI-1553 y de forma más 
acusada el BKI-1294 presentan un aclaramiento plasmático rápido. El BKI-1553 parece tener una 
mejor farmacocinética que el BKI-1294 en ovejas gestantes, de forma similar a como se describió 
previamente en ratones y terneros. Además el BKI-1553 es capaz de atravesar la barrera placentaria, 
encontrándose concentraciones terapéuticas de este fármaco en los fetos.  
Segunda. Tanto el BKI-1294 como el BKI-1553 parecen ser seguros ya que no se han 
encontrado alteraciones de la temperatura rectal ni de los parámetros hematológicos y bioquímicos ni 
de la gestación o daño local asociado a estos fármacos. Sin embargo, se ha observado diferente 
seguridad en función de la vía de administración. Mientras que la administración oral no incrementó 
la temperatura rectal ni modificó la consistencia fecal, la administración subcutánea provocó la 
aparición de nódulos dérmicos asociados a un incremento de temperatura rectal y a una monocitosis.  
Tercera. La administración del BKI-1294 a ovejas infectadas con T. gondii durante la gestación 
se asocia a un menor incremento de las temperaturas rectales, a unos niveles mayores de IFN-gamma 
a nivel periférico que en ovejas no tratadas, a una menor respuesta inmunitaria humoral a antígenos 
solubles pero a niveles elevados de anticuerpos anti-SAG1 y una disminución de la mortalidad 
perinatal del 76%. En la descendencia, el BKI-1294 evita la transmisión vertical en el 53% de los 
corderos. Por tanto, la eficacia del BKI-1294 es mayor comparada con aquella observada previamente 
con monensina, decoquinato e inhibidores de la síntesis del folato.  
Cuarta. La administración del BKI-1553 a ovejas infectadas con N. caninum durante de la 
gestación se asocia a un menor incremento de las temperaturas rectales, produce un incremento del 
IFN-gamma, reduce los niveles de IgG específicas a nivel periférico y consigue reducir in 37-50% la 
tasa de abortos. En los fetos, la administración del BKI-1553 no evita la transmisión vertical pero 
disminuye los efectos de la infección, con una reducción de las lesiones y de la presencia y carga del 
parásito en el cerebro fetal.  
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Objective 1. Standardization of pregnant mice and sheep models of T. gondii infection and 
comparison of the virulence of T. gondii type II isolates in mice and sheep. 
First. Higher growth and in vitro cyst formation for the TgME49 isolate and higher pup mortality 
and vertical transmission are observed after infection of pregnant mice with the laboratory TgME49 
isolate compared to the recently obtained TgShSp1 isolate. These results suggest an enhanced 
virulence for the TgME49 isolate, maybe due to successive passages in cell culture and mice. 
Therefore, it could be recommended the use of low passage stocks for future studies comparing 
phenotypic traits between T. gondii isolates.   
Second. The low morbidity and absence of mortality in non-pregnant and pregnant mice 
inoculated either with tachyzoites intraperitoneally or with oocysts by the oral route using the 
TgShSp1 isolate suggest a low pathogenic effect for this isolate in adult mice.  
Third. In sheep challenged at mid-pregnancy with oocysts no differences are present on the 
perinatal mortality or lesions and number of T. gondii-positive lambs between TgME49 and TgShSp1 
isolates. 
Fourth. Inoculation of mice and sheep at mid-pregnancy with similar TgShSp1 oocyst doses 
induce higher perinatal mortality rates in sheep than in mice. All surviving offspring from mice 
inoculated with 100 TgShSp1 oocysts were positive for T. gondii in the same way as stillbirths/lambs 
born alive from ewes infected with 50 TgShSp1 oocysts. However, while all stillbirths/lambs born 
alive from ewes challenged with 10 TgShSp1 oocysts were positive for T. gondii, only 37% of the 
surviving offspring from mice inoculated with 25 TgShSp1 oocysts were positive for T. gondii. 
Consequently, the virulence of T. gondii type II isolates in pregnant mice is not a reliable predictor 
for the outcome of infection in pregnant sheep.    
 
Objective 2. Standardization of the pregnant sheep model of N. caninum infection by a 
dose-titration assay and evaluation of different routes of administration of the virulent Nc-
Spain7 isolate. 
First. Only ewes challenged with the higher intravenous dose used in this study (105 tachyzoites) 
show 100% abortion. This ewes exhibit an earlier increase on rectal temperature and IFN-gamma 
levels and higher humoral immune responses. In addition, parasite load in the foetal brain compared 
to ewes challenged intravenously with lower doses is also higher.   
Second. Ewes challenged subcutaneously with 104 tachyzoites exhibited lower rectal 
temperature and IFN-gamma levels compared to ewes challenged intravenously with the same dose 
of tachyzoites. However, no differences between both routes of administration are found on humoral 
immune responses, foetal mortality and vertical transmission.  
Third. A pregnant sheep model of primoinfection with N. caninum based on intravenous 
inoculation of 105 tachyzoites is proposed. This dose, 10 times lower than previously assayed, and 
infection route, seems to be sufficient to trigger 100% abortion. This adjustment will allow to obtain 
more accurate results in studies testing vaccine and drug candidates.  
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Objective 3. Evaluation of the safety and efficacy against T. gondii and N. caninum of BKI 
compounds in pregnant sheep.  
First. The oral administration of BKI-1294 and the subcutaneous administration of BKI-1553 in 
pregnant sheep at the dose regimes assayed provide therapeutic plasmatic levels for T. gondii and N. 
caninum, respectively. However, BKI-1553 and more markedly BKI-1294 exhibit a rapid plasma 
clearance. BKI-1553 seems to have a better pharmacokinetic profile than BKI-1294 in pregnant 
sheep, in accordance to previous reports in mice and calves. Additionally, BKI-1553 is able to cross 
the placental barrier since therapeutic concentrations of this drug are found in the foetuses.  
Second. Both, BKI-1294 and BKI-1553, seem to be safe since no alterations on rectal 
temperature, hematological and biochemical parameters, pregnancy or local damage are associated 
with the drugs. However, differences on safety between both routes of administration are found. 
While oral administration does not increase rectal temperature or modifies fecal consistency, 
subcutaneous administration induces the formation of dermal nodules with associated increase on 
rectal temperature and monocytosis.  
Third. The administration of BKI-1294 to T. gondii infected ewes during pregnancy is 
associated with a lower rectal temperature increase, a higher peripheral IFN-gamma than untreated 
ewes, a low humoral immune response to soluble antigens but high levels of anti-SAG1 antibodies, 
and a decrease of 76% in the perinatal mortality. In the offspring, BKI-1294 prevents vertical 
transmission in 53% of the lambs. Therefore, the efficacy of BKI-1294 is higher than those observed 
previously using monensin, decoquinate and folate inhibitors.  
Fourth. The administration of BKI-1553 to N. caninum infected ewes during pregnancy causes 
a lower rectal temperature increase upon infection, triggers an increase in peripheral IFN-gamma 
levels and a reduction in the specific IgG responses, and achieves a reduction of 37-50% in the 
abortion rate. In foetuses, vertical transmission is not prevented, but the effects of infection are 
partially alleviated by reducing lesions, parasite presence and parasite loads in foetal brains. 
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Artículo de revisión 
Tratamiento de la toxoplasmosis y neosporosis en rumiantes: 
conocimiento actual y perspectivas futuras  
 
 
La toxoplasmosis y neosporosis son enfermedades causadas por protozoos  ampliamente 
relacionadas entre si que ocasionan importantes pérdidas económicas en rumiantes de producción. La 
infección por Toxoplasma gondii causa principalmente problemas reproductivos en pequeños 
rumiantes y es una zoonosis ampliamente distribuida, mientras que la infección por Neospora 
caninum es una de las principales causas de aborto en ganado vacuno en todo el mundo. La 
vacunación ha sido considerada la medida de control más rentable economicamente para controlar 
estas enfermades. Sin embargo, a pesar de los esfuerzos en el desarrollo de vacunas, solo una vacuna 
viva atenuada de T. gondii ha sido registrada para su uso en medicina veterinaria., y no se han 
conseguido vacunas prometedoras frente a la neosporosis; por lo tanto el desarrollo de vacunas es un 
objetivo primordial. Adicionalmente, el tratamiento farmacológico podría ser una estrategia valiosa 
para el control de estas enfermedades en rumiantes de producción ya que varios fármacos que limitan 
la proliferación y diseminación han sido evaluados. Asimismo, experimentos en animales de 
producción podrían ser relavantes como testaje inicial de fármacos frente a parásitos zoonóticos. Los 
tratamientos pueden ser aplicados frente a infecciones en rumiantes adultos para minimizar las 
consecuencias de una primoinfeccion o de la reactivación de una infección crónica durante la 
gestación ó en rumiantes recién nacidos para evitar la cronificación de la infección. En esta revisión 
se presenta el conocimiento actual del desarrollo de fármacos frente a la toxoplasmosis y la 
neosporosis en rumiantes, y en un intento de impulsar otras opcionas fármacológicas adicionales, se 
recogen potenciales fármacos que han mostrado eficacia in vitro y en  modelos de animales de 
laboratorio frente a la toxoplasmosis y neosporosis.  
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Abstract 
Toxoplasmosis and neosporosis are closely related protozoan diseases that lead to important 
economic impacts in farm ruminants. Toxoplasma gondii infection mainly causes reproductive failure 
in small ruminants and is a widespread zoonosis, whereas Neospora caninum infection is one of the 
most important causes of abortion in cattle worldwide. Vaccination has been considered the most 
economic measure for controlling these diseases. However, despite vaccine development efforts, only 
a live-attenuated T. gondii vaccine has been licensed for veterinary use, and no promising vaccines 
against neosporosis have been developed; therefore, vaccine development remains a key goal. 
Additionally, drug therapy could be a valuable strategy for disease control in farm ruminants, as 
several drugs that limit T. gondii and N. caninum proliferation and dissemination have been evaluated. 
This approach may also be relevant to performing an initial drug screening for potential human 
therapy for zoonotic parasites. Treatments can be applied against infections in adult ruminants to 
minimize the outcomes of a primo-infection or the reactivation of a chronic infection during gestation 
or in newborn ruminants to avoid infection chronification. In this review, the current status of drug 
development against toxoplasmosis and neosporosis in farm ruminants is presented, and in an effort 
to promote additional treatment options, prospective drugs that have shown efficacy in vitro and in 
laboratory animal models of toxoplasmosis and neosporosis are examined. 
 
Keywords 
Toxoplasma, Neospora, cattle, sheep, goats, chemotherapy, chemoprophylaxis. 
 
 
 
 
 
 
 
 
 
 
 
Appendix I ~ Literature review 
Treatment of toxoplasmosis and neosporosis in farm ruminants 
 
  ~ 243 ~ 
Introduction 
The cosmopolitan obligate intracellular 
protozoan parasites Toxoplasma gondii and 
Neospora caninum are considered major causes 
of reproductive failure in small ruminants and 
cattle, respectively (Dubey et al., 2007; Dubey, 
2009b; Reichel et al., 2013). Thereby, 
toxoplasmosis and neosporosis deserve special 
attention since they lead to severe economic 
losses to ruminant livestock producers (Trees et 
al., 1999; Innes et al., 2009; Reichel et al., 
2013). In fact, the negative economic effects 
are more devastating in the case of epidemic 
abortion storms than in herds/flocks with 
endemic cases (Reichel et al., 2013; Castaño et 
al., 2016). In addition, despite the undoubtedly 
under-detection and underreporting of cases 
(Olivier et al., 2007; Halsby et al., 2014), 
toxoplasmosis affects 25-50% of the world 
population (Montoya and Liesenfeld, 2004; 
Flegr et al., 2014; Neville et al., 2015) and it is 
recognized as the parasitic zoonosis with the 
highest human incidence by the European Food 
Safety Authority (EFSA) (Olivier et al., 2007).  
T. gondii and N. caninum are closely related 
apicomplexan parasites, sharing many 
morphological and biological features and 
showing remarkably conserved genomes 
(Mugridge et al., 1999; Speer et al., 1999; Reid 
et al., 2012). Moreover, they present similar 
facultative heteroxenous coccidian life cycles, 
including three invasive stages: i) the rapidly 
replicating and abortion-causing tachyzoites, 
ii) the slowly replicating or quiescent 
bradyzoites harboured in tissue cysts, 
especially those within the brain and skeletal 
muscle, and iii) the sporulated oocysts bearing 
sporozoites (Dubey et al., 1998; Hemphill and 
Gottstein, 2006; Robert-Gangneux and Darde, 
2012). However, large differences are found 
between them in relation to the host range of 
definitive and intermediate hosts, the zoonotic 
potential, which has been proven for only T. 
gondii, and the importance of horizontal and 
vertical routes of transmission in maintaining 
natural infections in the ruminant populations 
(Dubey and Schares, 2011; Robert-Gangneux 
and Darde, 2012).   
Parasites and diseases  
Host range and transmission  
According to current knowledge, the 
members of the family Felidae, especially 
domestic cats (Felis catus), are the definitive 
hosts of T. gondii. They commonly become 
infected after eating wild rodents and birds 
containing T. gondii tissue cysts (bradyzoites) 
and, to a lesser extent, by ingesting oocysts 
shed by other cats (Dubey, 1993; Innes et al., 
2009). In turn, any warm-blooded mammal, 
including humans and birds, can act as an 
intermediate host (Innes et al., 2009).  
Most infections in sheep and goat flocks 
occur postnatally, mainly by the horizontal 
route after the ingestion of water and food 
contaminated with viable sporulated oocysts 
shed by cats (Dubey, 2009b; Innes et al., 2009). 
However, the vertical transmission of T. gondii 
(from the dam to the foetus during gestation) 
can also occur in these two small ruminant 
species by both ‘exogenous transplacental 
transmission’ (ExTT) and ‘endogenous 
transplacental transmission’ (EnTT) 
mechanisms. The former mechanism, which is 
the most frequent, occurs during pregnancy as 
a consequence of an exogenous source while 
the latter, whose importance remains 
controversial (Innes et al., 2009), occurs after 
the recrudescence of a latent infection acquired 
in utero by the reactivation of bradyzoites and 
their reconversion to tachyzoites. In human 
hosts, the consumption of raw or undercooked 
meat with T. gondii tissue cysts containing the 
bradyzoite stage is commonly considered the 
main source of infections in developed 
countries (Kijlstra and Jongert, 2009), although 
water is increasingly being investigated as a 
risk factor. In fact, oocyst contamination has 
been demonstrated to be an important source of 
infection in tropical and subtropical countries, 
and also in some European countries (Jones and 
Dubey, 2010; Hussain et al., 2017). 
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The domestic dog (Canis lupus familiaris) 
and wild canids, such as American coyote 
(Canis latrans), Australian dingo (Canis lupus 
dingo) and Eurasian grey wolf (Canis lupus 
lupus) are the deﬁnitive hosts of N. caninum, 
while farm ruminants (cattle and sheep), horses 
and wildlife white-tailed deer and water buffalo 
are assumed to be intermediate hosts in the life 
cycle of N. caninum based on its successful 
isolation (Dubey and Schares, 2011).  
Dogs are usually infected through 
consumption of N. caninum-infected bovine 
tissues (mainly foetuses and placentas). Cattle 
can become infected through the oral uptake of 
N. caninum sporulated oocysts that are shed by 
dogs from the farm environment (Hall et al., 
2005; McCann et al., 2007), but the relative 
frequency with which cows are infected 
postnatally compared to that of cows infected 
by transplacental transmission remains 
unknown (Williams et al., 2009). Highly 
efficient transplacental infections (ExTT and 
EnTT) through tachyzoites are responsible for 
the majority of natural neosporosis outbreaks in 
livestock (Davison et al., 1999; Trees and 
Williams, 2005; Ortega-Mora et al., 2006). As 
mentioned above for toxoplasmosis, ExTT of 
N. caninum is associated with dams that are 
oocyst-derived primo-infected during 
gestation, while EnTT of N. caninum is related 
to the reactivation and recrudescence of a 
previous latent infection during gestation. The 
efficiency of transplacental infection has been 
estimated to range from 44% (Bergeron et al., 
2000) to over 95% (Davison et al., 1999), 
according to precolostral serology in calves 
born to seropositive dams. In fact, this route of 
infection is crucial to maintaining the infection 
within cattle herds, especially in herds with 
a high prevalence of seropositive cows 
(Bergeron et al., 2000). Nevertheless, it has 
been proposed that transplacental transmission 
alone is not enough to maintain the infection 
within the herds, and thus horizontal 
transmission is required (French et al., 1999; 
Bartels et al., 2007). 
Pathogenesis: outcome of infection in 
pregnant ruminants 
The complex pathogenesis of both 
reproductive ruminant diseases is not fully 
understood (Dubey et al., 2006; Dubey et al., 
2007), and there is still much to know 
concerning the role of parasite multiplication in 
the target tissues, maternal-foetal immunity 
(Buxton et al., 2002) and other essential 
factors, such as variations in virulence and 
parasite stages. However, it is well documented 
in the literature that the outcome of 
toxoplasmosis, as well as the effects of 
neosporosis in pregnant sheep, goats and cattle, 
are strongly associated with the period of 
gestation at the time of primary infection 
(Buxton and Finlayson, 1986; Lindsay et al., 
1995; Arranz-Solis et al., 2015b; Porto et al., 
2016). 
Ewes infected prior to mating will develop 
an anti-T. gondii immune response, enhancing 
protection against abortion in subsequent 
pregnancies (Innes et al., 2009), whereas 
repeated abortion in the next pregnancies has 
been described in goats (Dubey, 1982). In 
particular, if T. gondii tachyzoites reach a 
relatively immunologically immature foetus 
during the early stages of pregnancy, the 
infection usually results in foetal death. In turn, 
the birth of a stillborn or weak lamb, which is 
sometimes accompanied by a small, 
mummified foetus, is highlighted at mid-
gestation stages, whereas the birth of healthy 
and clinically normal lambs that are 
congenitally infected is the main finding for 
ewes with late T. gondii infections or after the 
recrudescence of an endogenous infection 
(Trees and Williams, 2005).  
Typically, N. caninum infection leads to a 
latent and asymptomatic course in non-
pregnant cows. Conversely, bovine neosporosis 
in pregnant cows is associated with repeated 
abortion and the birth of clinically healthy, but 
persistently infected, calves (Buxton et al., 
2002). The likelihood of abortion by N. 
caninum also greatly depends on the period of 
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gestation in which the infection occurs. 
Although N. caninum-infected cows of any age 
may abort from 3 months gestation to term, 
most abortions are concentrated in the mid-
gestation stages, between 5 to 7 months of 
gestation (Thurmond and Hietala, 1997a; 
Pereira-Bueno et al., 2003; Collantes-
Fernández et al., 2006b). The outcome of 
infection at the late stages of gestation is 
consistent with most foetuses going-on-to-
term, and thus these infections lead to the birth 
of congenitally infected calves that are 
clinically normal, but persistently infected 
(Pereira-Bueno et al., 2000; Quintanilla-
Gozalo et al., 2000). A limited number of 
calves may show neuromuscular disorders (De 
et al., 2005). It is also possible that congenitally 
infected cows may abort in successive 
gestations. In fact, around one in twenty cows 
that aborted once due to an N. caninum 
infection will abort again (Thurmond and 
Hietala, 1996; Ortega-Mora et al., 2006).  
Control 
For the control of toxoplasmosis and 
neosporosis, different measures have been 
suggested; however, the combination of 
different approaches is known to be the optimal 
strategy (Dubey et al., 2007; Dubey, 2009b). 
The implementation of farm biosecurity 
protocols, hygienic measures and management 
practices should be adopted in all farms, for 
reducing the level of environmental 
contamination with T. gondii oocysts via cat 
faeces or N. caninum oocysts via dog faeces (if 
present) and for avoiding novel infections 
through the introduction of infected animals to 
the herd. Among the biosafety practices that 
should be conducted to achieve this aim, the 
following are highlighted: limit cat and dog 
access to ruminant areas, especially to those 
housing pregnant ruminants, or to the areas for 
food storage and water supplies; promptly 
remove of placentas or foetal materials; 
appropriately dispose of dead livestock; and 
establish rodent control. Reproductive 
practices considering the artificial insemination 
of seropositive dams or the use of embryo 
transfer and test and cull strategies based on 
serological diagnosis are also recommended for 
the control of N. caninum infections (Dubey et 
al., 2007; Reichel et al., 2014; McAllister, 
2016). Despite being properly designed and 
meticulously practised, globally, these control 
measures alone are not cost-viable or 
completely effective in eliminating 
toxoplasmosis and neosporosis from a herd, 
and it is necessary to complement them with an 
immune-chemotherapeutical approach (Zhang 
et al., 2013; Hemphill et al., 2016; McAllister, 
2016).  
 
In particular, vaccination has been 
considered a promising and economically viable 
solution to preventing the transmission of both 
infectious agents, despite its two current 
principal limitations related to efficacy and 
safety (Innes et al., 2009; Horcajo et al., 2016). 
In fact, to date, the control of ovine 
toxoplasmosis is primarily based on preventing 
its horizontal transmission and on the 
establishment of a vaccination programme with 
a live attenuated S48 strain (Toxovax™, 
MSD). The benefits are associated with 
protection against abortions induced by T. 
gondii during pregnancy and a decrease in 
tissue cyst development (Innes et al., 2009; 
Verma and Khanna, 2013). Although the 
protective immunity against T. gondii can 
persist over one year, vaccination does not 
imply latent infections, and its use has two main 
drawbacks: a short shelf-life and a risk of 
infection to the humans who are handling live 
vaccines (Innes et al., 2009; Verma and 
Khanna, 2013). In terms of efficacy, the design 
of successful vaccines requires blocking the 
stages of the life cycle (e.g., cell invasion, 
intracellular replication) and simulating the 
natural immune responses of the hosts (Zhang et 
al., 2013). Therefore, vaccine development 
against T. gondii infection in humans and food-
producing animals represents an adequate and 
global challenge that could greatly improve 
disease control. Regarding bovine neosporosis 
and vaccination, economic analyses suggest 
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that vaccination may be a more cost-effective 
and largely preferred approach than a test and 
cull programme (Reichel and Ellis, 2006). In 
the United States, a commercial killed vaccine 
for pregnant cows was available until 2009 
(C548 NeoGuard™, Intervet), but it showed 
variable efficacy. At this time, no commercial 
vaccine is available, which precisely represents 
a major handicap that needs to be solved 
(Horcajo et al., 2016). Live-attenuated vaccines 
appear to be the most promising approach, 
although subunit vaccines have also been 
investigated in relation to two functional points 
of view: the physical interaction between the 
parasite and its host cell during invasion or 
tachyzoite-to-bradyzoite stage conversion 
(Hemphill et al., 2016), and these vaccines 
have emerged as the best way forward (Horcajo 
et al., 2016).  
 
Alternatively, several drugs appear to have 
a potentially beneficial effect on controlling 
these infections. Effective chemotherapy has 
been identified as an economically promising 
option in the literature (Häsler et al., 2006a; 
Häsler et al., 2006b). However, the 
disadvantage of using pharmacological 
treatments against toxoplasmosis and 
neosporosis is related to the timing of their 
administration; there is no evidence of infection 
until abortion cases are observed, and this 
timing could be indicative of a stage that is too 
late for treatment administration (Benavides et 
al., 2014). An oral administration of drugs is 
expected to be effective against the T. gondii 
and N. caninum sporozoites released from 
oocysts. In addition, the drugs should be 
effective against the tachyzoite stage, which is 
associated with acute disease, and the 
bradyzoite stage, which occurs in the chronic 
phase of infection (Debache et al., 2011). The 
ideal treatment would be parasiticidal against 
sporozoites and bradyzoites, but a parasitostatic 
capability against the tachyzoite stage, since 
tachyzoites have greater difficulty resisting the 
host cell’s adaptive immune response. 
Additionally, a suitable drug should have low 
toxicity and should be able to cross the blood–
brain barrier to effectively eliminate parasitic 
brain cysts (Neville et al., 2015).  
In practical terms, the treatment of ruminant 
toxoplasmosis and neosporosis should be 
focused on 3 main levels: i) chemotherapy or 
chemoprophylaxis in infected cows, ewes and 
goats (Figure 1), ii) treatment of newborn 
congenitally infected calves, lambs and kids 
(Figure 1) and iii) treatment of definitive hosts 
in order to reduce environmental contamination 
with T. gondii and N. caninum oocysts.  
The comprehensive immune-
chemotherapeutical approach with a 
combination of protective immunity generated 
by vaccines (applied before mating) and the 
capability of bioactive compounds (applied in 
the gestation period where abortions are more 
likely to occur) to limit the proliferation and 
dissemination of tachyzoites or to abrogate 
tissue cysts would be a great option for 
controlling toxoplasmosis and neosporosis in 
farm ruminants (Hemphill et al., 2016). In a 
context where vaccination against both 
parasites needs to be improved, the objective of 
this review is to summarize relevant studies on 
the treatment of toxoplasmosis and neosporosis 
in farm ruminants that could serve as 
chemotherapeutical guidelines. Furthermore, in 
order to address novel therapeutic approaches, 
considerations on promising drugs will be 
described. 
Available drug treatments for ruminant 
toxoplasmosis and neosporosis  
Published research, including ruminant 
studies on drug therapy against toxoplasmosis 
(Table 1) 
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Figure 1- Intervention points for chemotherapy and chemoprophylaxis in toxoplasmosis and  
neosporosis in farm ruminants.  
and neosporosis (Table 2), are reviewed. Each 
pharmacological group, with its chemical 
structure, main uses for therapy, mode/s of 
action, and in vitro and in vivo activities, are 
summarized.  
Macrolide antibiotics 
Macrolide antibiotics, which were 
discovered in the early 1950s, are a well-
established class of antimicrobial agents 
containing 12- to 16-membered lactone rings 
that have been substituted with one or more 
sugar residues, some of which may be amino 
sugars (Schönfeld and Kirst, 2002). All 
macrolides inhibit bacterial protein synthesis to 
varying extents. The macrolides bind to the 50S 
ribosomal subunit with a specific target in the 
23S ribosomal RNA molecule and various 
ribosomal proteins. The most recent hypothesis 
suggests that all macrolides stimulate the 
dissociation of peptidyl-tRNA from the 
ribosomes during the elongation phase, leading 
to the inhibition of protein synthesis (Brisson-
Noël et al., 1988; Mazzei et al., 1993). The 
spectrum of activity includes many common 
pathogens, such as gram-positive bacteria (e.g., 
Streptococcus pyogenes, Corynebacterium 
diphtheria and Staphylococcus aureus), gram-
negative bacteria (e.g., Neisseria gonorrhoeae, 
Moraxella catarrhalis and Bordetella 
pertussis) and protozoan parasites, including T. 
gondii, Plasmodium falciparum and 
Entamoeba histolytica (Root, 1999). 
 
Spiramycin (2-
[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[5-
(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-
(dimethylamino)-3-hydroxy-6-methyloxan-2-
yl]oxy-10-[5-(dimethylamino)-6-methyloxan-
2-yl]oxy-4-hydroxy-5-methoxy-9,16-
dimethyl-2-oxo-1-oxacyclohexadeca-11,13-
dien-7-yl]acetaldehyde), a 16-membered 
macrolide derived from Streptomyces 
ambofaciens, has been used for the treatment of 
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acute toxoplasmosis in pregnant women for 
decades because it is a safe and well-tolerated 
drug with no known adverse effects on the 
foetus (Desmonts and Couvreur, 1974; Daffos 
et al., 1988; McCabe, 2001); however, its 
effectiveness and benefits are still unclear 
(Wallon et al., 1999; Serranti et al., 2011; 
Rodrigues et al., 2014). Spiramycin showed 
limited in vitro activity against T. gondii, with 
a 50% inhibitory concentration (IC50) of 20.16 
µg/ml and an inhibitory, rather than a curative, 
effect (Chang and Pechere, 1988; Chamberland 
et al., 1991). Despite its low in vitro efficacy, 
spiramycin was the first macrolide to 
demonstrate activity against acute 
toxoplasmosis in mice (Garin and Eyles, 1958). 
Spiramycin improves mouse survival after an 
acute T. gondii infection and reduces brain cyst 
burdens in both acute and chronic 
toxoplasmosis (Grujić et al., 2005; Chew et al., 
2012). These paradoxical results are explained 
by spiramycin’s ability to achieve intra-cellular 
and tissue concentrations that exceed its serum 
concentrations. Furthermore, spiramycin 
clearance is low, resulting in sustained tissue 
and intracellular concentrations (Smith, 1988). 
 
Spiramycin has also been tested in pregnant 
ewes infected with T. gondii (RH strain) 
between the 85th and 100th days of pregnancy 
and treated orally (PO) with 100 mg/kg 
spiramycin from 3 weeks after infection until 
parturition. All ewes gave birth, with only one 
stillbirth in the untreated group. Analysis of the 
placental tissues did not show differences 
neither in the histopathological lesions, nor in 
the presence of T. gondii between the treated 
and untreated groups. However, the humoral 
immune response in pregnant ewes decreased 
in the treated group compared to that in the 
untreated group. Additionally, a lower number 
of lambs were seropositive to T. gondii in the 
treated group than in the untreated one. It was 
concluded that spiramycin treatment in ewes 
during the mid-stage of gestation exhibited a 
reduction in the humoral immune response in 
dams and in T. gondii seropositive lambs 
(Dubreuil, 1972).  
Polyether ionophore antibiotics 
Polyether ionophore antibiotics, whose 
structures involve an alkyl-rich, lipid-soluble 
exterior and a cage-like interior, are produced 
by Streptomyces spp. and form complexes with 
metal cations, transporting these complexes 
across hydrophobic membranes (Wang et al., 
2011). Polyether antibiotics form mainly 
neutral complexes with monovalent cations 
(i.e., monensin, salinomycin) or divalent metal 
cations (i.e., lasalocid, calcimycin) and with 
organic bases (i.e., lasalocid) (Westley, 1982; 
Bakker et al., 1997; Rutkowski and Brzezinski, 
2013). Polyether antibiotics induce ionic 
gradient perturbations, acting on different 
metabolic pathways (Couzinet et al., 2000), 
and show broad spectrum bioactivity, including 
antibacterial, antifungal, antiparasitic and 
antiviral effects, as well as tumour cell 
cytotoxicity (Rutkowski and Brzezinski, 
2013).Monensin (4-[2-[5-ethyl-5-[5-[6-
hydroxy-6-(hydroxymethyl)-3,5-dimethyl-
oxan-2-yl]-3-methyl oxolan-2-yl]oxolan-2-yl]- 
9-hydroxy-2,8-dimethyl-1,6-dioxasp 
iro[4.5]dec-7-yl]-3-methoxy-2-methyl-
pentanoic acid) was shown to have 
coccidiostatic effects (Bergstrom and Maki, 
1976; McDougald and Dunn, 1978) and growth 
promoting properties (Herberg et al., 1978) by 
favouring ruminal propionic acid production 
(Richardson et al., 1976). However, European 
Union regulations on the additives for use in 
animal nutrition banned the use of growth 
promoting agents as feed additives in animals 
(European Commission, 2005). 
In vitro studies showed that polyether 
ionophore antibiotics affect all endogenous 
apicomplexan parasite forms, whether they are 
dividing or not (Couzinet et al., 2000). 
Lasalocid (6-[(3R,4S,5S,7R)-7-[(2S,3S,5S)-5-
ethyl-5-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-
methyloxan-2-yl]-3-methyloxolan-2-yl]-4-
hydroxy-3,5-dimethyl-6-oxononyl]-2-
hydroxy-3-methylbenzoic acid) at 0.05 µg/ml 
is directly toxic to extracellular T. gondii 
tachyzoites and inhibits cell penetration and 
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intracellular multiplication (Melton and 
Sheffield, 1975). Monensin at 0.001 µg/ml has 
also shown in vitro efficacy (IC50) against T. 
gondii tachyzoites (Ricketts and Pfefferkorn, 
1993; Rutkowski and Brzezinski, 2013). 
Working against the T. gondii cyst form, 
monensin inhibits the infectivity and viability 
of bradyzoites at low concentrations (0.1 
ng/ml) (Couzinet et al., 2000). Recently, it has 
been demonstrated that monensin, through 
TgMSH-1 protein, disrupts the mitochondrial 
function of T. gondii, triggering a disruption of 
cell cycle progression that precedes the events 
that resemble an autophagy-like death process 
(Lavine and Arrizabalaga, 2011; Lavine and 
Arrizabalaga, 2012). In addition, the disruption 
of mitochondrial function results in the 
generation of reactive oxygen species (Charvat 
and Arrizabalaga, 2016). T. gondii monensin 
resistance has been described after chemical 
mutagenesis in vitro (Ricketts and Pfefferkorn, 
1993) or as a result of a disruption of TgMSH-
1 (Garrison and Arrizabalaga, 2009). 
Furthermore, lasalocid and monensin at 0.001 
ng/ml showed a 95% reduction of N. caninum 
tachyzoites in cell cultures (Lindsay et al., 
1994).  
The efficacy of monensin against ovine 
toxoplasmosis was evaluated in experimentally 
infected pregnant sheep. Ninety-days pregnant 
ewes were experimentally infected PO with 
2,000 and 12,000 T. gondii (M1 strain) oocysts 
and were treated PO with monensin (15 or 30 
mg) daily from day 80 of gestation until 
parturition (Buxton et al., 1988). Ewes 
receiving monensin showed a reduction in 
foetal mortality compared with the non-treated 
ewes (83.3% vs 44.8% alive lambs, 
respectively). In this study, monensin seems to 
act earlier in the infection, possibly by effects 
on the sporozoites released from infectious 
oocysts within the intestinal lumen. Ewes 
infected and treated with monensin showed a 
lesser febrile response. In addition, ewes 
receiving monensin showed lower anti-T. 
gondii IgG levels. However, when monensin 
administration ceased after lambing, 
circulating specific IgG antibodies against T. 
gondii increased over three months to reach 
values similar to those observed in infected and 
non-treated ewes. This observation suggests 
that monensin could also have a systemic 
effect, possibly acting on the tachyzoites 
present in the pregnant uterus. In addition, 
lambs born from ewes receiving monensin had 
higher live weights, and less of these animals 
showed evidence of infection and pathological 
changes in foetal or placental tissues than the 
lambs born from infected and non-treated ewes. 
The possible systemic effect of monensin 
after T. gondii infection could be of value, as 
the time of infection during natural outbreaks 
of toxoplasmosis can only rarely be clearly 
defined. To avoid intestinal infection, and 
hence any intestinal effect of monensin PO at 
day 90 of pregnancy, the pregnant ewes were 
challenged subcutaneously (SC) with 100 T. 
gondii (M1 strain) tissue cysts (Buxton et al., 
1987). No differences in febrile and serological 
responses were found between the treated and 
non-treated groups. However, the treated ewes 
produced more viable lambs (less premature 
and greater live weight) than the untreated ewes 
(75% vs 42%, respectively). In addition, 58% 
of the lambs from treated ewes survived 72 
hours after birth, whereas only 33% survived 
from the untreated ewes. Based on this 
evidence, it would appear that monensin, while 
being most effective in the gut lumen, does 
have a lesser systemic action, presumably by 
suppressing the multiplication of T. gondii in 
the placentome. 
The accidental poisoning of domestic 
animals with monensin PO has been reported in 
cattle, horses, poultry and dogs (Beck and 
Harries, 1979; Wilson, 1980). The clinical 
findings in sheep include lethargy, stiffness,
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muscular weakness, a stilted gait and 
recumbency, followed by a decrease in the 
muscle volume of the rump and thigh. The post-
mortem lesions in the skeletal muscles 
consisted of pale streaking, with atrophy in the 
chronic stages. In lambs younger than one 
month old, diffuse gastrointestinal 
haemorrhage was the only finding (Nation et 
al., 1982). Later, another researcher reported an 
outbreak of monensin poisoning in sheep and 
highlighted the need for a licensed, safe product 
(Synge, 1989). An option to avoid monensin 
poisoning in sheep would be to use blocks 
containing monensin or slow-release boluses. 
In addition, this option would overcome the 
practical problems of monensin delivery to 
grazing sheep (Trees, 1989; Ellis and Costigan, 
1990). 
Lasalocid has also been tested for its 
efficacy against ovine toxoplasmosis 
(Kirkbride et al., 1992). Ewes were treated PO 
with lasalocid (30 g/day) daily
 
from day 55 of 
pregnancy until lambing and were PO 
inoculated with 100 T. gondii (TS-1 strain) 
oocysts 5 days after beginning lasalocid 
administration. Similar specific antibody titres 
and histopathological lesions were found in the 
ewes and foetuses, and there were no 
differences in the rate of abortion and neonatal 
mortality in both the treated and untreated 
ewes. These results suggest that lasalocid was 
not effective in preventing T. gondii abortion in 
sheep.  
Concerning N. caninum infection in cattle, a 
risk factor analysis in dairy farms showed that 
cows receiving monensin as a feed additive 
were 1.5 times less likely to be infected with 
this parasite than the cows that did not receive 
monensin (Vanleeuwen et al., 2010). Thus, the 
effect of monensin was tested against 
experimental neosporosis in cattle 
(Vanleeuwen et al., 2011). Non-pregnant cows 
were treated with a slow-release bolus PO that 
delivered 100 days of monensin (335 mg/day) 
and were challenged with 5x106 N. caninum 
(Nc-1 strain) tachyzoites by the SC route three 
weeks after bolus administration. The cows 
treated with monensin showed a significantly 
lower humoral immune response than those 
treated with a placebo at week 4 post-challenge. 
Before recommendations on monensin use for 
neosporosis could be made, further research on 
other larger populations of cattle, preferably 
pregnant, must be explored. Furthermore, trials 
on monensin’s effectiveness in more natural 
modes of N. caninum transmission (e.g., 
bradyzoite recrudescence leading to 
transplacental transmission, or oocyst 
ingestion) would also be needed. 
In summary, PO administered monensin 
was shown to be partially effective in the 
control of ovine toxoplasmosis, but it is not 
licensed for use in the EU and may be toxic at 
high dosages. In contrast, PO dosed lasalocid 
did not exhibit efficacy in reducing the ovine 
toxoplasmosis outcome. In N. caninum-
infected non-pregnant cows, monensin was 
associated with a lower specific humoural 
immune response, but further research on the 
outcome of infection in pregnant animals is 
needed.  
 
Folate inhibitors  
Folate inhibitors, such as sulphonamides 
and pyrimethamine, and their mechanism of 
action were identified years ago (Hitchings and 
Burchall, 1965). Sulphonamides are para-
aminobenzoic acid analogues that 
competitively inhibit parasite dihydropteroate 
synthetase (DPHS). Pyrimethamine is a folate 
analogue that competitively inhibits parasite 
dihydrofolate reductase (DHFR). DHPS is one 
of the enzymes responsible for folate 
compound synthesis while DHFR maintains 
folate in a reduced state. Folate compounds are 
essential for parasite metabolism, including 
nucleoside biosynthesis and therefore nucleic 
acid formation. Sulphonamides, in combination 
with pyrimethamine, are a mainstay of 
chemotherapy in human toxoplasmosis 
(Montoya and Liesenfeld, 2004). 
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Sulphonamides, such as sulphadiazine (IC50 
of 2.5 µg/ml), were found to have important 
inhibitory effects on T. gondii. This inhibitory 
effect on parasite growth was associated with a 
reduction in the number of parasitized cells and 
intracellular parasites that were 
morphologically normal (Derouin and 
Chastang, 1989).  
In contrast, sulphonamides demonstrate 
little activity against N. caninum tachyzoites at 
100 µg/ml (Lindsay et al., 1994). With DHFR 
inhibitors, a strong inhibition of T. gondii 
growth was observed with pyrimethamine (IC50 
of 0.04 µg/ml) and trimethoprim (IC50 of 2.3 
µg/ml), along with striking morphological 
changes in the parasites. Additionally, 
trimethoprim is effective against N. caninum 
tachyzoites at 10 µg/ml (Lindsay et al., 1994). 
When sulphonamides and DHFR inhibitors 
were used in combination, a remarkable 
synergistic activity against the replicating 
forms of T. gondii and N. caninum was 
observed (Derouin and Chastang, 1989; 
Lindsay et al., 1996). Laboratory-induced 
resistance to antifolates has been described for 
T. gondii and N. caninum (Pfefferkorn et al., 
1992; Lindsay et al., 1996). In addition, it is 
also known that sulphonamide resistance in T. 
gondii can be associated with nucleotide 
polymorphism in DHPS (Aspinall et al., 2002). 
When pyrimethamine and sulphadiazine were 
administered in combination to non-pregnant 
mice for 10 days from day 1 after 
intraperitoneal (IP) infection with T. gondii 
tachyzoites, 100% of the mice survived, and 
they were considered cured because the 
parasites remained undetectable (Piketty et al., 
1990). Likewise, sulphadiazine is effective in 
preventing deaths and clinical disease in N. 
caninum infected mice (Lindsay and Dubey, 
1990a). 
Experimentally induced toxoplasmosis in 
pregnant ewes with 2,000 oocysts (M3 strain) 
at 89 days of pregnancy was treated with a 
combination of sulphamezathine and 
pyrimethamine sulphate for three consecutive 
days on days 100, 115 and 130 of gestation. 
Sulphamezathine (1 g per 3 ml of solution) was 
injected SC at an initial dose of 5 ml/10 kg on 
the first day, with subsequent doses on the 
following two days of 2.5 ml/10 kg. 
Pyrimethamine sulphate (10 mg/ml) was 
injected IP at 2 mg/kg on the first treatment day 
and at 1 mg/kg on the two subsequent days. 
After 130 days of gestation, 30% of foetuses 
from untreated ewes died, whereas all the 
lambs from the treated ewes were born and 
were viable. In addition, the gestational period 
of infected and untreated ewes was shorter than 
that observed in the infected and treated ewes. 
At birth, all the lambs showed a specific 
antibody response to the protozoa, indicating 
that the infection was in utero. However, the 
mean IFAT titres of lambs born from the 
infected and treated ewes were lower than those 
of the lambs born from the infected and 
untreated ewes (1/256 vs 1/730 for IgG and 
1/665 vs 1/5206 for IgM). Histopathological 
examination showed less severe placental 
lesions in the lambs born from the treated ewes 
(Buxton et al., 1993a). 
In field conditions, the therapeutic efficacy 
of sulphonamides in an ovine toxoplasmosis 
outbreak has been evaluated. Before treatment, 
60% of the ewes in the flock had aborted, and 
treatment with sulphadimine at 20 mg/kg 
intramuscularly (IM), 4 times every 48 hours, 
reduced the abortion rate to 25%; the rest of the 
ewes gave birth normally, but 61.1% of their 
lambs were stillbirths and did not survive. A 
higher dosage at 33 mg/kg IM, 4 times every 48 
hours, reduced the abortion rate to 7%, and 
75% of the lambs survived (Giadinis et al., 
2011). Folate inhibitors have also been 
evaluated in field conditions for the treatment 
of neosporosis in cattle. A combination of 
toltrazuril given intravenously (IV) at 20 
mg/kg/day for 3 consecutive days to newborn 
calves during the first week of age and 
sulphadiazine/trimethoprim given IV at 20 
mg/kg to cattle once a year from 3 months of 
age along with dog treatment with toltrazuril 
and periodic disinfection of environment 
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resulted in a significant reduction of abortion 
(from 188 to 9) (Cuteri et al., 2005). 
In brief, parenteral administration of 
sulphonamides, in combination with 
pyrimethamine, could be a valuable option for 
chemotherapy of ovine toxoplasmosis in the 
third term of gestation, as a reduction in 
abortion rates, but not in the percentage of 
transplacental transmission, is observed. There 
is some evidence in field experiments that 
folate inhibitor administration can reduce 
abortions in ruminants, although more research 
is needed. 
Quinolones 
Quinolones were derived from quinine 
[112]. Decoquinate (6-ethyl-(decycloxy)-7-
ethoxy-4-hydroxy-3-quinolinecarboxylate) is a 
quinolone derivative coccidiostat that was 
initially developed as an anticoccidial for 
poultry in 1967 (Williams, 2006). 
Decoquinate’s effects are mainly observed 
earlier in the life cycle of coccidia by acting on 
the sporozoites that are released from the 
ingested sporulated oocysts during the first day 
of their life cycle (Joyner and Norton, 1971; 
Fitzgerald and Mansfield, 1986). Decoquinate 
significantly inhibits mitochondrial respiration 
and electron transport in Eimeria (Fry and 
Williams, 1984). 
It has been used for over 20 years in the 
control of coccidiosis in domestic ruminants 
(Laval and Remy, 1994; Daugschies and 
Najdrowski, 2005). Decoquinate is registered 
and commercialized for use in ruminants in 
multiple countries worldwide, including the 
USA and several countries in Latin America, 
Europe and the Middle East (Taylor and 
Bartram, 2012). Decoquinate is poorly 
absorbed by the target species when 
administered PO and is largely eliminated 
unchanged in faeces. A recent study in cattle 
showed that only small quantities of 
decoquinate become systemically available and 
that the drug is rapidly eliminated with 
negligible residues in milk (Quintero-de 
Leonardo et al., 2009). Therefore, decoquinate 
is in Annex II of the EU Council Regulation 
No.2377 ⁄ 90 (European Commission, 1994), 
which means that it is not subject to maximum 
residue levels, with a meat withdrawal time of 
zero days in cattle and sheep in Europe (EMEA, 
2000). 
Research has shown decoquinate to have in 
vitro activity against T. gondii tachyzoites with 
an IC50 of 0.005 µg/ml (Ricketts and 
Pfefferkorn, 1993), although chemical 
mutagenesis revealed T. gondii resistant 
mutants (Pfefferkorn et al., 1993; Ricketts and 
Pfefferkorn, 1993). Likewise, intracellular N. 
caninum tachyzoites were killed quickly at 0.1 
µg/ml (Lindsay et al., 1997). 
In a study, sheep were challenged PO with 
200 T. gondii (M3 strain) oocysts at 90 days of 
gestation, and decoquinate was administered 
PO at 1 or 2 mg⁄kg⁄day from 10 days prior to 
oocyst challenge until lambing (Buxton et al., 
1996). The administration of decoquinate at the 
higher rate of 2 mg⁄kg⁄day was associated with 
a delayed onset of the febrile response to 
infection, reduction in the overall severity of 
fever and a delay in the production of specific 
antibodies to the parasite. This treatment also 
reduced the placental damage caused by the 
protozoa, lengthened the mean gestation period 
by five days and increased the proportion of 
viable lambs (up 61.8%) and the mean weight 
of the lambs (up 33.3%) in comparison with 
ewes that were not treated with decoquinate but 
were challenged with T. gondii oocysts. 
In addition, it is necessary to note that the 
decoquinate-medicated feed distributed to 
pregnant heifers that are chronically infected or 
primo-infected with N. caninum at the dose of 
2 mg/kg from 1.5 months of gestation until the 
end of the 8th month of pregnancy tends to 
reduce the associated abortions (from 38% to 
21% in chronically infected heifers and from 
17% to 6% in primo-infected heifers) and 
neonatal infections, as more seronegative 
calves were born (28% in the treated group vs 
21% in the untreated group for chronically 
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infected heifers and 59% in the treated group vs 
35% in the untreated group for primo-infected 
heifers) (Journel et al., 2002) 
To summarize, PO administration of 
decoquinate reduces the effect of 
experimentally induced toxoplasmosis in 
pregnant ewes. These results support the 
indication of decoquinate as an aid in the 
prevention of abortion due to ovine 
toxoplasmosis if used during mid and late 
pregnancy. Decoquinate may have an 
application in the treatment of bovine 
neosporosis. 
Triazinones 
The triazine structure is a heterocyclic ring, 
analogous to the six-membered benzene ring, 
but with three carbons replaced by nitrogen. 
The three isomers of triazine are distinguished 
from each other by the positions of their 
nitrogen atoms and are referred to 1,2,3-
triazine, 1,2,4-triazine and 1,3,5-triazine 
(Arshad et al., 2015). 
Toltrazuril, a symmetric 1,3,5-triazine 
derivative, is metabolized into an active 
metabolite, toltrazuril sulphone (ponazuril). 
Both toltrazuril and ponazuril are effective 
against a broad spectrum of cyst-forming and 
non-cyst-forming apicomplexan protozoa 
(Haberkorn, 1996). Several studies have shown 
that toltrazuril and ponazuril affect the 
respiratory chain through the reduction of some 
enzymes of the respiratory chain, such as 
succinate-cytochrome C reductase, NADH 
oxidase and succinate oxidase. Second, the 
DHFR involved in pyrimidine synthesis is also 
affected, but the effect is weaker than that 
observed with pyrimethamine (Harder and 
Haberkorn, 1989). In addition, nuclear division 
is affected, mitochondrial activity is impaired, 
and the endoplasmic reticulum is vacuolized 
(Mehlhorn et al., 1984). Additionally, 
differential phenotypic changes between the 
tachyzoites of N. caninum and T. gondii were 
observed after ponazuril treatment (Mitchell et 
al., 2005). 
In vitro, toltrazuril has positive effects 
against T. gondii with an IC50 of 0.4 µg/ml 
(Ricketts and Pfefferkorn, 1993; Greif et al., 
2001; Mitchell et al., 2004). Toltrazuril also 
shows in vitro efficacy against N. caninum, 
although a concentration of 30 µg/ml for 14 
days is required to eliminate parasites (Darius 
et al., 2004), and no NcGRA2 expression is 
found, showing a lack of parasite viability after 
treatment (Strohbusch et al., 2008). Ponazuril 
administered prophylactically or after 
treatment in mice is effective in preventing 
acute toxoplasmosis based on a lack of 
mortality (Mitchell et al., 2004). Toltrazuril 
and ponazuril administered in N. caninum-
infected non-pregnant mice abrogate the 
formation of cerebral lesions, and 90% of the 
treated mice had N. caninum-DNA-free brains 
(Gottstein et al., 2001). In addition, toltrazuril 
reduces foetal losses and transplacental 
transmission in N. caninum-infected pregnant 
mice (Gottstein et al., 2005), and it has an 
impact on the course of infection in 
congenitally N. caninum-infected newborn 
mice (Strohbusch et al., 2009a). 
It has been emphasized that the production 
of T. gondii free lamb, sheep or goat meat for 
human consumption is critically important for 
public health (Kijlstra and Jongert, 2009). The 
in vivo therapeutic efficacy of toltrazuril on T. 
gondii tissue cysts in experimentally infected 
lambs has been studied after a chronic infection 
in newborn lambs through a parenteral 
inoculation of 105 T. gondii (ME-49 strain) 
oocysts (Kul et al., 2013). Beginning at the 15th 
day after inoculation, the lambs were treated 
with toltrazuril PO 2 times, once every week at 
a dose of 20 mg/kg and 40 mg/kg. Following 
toltrazuril treatment, at day 90 after 
inoculation, the specific immune humoral 
response in lambs of both treatment groups was 
lower. On day 90 after inoculation, the lambs 
were necropsied. The histopathological 
findings in the toltrazuril-treated lambs include 
morphologic and structural changes of the 
tissue cysts in the musculature, which were 
characterized by initial degenerative changes in 
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the cyst wall and a minimal inflammatory cell 
response. The presence of T. gondii DNA in 
heart, brain and semitendinosus muscle from 
the treated groups was lower than that in tissues 
of the non-treated lambs. Moreover, in the 
treated groups, 4 out of 9 (44.4%) lambs did not 
contain any tissue cysts in the examined tissues, 
but untreated animals showed T. gondii tissue 
cysts at least in one of the sampled muscles. 
The administration of toltrazuril seems to be 
associated with a reduction of T. gondii cysts in 
the musculature. 
It is doubtful that encysted N. caninum 
bradyzoites were susceptible to toltrazuril 
treatment. Congenitally infected calves born 
from Neospora-seropositive cows were PO 
treated with toltrazuril at 20 mg/kg three times 
at 48-hour intervals within 7 days after birth, 
following a humoral immune response (Haerdi 
et al., 2006). Four to six months after birth, a 
stronger antibody reactivity was found in the 
treated animals than in the untreated calves. 
Conversely, in a study to evaluate whether the 
treatment of congenitally infected lambs with 
toltrazuril PO at 20 mg/kg on days 0, 7, 14 and 
21 after birth eliminated N. caninum, toltrazuril 
did not show any effect on the reduction of N. 
caninum presence or on the severity of 
histopathological lesions, and the lambs were 
all seropositive, although they had significantly 
lower specific antibody levels than those in the 
untreated animals, suggesting higher antigenic 
stimulation in the non-treated lambs than in the 
treated lambs (Syed-Hussain et al., 2015a). 
The efficacy of ponazuril has been tested in 
calves that were experimentally infected with 
N. caninum at 2x108 tachyzoites (Nc-1 strain) 
(Kritzner et al., 2002). Medication was 
performed PO with 20 mg/kg of ponazuril. The 
first medication dose was applied 24 hours after 
infection, and if repeated, it was administered 
every subsequent 24 hours for six days. 
Ponazuril allows a complete abrogation of 
parasite DNA detection by PCR in the brain 
and other organs. Regarding the non-medicated 
calves, it is noteworthy that there was a 
relatively lower susceptibility of calves to 
experimental infection, since only 50% of the 
calves became PCR-positive in the brain and 
muscles. The efficacy of a six-day treatment 
was also suggested by the significantly lower 
anti-N. caninum antibody response and later 
seroconversion than those in the infected and 
non-medicated calves. 
In addition, as explained above, toltrazuril 
administration to newborn calves, along with 
sulphadiazine/trimethoprim administration, 
resulted in reduced abortions and N. caninum 
seroprevalence in naturally infected cattle 
herds (Cuteri et al., 2005). 
In summary, toltrazuril PO administered in 
lambs would be a valuable strategy to minimize 
human exposure to T. gondii tissue cysts from 
the consumption of raw or undercooked 
mutton. Triazinon derivatives are directed 
against an N. caninum tachyzoite challenge, 
whereas treatment of congenitally infected 
young ruminants remains an elusive goal. In 
addition, it would likely result in considerable 
unacceptable milk or meat residues or 
withdrawal periods (Dubey et al., 2007). 
Present approaches in drug development 
for ruminant toxoplasmosis and 
neosporosis 
Experimental studies have revealed that 
several compounds have potentially interesting 
effects on T. gondii and N. caninum in vitro, but 
only a few drugs have been tested in laboratory 
animal models in vivo. The most interesting 
drugs tested for toxoplasmosis and neosporosis 
were derived from screenings in other 
intracellular protozoan parasites, including 
Plasmodium, Trypanosoma and Leishmania 
species, and some drugs exhibited broad-
spectrum anti-parasitic activity against various 
protozoan and helminth parasites. However, it 
is notable that T. gondii was the least 
responsive to these sets of drugs, suggesting 
that it may be more difficult to target 
chemotherapeutically than the aforementioned 
parasites (Guiguemde et al., 2010). In addition, 
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other approaches identified compounds that 
inhibited targets that were conserved almost 
exclusively within the group of apicomplexan 
parasites; thus, drug repurposing is a valuable 
option (Brown and Superti-Furga, 2003; 
Hemphill et al., 2016). The main prospective 
drug classes with in vitro and in vivo activity in 
small animal models against T. gondii and N. 
caninum are reviewed below (Table 3), 
although more chemotherapeutic options for 
toxoplasmosis and neosporosis have been 
described (Neville et al., 2015; Hemphill et al., 
2016).  
Thiazolides 
Nitazoxanide (2-acetolyloxy-N-(5-nitro 2-
thiazolyl) benzamide), the mother compound of 
this class, is essentially composed of a 
nitrothiazole-ring and a salicylic acid moiety, 
which are linked together through an amide 
bond (Hemphill et al., 2006; Hemphill et al., 
2007). Since nitazoxanide non-selectivity can 
lead to undesired side effects in both human 
and animals, nitazoxanide derivatives were 
designed without the undesirable nitro group 
(Esposito et al., 2007b). The nitazoxanide 
derivative RM4847 produces the upregulation 
of NQO1 (quinone reductase) expression by N. 
caninum but not by T. gondii. This fact may 
reflect differences between these parasites in 
terms of the mechanisms of circumventing host 
cell apoptosis (Muller and Hemphill, 2011). 
Thiazolides have favourable effects against N. 
caninum in vitro, with an IC50 of 4.23 µM and 
13.68 µM for nitazoxanide and RM4847, 
respectively. Host cell invasion of extracellular 
N. caninum tachyzoites is inhibited by 
RM4847, but not by nitazoxanide (Esposito et 
al., 2007a), and RM4847 was shown to be 
much more effective against T. gondii 
tachyzoites, with an IC50 of 0.2 µM (Müller et 
al., 2009). For the treatment of N. caninum in 
mice, nitazoxanide fails when it is applied PO, 
or it is even toxic when applied IP (Debache et 
al., 2011). In calves, the use of nitazoxanide to 
treat Cryptosporidium infection showed acute 
diarrhoea in non-infected animals, which 
indicates that this compound severely affects 
the intestinal flora (Schnyder et al., 2009). In 
conclusion, thiazolides might be interesting 
tools to study the biology of N. caninum and 
possibly T. gondii, but they are useless as drugs 
since they exert acute toxicity in small and 
large animals.  
 
Diamidines 
Diamidines represent a class of broad-
spectrum antimicrobial compounds in which 
pentamidine and its analogues exhibit activity 
against intracellular and extracellular 
protozoan parasites (Wilson et al., 2008; 
Buckner and Navabi, 2010). Pentamidine 
displays in vitro activity against T. gondii by 
inhibiting the replication of the parasites in cell 
cultures (Lindsay et al., 1991).  
Pentamidine derivatives, and the more 
recently synthesised di-cationic 
arylimidamides, which have more favourable 
pharmacokinetic profiles, improved 
bioavailability, lowered host toxicity and had a 
higher chance of passing the blood-brain 
barrier to exert its activity by binding to AT-
rich sites in the DNA minor groove, thus 
inhibiting transcription or the interaction with 
DNA-binding enzymes, such as 
topoisomerases or nucleases (Wilson et al., 
2008). This result indicates that these 
compounds could influence gene expression, 
and thus many diverse cellular functions could 
be affected. Di-cationic arylimidamides, such 
as DB786, DB750 and DB745, showed in vitro 
activity against T. gondii tachyzoites, with an 
IC50 of 0.22 µM, 0.16 µM and 0.03 µM, 
respectively (Leepin et al., 2008; Kropf et al., 
2012). In contrast to DB750, DB745 also had a 
profound negative impact on extracellular T. 
gondii tachyzoites. In addition, a lower 
adaptation of T. gondii tachyzoites to DB745 
was observed (Kropf et al., 2012). The lowest 
IC50s against N. caninum tachyzoites were 
found for DB786, DB750 and DB745 (0.21 
µM, 0.23 µM, 0.08 µM, respectively), which 
caused damage to the parasite’s ultrastructure. 
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The activities of DB750 and DB786 are limited 
to intracellular N. caninum tachyzoites; 
however, DB745 had an impact on both host 
cell invasion and intracellular proliferation 
(Leepin et al., 2008; Schorer et al., 2012). Di-
cationic arylimidamides have also been found 
to be effective against neosporosis in mice. 
DB750 that was administered IP prior to 
infection or 14 days after infection reduced the 
severity of clinical signs and the cerebral 
parasite load, while PO application resulted in 
weight loss, indicating toxicity (Debache et al., 
2011; Schorer et al., 2012). In addition, DB745 
IP treatment initiated 14 days after infection 
had similar positive effects on the percentage of 
surviving mice and the parasite load in the brain 
(Schorer et al., 2012). Arylimidamide 
treatments in mice beginning 14 days post-
infection, after the N. caninum tachyzoites had 
crossed the blood-brain border and invaded the 
central nervous system (CNS) (Collantes-
Fernández et al., 2006a), indicated that DB745, 
just like DB750, most likely crossed the blood–
brain barrier and also exerted its action within 
the cerebral tissues (Debache et al., 2011; 
Schorer et al., 2012). Potentially, features of 
DB745 could open the door for testing this 
compound against neosporosis in ruminants.  
Artemisinins 
Chinese herbal extracts are thought to 
possess the desired properties of potency and 
low toxicity, and they show promise for the 
identification of new therapeutic agents. 
Artemisinin, a sesquiterpene lactone with an 
unusual endoperoxide bond in a unique 1,2,4-
trioxane heterocycle 
[3R,5aS,6R,8aS,9R,12S,12aR)-octahydro-
3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-
j]-1,2-benzodioxepin-10(3H)-one] is present in 
the leaves and flowers of the sweet wormwood 
(Artemisia annua) (Bilia et al., 2006), and its 
derivatives are highly potent antimalarial 
drugs. This safe drug class is also effective 
against apicomplexan parasites causing 
abortions in ruminants such as T. gondii and N. 
caninum. The mechanism of action of 
artemisinin and its derivatives is dependent 
upon the presence of the endoperoxide bridge 
(Haynes and Krishna, 2004), although the 
difference in potencies between P. falciparum 
and T. gondii suggests that different targets 
may be affected in these two organisms (Dunay 
et al., 2009). Additionally, it is known that 
artemisinin perturbs calcium homeostasis in T. 
gondii, supporting the idea that Ca2-ATPases 
(SERCA) are potential drug targets in parasites 
(Nagamune et al., 2007). Artemisinin, when 
administered in vitro at 0.4 µg/ml for 5 days or 
1.3 µg/ml for 14 days, completely eliminated T. 
gondii (Ke et al., 1990). Artesunate showed an 
IC50 of 0.075 μM (Gomes et al., 2012). 
Artesunate and its active metabolite, 
dihydroartemisinin, resulted in approximately 
40% and 70% growth inhibition in vitro, 
respectively, and the combination resulted in 
approximately 65% inhibition. As they are able 
to cross the blood-brain barrier, in vivo 
experiments with low virulence T. gondii 
(DUR strain) challenge causing a chronic 
infection in mice, different from previous 
artemisinin derivatives studies with RH strain, 
showed a 40% reduction in the number of T. 
gondii tissue cysts found in the brain of mice 
treated 5 days with artesunate-
dihydroartemisinin and also modifications in 
the microscopic aspect of the cysts (Sarciron et 
al., 2000). Artemisone, a second-generation 
semi-synthetic artemisinin derivative, and 
artemiside, the thiomorpholine precursor of 
artemisone, with an improved half-live, oral 
bioavailability, metabolic stability in various 
animal systems (Haynes et al., 2006), tolerance 
in vivo (Nagelschmitz et al., 2008) and a lack 
of detectable neurotoxic potential (Nontprasert 
et al., 1998; Schmuck et al., 2009), are the most 
potent artemisinin analogues to date in terms of 
inhibiting the growth of T. gondii in vitro, with 
an IC50 of 0.12 µM and 0.10 µM for artemisone 
and artemiside, respectively. Both of these 
compounds (artemiside and 
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artemisone) were effective in reducing 
mortality during an acute challenge (60% of 
artemiside-treated mice and more than 50% of 
artemisone-treated mice survived) and during 
the reactivation of chronic infection in a mouse 
model (80% of artemiside-treated mice and 
60% of artemisone-treated mice). Furthermore, 
there was an accompanying reduction in the 
chronic burden of tissue cysts in the CNS 
(Dunay et al., 2009). 
Against N. caninum, artemisinin reduces the 
intracellular multiplication of tachyzoites at 
≥0.1 µg/ml for 30 hours or 1 µg/ml for 14 days 
(Kim et al., 2002), and artemether exhibited 
activity against tachyzoite replication with an 
IC50 of 1.0 µg/ml (Qian et al., 2015). 
Additionally, artemisone, when added prior to 
infection or in established infection, reduced 
the number of N. caninum-infected cells 
(Mazuz et al., 2012) with an IC50 of 3 nM, 
exerting their activity against intracellular 
parasites, causing ultrastructural alterations and 
switched aberrant gene expression, including 
bradyzoite markers (Muller et al., 2015b). In a 
gerbil model for acute neosporosis, artemisone 
increased survival, as 1 out of 8 mice died in 
the artemisone-treated group, while 8 out 9 
mice succumbed in the control group (Mazuz et 
al., 2012). However, in a mouse model of 
neosporosis, artemiside and artemisone had no 
effect on parasite loads in the brain or in the 
lungs (Müller et al., 2016). In short, artemiside 
seems to be useful against T. gondii in vitro and 
in mice models whereas artemisone is less 
likely to be promising for neosporosis in 
ruminants.  
Naphthoquinones  
Naphthoquinone is a class of organic 
compounds derived from naphthalene. 
Buparvaquone (2-((4-tert-
butylcyclohexyl)methyl)-3-hydroxy-1,4-
naphthoquinone) and atovaquone (trans-2[4-
(4-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-
naphthalenedione) are 
hydroxynaphthoquinones related to 
parvaquone and were originally developed as 
anti-malarial compounds (Hudson et al., 1985; 
Hudson et al., 1991). 
Buparvaquone is currently commercially 
available for use in endemic regions against 
theileriosis in cattle (Wilkie et al., 1998); 
however, in other regions of the world, e.g., the 
EU, it is not registered. A focus on the parasite 
mitochondrion as an anti-parasitic target has 
been a priority in the drug development field 
for decades (Mather and Vaidya, 2008; Sen and 
Majumder, 2008). Hydroxynaphthoquinones 
are structurally similar to the inner 
mitochondrial protein ubiquinone (also called 
coenzyme Q), which is an integral component 
of electron flow in aerobic respiration. 
Ubiquinone accepts electrons from the 
dehydrogenase enzymes and passes them to the 
electron transport cytochromes (Sun et al., 
1992). The passage of electrons from 
ubiquinone to the cytochrome bc1 (complex 
III) requires the binding of coenzyme Q 
complex III at the Qo cytochrome domain; it is 
this step that is inhibited by 
hydroxynaphthoquinones (Fry and Pudney, 
1992; Pfefferkorn et al., 1993; McFadden et al., 
2000). The consequence of this inhibition is the 
collapse of the mitochondrial membrane 
potential (Srivastava et al., 1997). On the one 
hand, atovaquone inhibited the replication of T. 
gondii tachyzoites in vitro with an IC50 of 64 
nM (Romand et al., 1993; Meneceur et al., 
2008). Moreover, atovaquone is active in vitro 
against the cyst stage of T. gondii (Huskinson-
Mark et al., 1991), although high 
concentrations of it are required (Araujo et al., 
1991; Araujo et al., 1992). In a mouse model of 
acute toxoplasmosis, atovaquone 
administration resulted in prolonged survival, 
with a reduction of parasite burdens in the 
blood and tissues during the course of treatment 
(Araujo et al., 1991; Romand et al., 1993). In a 
mouse model of chronic toxoplasmosis, 
atovaquone showed a decline in the number of 
tissue cysts and a decrease in the inflammatory 
response in the brain (Araujo et al., 1991; 
Araujo et al., 1992; Ferguson et al., 1994). 
Indeed, atovaquone is effective against 
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reactivation, as it protected mice against 
reactivated toxoplasmic encephalitis (Dunay et 
al., 2004).  
In short term studies, buparvaquone 
efficiently inhibited the replication of N. 
caninum tachyzoites with an IC50 of 4.9 nM 
exerting parasiticidal activity after 9 days of 
culture in 0.5 μM or 6 days in 1 μM 
buparvaquone. However, in the long-term 
studies, the tachyzoites reached an adaption to 
high levels of buparvaquone. Additionally, 
ultrastructural changes confirm that 
buparvaquone acted rather slowly (Muller et 
al., 2015a). In a non-pregnant mouse model of 
neosporosis, buparvaquone reduced the 
mortality and parasite load in the lungs, while 
the brain parasite load was higher than in 
untreated mice (Müller et al., 2015a); the brain 
parasite load was lower when a 20-times 
reduced challenge dose was used (Müller et al., 
2016). In addition, in a pregnant mouse model 
of neosporosis, pup mortality and the 
transmission of N. caninum to offspring were 
strongly reduced by buparvaquone treatment of 
the dams (Müller et al., 2016). In light of these 
results, atovaquone represents a valuable 
candidate to be tested for toxoplasmosis in 
ruminants and, although further studies are 
required to improve the efficacy in a mouse 
model, buparvaquone represents an obvious 
candidate to be tested against neosporosis in 
ruminants.  
Anticancer agents 
Another example of prospective compounds 
that provide interesting results is anticancer 
drugs, as parasites have several of the common 
characteristics of malignant tumours (Klinkert 
and Heussler, 2006; Dissous and Grevelding, 
2011; Dissous and Grevelding, 2011), sharing 
a crucial feature of living and multiplying in a 
host organism. Tumour cells are defined by 
their independence from exogenous growth 
factors, their resistance to programmed cell 
death (apoptosis), and their infinite 
proliferative capacity. Unlimited proliferation 
and independence of growth factors are also 
characteristics of many parasites. Although it 
remains controversial whether apoptosis occurs 
in unicellular parasites (Debrabant et al., 2003), 
it seems to be clear that intracellular parasites 
interfere with the programmed host cell 
apoptosis (Lüder et al., 2001). Parasite and 
cancer cells disseminate in immune 
compromised tissues in order to escape host 
immune responses. Anticancer drugs may 
affect parasite survival at two completely 
different levels. Firstly, they might kill the 
parasite directly, if the target molecules of 
parasite and cancer cell are sufficiently similar. 
In this case, the original cancer drugs may serve 
as leader compounds and can be modified 
accordingly to specifically inhibit the parasite 
homologue. Secondly, to kill intracellular 
parasites successfully, the drug might also act 
on a host cell signalling pathway, which is 
essential for the parasite's survival. The 
advantage here is that the drug need not be 
modified, since it is already directed against the 
target molecule (Klinkert and Heussler, 2006). 
Miltefosine (2-[hexadecoxy-oxido-
phosphinoyl] oxyethyl-trimethyl-ammonium), 
an alkyl phospholipid and an analogue of the 
ubiquitous compound phosphatidyl choline 
found in eukaryotic cell membranes, was 
initially developed as an anticancer agent 
(Wieder et al., 1999) and widely used for 
Leishmania therapy (Solano-Gallego et al., 
2011). It is highly active against extracellular T. 
gondii tachyzoites and exerts its activity by 
triggering apoptosis (Nyoman and Lüder, 
2013). Miltefosine has no effect on a mouse 
model of acute toxoplasmosis after 5 days of 
treatment, but it shows activity in a 15-day 
treatment against chronic experimental 
toxoplasmosis, with a 78% reduction in the 
brain cyst burden. Pathological findings 
showed that the tissue cysts were smaller in size 
upon microscopical examination and that there 
were ultrastructural changes in the remaining 
cysts, suggesting that miltefosine effectively 
penetrates the blood-brain barrier (Eissa et al., 
2015). Against N. caninum, miltefosine showed 
an IC50 of 5.2 μM in vitro with a parasitostatic 
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effect at 25 μM for 10 hours and parasiticidal 
activity after 20 hours. In addition, N. caninum 
tachyzoites revealed ultrastructural changes 
after miltefosine exposure. In a mouse model of 
neosporosis, miltefosine improved mouse 
survival and reduced the cerebral parasite 
burden (Debache and Hemphill, 2012).  
Recently, organometallic ruthenium 
complexes are object of great attention as 
antitumor agents with acceptable toxicity 
(Kostova, 2006; Bergamo and Sava, 2011). 
They also have antibacterial activity against 
some bacteria and parasites (Beckford et al., 
2011; Caroli et al., 2012). Earlier studies 
indicated that ruthenium compounds interact 
with DNA (Schwietert and McCue, 1999), but 
more recent investigations showed that 
ruthenium compounds bind more strongly to 
proteins (Ravera et al., 2004). Ruthenium 
compounds (compounds 16 and 18) were 
reported to exhibit IC50 values of 6–12 nM for 
N.caninum and 18-41 nM for T.gondii (Barna 
et al., 2013). Furthermore, dinuclear thiolato-
bridged arene ruthenium complexes (complex 
9, complex 1 and complex 2) showed 
promising activities against T. gondii with IC50 
values of 1.2 nM, 34 nM and 62 nM (Basto et 
al., 2017). Therefore, anticancer drug such as 
miltefosine could be considered as an 
appropriate drug to be evaluated in ruminant 
model for toxoplasmosis and neosporosis 
whereas ruthenium complexes need to be 
evaluated in mice models before contemplate 
the option of testing in ruminants. 
Endochin-like quinolones  
Endochin is a 4-(1H)-quinolone initially 
investigated as an antimalarial drug (Salzer et 
al., 1948). Subsequently, endochin was active 
against avian and murine toxoplasmosis 
(Gingrich and Darrow, 1951). Recent 4-(1H)-
quinolone derivatives, endochin-like 
quinolones (ELQ), compounds that are analogs 
of ubiquinone, have been developed and tested 
against apicomplexan parasites such as P. 
falciparum and T. gondii, as well as other 
protozoa such as Leishmania parasites (Ortiz et 
al., 2016). ELQs exert their activity by inhibit 
cytochrome c reduction by the cytochrome bc1 
complex (Winter et al., 2008; Doggett et al., 
2012). The cytochrome bc1 complex is a 
membrane-bound enzyme complex located in 
the inner mitochondrial membrane that 
contributes to pyrimidine biosynthesis and 
oxidative phosphorylation (Vercesi et al., 
1998). 3-alkyl-2-methyl-4(1H)-quinolones 
exhibited excellent in vitro activity against P. 
falciparum (Winter et al., 2011). 4(1H)-
quinolone-3-diarylethers, with improved stable 
and solubility properties, have been tested 
against T. gondii and ELQ-271 and ELQ-316 
showed in vitro IC50 values of 0.1 nM and 0.007 
nM, respectively. ELQ-271 and ELQ-316 were 
also efficacious against acute toxoplasmosis in 
mice when administered orally and against the 
cyst form of T. gondii in mice when 
administered intraperitoneally (Doggett et al., 
2012). Against N. caninum, ELQ-400 showed 
an IC50 value below 10 nM, had an impact on 
intracellular proliferation of tachyzoites and 
transmission electron microscopy showed that 
the primary target of ELQ-400 was the 
mitochondrion. In experimentally infected non-
pregnant mice, ELQ-400 orally showed a 
reduction in the number of animals with lung 
and brain infection, as well as a reduction in the 
humoral immune response against N. caninum 
(Müller et al., 2017a). Thus, ELQ-316 is a 
promising starting point for the development of 
a future toxoplasmosis therapy in ruminants, 
and ELQ-400 showed hopeful results against 
N. caninum, but further studies are needed to 
assess efficacy in pregnant animal models. 
Calcium-dependent protein kinase inhibitors 
Calcium signalling is a very important 
pathway that regulates diverse cellular 
processes (Berridge et al., 2000). In 
apicomplexan parasites, this signalling 
pathway directs motility, cell invasion and 
egression (Lourido et al., 2012). Members of 
the family of calcium dependent protein 
kinases (CDPK’s) are abundant in certain 
pathogenic parasites and absent in mammalian 
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cells making them strong drug target 
candidates. Genetic disruption of CDPKs has 
shown they control a wide range of phenotypes 
in T. gondii including egress (TgCDPK1 and 
TgCDPK3) (Lourido et al., 2010; Garrison et 
al., 2012; Lourido et al., 2012; McCoy et al., 
2012), microneme secretion (TgCDPK1) 
(Lourido et al., 2012), motility (TgCDPK1) 
(Lourido et al., 2010), or cell division 
(TgCDPK7) (Morlon‐Guyot et al., 2014). 
Other CDPKs in T. gondii (CDPK4, CDPK4A, 
CDPK5, CDPK6, CDPK8, and CDPK9) were 
described non essential for the lytic cycle 
(Wang et al., 2016). CDPKs may are also 
involved in other functions in T. gondii, for 
example, CDPK2 is essential for bradyzoite 
development (Uboldi et al., 2015) and 
CDPK4A, CDPK6 and CDPK7A may play 
roles during sporozoite formation or 
transmission via oocysts (Long et al., 2016). 
Bumped kinase inhibitors (BKIs), a 
particular class of pyrazolopyrimidine 
inhibitors of CDPK1, have bulky C3 aryl 
moieties entering a hydrophobic pocket in the 
ATP binding site. BKIs selectively inhibit 
CDPK1 from apicomplexans in a good 
structure-activity relationship (Keyloun et al., 
2014), but they do not inhibit mammalian 
kinases because they have larger amino acid 
residues adjacent to the hydrophobic pocket, 
thereby blocking the entry of the bulky C3 aryl 
group. CDPK1 is found in most 
apicomplexans, and the highly conserved 
nature of the ATP binding domain shared by 
apicomplexan CDPK homologues could be 
exploited, to some extent, in the development 
of potential broad-spectrum inhibitors 
(Keyloun et al., 2014). BKIs were originally 
developed to combat malaria (Ojo et al., 2012), 
but they have been tested for many 
apicomplexan parasites (Van Voorhis et al., 
2017). BKI-1294 acted with an IC50 of 20-220 
nM in vitro for different strains of T. gondii 
(Winzer et al., 2015). BKI-1294 was highly 
effective against acute toxoplasmosis in mice, 
decreasing the numbers of T. gondii tachyzoites 
in the peritoneal lavage fluid (Doggett et al., 
2014) and in a murine vertical transmission 
model of T. gondii (Müller et al., 2017).  
 
BKI-1517 showed a 3-times lower IC50 than 
BKI-1553 and BKI-1294 against N. caninum in 
vitro (Ojo et al., 2014; Müller et al., 2017b). In 
a pregnant mouse model, BKI-1294, BKI-1517 
and, less clearly, BKI-1553 achieved protection 
against the vertical transmission of N. caninum, 
but BKI-1553 and more markedly BKI-1517 
showed detrimental effects on fertility (Winzer 
et al., 2015; Müller et al., 2017b). Hence, BKI-
1294 could be considered a promising drug to 
be tested in ruminant models for toxoplasmosis 
and neosporosis.   
 
Since BKIs showed parasitostatic rather 
than parasiticidal effects, they are appropriated 
for a combined immunization plus treatment 
protocol. These compounds triggered the 
formation of relatively long-lived 
multinucleated complexes where parasites are 
blocked in the process of cytokinesis and 
remain trapped within the host cell but are still 
viable. These multinucleated complexes 
express specific antigen SAG1 and the 
bradyzoite marker BAG1 (Winzer et al., 2015; 
Müller et al., 2017b). Thereby, these antigens 
may be presented to the immune system 
eliciting stable immune responses against 
tachyzoite as well as bradyzoite stages.  
 
Apart from CDPK1, the rarity of kinases 
containing small gatekeeper residues in the 
apicomplexan genome reduces the chance of 
off-target effects, although intermediate 
sensitivity is expected for kinases containing A, 
S, or T in the gatekeeper position, thus 
potentially limiting this approach in some 
cases. However, an interesting strategy based 
on the exploitation of the kinase gatekeeper 
residue was recently developed to identify 
parasite CDPKs substrates (Lourido et al., 
2013). 
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Conclusions 
Although vaccination has been considered 
the better control option for ovine and caprine 
toxoplasmosis and bovine neosporosis, drug 
therapy should be a viable approach, possibly 
when combined in an immune-chemotherapy 
strategy. A large number of experimental 
efficacy drug studies against T. gondii and N. 
caninum infections has been carried out so far 
in mouse models, but studies in farm ruminants 
are scarce, showing a lack of efficacy. 
Regarding toxoplasmosis, several drug 
treatments that were applied before 
(spiramycin or sulphonamides and 
pyrimethamine) or after infection (monensin or 
decoquinate) have been carried out in pregnant 
ewes to reduce the outcome of ExTT after 
experimental infection of the ewes at the mid-
stage of pregnancy. Sulphonamides are also 
useful in field conditions to reduce T. gondii-
related abortions, and toltrazuril is applied to 
chronically infected lambs to reduce tissue 
cysts. Concerning neosporosis, the triazinones 
administered in infected newborn calves or 
lambs modulate the humoral immune response 
and reduce the clinical signs and N. caninum 
detection in organs. In addition, triazinones, 
along with folate inhibitors, can reduce 
abortions due to neosporosis under natural 
conditions. Finally, monensin seems to reduce 
the humoral immune response in non-pregnant 
cattle, and decoquinate could decrease 
abortions and transplacental transmission in 
chronically and primo-infected pregnant 
heifers. Despite these efforts, no safe and 
effective drug is available for toxoplasmosis 
and neosporosis in farm ruminants at present, 
so new approaches in drug development are 
needed. These new developments should also 
focus on the therapy of toxoplasmosis in 
humans. Highly promising future drugs against 
T. gondii and N. caninum have been tested in 
vitro and in small animal models; most of them 
target tachyzoites efficiently, but they are 
missing information regarding their efficacy 
against the bradyzoite stage. Best results have 
been reported with artemiside, atovaquone, 
miltefosine, ELQ-316 and BKI-1294 against T. 
gondii and with DB745, buparvaquone, 
miltefosine, ELQ-400 and BKI-1294 against N. 
caninum.  
Conflic of interest  
The authors declare that they have no 
conflicts of interest. This work was supported 
by the National Institutes of Child Health and 
Human Development (NICHD, grants R01 AI 
111341 and R01 HD 080670), the United States 
Department of Agriculture (USDA, grant 2014-
67015-22106), the Community of Madrid 
(PLATESA grant No. S2013/ABI2906) and the 
Iberoamerican Science and Technology 
Programme for Development (CYTED, Grant 
No. 113RT0469). Roberto Sánchez Sánchez 
was financially supported through a grant from 
the Spanish Ministry of Education, Culture and 
Sports (grant No. FPU13/03438). Patricia 
Vázquez was supported by the postdoctoral 
Juan de la Cierva-Formación program of the 
Spanish Ministry of Economy and 
Competitiveness (grant No. FJCI-2014-20982).  
Acknowledgements  
Roberto Sánchez Sánchez is supported by a 
fellowship from the Spanish Ministry of 
Education, Culture and Sports (MECD), as a 
part of the Program of Training of University 
Teaching Staff (FPU, grant number 
FPU13/03438). Patricia Vázquez has a Juan de 
la Cierva-Formación post-doctoral contract 
(FJCI-2014-20982) from the Spanish Ministry 
of Economy and Competitiveness (MINECO). 
Also, Public Health Service, National Institutes 
of Health, Bethesda, MD (grants R01 AI 
111341 and R01 HD 080670), the U.S. 
Department of Agriculture (grant 2014-67015-
22106) and the Community of Madrid, Spain 
(PLATESA, S2013/ABI2906) are 
acknowledged for their financial support.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"El éxito es la habilidad de ir de fracaso en fracaso sin perder el entusiasmo"                                     
Winston Churchill (1847-1965) 
 
